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Abstract 
Environmental xenoestrogens (EEs) are chemicals that when they enter the body, the body 
responds to them as it would to endogenous estrogens.  Humans are exposed to these 
chemicals on a daily basis via natural components, additives and contaminants in food and 
water, through the use of pharmaceuticals and personal care products such as sunscreens, 
lotions and toothpaste.  Exposure to EEs is thought to result in adverse effects on humans 
such as decreased fertility, increased susceptibility to hormone-sensitive cancers, deformities 
of the male genitalia and precocious puberty in females.  The critical window of exposure is 
thought to be early fetal development, when tissues are rapidly differentiating under the 
control of endogenous estrogens.  However, there is limited data in the literature on human 
fetal exposure to EEs.  The first objective of this study was to assess human fetal exposure to 
a suite of 35 EEs by analysis of paired samples of amniotic fluid and maternal urine were 
collected from 32 New Zealand women between 14 and 20 weeks gestation.  The analytical 
chemistry methods required for this study were developed and validated.  The results 
demonstrate that fetal exposure is highly correlated with maternal exposure.  This study is the 
first to report maternal urine levels of two UV filters and amniotic fluid levels of parabens, 
UV filters and triclosan.  A model based on simple additivity of effect was developed that 
combined the measured concentrations with literature data on relative estrogenic potency to 
assess the magnitude of the estrogen signal that may be attributed to the EEs.  This model 
suggests that the fetus may experience an estrogen signal due to the measured EEs that could 
be as large as the endogenous estrogen signal.  A second objective was to use computational 
docking to study the interactions of the EEs with the human estrogen receptor (hER) protein.  
The docking studies show that the rigid endogenous ligand, 17β-estradiol (E2) interacts with 
the hER to produce a single, well-defined complex with the receptor and the flexible EEs 
produce multiple, distinct energy-equivalent complexes.  EEs are not able to interact with the 
binding cavity to stabilise the rigid hER-E2-like topology of the complex. As a result, the 
hER-EE complexes can be thought of as more pliable or ‘floppy’ and thus able to respond to 
the cell context in multiple ways, leading to variations in gene expression in different target 
tissues.  These multiple pathways may explain the range of physiological responses attributed 
to exposure that depend on the timing of exposure and the sex of the individual exposed. 
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Glossary 
Much of the terminology used in this work may have different meanings to different readers.  
For clarity, the definitions for key terms are collected in this section.  These definitions also 
include important underlying concepts and are arranged in order to develop these concepts in 
a logical fashion.     
Estrogens:  the female sex hormones; refers to a group of 3 compounds (estrone, estradiol 
and estriol). Estrone (E1) is found in women and men in small amounts. It is produced in the 
adrenal gland and produced and stored in fatty tissue.  Estradiol (E2) is the most active of the 
three compounds.  It is produced by the ovaries in women and by the testes and adrenal 
glands in men.  Estriol (E3) is the major estrogen produced during pregnancy.  E3 is 
produced in large amounts in the placenta and levels in the mother and fetus rise continuously 
until just before birth.   
Androgens:  the male sex hormones; refers to a group of 5 compounds, of which testosterone 
(T) dihydrotestosterone (DHT) are the primary active hormones.  DHT is metabolite of T and 
is a more potent androgen than T because it has a higher affinity for the androgen receptor 
than T.  The other three androgens are intermediates in steroid hormone biosynthesis. 
Agonist:  a compound that is able to bind to a receptor in a cell and produce the biological 
response that is controlled or triggered by the receptor.  The ability to bind is called affinity.  
The ability to produce the biological response is called efficacy.  An agonist can be an 
endogenous such as the sex hormones or a foreign substance such as a drug or other 
chemical.  For the sex hormone receptors, the biological response that is of interest is gene 
transcription.  For the sex hormone receptors, agonists activate (initiate, up-regulate) receptor 
mediated gene transcription. 
Antagonist: a compound that is able to bind to a receptor in a cell and blocks or inhibits the 
biological response that is controlled or triggered by the receptor.   An antagonist has affinity 
for the receptor but no efficacy.  For the sex hormone receptors, antagonists block (inhibit, 
down-regulate) receptor mediated gene transcription. 
Agonist and antagonist are also used to describe the 3D conformation of the hER protein 
ligand binding domain (LBD) on ligand binding, specifically the difference in position of 
helix 12 (H12) of the LBD that occurs when an agonist or antagonist ligand is bound.  Thus, a 
 xxx 
 
ligand can be described as an agonist or antagonist and the hER can be described as taking an 
agonist or antagonist conformation. 
Selective Estrogen Receptor Modulators (SERMs): a class of compounds that interact with 
the estrogen receptor but unlike pure agonists or antagonists their mode of action depends on 
the cell type (tissue) they are acting on, resulting in selective inhibition or stimulation of 
estrogen-like action in the tissue. 
Antiestrogen: an antagonist for the estrogen receptor.  Functionally, there are three types of 
antiestrogens:  type I or pure antiestrogens oppose estrogen activity in all tissues; type II and 
III are SERMs and display tissue selective agonist-antagonist activities [1].  Antiestrogens 
have a range of potency – the efficiency with which they block hER mediated gene 
transcription. 
Antiandrogen:  an antagonist for the androgen receptor.   
Environmental Estrogen (EE):  a compound that an organism is exposed to via interaction 
with its environment that promotes or interferes with ER-mediated gene transcription via 
binding with the ER. 
Transcription factor:  a cellular protein that binds to a specific DNA sequence, thereby 
controlling the transcription of genetic information from DNA to mRNA.  Transcription 
factors recruit the RNA polymerase to the specific gene.   Transcription factors contain one or 
more DNA-binding domains which attach to specific sequences of DNA (the target promoter) 
adjacent to the genes that they regulate.  Additional proteins such as coregulators, chromatin 
remodelers, histone acetylases, deacetylases, kinases, and methylases are also recruited to the 
transcription factor/RNA polymerase complex to achieve gene transcription.   
Target promoter:  a region of DNA that facilitates the transcription of a particular gene. 
Promoters are located near the genes they regulate, on the same strand and typically upstream 
of the gene. In order for the transcription to take place the RNA polymerase must attach to 
the DNA near a gene. Promoters contain specific DNA sequences and response elements 
which provide a secure initial binding site for the RNA polymerase and for proteins called 
transcription factors that recruit RNA polymerase. These transcription factors have specific 
activator or repressor sequences of corresponding nucleotides that attach to specific 
promoters and regulate gene expressions. 
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Coregulator: a cellular protein that interacts with the ligand bound transcription factor/RNA 
polymerase complex that enhances or suppresses gene transcription.  Coregulators that 
enhance or increase the rate of gene transcription are called coactivators and those that 
suppress or decrease the rate of gene transcription are called corepressors.  Coregulator 
activity is regulated by their absolute and relative expression levels in different cell types.  
Coregulators allow for cell type and promoter specificity for transcription factors. 
Crystal structure refers to the molecular structure of the protein (with or without a co-
crystallised ligand) obtained directly from the published atom co-ordinates of the solved and 
refined molecular structure produced experimentally by x-ray crystallography.   
Model refers to the protein structure used for ligand docking obtained after the required 
processing and preparation of the published crystal structure is completed.  The model also 
still contains the co-crystallised ligand. 
Apo describes an empty receptor structure, one without a bound ligand. 
In the context of computational docking, native is used to identify the ligand that has been 
co-crystallised with the protein in the crystal structure or the resulting model.   
In the context of analytical chemistry, native is used to identify the target analyte as distinct 
from the isotopically labelled analyte identified as the surrogate. 
To be concise, amino acid residues will be referred to simply as ‘residues’.   When 
identifying a particular residue in a protein, the standard 3-letter abbreviation followed by its 
number in the protein sequence will be used.  For example, His524 refers to the 524
th
 residue 
in the protein sequence, which is a histidine residue. 
Small molecules, for example the endogenous hormones or EEs, may be present in bodily 
fluids in three forms: free, conjugated and protein bound.  The free form is the molecule in 
its original form simply dissolved in the fluid.  The conjugated form has a highly water 
soluble substituent such as sulphate or glucuronate covalently bound to the parent molecule at 
the site of an active hydrogen such as on a hydroxyl group.  These conjugates are products of 
specific metabolic enzymes.  The protein bound form is the parent molecule non-covalently 
bound to a carrier protein molecule in the blood or amniotic fluid.  The free form is readily 
bioavailable.  The protein bound form is sequestered but is readily available in response to a 
shift in equilibrium in the fluid.  The conjugated form is not readily bioavailable and is 
 xxxii 
 
normally destined for elimination, unless it meets deconjugation enzymes located on the 
surfaces of specific cell types in the body. 
Nomenclature 
The notation for ring designation and numbering substituent positions is illustrated in Figure 
A.  The ring designation is often used in reference to other ligands that do not have this 
structure to describe the type of interactions with the receptor.  Note that the ring designation 
given in Figure A for GEN does not follow the common convention for flavone ring 
designation
1
, but is used in the ER literature.  
The binding cavity of the ERs is also described as having an A-ring end and a D-ring end, in 
reference to the usual orientation of E2 in the binding cavity.  The A-ring end is the 
Glu/Arg/water molecule end.  The D-ring end is the His end and is also described as the 
entrance channel end. 
 
 
17β-estradiol (E2) 
 
 
 
Genistein (GEN) 
 
Figure A.  Position numbering and ring notation for ligands, illustrated with 17β-estradiol and genistein. 
 
 
                                                 
1 There is currently no standardised IUPAC convention for flavones nomenclature http://www.iupac.org/web/ins/2009-018-2-800 .The 
common convention is illustrated at http://www.friedli.com/herbs/phytochem/flavonoids.html#intro 
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Modern chemistry has brought us many benefits from pharmaceuticals to advanced materials. 
With these advances comes a responsibility to balance the benefits against undesirable 
environmental effects. This balance is critical when chemicals interfere with the most 
fundamental of biological processes – reproduction [2]. Recently, interference of this type 
was demonstrated on a grand scale when the population of fathead minnows in an isolated 
Canadian lake was brought to near extinction in just 7 years by exposure to parts per billion 
concentrations of 17α-ethynylestradiol (EE2, Figure 2.29), the synthetic estrogen used in 
birth control pills [3]. The exposure dramatically reduced the reproductive capacity of both 
male and female fish. This is but one example of a larger issue known as endocrine 
disruption:  the interference with the synthesis, secretion, transport, binding, action, or 
elimination of natural hormones in the body that are responsible for the maintenance normal 
cell metabolism, reproduction, development and behaviour.  A similar outcome is possible 
for humans on exposure to hormonally active chemicals at inappropriate times [4-12].   
The Endocrine Society defines an endocrine-disrupting chemical (EDC) as a compound, 
either natural or synthetic, which through environmental or inappropriate developmental 
exposures alters the hormonal and homeostatic systems that enable the organism to 
communicate with and respond to its environment [13]. EDCs were originally thought to 
exert actions primarily through nuclear hormone receptors such as the estrogen receptors 
(ERs), androgen receptors (ARs) and thyroid receptors (TRs). However, the mechanisms of 
action are much broader than originally recognized and include non-nuclear steroid hormone 
receptors (e.g., membrane-bound ERs), nonsteroid receptors such as neurotransmitter 
receptors and enzymatic pathways involved in steroid biosynthesis and/or metabolism [13]. 
It has long been accepted that exposure to environmental pollutants can produce mutations in 
DNA [14].  These DNA mutations can be passed to the individual’s offspring.  Recently, 
heritable changes in gene expression without DNA mutation have been identified in animals 
and humans [15, 16].  Such changes in gene expression are described as ‘epigenetic’ and are 
mediated by external chemical signals such as hormones or immune status and by 
environmental pollutants.  If undesirable epigenetic changes in an individual occur early in 
development, they can lead to increased susceptibility to disease or dysfunction later in life 
and to similar effects in the individual’s offspring [16, 17].  At the molecular level, epigenetic 
mechanisms include chemical modification of the cytosine bases in DNA by methylation; 
chemical modification of histones (globular proteins that package DNA); and production of 
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microRNAs (short, single stranded RNAs that down-regulate gene expression by interfering 
with mRNA function) [15, 17].  These modifications are passed down via cell mitosis [17]. 
The changes in genome function that result from unintended external influences are insidious 
and potentially devastating to a species.   
In mammalian germ cells and preimplantation embryos, DNA is actively demethylated and 
remethylated, selectively erasing certain parts of the methylation patterns inherited from the 
parents and copying others [16].  This process produces cells in the new embryo with the 
capacity to develop into any of the required tissue types.  Methylation is influenced by the 
external chemical environment of the cell such as the presence of endogenous hormones.  
Any upset in the reprogramming of the cells at this stage could induce persistent changes in 
the individual that become heritable in that individual’s offspring.  For example, gestational 
exposure of female rats to vinclozolin (a fungicide that acts as an antiandrogen) at the time of 
gonadal sex determination results in a decrease in fertility of her male offspring.  This 
decrease in fertility was transmitted for at least 3 generations, but only down the male 
offspring line [18].  
In humans, exposure to EDCs is implicated in a wide range of adverse outcomes including 
uterine fibroids and ovarian tumours [19, 20], hormone related cancers [4, 21, 22], 
deformities of the male genitalia [7], precocious puberty in girls [23-25], declining male and 
female fertility [26-28], obesity [29-31], developmental disabilities [32-34] and changes in 
sexual behaviour [32-34]. 
The primary focus of this study is human gestational exposure to endocrine active chemicals, 
specifically environmental estrogens (EEs).  The main objective is to assess human fetal 
exposure to EEs and estimate the increase in estrogenic signal due to this exposure in relation 
to that due to endogenous estrogens.  To achieve this objective, samples of human amniotic 
fluid with matched maternal urine samples were analysed for a suite of 35 EEs.  The EEs of 
interest were chosen because there is a high probability of exposure through either the diet or 
use of common products.  These compounds are present in personal care products such as 
toothpaste, antibacterial soaps, deodourants, shampoo, skin lotion and sunscreens; are 
naturally occurring in soy, legumes and some green vegetables; and potentially present as 
contaminants in food or drinking water due to contact with plastics.  The samples of urine 
and amniotic fluid were obtained from a cohort of 32 women through collaboration with The 
University of Otago Christchurch Medical School, the Christchurch Women’s Hospital and 
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the Canterbury Health Laboratories.  The study was granted human ethics approval from both 
the Upper South Regional A Ethics Committee and the University of Canterbury Human 
Ethics Committee.  The required chemical analysis methods were developed and validated 
and then applied to the samples.  Finally, a model was developed to quantify the magnitude 
of estrogenic signalling that the fetus experiences that can be attributed to the measured levels 
of EEs and endogenous estrogens. 
The secondary focus of this study is an investigation of the interactions, at a molecular level, 
of the EEs with the human estrogen receptor (hER) protein.  This investigation was done 
using a computational technique widely used in the pharmaceutical industry called ligand-
receptor docking.  The objective of this part of the study was to consider the biomolecular 
interaction of the EEs with the hER in an attempt to rationalise the varied and sometimes 
contradictory observed adverse outcomes that have been hypothesised to result from such 
exposure. 
To achieve the two objectives, several large and diverse bodies of literature have been 
brought together to find the critical pieces of information that form the foundation of the 
overarching story.  The areas for the literature review presented in Chapter 2 are 
 Hormone control of gene expression  
 Structure and function of the hER 
 Human gestational development 
 Adult exposure and metabolic fate of EEs 
 The maternal-fetal-placental unit 
 Fetal exposure and metabolic fate of EEs 
 Sources, activity and potency of EEs 
The key findings from the literature review form the basis for the exposure assessment 
presented in Chapter 6.  The computational docking study presented in Chapter 3 provides 
insight into the molecular interactions between the EEs and the hER which could explain 
some of the variability in in vitro and in vivo studies of estrogenicity for these compounds.  
Chapter 4 presents the development and validation of the methods applied to the analysis of 
amniotic fluid and maternal urine for the EEs of interest.  Chapter 5 presents the study design 
and the results of the analysis of amniotic fluid and maternal urine.  Chapter 6 presents a 
comparison of the results of this study to the literature.  The key findings of the literature 
review of Chapter 2 are integrated with the results of this study to provide an assessment of 
fetal exposure. Chapter 7 and Chapter 8 present results of experiments intended to 
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characterise the kinetics and thermodynamics of binding of EEs to the hER and to develop a 
relative estrogenicity screening method to characterise biological samples.  Finally, Chapter 9 
presents overall conclusions of this work and future directions.  
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2.1 Hormone Control of Gene Expression 
2.1.1 Role of hER 
The endocrine system is a collection of glands in the body.  Each gland produces and secretes 
specific hormones (small molecules) directly into the bloodstream to regulate bodily 
functions.  The endocrine system functions as an information signalling network to control 
critical growth, development and maintenance functions of the body.   
In general, endogenous hormones such as estrogens and androgens act via the nuclear 
receptor proteins, the estrogen receptor (ER) and the androgen receptor (AR), which 
recognise and specifically respond to their cognate hormones.  These nuclear receptor 
proteins are located in the cytoplasm or nucleus of target cells.  They are ligand-inducible 
transcription factors, meaning that when the endogenous hormone diffuses into the cell, it 
binds to its specific receptor protein and initiates transcription of the target genes [35-39].  
There are two hERs, α and β. They are found in different amounts in different tissues and 
respond differently to the estrogens. 
The uterus, mammary gland, placenta, liver, central nervous system (CNS), cardiovascular 
system and bone are the classical estrogen target tissues.  hERα is the predominant subtype in 
these tissues and they respond to estrogen challenges with an increase in transcription of 
estrogen-responsive genes [40-42].  hERα mediates the physiological actions of estrogens in 
mating behaviour and glucose metabolism.  hERβ is primarily expressed in the prostate, 
testis, ovary, pineal gland, thyroid gland, parathyroids, adrenals, pancreas, gallbladder, skin, 
urinary tract, lymphoid and erythroid tissues, lung, thymus, spleen and in localised areas of 
the brain [41, 43].  hERα is either very low or undetected in these tissues.  hERβ is essential 
for normal ovulation efficiency [44] and some aspects of mating behaviour [45] and immune 
responses [42], but is not essential for female or male sexual differentiation, fertility or 
lactation [44].  hERβ also acts to regulate expression of hERα, reducing the potency of 
estrogens acting through hERα [46-48].  According to KBERG:  KnowledgeBase for 
Estrogen Responsive Genes [49], there are 1069 estrogen responsive human genes 
corresponding to 1051 unique target promoters. 
2.1.2 Role of Estrogens 
The physiological effects of estrogens in both males and females have been reviewed by 
Nilsson et al. [37] and Kuiper et al. [50], and are briefly summarised here. 
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In females, the ovaries are the main producer of E2 and it stimulates pubescent growth and is 
responsible for female characteristics such as breasts, a wider pelvis and fatty tissues around 
the buttocks and hips. In adult females, E2 regulates the menstrual cycle, stimulates the 
development of vaginal secretions and prepares the body for pregnancy by thickening the 
uterine lining. 
In males, most of the E2 is produced in the testes but the adrenal and pituitary glands also 
produce small amounts. In males, E2 promotes the growth of the penis and the development 
of testicles and plays an important role in prepubescent boys by stimulating the growth of 
facial and body hair, deepening the voice and aiding the development of thick masculine 
muscles.  E2 also stimulates the growth and maturation of sperm. Healthy levels of E2 in men 
also result in higher libidos.  
In both males and females, estrogens have a role in the cardiovascular system in response to 
vascular injury.  Estrogens also influence a variety of functions in the central nervous system 
such as learning, memory, awareness, fine motor skills, temperature regulation, mood and 
reproductive functions. 
In human female fetus, estrogen signalling is critical to the onset and completion of 
primordial follicle formation (primordial follicles contain immature oocytes) [51].  
Androgens are also important but their role is less clear [51].   
The role of both estrogens and androgens in early brain development is well recognised.  
Their influence contributes to the differences in cognition and behaviour between males and 
females and to individual variations within the sexes [52].  Strong correlations exist between 
prenatal hormone levels and childhood play behaviour and for sexual orientation and 
tendencies toward anger [52].   
In adults, circulating hormones are bound to plasma-steroid binding proteins and albumin in 
the blood and are also present as water soluble sulphate and glucuronide conjugates.  Only a 
small fraction of the hormones are free (unbound and unconjugated) in the blood [53].  In 
humans the human sex-hormone-binding globulin (hSHBG) is the main, specific transport 
protein for steroid hormones.  The steroid hormones bind with high affinity to different sites 
on the protein and T binds with slightly higher affinity than E2 (KD ≈ 0.63 and 1.5 nM 
respectively).  Hormones can also bind to albumin, but the binding is non-specific and of low 
affinity [54].  Because the amount of albumin in adult blood is much greater than hSHBG, 
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most of the circulating hormones are bound to albumin. It is the small fraction of free 
hormone (<2% in adult humans) that is responsible for biological activity.  The unbound 
steroid hormones passively diffuse into and out of the cells.  There are no known active 
transport mechanisms for the free steroid hormones [53].   
In contrast, the fetus does not produce a high affinity hormone binding protein and exactly 
how the levels of steroid hormones are controlled in the fetus in the first and second 
trimesters while differentiation is occurring is not fully understood [53].  All three estrogens 
(E1, E2 and E3) are secreted from the placenta into the umbilical vein in the unconjugated 
form [55]. The fetus sulphates the estrogens for return to the placenta via the umbilical artery 
[53, 55]. Fetal metabolism is further discussed in Section 2.5.4. 
Total serum (free + protein bound) E2 levels vary substantially over the development and 
lifetime of a human and are different in males (blue bars) and females (pink bars) as shown in 
Figure 2.1.  Note the dramatic increase in E2 levels that occur between mid-gestation and 
birth and the subsequent rapid decline in the first few days of life.  In adults, approximately 
1.5% to 3% of the total serum E2 concentration is free E2.  No information was found for the 
%free levels in fetal blood during gestation. 
 
 
Figure 2.1.  Human total (free + protein bound) serum E2 concentrations [51, 55, 56].  
Blue bars indicate male levels, pink bars indicate female levels. The overlap of male and 
female levels appears grey. 
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2.1.3 Endocrine Disruption 
Endocrine disruption is a broad topic that deals with upsetting the balance of the natural 
hormone levels in an organism [4, 6, 24, 57-59].  Of particular concern is the disruption of 
the reproductive hormone balance caused by exposure to chemicals.  These disruptions have 
adverse effects not only on the exposed individual but on future generations by permanently 
altering gene expression via epigenetic mechanisms [60, 61].   
There are several mechanisms of disruption that affect hormone signalling.  Using the 
disruption of sex hormone signalling as an example, different mechanisms are illustrated in 
Figure 2.2.  The mechanisms can be categorised as genomic (acting directly through nuclear 
receptor binding) or non-genomic (influencing the balance of endogenous hormones via other 
means such as interfering with hormone synthesis or metabolism).  In Figure 2.2, the 
genomic mechanisms are indicated in red and the non-genomic mechanisms are indicated in 
blue.   
DNA Interaction
Direct via classical EREs 
or 
Indirect via transcription factors 
such as AP-1or NF-κB
ER AR
Altered 
Gene 
Expression
ER Antagonist
AR Agonist
AR Antagonist
Free Endogenous 
Androgen
Target Cell
Free Endogenous 
Estrogen
ER Agonist
Carrier Protein 
Bound Estrogen Carrier Protein 
Bound Androgen
Competition for carrier protein increases 
concentration of free hormone
Alteration of synthesis or metabolism 
of hormones by enzyme inhibition or 
up/down regulation of enzyme gene
E2T
CYP19A1
SULT
UGT
 
Figure 2.2.  Mechanisms of endocrine disruption illustrated using sex hormone 
signalling as an example.  Disruption can occur by interference with receptor mediated 
gene transcription (red) or by upset of hormone biosynthesis (blue). 
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EEs are able to bind to the ER and either up-regulate or down-regulate estrogen target gene 
expression.  To further complicate matters, a chemical may simultaneously act on more than 
one of the pathways or mechanisms shown in Figure 2.2.  For example, a chemical may 
simultaneously be estrogenic (up-regulates estrogen target genes) and antiandrogenic (down-
regulates androgen target genes) or act on both genomic and non-genomic pathways, 
depending on where they are found in the body.  For these reasons a phenotypic definition of 
environmental estrogen is difficult to provide [62]. 
The focus of this project is the disruption of estrogen signalling in humans.  It is important to 
realise that estrogen signalling disruption does not occur in isolation, but is only one part of 
the highly complex and poorly understood issue of endocrine disruption [63].   
2.2 Human Estrogen Receptor Structure and Function 
2.2.1 hER Structure  
The ER is a member of the nuclear receptor superfamily of ligand-inducible transcription 
factors [39].  There are two genetically distinct forms of the hER, referred to as hERα and 
hERβ.  The hERα gene ESR1 is located on chromosome 6q25.1 and the hERβ gene ESR2 is 
located on chromosome 14q23.2 [64, 65].  The hERα consists of 595 amino acids and has a 
molecular weight of 66 kDa and hERβ consists of 530 amino acids and has a molecular 
weight of 55 kDa. The hERα was identified in 1958 [35, 66] and cloned in 1986 [67].  The 
hERβ was first reported in 1996 [68, 69].  
As illustrated in Figure 2.3, there are six functional domains (A-F) in the hER proteins [40, 
70].  The N-terminus A/B region does not have a well-defined tertiary structure [65].  It is 
involved in transcriptional activation and holds the activation function AF-1.  AF-1 activates 
target genes by directly interacting with components of the transcriptional machinery and 
with coregulatory proteins that regulate gene transcription [35].  AF-1 is constitutively active 
(ligand independent) and regulated by polypeptide growth factors such as epidermal growth 
factor (EGF) and insulin-like growth factor (IGF) [70, 71].  The C region or mid-region is the 
DNA binding domain (DBD) that binds with high affinity to specific DNA sequences in 
target gene promoter regions called estrogen response elements (EREs).  This region plays a 
central role in receptor dimerisation, providing the surfaces necessary for the ‘head to head’ 
dimerisation of two receptor molecules.  Binding of the dimerised hER at the ERE sites 
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allows recruitment of transcriptional machinery and specific coregulatory proteins to 
transcribe the specific ER target gene.  The D domain is the hinge domain and has not been 
well characterized.  It is thought to contribute flexibility to the receptor structure as it is 
located between the two highly structured domains of the receptor molecule:  the DBD and 
the ligand binding domain (LBD).  It also influences DNA binding properties of the 
individual receptors and it may also serve as an anchor for certain corepressor proteins [35, 
65].  The E domain is the LBD and holds the ligand binding pocket, the activation function 
AF-2, sites for coregulatory protein binding and for interactions with heat-shock proteins 
[40].  The two separate activation functions, AF-1 and AF-2, function co-operatively and 
synergistically with one another. AF-2 is strictly ligand-dependent [71].  hERα has both  AF-
1 and AF-2 activation functions.  ERβ has only the AF-2 domain [72].  The C-terminus F 
domain is involved in homo- and hetero-dimerisation of the receptor and is the binding site 
for chaperone proteins such as the heat-shock proteins Hsp70 and Hsp90.  In the unliganded 
state, the chaperone proteins interact with the receptor protein to open the binding cavity so 
that it is accessible to the ligand [65].   
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Figure 2.3.  Schematic representation of estrogen receptor protein structural domains.  
Within each segment, the number of amino acid residues is given.  The %homology is 
indicated below each domain. 
 
The two hERs are highly conserved (97%) in the DBD but are less similar in the LBD (58%). 
This suggests that hERβ would recognize and bind to similar EREs as hERα but that each 
receptor would have a distinct spectrum of ligands [40].  The DBD contains two zinc fingers 
which are involved in DNA binding and receptor dimerisation.  The balance of the structure 
is much less similar between the two receptors, around 30% [68, 73], suggesting that proteins 
interacting with the two receptors for essential function are considerably different, thus 
directing the two receptors to different specific target genes [40, 74]. 
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All ER ligands bind exclusively to the LBD of the receptor [75].  E2 interacts with hERα via 
a hydrogen bonding network formed from the 3-OH of the A-ring of E2 interacting with 
Arg394, Glu353 and a single water molecule. The 17β-OH on the D-ring of E2 forms a 
hydrogen bond with His524 [76, 77]. The remainder of the molecule participates in a number 
of hydrophobic contacts at various points around the cavity. The binding interactions for 
hERα are illustrated in Figure 2.4.  The binding mode of E2 with hERβ is identical to that 
shown for hERα.   
The role of the water molecule as a pivot in the ligand recognition mechanism is observed in 
all published crystal structures of ligand bound hER.  It is thought to participate in 
positioning the ligand into the pocket rather than acting as a bridge for binding [71, 76].  The 
hER is able to bind a wide range of non-steroidal ligands. A phenolic A-ring is highly 
favourable but not essential for ligand binding.  The remainder of the binding pocket can 
interact with a number of different hydrophobic groups. This ability to bind a variety of 
compounds is attributed to the relatively large size of the binding pocket (hERα 450 Å3; 
hERβ 390 Å3) compared to the volume of E2 (245 Å3) [77, 78]. The LBD is composed of 12 
α-helices, of which H3 through H12 form a ‘wedge’ shaped ligand binding cavity with H12 
acting as a ‘lid’ [77].  This structure is illustrated in Figure 2.5. 
 
 
Figure 2.4.  Hydrogen bonding network of E2 in hERα.  Atom co-ordinates from PDB 
entry 1ERE.  Image produced in Schrodinger Suite 2010 Maestro. 
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Figure 2.5.  Tertiary structure of the hERα LBD with E2 (shown in space-filling 
representation) and the water molecule (shown in tube representation) in the binding 
cavity.  Ribbons illustrate the α-helix protein structure.  Thin lines illustrate flexible 
loops which are disordered regions connecting two ordered regions.  Ribbons with 
arrows illustrate β-sheet structure. Atom co-ordinates from PDB entry 1ERE.  Image 
produced in Schrodinger Suite 2010 Maestro. 
 
Within the LBDs of hERα and hERβ, there are only two substitutions of residues in close 
proximity to bound agonists:  hERα Leu384 is replaced by hERβ Met336 and hERα Met421 
is replaced by hERβ Ile373.  The reduction in binding pocket volume in hERβ is due 
primarily to the replacement of Leu384 with Met366.  Given the conservative nature of these 
substitutions, it is not surprising that E2 is non-selective for hERα and hERβ.  Other 
compounds exhibit a preference for one of the hERs. For example, the phytoestrogen GEN is 
moderately selective, with a higher affinity for hERβ over hERα [79].   
The binding of an agonist such as E2 causes a major reorganisation of the tertiary structure of 
the receptor LBD.  The C-terminal H12 folds against H3, H5/6 and H11, closing the binding 
pocket.  This exposes the functional AF-2, a hydrophobic groove on the surface of the hER 
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LBD as shown in Figure 2.6(a).  The positioning of the H12 helix is critical for recruiting 
coactivators to the AF-2 site and subsequent initiation of gene transcription and has been 
proposed as an important mechanism for determining the agonist efficacy of different ligands 
[75, 80, 81]. Antagonist binding repositions H12 so that it occupies this hydrophobic groove, 
preventing coregulator recruitment [81] as shown in Figure 2.6(b).  The coregulators have a 
conserved motif (LxxLL; L=leucine, x = any other amino acid) called the NR box that is 
necessary and sufficient for binding to the AF-2 site of the agonist-bound receptor [75, 82]. 
As stated earlier in this section, the main surfaces for receptor dimerisation are located in the 
C region (DBD).  The C-terminus F region is also involved in dimerisation.  Within the LBD, 
residues 507-518 in hERα (460-469 in hERβ) are essential for dimerisation [83, 84].  These 
residues are located upstream of His524, directly under the end of H12 when the receptor is 
in the agonist conformation.  The agonist conformation also places the F region in close 
proximity to these LBD residues. 
 
 
(a) Agonist (PDB 1ERE) 
 
(b) Antagonist (PDB 1ERR) 
 
Figure 2.6.  Positioning of H12 in the agonist and antagonist conformation.  The AF-2 
site is exposed in the agonist conformation and occupied by H12 in the antagonist 
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conformation.  Atom co-ordinates from PDB entries 1ERE and 1ERR.  Images 
produced in Schrodinger Suite 2010 Maestro. 
The entire ER has never been crystallised, likely because of the large regions of ill-defined 
tertiary structure (A/B region, D region, F region).  The ER LBD also has not been 
crystallised without a bound ligand.  As will be discussed in Chapter 3, a single ‘apo’ crystal 
structure of hERα has been solved, but this structure was obtained by crystallising the protein 
with a ligand, then literally ‘soaking’ the ligand out of the crystal before collecting x-ray 
crystallographic data [85].  
2.2.2 hER Function  
A general review of transcription is provided by Latchman et al. [86].  Three excellent 
reviews of hER mediated transcription are provided by Hall and McDonnell [70], Ascenzi et 
al. [65] and Gronemyer et al. [87] and are briefly summarised here.    
In the absence of the hormone, the hER is sequestered in a multi-protein inhibitory complex 
with heat shock proteins (Hsp70 and Hsp90) and other chaperone proteins in either the 
cytoplasm or the nuclei of target cells.  The chaperone proteins hold the ER binding cavity 
open for ligand entry.  Hormone binding induces a conformational change in the receptor that 
causes dissociation of the chaperone proteins and closing of H12 over the binding cavity.  
This conformational change promotes dimerisation of the receptor protein followed by high-
affinity binding to specific EREs located within the promoter regions of target genes.  From 
the EREs the hER complex recruits RNA polymerase and other coregulatory proteins to 
positively or negatively regulate gene transcription.  In the case of the hER, gene 
transcription occurs very slowly, at a basal rate, without the recruitment of coregulatory 
proteins.  Coregulatory proteins are classed as coactivators or corepressors that respectively 
increase or decrease the rate of transcription.  The specific suite of coregulatory proteins 
present in a cell depends on the type of cell and may vary in time or with stages of 
development.   
Receptor dimerisation is required for gene expression through interaction with EREs, but the 
ligand bound receptor monomer can interact with other transcription factors (e.g. AP-1 and 
NF-κB) to initiate expression of those target genes [65]. Gene expression regulated via the 
EREs is described as direct and expression regulated through interactions with other 
transcription factors is described as indirect. 
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Not all tissues respond to ligand-bound hERs.  The transcriptional activities of hER ligands 
are tissue-selective suggesting that the hER requires specific cellular factors for maximum 
response.  Many of these coregulators are used by more than one nuclear receptor.  These 
coregulators are present in limiting quantities in the cells so that ligand bound receptors must 
compete for the coregulators needed for transcription.  The coregulator proteins are recruited 
at AF-2.  There are at least 20 identified coactivators and 6 identified corepressors [70].  The 
populations of these factors vary by cell type. 
2.2.3 Agonism and Antagonism 
As was illustrated in Figure 2.6, estrogens function as AF-2 agonists, meaning that they 
induce a conformational change in the hER that results in the formation of the coactivator 
binding site (AF-2 site) where coactivator proteins bind.  Most antiestrogens function as AF-2 
antagonists meaning that the conformational change they induce in the hER prevents the 
coregulators from binding at the AF-2 site.  However, some antiestrogen-hER complexes are 
able to bind DNA suggesting that they mediate active repression of gene expression by 
recruiting corepressors to target promoters. 
The activity of hER ligands spans a range from full agonist (estrogenic in all tissues) through 
mixed agonist/antagonistic (SERM) to pure antagonist (antiestrogenic in all tissues).  The 
mechanism of mixed agonism/antagonism may differ depending on the chemical structure of 
the SERM.  For some SERMs the mechanism is related to the ratio of coactivator to 
corepressor proteins in different cell types and the exact topology of the ER-ligand complex.  
The topology in turn determines how strongly the ligand-receptor complex recruits 
coactivators (resulting in an agonist response) relative to corepressors (resulting in an 
antagonistic response) [88]. This range of possible ligand action and the potential variation 
depending on the specific target cell in which the ligand is acting results in the wide variety 
of observed effects obtained in in vivo exposure studies. 
One example of this variation in observed effects is the difference in action of two breast 
cancer drugs: RAL and tamoxifen (TAM).  The SERM action of TAM is actually produced 
by its metabolite 4-hydroxytamoxifen (OHT) [89].  The structures of TAM, OHT and RAL 
are shown in Figure 2.7.  TAM (OHT) acts as an antagonist in breast cancer cells and as an 
agonist in uterine cells [90, 91].     
Chapter 2 – Literature Review 
19 
 
 
 
 
 
 
(a) TAM 
 
 
 
 
 
(b) OHT 
 
 
 
(c) RAL 
 
Figure 2.7.  Structures of (a) tamoxifen (TAM), (b) 4-hydroxytamoxifen (OHT) and (c) 
raloxifene (RAL). 
The complexity of effects on gene expression exemplified by TAM and RAL [90, 92, 93] is 
illustrated in Figure 2.8.  The actions of TAM and RAL have been extensively studied in 
vitro using cell lines derived from human breast cancer (MCF-7 cells) and human 
endometrial cancer (Ishikawa cells).  Both TAM and RAL are used in the treatment of 
hormone-responsive breast cancer.  RAL is also used in the treatment of osteoporosis. TAM 
is associated with an increase in uterine cancer but RAL is not.  At the molecular level, both 
RAL and OHT are hERα and hERβ antagonists.  Both compounds bind to the hER and 
induce the antagonist conformation [77, 81].  However, in the uterus, the two compounds 
have different effects due to cell context and promoter context.  Even though OHT binds to 
the hER and induces the antagonist conformation in the receptor, the hER-OHT complex is 
able to recruit the specific coactivator proteins necessary to up-regulate the genes that lead to 
the development of uterine cancer.  The hER-RAL complex does not.  The concentration of 
one coactivator protein, steroid receptor coactivator 1 (SRC-1), is higher in the uterus than in 
the breast.  The specific morphology of the hER-OHT complex is able to recruit this 
coactivator and therefore is more agonistic in the uterus than in the breast. In contrast, the 
hER-RAL complex more strongly recruits corepressor proteins and consequently is still an 
antagonist in the uterus, despite the higher concentration of coactivators relative to 
corepressors.   
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(DNA promoter region 
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(DNA promoter region 
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CATD
IGF-1EBAG9
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OHT and RAL both recruit 
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both cell lines
OHT and RAL do not 
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genes in either cell 
line
OHT is able to up-regulate 
these genes in Ishikawa 
cells by recruiting a specific 
coactivator that is not 
present in MCF-7 cells
RAL does not 
upregulate these 
genes in either cell 
line
E2 upregulates all genes 
in both cell lines
Cell Context 
Tissue-specific responses resulting from 
Relative expression levels of hERα / hERβ
Relative expression levels of Coactivators / Corepressors
Promoter Context 
Direct regulation via hER interaction with classical ERE 
sequence in DNA promoter region 
Indirect regulation via interaction with non-ERE 
promoters facilitated by other transcription factors.
 
 
 
Figure 2.8.  Complexity of hER gene expression exemplified by the actions of 4-
hydroxytamoxifen (OHT) and raloxifene (RAL) in MCF-7 and Ishikawa cell lines [90, 
92, 93].  Different patterns of gene expression are observed in these cell lines.   The 
differences in receptor-ligand complex topology induced by the two different ligands 
result in different abilities of the hER to recruit the cofactors present in the different 
cell lines. 
 
The ligand bound hER complex is also able to function as a transcriptional repressor.  For 
example, the activity of the transcription factor NF-κB involved in immune response can be 
inhibited by hER [94], explaining in part the bone maintenance actions of E2 and the anti-
inflammatory actions of E2 observed in brain and the cardiovascular system [95].  Counter-
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intuitively, both TAM and RAL are able to mimic the effect of E2 in these tissues.  These 
ligand-receptor complexes remain able to recruit the corepressors needed to achieve this 
action because the NF-κB pathway is mediated by the AF-1 domain, not the AF-2 domain.   
The wide variety of physiological responses to the genomic action of estrogens begins with 
the same first step – binding of the ligand to the receptor protein.  Ligand binding induces a 
conformational change in the receptor that can be broadly classified as either agonist or 
antagonist, but it is clear from these examples that small differences in the overall 
conformation of the ligand-bound receptor strongly influence the degree to which a particular 
pathway in a particular cell is initiated [85].  But, as demonstrated by OHT and RAL, ligand-
bound receptor conformation is not the only determinant of agonist or antagonist action in 
target cells. 
It is known that both the magnitude of exposure to EEs and the timing of this exposure are 
critical to the observed outcome [23, 96-101].  For example, exposure of a fetus in utero early 
in gestation when tissues are rapidly differentiating can have very different physiological 
outcomes than exposure as an adult.  The sex of the individual exposed is also an important 
factor since the chemicals interfere with sex hormone signalling.  The physiological outcome 
of exposure to EEs is difficult to predict because not all of the hormone target genes are fully 
known or understood and because the actions of many chemicals have not been fully 
investigated.  Also, exposure is usually to a mixture of EEs, not just a single chemical.  The 
subtleties of the interaction of EEs with the ER can also lead to situations similar to that seen 
with OHT and RAL, where cell context is the deciding factor in the observed effect of the 
molecule.  This concept is the topic for Chapter 4.   
2.3 Human Gestational Development 
In humans, childbirth occurs about 38 weeks after conception and pregnancy begins with 
implantation of the embryo in the uterus.  Implantation occurs approximately 9 days after 
conception.  The term embryo is used to describe the developing offspring during the first 8 
weeks following conception, and the term fetus is used from about 2 months of development 
until birth.  Pregnancy is typically broken into three periods, or trimesters, each of about three 
months.   
Human development, as with vertebrate development in general, is described as epigenetic 
because the genes that regulate development are in turn regulated by the chemical micro-
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environment of the differentiating cells [53].  An individual cell has the capacity to develop 
along different paths.  The path that is chosen is determined to a large extent by the cells it 
neighbours and the chemical (hormonal or immune) signals that are passed from cell to cell.  
This external influence determines which genes are permanently turned on or off, resulting in 
the cell developing the functions required of its location [53].  As mentioned earlier, 
hormonal signalling is vulnerable to interference from external factors such as exposure to 
environmental pollutants which can result in permanently altered gene expression for the 
exposed individual and their offspring.  In humans, these critical tissue differentiation 
processes occur early in development, within the first 16 weeks [96].   
In humans, organogenesis occurs between days 18 and 60 of gestation and it is during this 
time that the conceptus is most vulnerable to interference in the development of these organs 
caused by exposure to chemicals.  The CNS, however, is susceptible throughout pregnancy 
[102]. 
2.3.1 Sexual Differentiation 
From early first trimester through early second trimester (from approximately 4 to 16 weeks 
gestation) primary and secondary sexual differentiation occurs in humans [96].  For the first 
few weeks, the male and female genitalia develop along very similar paths and are described 
as ‘indifferent’.  From these initial structures, the development of female genitalia is 
straightforward, but the changes necessary to produce male genitalia are substantial and 
expression of these genes is controlled by the androgens.  The Y chromosome initiates 
development of the testes.  The testes then take control with production of the two main male 
sex hormones, T and DHT.  T suppresses development of oviducts, uterus and vagina which 
would develop from the Müllerian duct.  T is produced by the male fetal testes and interacts 
with target tissues in the undifferentiated genitals transforming these tissues into the male 
genitalia. At the same time, T affects the developing brain, programming typical male 
behaviours and preferences [96].   
2.3.2 Estrogen Receptors in the Fetus 
The ER has been detected in the human fetal vagina and urogenital sinus as early as the 10
th
 
week of gestation [103] and by mid-gestation ERs are present in many human fetal tissues as 
summarised in Table 2.1 [104].  The relative distribution of hERα and hERβ is indicated by 
the number of + in Table 2.1. 
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Table 2.1.  Distribution of hERs in human fetal tissues [104].  Relative abundance is 
indicated by the number of + . 
Tissue hERα hERβ 
Placenta  + 
Skin + ++ 
Spleen  +++ 
Kidney  ++ 
Thymus + ++ 
Adrenal  ++ 
Uterus +++ + 
Ovary + +++ 
Testis + +++ 
Brain  ++ 
2.3.3 Hormones in the Fetus 
The ovaries of the human female fetus secrete estrogens during sexual differentiation [53].  
All three estrogens are also synthesised in the placenta from androgens produced in both the 
maternal and fetal adrenals [53].  In the human male fetus, the aromatase activity required to 
produce estrogens from androgens is localised in the Leydig and Sertoli cells of the testes, 
where high levels of hERβ are found.  Androgens are also produced in large quantities in the 
human fetal testis from approximately the 6
th
 week of gestation.        
2.4 Maternal Exposure to Environmental Estrogens 
Assessing human fetal exposure to EEs requires an understanding of maternal exposure, 
maternal metabolism, the functions and metabolic pathways of the placenta and the metabolic 
capacity of the fetus.  Differences in drug metabolism between male and female adult humans 
are well known, as are differences between pregnant and non-pregnant females [105, 106].  
These differences may be reasonably well characterised for pharmaceuticals, but they are not 
well characterised for EEs [107].  In the absence of pregnant female specific data, 
information on adult humans must be used as a surrogate.  While the placenta plays a critical 
role in the control of endogenous hormones in both the mother and the fetus [108], and it has 
active transport mechanisms that are specifically dedicated to removal of xenobiotics and 
toxic endogenous compounds [109], it is now commonly accepted that almost all drugs cross 
the placenta to some extent [110].  It is therefore not unreasonable to expect EEs to behave in 
the same way.   
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2.4.1 Exposure routes  
The EEs of interest are components of cosmetics, personal care products and pharmaceuticals 
and are contaminants in food and water so maternal exposure occurs by several routes 
including ingestion [111-115], absorption through the skin [114, 116-119] and inhalation 
[120].  Once EEs reach the bloodstream, they are subject to a variety of metabolic reactions 
designed to facilitate elimination from the body.  Depending on the specific EE and the 
metabolic reactions it is subjected to, it is possible for the compound to be deactivated by 
metabolic transformations or conjugation reactions.  It is also possible for metabolites to be 
estrogenic [121]. 
2.4.2 Metabolic Fate 
To be eliminated from the body in either urine or feces, a compound needs to be water 
soluble.  This is accomplished by covalently attaching a highly water-soluble functional 
group to an otherwise insoluble molecule.  In humans, the primary conjugation pathways are 
glucuronidation and sulphation [122], as illustrated in Figure 2.9.   
Glucuronidation via the uridine 5’ diphospho-glucuronosyltransferase (UGT) family of 
enzymes is the major drug detoxification and elimination pathway in humans [123] and this 
reaction occurs primarily in the liver.  The UGT enzyme transfers a glucuronic acid molecule 
from UDP-glucuronic acid to the target molecule to increase the water solubility of the target 
molecule, facilitating its elimination.  There are 18 known isoforms of the UGT enzyme in 
humans [124].  Each of the isoforms has a preferred set of substrates on which it acts.  For 
example, morphine (Figure 2.10(a)) is glucuronidated exclusively by the UGT2B7 isoform at 
both the 3- and 6- positions.  Paracetamol (Figure 2.10(b)) is glucuronidated primarily by 
UGT1A6 and to a lesser extent by UGT1A9 [124].  This type of substrate specificity is likely 
to hold for the suite of EEs of interest in this study.  Substrate specificity of the UGTs has not 
been extensively studied, and where information is available, the substrates of interest are 
mainly pharmaceuticals and endogenous hormones. 
Sulphation is accomplished by the cytosolic sulfotransferase (SULT) superfamily of enzymes 
[125].  In humans, 11 isoforms of the SULT enzymes have been identified and represent 3 of 
the 6 SULT families.  The expression of SULT enzymes in humans is carefully regulated, 
with expression levels differing by tissue type, stage of development.  Hormonal influences 
also affect SULT expression levels [125].  In the adult, SULT1A3 (catecholamine 
sulfotransferase) is highly expressed in the gastrointestinal tract for the production of 
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dopamine sulphate.  SULT1E1 (estrogen sulfotransferase) is highly expressed in the 
endometrium and is crucial for controlling levels of estrogen in the endometrium during the 
menstrual cycle, particularly at the time of potential implantation of an embryo [125].  The 
endogenous hormones exist in the human circulatory system primarily as sulphate conjugates.  
Hydroxylated PCBs are well known and potent inhibitors of SULT1E1 giving rise to their 
endocrine disrupting effects. The 4A family of SULTs are found only in the brain and no 
natural or xenobiotic substrates have been identified [125]. The human SULTs, with the 
exception of 1A1, are substrate specific.  SULT1A1 is highly efficient in the sulphation of a 
wide array of xenobiotics [125]. 
The glucuronidation and sulphation reaction pathways require a nucleophilic site (-OH, -NH2, 
-SH, -COOH) on the target molecule to which the glucuronide or sulphate is attached.  If the 
target molecule does not have a suitable site for conjugation, the cytochrome P450 (CYP) 
superfamily of enzymes or other enzyme metabolic pathways capable of hydrolysis, 
reduction or oxidation will provide such a site [122].   
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(a) Glucuronidation 
 
(b) Sulphation  
 
Figure 2.9.  Glucuronidation and sulphation conjugation reactions using BPA as an 
example. 
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(a) morphine 
 
 
 
 
(b) paracetamol 
 
Figure 2.10.  Chemical structures of morphine and paracetamol. 
The CYP enzymes are a superfamily of heme-containing monooxygenases that use O2 and 
electrons to oxidise substrates [102].  There are 14 known families of CYP enzymes in 
humans.  CYP enzymes play a role in fatty acid hydroxylations, steroid biosynthesis and 
xenobiotic metabolism.  Most of the xenobiotic metabolising enzymes are expressed in the 
liver. 
Most of the EEs of interest in this study already have a suitable nucleophilic site, so further 
transformations are not usually required before the conjugation reaction.  This does not mean 
these reactions do not occur.  For some of the EEs of interest, main transformation products 
have been reported in the literature and are included in the suite of target analytes if the 
compound is commercially available.  For others, their metabolism has not been reported, so 
the parent compound is the only target analyte.  Identifying metabolites is beyond the scope 
of this project. 
The route of exposure determines how quickly a compound can be eliminated.  Chemicals 
that are ingested and pass through the digestive system reach the sites of metabolic reactions 
very quickly and a large fraction of the ingested amount can be eliminated before it reaches 
the circulatory system.  Exposure through the skin or by inhalation bypasses this ‘first-pass’ 
elimination and the chemical can enter the circulatory system directly [122]. 
Table 2.2 summarises the pertinent information on metabolic clearance, metabolic pathways 
and identified metabolites for the EEs of interest. 
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Table 2.2.  Metabolites of environmental estrogens 
Environmental  
Estrogen 
Parent 
Compound 
Other Metabolites Glucuronide 
Conjugate 
Sulphate Conjugate 
BPA Serum levels 
of 
unconjugated 
BPA remain in 
the low ng/mL 
range 24 h 
after ingestion 
[126]. 
 Orally ingested 
BPA is rapidly but 
not completely 
converted to the 
monoglucuronide 
[126, 127]. 
BPA is also sulphated 
at one or both 
hydroxyls [128]. 
Phthalates  Phthalates are rapidly 
hydrolysed to the 
monoesters (Figure 2.27) 
[129, 130].   
Higher molecular weight 
phthalates can undergo 
additional oxidation of the 
monoester at the terminal 
end of the alkyl substituent, 
forming a secondary 
alcohol or ketone (ω-1 
oxidation) or carboxylic 
acid (ω-oxidation).   
The monoesters are also 
detected in serum, but at 
much lower levels than in 
the urine [129, 130]. 
The monoester is 
excreted in the 
urine as both the 
free molecule and 
the glucuronide 
conjugate [129, 
130] 
 
Alkylphenols 
 
 Metabolism is complex and 
occurs by several 
mechanisms, resulting in 
many possible metabolites.   
 
N-alkylphenols (e.g. NP, 
Figure 2.24) undergo 
extensive β-oxidation of the 
alkyl side chain.  The main 
metabolite found in the 
urine was 4-
hydroxybenzoic acid ( free, 
glucuronidated and 
sulphated) [121, 131]. 
 
Branched alkylphenols (e.g. 
4t-OP, Figure 2.25) are 
more resistant to 
metabolism.  They undergo 
β-oxidation, but only until 
the primary carbon atoms 
in the chain are exhausted 
[132].   
Parent compound 
and other 
metabolites are 
glucuronidated at 
the phenolic 
hydroxyl and are 
excreted in the 
urine[121, 131, 
132] 
Parent compound and 
other metabolites are 
sulphated at the 
phenolic hydroxyl 
and are excreted in 
the urine [121, 131, 
132] 
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Environmental  
Estrogen 
Parent 
Compound 
Other Metabolites Glucuronide 
Conjugate 
Sulphate Conjugate 
Benzophenones Unconjugated 
benzophenones 
are eliminated 
in the feces 
[133]. 
 
BP-3 is demethylated to 
form BP-1 [134].   
 
2,3,4-
trihydroxybenzophenone 
has also been reported as a 
metabolite of BP-3 [119]. 
Benzophenones are 
glucuronidated and 
eliminated in the 
urine [119, 133, 
134].   
Benzophenones are 
sulphated and 
eliminated in the 
urine [119, 133, 134].   
Parabens  The major metabolites of 
the parabens are 4HBA, p-
hydroxyhippuric acid but 
neither compound is a 
specific biomarker of 
paraben exposure. 
Glucuronides 
comprise 28-43% 
of total 
concentration in 
adult urine [135] 
Sulphates comprise 
55-67% of total 
concentration in adult 
urine [135] 
Triclosan   Triclosan is 
assumed to be 
glucuronidated 
[136]. 
 
Phytoestrogens 
 
  GEN is 
glucuronidated 
[137].    
GEN is sulphated 
[137].    
 
Endogenous 
Estrogens 
   Sulphate conjugates 
of estrogens are the 
main form of 
circulating estrogens 
in both the mother 
and fetus [132, 138]. 
 
2.4.3 Concentrations of EEs in Adult Urine 
Adult exposure to environmental pollutants is most often characterised by determining the 
concentration of the compound of interest or its metabolites in urine.  The total concentration 
(free + conjugated) is most often reported.  Figure 2.11 illustrates the range of adult urine 
levels reported in the literature for the compounds of interest in this study.  The range of 
concentrations shown in Figure 2.11 is large because each of the literature studies considered 
cohorts of different sizes and nationalities and therefore the aggregate data represent diverse 
lifestyles and levels of maternal exposure as summarised in Table 2.3.  To obtain the broadest 
representation of the literature data, the minimum, median and maximum values reported in 
each study were used.  In the studies where the median value was not reported, the mean 
value was used.  The lowest minimum, highest maximum and the lowest and highest median 
concentrations for each target analyte in the aggregate data set were determined.  The data 
from individual studies and the corresponding references are given in Table A. 1.   
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Figure 2.11.  Range of reported total EE concentrations in adult human urine.  Lines 
indicate range of reported values, bars indicate lowest and highest median reported 
values. 
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Table 2.3.  Description of human urine studies included in literature aggregate data set. 
Study Name  
and 
Reference 
Country / 
Cohort 
Target Analytes Analytical  
Method 
Deconjugation 
Huang [139] Taiwan 
Maternal, 
female fetus 
mMP, mEP, mBP, mEHP, 
mBzP 
LC-
MS/MS 
β-glucuronidase  
only 
Huang [139] Taiwan 
Maternal, male 
fetus 
mMP, mEP, mBP, mEHP, 
mBzP 
LC-
MS/MS 
β-glucuronidase  
only 
Ye [135] USA 
Adults 
mParaben, eParaben, 
pParaben, bParaben 
LC-
MS/MS 
β-glucuronidase  
and 
arylsulphatase 
Ye [140] USA 
Adults 
BPA, TRIC, BP-3, 
mParaben, eParaben, 
pParaben, bParaben 
LC-
MS/MS 
β-glucuronidase  
and 
arylsulphatase 
Calafat [141] USA 
Adults 
BPA, NP GC-MS β-glucuronidase  
only 
Swan [142] USA 
Maternal 
mMP, mEP, mBP, mEHP, 
mBzP 
LC-
MS/MS 
β-glucuronidase  
only 
Liu [143] USA 
Adults 
GEN, DAID, ENT, BPA HPLC β-glucuronidase  
only 
Valentin-
Blasini [144] 
USA 
Adults 
GEN, DAID, EQ, ENT LC-
MS/MS 
β-glucuronidase  
and 
arylsulphatase 
Janjua [116] Adult males unknown unknown unknown 
Janjua [116] Post-
menopausal 
females 
unknown unknown unknown 
Kato [145] USA 
Adults 
mMP, mEP, mBP, mEHP, 
mBzP, mOP 
LC-
MS/MS 
β-glucuronidase  
only 
Blount [146] USA 
Adults 
mMP, mEP, mBP, mEHP, 
mBzP, mOP 
LC-
MS/MS 
β-glucuronidase  
only 
Wolff [147] USA 
Maternal 
BPA, TRIC, BP-3, mMP, 
mEP, mBP, mEHP, mBzP 
LC-
MS/MS 
β-glucuronidase  
only 
Choi [148] Korea 
Adults 
GEN, DAID, EQ, ENT, 
E2 
GC-MS β-glucuronidase  
and 
arylsulphatase 
Moors [149] German 
Adults 
GEN, DAID, EQ, BPA GC-MS β-glucuronidase  
only 
Grace [150] UK 
Women 
GEN, DAID, ENT, EQ GC-MS β-glucuronidase  
and 
arylsulphatase 
Wittassek 
[151] 
German 
Maternal 
mBP, mBzP, mEHP LC-
MS/MS 
β-glucuronidase 
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2.5 Maternal-Fetal-Placental Unit 
Fetal exposure is usually assessed in the context of the maternal-fetal-placental unit.  
Exposure of the mother results in a circulating concentration of the compound that is 
determined by her metabolic clearance of that compound.  The compound reaches the 
placenta via maternal circulation where it must cross a membrane barrier to reach the fetal 
circulation.   
A diagrammatic representation of a 15-week pregnancy is shown in Figure 2.12.  As the 
pregnancy progresses, the chorion and amnion membranes fuse, leaving a small chorion 
cavity located in close proximity to the placenta. The placenta is a complex structure of blood 
vessels with membranes separating the maternal and fetal circulations and is the interface 
between mother and fetus.  On the fetal side, the umbilical cord with vein and artery carries 
blood to and from the fetus.  The placenta facilitates nutrient and oxygen exchange and 
removal of waste products from the fetus [108, 152].   
 
Myometrium 
(middle layer of uterine wall)
Uterine cavity
Chorion
Placenta
Amnion
Fetus
Umbilical Cord
Amniotic Cavity
Chorion Cavity
 
Figure 2.12.  Diagrammatic representation of a 16-week pregnancy (adapted from 
http://media.web.britannica.com/eb-media/31/117431-004-FD591591.jpg). 
 
2.5.1 Placental Metabolism 
The placenta also plays a critical role in regulating the levels of endogenous hormones that 
the fetus is exposed to via blood circulation [108, 153, 154].  Enzymes that conjugate and 
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deconjugate estrogens (estrogen sulfotransferase and estrone sulphatase respectively) are 
present in the placenta [132, 138].  The balance in activity between these two enzymes is 
critical to the control of hormone levels [128].  Several EEs and their conjugates are 
inhibitors of and/or substrates for the sulphotransferases and sulphatases as summarised in 
Table 2.4. It is therefore likely that EEs can be both conjugated and deconjugated in the 
placenta for recirculation to the fetus. 
Table 2.4.  EEs are inhibitors of and substrates for estrogen metabolism enzymes. 
EE Estrogen Sulfotransferase 
(SULT1E1) 
Estrone Sulphatase (ES) 
Triclosan competitive inhibitor in sheep 
placenta [155] 
 
BPA  substrate [128] BPA sulphate conjugates are 
substrates [128] 
Parabens inhibitors in the skin [156]  
Alkylphenols substrates and inhibitors [157]  
Phytoestrogens  GEN, DAID and EQ are inhibitors 
[158] 
DAID sulphate conjugate is an 
inhibitor [159] 
 
Historically, it was believed that the placenta protected the fetus from ‘harmful agents’ [153], 
but it is now known that many of the EEs are able to cross the placenta [152].  Simple passive 
diffusion, facilitated diffusion and active transport are the primary mechanisms by which 
chemicals cross the placenta [153].  The placenta has transport protein mechanisms that are 
active in protecting the fetus by preventing entry of certain classes of toxic substances.  The 
placenta also expresses many of the xenobiotic-metabolising enzymes that are present in the 
adult liver, though they are not as functionally active as in the liver.  These enzymes are also 
more active in the first trimester than at term [153].  The activity of these enzymes is thought 
to help limit the transfer of chemicals across the placenta to the fetus [160].  Placental 
enzyme activity has been shown to increase with maternal lifestyle choices such as smoking 
and alcohol consumption and with certain medications [153]. Overall, placental metabolism 
is not a significant factor in limiting the passage of most drugs to the fetus [161]. 
2.5.2 Placental Transport 
Once a compound is within the mother’s circulation, the primary pathway for fetal exposure 
is via the placenta.  The maternal and fetal circulations are separated by membranes in the 
placenta.  Hydrophobic, non-ionised molecules less than 600 Da cross the placental 
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membranes by simple diffusion, provided the concentration in the mother’s circulation 
remains higher than in the fetal circulation.   
The placenta also has facilitative transport mechanisms for transport of plasma protein bound 
molecules and active transport mechanisms for hydrophilic and ionic molecules.  Facilitative 
transport is also driven by a concentration gradient but makes use of a carrier molecule such 
as a plasma protein to which the small molecule can bind.  The transporter protein recognises 
the carrier molecule for transport across the membrane. Active transport requires energy in 
the form of ATP and is the dominant pathway for highly hydrophilic and ionic species to 
cross the placenta.   
Simple diffusion is by far the most important transport pathway for chemicals to enter fetal 
circulation from maternal circulation [102, 161].  The main driving force for diffusion is the 
concentration gradient across the membrane.  So, with continuous maternal exposure, once a 
chemical has passed through the maternal/placental barrier it may become trapped in the fetal 
compartment.  
The anatomy of the placental villus, the region where the maternal and fetal circulations are 
in closest proximity is illustrated in Figure 2.13.  As gestation advances, the space occupied 
by fetal connective tissue contracts and at term the fetal capillary epithelium and the 
basolateral membrane are separated by as little as 2-4 μm [162].  The blood vessels begin to 
develop in the placenta about 21 days post conception but maternal blood does not begin to 
flow into the villus space until about 10-12 weeks.   Prior to the onset of maternal blood flow 
in the placenta, the intervillous space is filled with endometrial glandular secretions [162]. 
The placenta is highly permeable to respiratory gases, but glucose transport across the 
placenta requires specific facilitative transporters.  Transport of lipids and amino acids across 
the placenta requires specific active transporters but free fatty acids and glycerols can also 
diffuse. 
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Figure 2.13.  Anatomical arrangement of syncytiotrophoblast, cross section of a human 
placental villus (adapted from [109, 162]) 
 
The role of placental transporters in fetal drug exposure is virtually unstudied in humans 
[163] and what is known comes primarily from animal models or from ex-vivo placental 
perfusion studies of human term placentae.  Several recent reviews of placental transporters 
have been published [109, 161, 163-166] and are briefly summarised as follows.   
The current understanding suggests that facilitative and active transport proteins are located 
at specific sites within the placental membrane, as illustrated in Figure 2.14.  Some 
transporters are located only on the maternal side of the membrane while others are only 
found on the fetal side of the membrane.  Some transporters are unidirectional.  They can 
either transport molecules that have entered the placenta out to the maternal circulation or the 
fetal circulation, depending on their location in the membrane or they can transport molecules 
from the maternal or fetal circulation into the placenta.  Other transporters are bidirectional 
transporters which transport molecules either into or out of the placenta into the maternal or 
fetal circulation, depending on where they are located.  There is evidence that specific groups 
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of the transporters are located in close proximity to one another and may work co-
operatively.  The transporters of interest are the P-glycoproteins (P-gp), the Multi-drug 
Resistance-associated Proteins (MRPs), the Breast Cancer Resistance Protein (BCRP) and the 
Organic Anion Transporters (OATs). 
 
 
Figure 2.14.  Location and directionality of active transport proteins in the placenta 
(adapted from [163]). 
 
Of the P-gps present in the placenta, only one (MDR1) is involved in xenobiotic transport.  
MDR1 prevents the entry of hydrophobic molecules into the fetal circulation.  It is located on 
the maternal side of the placental membrane and is a unidirectional transporter actively 
removing molecules from the placenta to the maternal circulation.  MDR1 is able to transport 
a wide range of lipophilic neutral and cationic drugs.  The endogenous steroids are substrates 
of MDR1.  The transport mechanism of P-gps located elsewhere in the body are inhibited by 
progesterone [167].  Progesterone has been shown to inhibit P-gp transport when present in 
high concentrations and stimulate transport when present in low concentrations [109] and is 
being investigated for co-administration with antitumor agents to reverse multi-drug 
resistance in cancer therapies [109]. 
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The MRPs are able to transport unconjugated amphiphilic anions, the polar conjugates of 
xenobiotics and endogenous compounds as well as some of the parent compounds.  The 
MRPs are located on both the maternal and fetal sides of the placental membrane and 
possibly in the fetal capillary endothelium.  Growing evidence suggests they work to reduce 
the accumulation of these compounds in the fetal compartment [109, 161].   
The BCRP is located on the maternal side of the placental membrane.  It is able to transport 
many of the same substrates as MDR1 and is thought to act in concert with the OATs in 
transport of steroid sulphate conjugates. 
The OATs of interest (OATP-B and OAT-4) are anion exchangers with a coupled uptake and 
expulsion mechanism.  They simultaneously take up a molecule on one side of the cell and 
expel a different molecule on the other side of the cell.  The substrate for OAT-4 is DHEA-
sulphate produced in the fetus and transported to the placenta for synthesis of E2.  OATP-B is 
less specific and is able to transport other steroid sulphates. 
BPA [168], NP [169] and GEN [170] all cross the human placenta to different extents intact, 
as shown by placental perfusion studies.  GEN is also conjugated by the placenta, BPA and 
NP are not [168-170].  The amount of NP on the fetal side of the placenta is much lower than 
supplied on the maternal side, and the absence of conjugates suggests that NP may be 
metabolised by the placenta. 
Nishikawa et al. [171] demonstrated that glucuronidated BPA is able to cross the rat placenta 
and that it is subsequently deconjugated in the fetus and amniotic fluid.  The rat placenta is 
used as a model of human placenta because of its structural similarities, but there are some 
important differences. In rodents, maternal blood and fetal blood vessels are primarily 
separated by two syncytiotrophoblast layers, but in humans, only a syncytiotrophoblast 
monolayer separates fetal blood vessels from maternal blood.  The authors concluded that it 
is possible that the human fetus is more sensitive and at greater risk than is the rodent fetus 
[171].  
2.5.3 Composition of Amniotic Fluid 
The fetus is suspended in and surrounded by amniotic fluid and it protects the fetus from 
physical trauma and allows the fetus to move.  Amniotic fluid begins to accumulate in the 
very early stages of embryogenesis [172, 173].  The water in amniotic fluid originally comes 
from maternal plasma.  As development continues, amniotic fluid volume increases and is 
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thought to be produced, in part, by ultrafiltration of fetal serum through the fetal skin and 
umbilical cord and by active secretion by the amnion, while the fluid in the chorionic cavity 
is thought be primarily a transudate of maternal serum produced and secreted by the 
trophoblast and chorion[174]. 
Amniotic fluid is composed of water (98-99%) and 1-2% dissolved solids.  One half of the 
dissolved solids are inorganic (electrolytes).  One half of the organic solids are proteins and 
the other half is composed of carbohydrates, amino acids, organic acids, urea, creatinine, 
lipids and hormones.[173-175].  The urea and creatinine levels in amniotic fluid are higher 
than in maternal serum and increase as the pregnancy progresses [175].  A number of 
enzymes are found in amniotic fluid including β-glucuronidase [175].  Estrogens in amniotic 
fluid are either conjugated or free, not protein bound [52].   
Hydrophobic molecules that enter the amniotic fluid are available to the developing 
embryo/fetus by simple passive diffusion.  For example, intra-amniotic injection of cortisol 
demonstrated that this is an efficient means of supplying glucocorticoids to the human fetus 
at 11 to 21 weeks gestational age [176].  Around the 11
th
 week of gestation, the fetus begins 
to produce urine that enters the amniotic fluid.  Fluid is also produced within the fetal lungs 
that is expelled and enters the amniotic fluid.  Amniotic fluid is actively swallowed by the 
fetus, absorbed by the gastrointestinal and recirculated.  Free diffusion occurs bidirectionally 
between the amniotic fluid and the fetus across the fetal skin up to 20 weeks gestation when 
skin keratinisation begins [173, 177].  Because of this intimate contact, the composition of 
amniotic fluid is similar to fetal plasma [173] and to fetal extracellular fluid [178] and 
provides a biologically relevant reflection of fetal exposure up to 20 weeks.  Specifically, 
amniotic fluid obtained between 16 and 20 weeks gestation is accepted as a valid means to 
assess fetal exposure during the period of development that spans organogenesis [172, 179].  
2.5.4 Metabolism in the Fetus 
The activity of the UGT family of enzymes is significantly lower in the human fetus as 
compared to the adult [123, 180-182].  This reduced activity prevents ‘trapping’ of the water 
soluble metabolites in the fetal compartment and thus their accumulation in the amniotic fluid 
[123].  Only 2 of the 18 UGT isoforms show appreciable activity in the fetus and both are 
involved in steroid metabolism. UGT1A3 is the most active at 30% of adult levels and its 
substrate is E1.  UGT2B7 is active at 10-20% of adult levels and androsterone and 
epitestosterone are the substrates.  UGT2B7 is also known to act on a large number of 
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pharmaceuticals (e.g. morphine) [124].  With the substrate specific activity of UGTs and the 
low level of activity in the fetus, glucuronidation of EEs reaching the fetus is likely to be low. 
In contrast, the activity of SULTs in the fetus is very high, making SULTs the major 
detoxification pathway in the developing human [125, 182].  Many of the pharmaceuticals 
that are predominantly glucuronidated in the adult are instead sulphated in the fetus, for 
example paracetamol [124].  The high activity of SULTs, particularly 1A1, in the fetus 
compensates to some extent the low UGT activity.  The SULT 1C enzymes are exclusively 
expressed in the fetus and are entirely absent in the adult.  SULT1A1 but not SULT1C1 is 
able to sulphate EEs such as BPA, 4t-OP, NP [183]. 
CYP activity in the human fetus and even embryo is well developed but is very different from 
that of the adult human [102].  Enzyme activity is generally lower in the fetus than in the 
adult.  Some enzymes that are present in the fetus are absent in the adult and vice versa.  
CYP3A7 is the most abundant CYP enzyme in the fetus and is present from 50 days of fetal 
life [184].  Substrates for CYP3A7 hydroxylation include testosterone, cortisol and a number 
of pharmaceuticals and xenobiotics.  The primary function of CYP3A7 is the protection of 
the fetus from maternal steroid hormones [184].  CYP3A7 function declines rapidly after 
birth when CYP3A4, the dominant isoform in the adult liver becomes active [184]. 
The deconjugation enzyme β-glucuronidase is present in cord blood and neonate liver, kidney 
and intestinal tissue [159].  β-glucuronidase is present in many fetal tissues at 7-17 weeks 
[185].  The activity level is highest in fetal liver and activity in the small intestine and 
adrenals is approximately 50% of the liver.  Activity is also found in the kidney, heart and 
lungs.  The β-glucuronidase activity in the placenta is about 30% of the liver activity.  
Sulphatase activity is also present in the fetal liver and small intestine and the placenta at 8-
16 weeks [186].  Placental sulphatase activity increases sharply from 10-12 weeks and then 
declines through gestation.   
BPA is the one EE that has been most extensively studied for its effects on the fetus.   
Schonfelder et al. [127] have demonstrated that as a result of reduced UGT enzyme activity, 
the rate of clearance of BPA is slower in the fetus than in maternal blood.  BPA metabolism 
to BPA-glucuronide may also be suppressed by testosterone as the expression of UGT 
enzymes is down-regulated by androgens [187].  BPA may stimulate testosterone production 
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by suppressing P450 enzymes associated with steroid synthesis and metabolism [188, 189]. 
These finding may also be true for other EEs.   
2.5.5 Measurements of Human Fetal Exposure 
Human fetal exposure has been measured for a few of the EEs of interest in this study.  
Measurements have been made in umbilical vein blood (oxygenated blood enroute to the 
fetus), placental tissue, meconium and amniotic fluid.  For this study, the measurements of 
interest are those in amniotic fluid collected around 16-20 weeks gestation.  Each of the 
literature studies considered cohorts of different sizes and nationalities and therefore the 
aggregate data represent diverse lifestyles and levels of maternal exposure as summarised in 
Table 2.5.  To obtain the broadest representation of the literature data, the minimum, median 
and maximum values reported in each study were used.  In the studies where the median 
value was not reported, the mean value was used.  The lowest minimum, highest maximum 
and the lowest and highest median concentrations for each target analyte in the aggregate data 
set were determined.  If a particular EE was not detected in a study, the reported detection 
limit for that EE was used.  The range of observed concentrations in adult human amniotic 
fluid is shown in Figure 2.15.  The data from individual studies and the corresponding 
references are given in Table A. 2. 
Table 2.5.  Description of human amniotic fluid studies included in literature aggregate 
data set. 
Study Name  
and Reference 
Country / 
Cohort 
Target Analytes Analytical  
Method 
Enzyme  
Deconjugation 
Huang [139] Taiwan / 
early 2
nd
 
trimester 
mMP, mEP, mBP, 
mEHP, mBzP 
LC-MS/MS β-glucuronidase  
only 
Engel [190] USA / 
early 2
nd
 
trimester 
GEN, DAID, ENT, 
BPA 
HPLC-
ELCD 
β-glucuronidase  
only 
Silva [130] USA / 
early 2
nd
 
trimester 
mEP, mBP, mEHP LC-MS/MS β-glucuronidase  
only 
Ikezuki [191] Japan / 
early 2
nd
 
trimester 
BPA ELISA Not required 
Yamada [180] Japan / 
early 2
nd
 
trimester 
BPA ELISA Not required 
Foster [99, 
179] 
USA / 
early 2
nd
 
trimester 
GEN, DAID GC-MS β-glucuronidase  
and 
arylsulphatase 
Chapter 2 – Literature Review 
41 
 
van de Beek 
[52] 
The 
Netherlands / 
early 2
nd
 
trimester 
E2  None.   
Free 
concentration 
Chen [192] USA / 
early 2
nd
 
trimester 
BPA LC/MS β-glucuronidase  
and 
arylsulphatase 
Aldercreutz 
[193] 
Japan / 
at birth 
GEN, DAID, EQ,ENT GC-MS β-glucuronidase  
and 
arylsulphatase 
Wittassek 
[151] 
Germany / 
at birth 
mBP, mBzP, mEHP LC-MS/MS β-glucuronidase 
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Figure 2.15.  Summary of EE concentrations measured in human amniotic fluid 
reported in the literature.  Lines indicate range of reported values, bars indicate lowest 
and highest median reported values.  
 
2.6 Assessing the Activity of Environmental Estrogens 
Environmental estrogens are not as efficient as endogenous estrogens at mediating gene 
expression; a much higher concentration is required to achieve the same magnitude of 
response.  In some cases, the same magnitude of response is not achieved and the compound 
is described as a partial agonist. 
2.6.1 In vitro Assays 
In vitro assays are the first stage in assessing the biological activity of EEs.  These assays can 
be broadly categorised as binding assays, cell proliferation assays and reporter gene assays.  
The simplest of the assays is the binding assay in which the ability of the test chemical to 
bind to the receptor protein is quantified.  These assays are not able to give any indication of 
the biological activity of the chemical, but are useful in screening out non-binders from 
binders.  Cell proliferation assays are the next most sophisticated type of assay in which the 
ability of a chemical to induce cell growth is quantified. The most sophisticated assays are the 
yeast or mammalian cell based reporter gene assays.  The ability of the test chemical to affect 
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gene transcription is assessed by quantifying a protein produced as a result of gene 
transcription.   
Most cell lines used in in vitro bioassays possess some metabolic activity and may lead to 
false negatives or false positives if metabolism leads to deactivation or activation of the 
chemical under study.  Assays based on mammalian cells are often more sensitive than those 
based on yeast cells and are considered more relevant to human health [194].  But, the 
mammalian cell environment is more complex and the levels of receptor expression and 
composition of coregulators vary among cell lines.  Therefore, the response to a particular 
EDC is different for different cell lines, making interpretation of results difficult [195]. 
Yeast-based assays are relatively simple and inexpensive to conduct compared to mammalian 
cell assays.  The β-galactosidase reporter gene assays (YES assay) involves cell lysis and 
takes several days to complete [196] while the yeast based firefly luciferase reporter gene 
assays can be completed in a day [196]. The permeability of compounds through yeast cell 
walls may be different than through mammalian cell membranes possibly accounting for 
some differences in response [197].  Yeast cells BMA64-1A often used in the luciferase 
reporter gene assay is not able to metabolise TAM to OHT [196] which is the cause of the 
negative response.   
The ER-CALUX assay is a reporter gene assay hosted in the human osteosarcoma cell line 
(U2-OS).  This assay may be able to metabolise some chemicals to give positive results [198] 
where other assays give negative results.   
Mammalian cell lines express endogenous receptor proteins.  The MCF-7 and T47-D cell 
lines are human breast cancer cells and the dominant ER is hERα [199, 200] but they also 
express androgen, progesterone, glucocorticoid and retinoid receptors [200].  The Ishikawa 
cell line is a human endometrial carcinoma cell line.  This cell line is dominant in hERβ but 
also has hERα and progesterone receptors [92].  Because of the difference in receptor protein 
expression, these two cell lines respond differently to some chemicals, as illustrated in 
Section 2.2.3 with TAM and RAL.  These differences in response have been confirmed and 
validated by comparative profiling of gene expression [201].  Thus, multiple in vitro assays 
are required to fully characterise the activity of EEs. 
An excellent review by Zacharewski [195] presents the advantages and limitations of in vitro 
assays in assessing EEs.  The main observations and assessments summarised in Table 2.6. 
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Table 2.6.  Summary of in vitro assays for assessing activity of EEs [195]. 
Assay Type Advantages Disadvantages 
Competitive binding   EEs by definition must 
bind ER 
 cannot distinguish between 
agonists and antagonists 
 high concentration of 
ligand may cause non-
competitive displacement 
 binding is necessary but 
not sufficient for 
estrogenicity.  The  ligand 
has to be bound long 
enough to initiate 
transcription 
Cell proliferation assays 
 
E-SCREEN (based on 
either MCF-7 or T47-D 
human breast cancer cells) 
 one of the most sensitive 
assays (30 pM E2) 
 agonist behaviour of test 
chemical is confirmed if 
proliferation is blocked 
by the standard reference 
anti-estrogen drug ICI-
182780 
 antagonist behaviour is 
confirmed if E2 
proliferation is blocked 
by the test chemical. 
 long incubation time (6 
days) 
 not unequivocal (result can 
depend on experimental 
conditions, e.g. cell line 
clone, culture conditions) 
Protein expression assays  
 
Vitellogenin (fish 
hepatocytes) 
 
Prolactin (immature rat 
pituitary cells) 
 sensitive (1 nM E2)  results restricted to specific 
cell lines,  not easy to 
generalise 
 labour intensive methods 
 susceptible to false 
positives 
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Endogenous promoter-
regulated reporter gene 
assays 
 
reporter genes such as 
firefly luciferase, β-
galactosidase used to 
provide easily measured 
and quantified response.  
 
ER-CALUX - luciferase 
reporter gene expression 
assay based on T47D 
human breast 
adenocarcinoma cell line. 
 excellent responsiveness 
and sensitivity 
 can assess relative 
potency of EEs 
 easily measured signal  
 can obtain a species 
specific or tissue specific 
response 
 ER has two activation 
functions, one is 
constitutively active (AF-
1) and the other is ligand 
induced (AF-2).  Need to 
control for AF-1 activity. 
 Can be susceptible to non-
ER ligand induction effects 
Response element 
regulated  reporter gene 
assays (mammalian cell 
based systems) 
 ensures response is 
controlled through ERE, 
not other effects. 
 sensitive to serum-borne 
estrogens (high 
background activity), so 
have poor response to test 
chemical 
Yeast-based systems  
YES =yeast based β-
galactosidase reporter gene 
assay. 
 cells do not have 
endogenous receptor 
proteins 
 media is devoid of 
hormones 
 highly responsive, very 
good sensitivity 
 function and potency 
response in yeast not 
always the same as in 
mammalian cell lines so 
results must be confirmed 
in another assay type 
 
2.6.2 In vivo Assays 
In vivo assays involve exposing a test organism (e.g. fish, mouse, rat) to the chemical under 
study, then measuring a change in biological function or phenotype.  The studies can look for 
changes in the exposed individual or the effects of exposure on the offspring.  A wide variety 
of biological end points have been used to monitor effects of exposure to EEs such as 
changes in expression levels of vitellogenin (egg yolk protein) in male fish or the increase in 
size and weight of the uteri of immature rodents.  These assays are usually applied as a last 
screening step, once significant positive results have been found in a variety of in vitro 
assays. 
One of the disadvantages of in vitro assays is that they do not account for metabolic 
activation of EEs and therefore result in ‘false negative’ responses (positive in vivo, but 
negative in vitro). These assays can also yield false positive responses when chemicals are 
tested at concentrations orders of magnitude above those seen in vivo. With in vivo assays, 
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the effects on the endocrine system are studied in context of other systemic functions such as 
metabolism and all potential modes of action of a compound are included [202, Van den Belt, 
2004 #525]. 
2.7 Sources, Activity and Potency of Environmental Estrogens 
The assessment of human fetal exposure to EEs presented in Chapter 7 is based on 
measurements of a suite of 35 chemicals in amniotic fluid.  This section introduces the 
chemicals of interest, their use in products relevant to human gestational exposure and 
summarises the available literature on their estrogenic activity and potency.  The compounds 
and classes of compounds are grouped according to their use.   
Relative estrogenic potency (REP) is defined for ER agonists as ratio of concentrations of E2 
to test compound required to produce the same level of activity.  Usually the relative 
estrogenic potency is obtained from the ratio of EC50 concentrations for E2 and the test 
compound:   
     
         
                    
 
The EC50 concentration is the concentration at which 50% of the compound’s maximal 
activity is achieved.  In some cases, another reference point may be used, such as EC10 [203].  
The larger the value of the potency ratio, the more estrogenic the compound is.  By definition 
E2 has a relative estrogenic potency of 1.  Values of the ratio less than 1 indicate the 
compound is less estrogenic than E2, values larger than 1 indicate the compound is more 
estrogenic than E2. 
For antagonists, the relative antagonist potency (RAP) is defined as the ratio of the 
concentration of the test compound needed to affect a 50% inhibition (IC50) of the activity 
achieved by a reference concentration of a full agonist (RCA).  The reference concentration of 
the agonist is one that just achieves the maximal activity, but not in a large excess of what is 
required to achieve the maximal response.  Typically, RCA is chosen as approximately twice 
the EC50. 
     
                    
   
 
For the ER, the full agonist is usually E2 and for the AR the full agonist is either T or DHT.   
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A test compound is described as a full ER agonist if it able to produce the same maximal 
response as E2 and a partial agonist if the maximal response is less than that achieved by E2.  
In this situation, the fractional activity is reported.  A similar distinction is applied to 
antagonists.  A compound is described as a full antagonist if it is able to completely inhibit 
the maximal response of the reference compound and partial if less than full inhibition is 
achieved.    
The activity results for the compounds of interest are often conflicting as the magnitude of 
the potency obtained is highly dependent on the assay used.  Each of the assays has a 
different sensitivity to E2 and differences in cell context (endogenous or transfected receptor 
and ERE, availability of coregulators, etc.). The measured relative estrogenic potencies for 
the compounds of interest are summarised in Table A. 3 through Table A. 5.  For each 
compound, the minimum, maximum and median potencies obtained by the various assays are 
shown in Figure 2.16.  The data shown in this figure include only reported values.  If a 
compound was reported as inactive in a particular assay, no value was included.  When 
available, antiestrogenic and antiandrogenic potencies are summarised within the subsection 
for the particular compound.   
 
 
Figure 2.16.  Comparison of relative estrogenic potency values for EEs.  Median values 
are indicated with blue triangles, red bars indicate range between maximum and 
minimum values. 
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2.7.1 Cosmetics and Personal Care Products 
Cosmetics and personal care products (PCPs) include a wide range of consumer products that 
are used for personal health and/or hygiene or for beautification.  These products are often 
applied to and left on the skin (e.g. lotions) or applied for a short period of time and washed 
away (e.g. shampoo, hand soap).  Some products may enter the body through the mouth (e.g. 
toothpaste). Some of the chemicals used to preserve PCPs are also found as preservatives in 
food. 
2.7.1.1 Parabens 
Parabens (esters of 4-hydroxybenzoic acid, Figure 2.17) are used as preservatives in 
cosmetics, topical pharmaceuticals and PCPs such as lotions and shampoos and in foods such 
as jams and baked goods [120].  They prevent bacterial and fungal growth in these products.  
An excellent review of parabens was published in 2008 by Darbre and Harvey [117].  
 
 
Figure 2.17. Molecular structure of parabens. 
 
Parabens including the major paraben metabolite 4-hydroxybenzoic acid (4HBA) are weakly 
estrogenic [117, 204-209]. Parabens induce cell proliferation in the E-SCREEN assay [210, 
211] and the two studies give different assessments of whether the individual parabens are 
full or partial agonists.  The characterisation of weakly estrogenic is due to the significantly 
higher concentration of the chemical required to elicit the same response as E2. 
Estrogenic potencies relative to E2 were measured for parabens for both hERα and hERβ 
mediated firefly luciferase reporter gene yeast assays [196] and the YES assay [203].  The 
results shown in Figure 2.16 indicate parabens are more potent in activating hERβ-mediated 
gene transcription.  The yeast assay results indicate the parabens may be more estrogenic than 
the E-SCREEN results suggest. 
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Parabens have also been assessed for androgenicity [212].  At concentrations between 1 nM 
and 10 μM, 4HBA and the parabens had no direct androgenic activity in a human embryonic 
kidney (HEK 293) based luciferase reporter gene assays but the parabens were able to inhibit 
testosterone induced AR transcriptional activity as summarised in Table 2.7.  These parabens 
are described as antiandrogens.  4HBA was unable to inhibit testosterone induced AR 
transcriptional activity.  
As shown in Table 2.8, parabens also inhibit 4-hydroxyandrostenedione induced CYP19A1 
(aromatase) activity [210] which indirectly affects endogenous steroid metabolism. 
Table 2.7.  Antiandrogenic potency of parabens [212]. 
Paraben Relative Antiandrogenic  
Potency 
% reduction in AR transcription   
(at 10 μM)  
Methyl 8 x 10
3
 40 
Propyl  8 x 10
3
 19 
Butyl  8 x 10
4
 33 
4HBA not active 0 
 
Table 2.8.  Inhibition of CYP19A1 (aromatase) activity by parabens [210]. 
Paraben Relative Antiaromatase  
Potency 
% reduction of aromatase  
activity (at 100 μM) 
Methyl 11.3 55 
Ethyl 10.6 55 
Propyl  3.5 55 
Butyl  26.4 45 
Benz 25.8 10 
iPropyl 16.2 55 
iButyl No effect observed up to 100 μM 
4HBA No effect observed up to 100 μM 
 
2.7.1.2 Triclosan 
Triclosan (TRIC, Figure 2.18 ) is an antibacterial and antifungal agent commonly used in 
antibacterial hand soaps, underarm deodorants and in one particular toothpaste product [213].  
It kills bacteria by inhibiting fatty acid synthesis necessary for building cell membranes and 
for reproduction [214]. The in vitro assay results for TRIC are conflicting as summarised in 
Table 2.9. TRIC is not androgenic by the hAR-mediated luciferase gene transcription assay 
but is anti-androgenic in that assay and is able to achieve a 92% reduction in testosterone 
induced transcription at a concentration of 10 μM [212].  TRIC was also shown to inhibit 
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testosterone-induced proliferation of androgen-responsive S115 mouse mammary tumour 
cells at a concentration of 20 μM and was not able to induce cell proliferation in the S115 
cells at concentrations up to 100 μM [213].  From these results, TRIC is classified as an 
antiandrogen. 
 
 
Figure 2.18.  Molecular structure of TRIC. 
 
Table 2.9.  Relative estrogenic potency results for TRIC in in vitro assays. 
Assay Result 
yeast-based hERα mediated 
firefly luciferase reporter gene 
assay [215] 
inactive 
YES assay [215] agonist 
ER-CALUX assay [216] antagonist 
MCF-7 based reporter gene assay 
[213] 
antagonist 
MCF-7 assay [210, 217] inactive 
possibly cytotoxic [217] 
MCF-7 cells [213]  partial agonist in the usual 7-14 day time frame allowed 
for this assay. Possibly a full agonist if assay was 
allowed to continue 
 
2.7.1.3 Methyl triclosan 
Methyl triclosan (mTRIC, Figure 2.19) is a biodegradation product [218] and possible 
metabolite [219] of triclosan and has a higher potential to bioaccumulate than the parent 
compound.  No information on its estrogenic activity was found in the literature.  
2.7.1.4 2,4-dichlorophenol 
2,4-dichlorophenol (24DCP, Figure 2.19) is a possible metabolite of triclosan [219] but no 
information on its estrogenic activity was found in the literature. 
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(a) mTRIC 
 
 
 
 
(b) 24DCP 
 
Figure 2.19.  Possible metabolites of TRIC, (a) mTRIC and (b) 24DCP. 
 
2.7.2 UV Filters 
UV filters absorb and dissipate UV radiation and are added to food packaging, cosmetics and 
personal care products to protect them from degradation.  They are the active compounds in 
topical sunscreens. 
2.7.2.1 Benzophenones 
Benzophenones (Figure 2.20) are the active ingredients in topical sunscreens and added are to 
cosmetics including lipsticks and to food container plastics to filter out UV light [220]. 
 
 
(a) BP-1 
 
 
(b) BP-2 
 
 
(c) BP-3 
 
Figure 2.20.  Molecular structures of benzophenone UV filters (a) BP-1, (b) BP-2 and (c) 
BP-3. 
BP-3 is estrogenic in both hERα and hERβ mediated HEK293 cell based luciferase reporter 
gene assays [134], the E-SCREEN assay [221] and the YES assay [203, 222, 223].  BP-3 
upregulates pS2 gene transcription in MCF-7 cells [224].  BP-3 is more potent in activating 
hERα mediated gene transcription.  BP-3 did not show any antiestrogenic activity [134] and 
is not an AR agonist but is an AR antiandrogen with a RAP of 2 x 10
4
 for the inhibition of 
dihydrotestosterone (DHT) induced gene expression in the AR-CALUX assay [198].  The 
main metabolite of BP-3 is BP-1 and it is a full agonist [134].   
BP-1 and BP-2 are estrogenic in the E-SCREEN assay [221] and the YES assay [203, 
222]and are able to up-regulate pS2 gene transcription in MCF-7 cells [224]. 
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2.7.2.2 Octyl methoxycinnamate  
Octyl methoxycinnamate (OMC, Figure 2.21) is used in topical sunscreens.  OMC is an 
hERα partial agonist in the HEK293 cell based luciferase reporter gene assay, showing 42% 
of E2 activation at maximum concentration of 100 μM.  OMC is not active in the hERβ 
mediated HEK293 cell based luciferase reporter gene assays and also did not show any 
antiestrogenic activity [134].  OMC is estrogenic in the MCF-7 cell proliferation assay [221] 
and is able to up-regulate pS2 gene transcription in MCF-7 cells [224]. OMC is androgen-
inactive as it did not activate or inhibit testosterone-induced gene expression in the AR-
CALUX assay [198]. 
 
 
Figure 2.21.  Molecular structure of OMC. 
 
2.7.2.3 4-methylbenzylidene camphor 
4-methylbenzylidene camphor (4MBC, Figure 2.22) is used in topical sunscreens.  4MBC is 
estrogenic in the hERα and hERβ mediated HEK293 cell based luciferase reporter gene 
assays [134], the MCF-7 cell proliferation assay [221] and is able to up-regulate pS2 gene 
transcription in MCF-7 cells [224].  4MBC is not an AR agonist but is an AR antiandrogen 
requiring a concentration ratio of 7 x 10
4
 to affect a 50% inhibition DHT induced gene 
expression in the AR-CALUX assay [198]. 
 
 
Figure 2.22.  Molecular structure of 4MBC. 
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2.7.3 Industrial Chemicals, Pesticides and Plastics 
2.7.3.1 Bisphenol A 
Bisphenol A (BPA,Figure 2.23) is used to manufacture polycarbonate plastics and epoxy 
resins used in protective coatings of food cans and sealants in dentistry [141]. 
BPA is a full agonist in the hERα and hERβ mediated firefly luciferase reporter gene yeast 
assays [196], the ER-CALUX assay [197], the YES assay [203], the  hERα and hERβ 
mediated firefly luciferase reporter gene assays in HepG2 cells [225], and the green 
fluorescent protein (GFP) reporter gene assay established in both MCF-7 and Ishikawa cell 
lines [226].  In hERα and hERβ mediated firefly luciferase reporter gene assays in U2-OS  
(human osteoblast) cells, BPA is a full agonist, able to elicit a response 1.2-1.7 times larger 
than E2 [227].  BPA is estrogenic in MCF-7 cell proliferation exceeding the maximal growth 
rate of E2 [228]. In the AR-mediated luciferase reporter gene assays in HepG2 cells, BPA has 
no activity [225] but in the ARhLBD-activating signal cointegrator 1 (ASC1) yeast two-
hybrid system, which reflects the androgen-dependent interaction between androgen receptor 
(AR) and its coactivator, ASC1, BPA acted as potent AR antagonists comparable to a known 
strong antagonist, cyproterone acetate [229].  BPA is able to reduce the affinity of the ligand 
bound ER to the co-activator SRC1 [230].  
 
 
Figure 2.23.  Molecular structure of BPA 
 
2.7.3.2 Nonylphenol  
Nonylphenol (NP, Figure 2.24) is used to make and is a degradation product of nonylphenol 
ethoxylates. Ethoxylates are non-ionic surfactants used as dispersants and emulsifiers in a 
range of consumer products [120, 141].   
NP is estrogenic in both hERα [196, 215]and hERβ [196]mediated yeast-based firefly 
luciferase reporter gene assays.  NP is a full agonist in the hERα mediated assay but in the 
hERβ mediated assay, a full dose-response curve was not obtained in the concentration range 
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studied, giving an estimated relative potency less than 10
-5
 [196].  NP is also estrogenic in the 
YES assay [215, 231, 232] and the ER-CALUX assay [197].  In hERα and hERβ mediated 
firefly luciferase reporter gene assays in U2-OS  cells, NP is a full agonist, able to elicit a 
response 1.2 times larger than E2 [227]. NP is able to reduce the affinity of the ligand bound 
ER to the co-activator SRC1 [230].  NP is also a potent anti-androgen in the ARhLBD-
activating signal cointegrator 1 (ASC1) yeast two-hybrid system [229]. 
 
 
 
Figure 2.24.  Molecular structure of NP. 
 
2.7.3.3 4-tert-octylphenol 
4-tert-octylphenol (4t-OP,Figure 2.25) is a surfactant and a degradation product of 
octylphenol ethoxylates [120].  4t-OP is a full agonist in the YES assay [203]. 
 
 
Figure 2.25.  Molecular structure of 4t-OP. 
 
2.7.3.4 Pyrethroid metabolites 
The pyrethroid compounds cypermethrin and permethrin are commonly used domestic 
insecticides (aerosols, pet flea treatments) and in agriculture applications.  The metabolites of 
these chemicals are shown in Figure 2.26.  The two aliphatic alcohol metabolites (3PBOH 
and 4OH-3PBOH) are estrogenic in the hERα YES assay [233] while the two acidic 
metabolites (3PBA and 4OH-3PBA) are not. 
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(a) 3PBOH (b) 4OH-3PBOH 
 
(c) 3PBA 
 
(d) 4OH-3PBA 
 
Figure 2.26.  Pyrethroid metabolites. 
 
2.7.3.5 Phthalates 
Phthalate diesters (Figure 2.27(a)) are used as plasticizers, as emulsifiers in personal care 
products and in the coatings on some medications [234].  These compounds are very quickly 
metabolised to the monoesters (Figure 2.27(b-d)).  The monoesters (mBP, mBzP and mEHP) 
had no activity in the hERα, hERβ or hAR mediated Chinese hamster ovary (CHO-K1) cell 
based firefly luciferase reporter gene assay [235].  Phthalates act as anti-androgens and the 
mechanism of action is interference with testosterone biosynthesis and metabolism [236, 
237]. 
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(a) generic phthalate diester 
 
(b) mBP 
 
(c) mBzP 
 
(d) mEHP 
 
Figure 2.27.  Phthalate diester and monoesters. 
 
2.7.4 Phytoestrogens 
Phytoestrogens (Figure 2.28) are naturally occurring in foods such as beans and other 
legumes, grains, green vegetables (e.g. Brussels sprouts and spinach) and coffee.  They are 
present in foods primarily as glycosides (e.g. Figure 2.28(a)), but are hydrolysed in the 
human gut by enteric bacteria to the aglycones [150] (Figure 2.28 (b)-(d)).  The aglycones are 
estrogenic.   There is also some evidence that the glycosides are also weakly estrogenic [238].  
The aglycones are then glucuronidated and sulphated by metabolic enzymes in the liver (see 
Section 2.4.2) and there is some evidence that the glucuronides [239] and sulphates [240] are 
at least weakly estrogenic.    Phytoestrogens have been associated with protective actions 
against a variety of cancers, cardiovascular disease and osteoporosis.  The health benefits and 
potential adverse effects attributed to phytoestrogens are varied and controversial and have 
been reviewed [241]. 
The phytoestrogen content of foods common in the western diet has been determined [242]. 
Soy products (particularly soy beans and soy nuts) contained the highest concentration of 
total isoflavones, primarily as daidzein and genistein.  Lignans were present in much lower 
concentrations than the isoflavones.  Coumestrol was present in most foods but in much 
lower concentrations than the lignans.  It is relatively rich in very few foods: mung bean 
Chapter 2 – Literature Review 
58 
 
sprouts, flaxseed, and soy nuts. Coumestrol’s contribution to total phytoestrogen intake may 
not be significant unless individuals eat considerable amounts of these foods [242]. 
 
 
(a) a glycoside of GEN 
 
 
(b) GEN 
 
 
(c) DAID 
 
 
(d) EQ-S 
 
(e) ENT 
 
 
(f) COUM 
 
Figure 2.28.  Molecular structures of phytoestrogens (a) a genistein glycoside, (b) 
genistein (c) daidzein and (d) equol (S-isomer) (e) enterolactone (f) coumestrol. 
 
2.7.4.1 Genistein 
Genistein (GEN) is a phytoestrogen found in beans such as soy [243] and coffee [244].  GEN 
is estrogenic in both the hERα and hERβ mediated firefly luciferase reporter gene yeast 
assays [196],  the ER-CALUX assay [197] and in both MCF-7 and Ishikawa cell lines [226].  
GEN is a partial agonist, able to induce cell proliferation in human endometrial stromal cells 
[245],  Ishikawa cells [245] and in the E-SCREEN assay [238].  Between 50% and 85% of 
the proliferation rate of E2 is obtained, depending on the cell line. GEN is a partial agonist in 
both hERα and hERβ mediated transcription in a yeast-based β-galactosidase reporter gene 
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assay (not the YES assay) [238].  GEN is more effective in the hERβ assay than the hERα 
assay.  GEN is also able to antagonise E2 induced cell proliferation by up to 20% in both 
MCF-7 and Ishikawa cell lines when both E2 and GEN are at the same concentration of 10
-8
 
M [245]. GEN is able to reduce the affinity of the ligand bound ER to the co-activator SRC1 
[230]. 
2.7.4.2 Daidzein 
Daidzein (DAID) is a phytoestrogen found in beans such as soy [243] and coffee [244].   
DAID is a partial agonist, able to induce cell proliferation in human endometrial stromal cells 
[245], Ishikawa cells [245] and in the E-SCREEN assay [238].  Between 50% and 85% of the 
proliferation rate of E2 is obtained, depending on the cell line. DAID is a partial agonist in 
both hERα and hERβ mediated transcription in a yeast-based β-galactosidase reporter gene 
assay (not the YES assay) [238].  DAID is more effective in the hERβ assay than the hERα 
assay. DAID is also able to antagonise E2 induced cell proliferation by up to 20% in both 
MCF-7 and Ishikawa cell lines when both E2 and DAID are at the same concentration of 10
-8
 
M [245]. 
2.7.4.3 Equol 
Equol (EQ) is a metabolite of DAID produced by bacteria present in the human gut [149].  
Two isomers are possible for EQ, but the gut bacteria produce only the S-isomer which is 
estrogenic.   
EQ is a full agonist in the E-SCREEN assay [238] and a partial agonist in both hERα and 
hERβ mediated transcription in a yeast-based β-galactosidase reporter gene assay (not the 
YES assay) [238].  In contrast to GEN and DAID, EQ is more effective in the hERα assay 
than the hERβ assay. 
2.7.4.4 Enterolactone 
Enterolactone (ENT) is a lignan that occurs as the aglycone and as glycosides in grains and 
seeds, especially linseed [150].  ENT is also a metabolite of other lignans and is produced in 
the human gut by microflora [242]. ENT is estrogenic as it is able to stimulate DNA synthesis 
in MCF-7 cells with an efficacy similar to that of DAID [246]. 
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2.7.5 Pharmaceuticals 
2.7.5.1 Ethynylestradiol 
Ethynylestradiol (EE2, Figure 2.29) is the main component of oral contraceptives.  In The US 
and Europe, it is estimated that up to 3% of the women taking oral contraceptives become 
pregnant accidentally due to missed pills and continue taking the pill for weeks to months 
before the pregnancy is discovered [247].  As a pharmaceutical, EE2 is designed to be a 
potent estrogen.  EE2 is estrogenic in the hERα mediated firefly luciferase reporter gene yeast 
assay and the YES assay [215].   
 
 
 
Figure 2.29.  Molecular structure of EE2 
 
2.8 Mixtures 
Exposure to EEs is an exposure to a mixture of changing composition and concentration.  
Because the end-point of concern is hormonal signalling, there is no safe threshold below 
which there is no activity [248].  The simplest approach to assessing the total estrogenic 
effect of mixtures is the simple additivity model where each component adds to the total in 
proportion to the concentration weighted by its relative potency.  Rajapakse et al [249] have 
demonstrated in principle that every xenoestrogen, however weak, may add incrementally to 
the total estrogenic effect, even at very low concentrations, and even in the presence of potent 
endogenous steroidal estrogens. 
It is also possible for the mixture to have higher potency than predicted by the simple 
additivity mode.  This behaviour is described as synergistic.  For example, mixtures of 
benzophenones, alone or including E2, showed synergistic activity, with substantial increases 
in observed effect even though each UV filter was present at its NOEC level [222]. Also, 
BPA, NP and GEN are additive in potency when tested in a mixture with E2 [197].  
Unfortunately, these studies were done at a single equipotent mixture composition, so how 
the synergistic effect changes with mixture composition, concentration level or with E2 
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concentration is not known.   There are mixture effects even with endogenous hormones.  E3 
is known to behave as an antagonist to E2 when present in equal or up to 10-fold excess 
concentrations of E2, but as a weak agonist when present in alone or in concentrations 50 
fold greater than E2. At a 10-fold excess concentration to E2, E3 is able to reduce E2-
dependent transcription by 85% [250]. 
The complexity of dealing with mixtures in exposure assessment is recognised but 
methodologies for the assessment of risk due to exposure to mixtures are still hotly debated 
[249, 251-255].  Nevertheless, some regulatory frameworks are beginning to consider groups 
of chemicals that act via the same mechanism collectively rather than evaluating the potential 
risks individually [256].   
One approach to simplifying the topic of endocrine disruption is to treat the effects of 
exposure individually according to the signalling pathway, e.g. estrogen signalling disruption 
separate from androgen or thyroid disruption.  While this approach disregards the potential 
for the different signalling pathways to interact, e.g. anti-androgenic effects contributing to an 
overall estrogenic outcome, there is insufficient information available at this time to 
completely address the problem.  It remains sufficient to recognise the shortcomings of the 
approaches used.  Within each signalling pathway, the effects of mixtures can be effectively 
assessed if the components of a mixture act through a common mechanism or to produce a 
common effect.  Again, it must be recognised that a single component of a mixture may act 
via different mechanisms within the signalling pathway and that these mechanisms may act in 
unison or opposition to produce an effect.  An example of this complex behaviour was noted 
with the parabens in section 2.7.1.1.  Parabens are simultaneously able to up-regulate hER 
gene expression, down-regulate hAR gene expression and inhibit aromatase activity thereby 
suppressing the biosynthesis of estrogens.  Parabens can contribute to a common effect 
(femininisation) via two distinct mechanisms (estrogenicity and anti-androgenicity) and also 
contribute to a contradicting effect (masculinisation) via suppressing endogenous estrogen 
biosynthesis.  This type of behaviour is likely present with other classes of compounds of 
interest to estrogenic signalling disruption, but the data is currently lacking. 
This study will be limited to assessing whether the human fetus is exposed to a quantity of 
EEs to significantly up-regulate hER gene expression.  This will be done by assuming the 
individual compounds act additively in this action.  The available evidence suggests this is a 
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valid approach [256].  The contribution of this mixture to anti-androgenic or hormone 
biosynthesis disruption cannot be addressed at this time. 
2.9 Conclusions 
Endocrine disruption is a complex topic with co-operating and competing aspects, many of 
which have received very little attention.  Some aspects are likely still not identified.  
Disruption to estrogen signalling has received the most attention in both environmental 
exposure research and in health-related areas such as breast cancer research, but the picture is 
far from clear.  The key parts of the puzzle that are currently recognised are summarised as 
follows. 
2.9.1 ER-mediated gene transcription 
ER mediated gene transcription is highly complex process and is currently not fully 
understood.  When a ligand binds to the ER, the ligand-receptor complex takes on a specific 
conformation that is determined to a certain extent by the structure of the ligand.  The 
receptor-ligand complex is not static, but dynamic, and can be considered an equilibrium of 
multiple favourable conformations.  Small variations in the topology of the AF-2 
coregulatory protein binding site on the receptor complex influence which of the available 
coregulatory proteins are recruited, which ER-responsive gene is transcribed and the 
efficiency with which it is transcribed.  Because each of the ER target cell types has a 
different suite of coregulatory proteins and different expression levels of the two ERs, the 
same ligand can have very different effects on different cell types.  This cell-type specific 
response to EEs is the first critical factor in determining the biological outcome of exposure.   
2.9.2 Maternal Metabolism 
Maternal metabolism is effective in clearing a large proportion of most EEs before they reach 
her circulation.  Depending on the route of exposure, the compound will be subject to 
different metabolic pathways.  The clearance rate of the EE from the body will be different 
for each of the routes of exposure and different tissues will be exposed to different amounts 
of the compound.  However, the parent compounds and/or their conjugates are present in the 
maternal circulation and in the placenta on the maternal side and thus available to diffuse or 
be transported across the placental membranes to the fetus. 
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2.9.3 Placental Transport and Fetal Metabolism 
The placental membranes separate maternal and fetal circulations with a barrier similar to the 
blood-brain barrier.  Being hydrophobic, EEs can cross this barrier by simple diffusion.  The 
rate of transport is determined primary by the concentration gradient across the membranes.  
The placenta has both facilitated and active transport mechanisms that transport protein 
bound and hydrophilic species in both directions. Some EEs compete with endogenous 
estrogens for binding sites on plasma binding proteins and may be transported across the 
placenta by facilitated transport. Conjugates are transported out of the placenta to maternal 
circulation by active transporters.   
Metabolic transformations of EEs by CYP, UGTs and SULTs occur in the human fetus.  In 
contrast to adults, UGT activity in the fetus is low and SULT activity is high. The UGT 
activity that is present is substrate specific for endogenous hormones, but limited 
glucuronidation of EEs is possible. Most xenobiotics that are glucuronidated in the adult are 
sulphated in the fetus.  Certain of the CYP enzymes are active in the fetus, mainly those 
involved in hormone biosynthesis and metabolism.  The activity of fetal CYP enzymes to 
xenobiotics is low in comparison to the adult.    
Fetal tissues and the placenta have both β-glucuronidase and arylsulphatase enzymes for 
deconjugating the conjugates of endogenous steroids.  BPA is deconjugated by these 
enzymes and it is likely that other EEs may be deconjugated as well.  This may provide a 
mechanism whereby EEs are recirculated within the fetal compartment. 
The fetus actively expels lung fluid and swallows amniotic fluid.  As a result, the respiratory 
and gastrointestinal tissues are in continuous contact with these fluids.  Until skin 
keratinisation begins around the 20
th
 week of gestation, fetal plasma, extracellular fluid, lung 
fluid and amniotic fluid compositions are similar because hydrophobic compounds can freely 
diffuse across fetal skin and other cell membranes.  This free movement coupled with the 
reduced metabolic capacity of the fetal liver means that hydrophobic EEs present in fetal 
blood have ready access to estrogen sensitive cells. 
Clearly, there are competing processes present in both the placenta and in fetal tissues that 
will have an effect on how easily an EE crosses the placenta into fetal circulation, how 
effectively and in what form it is metabolised and returned to the placenta for elimination via 
maternal circulation.  The limited quantitative information that is available is primarily for 
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pharmaceuticals.  The literature suggests that EEs enter fetal circulation as the parent 
compound and may be recirculated to some extent within the fetal compartment in the same 
way endogenous estrogens and some pharmaceuticals are.      
2.9.4 In vitro measurements of estrogenic activity 
Several different in vitro methods have been used to measure the ability of a compound to 
induce ER-mediated gene transcription.  These methods are hosted in different cell types 
including yeast and mammalian cells lines.  Each method differs in its sensitivity as measured 
by the EC50 for E2.  The diversity of host cells also influences the sensitivity of the specific 
assay for a given ligand for the reasons discussed in Section 2.9.1, and results in the wide 
variability of estrogenic potencies shown in Figure 2.16.  The variability makes it difficult to 
unambiguously assign a potency value to a ligand and to compare potencies of different 
ligands. 
Estrogenic potency values for the ligands of interest in the study range from 10
-3
 to 10
-6
, 
meaning that 3 to 6 orders of magnitude higher concentrations are required to elicit the same 
effect as E2.  Many of the ligands of interest are partial agonists, meaning that their 
maximum effect is less than that of E2, even at these much higher concentrations.  The 
general conclusions on the activity of the compounds of interest in this study are summarised 
in Table 2.10. 
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Table 2.10.  Summary of estrogenic and androgenic activity of the compounds of 
interest in this study. 
Compound Class ER Activity ER 
Preference 
AR Activity 
Parabens estrogenic β antiandrogenic 
Triclosan unclear 
results indicate 
antiestrogenic,  
inactive and estrogenic 
activity 
 antiandrogenic 
Benzophenones estrogenic α antiandrogenic 
OMC estrogenic α 
β inactive 
inactive 
4MBC estrogenic no preference antiandrogenic 
BPA estrogenic  
potential super-agonist 
no preference inactive 
NP estrogenic  
potential super-agonist 
α no information 
Pyrethroid 
Metabolites 
estrogenic no 
information 
no information 
Phthalate  
monoesters 
inactive  inactive in in vitro 
tests  
but antiandrogenic in 
vivo 
GEN, DAID estrogenic when acting 
alone, 
antiestrogenic in the 
presence of E2 
β no information 
EQ-S estrogenic α no information 
ENT estrogenic no 
information 
no information 
 
2.9.5 Other estrogenic modes of action 
In addition to ER-mediated estrogenic activity, many of the EEs also have non-genomic 
estrogenic activity.  Non-genomic activity includes interference with hormone biosynthesis 
and metabolic pathways and competing with endogenous estrogens for binding sites on 
plasma binding proteins.  Some of the EEs also exhibit anti-androgenic activity which has an 
indirect feminising effect.  Very little has been done to quantify these effects. 
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3.1 Introduction 
The wide range of adverse outcomes in humans that have been associated with exposure to 
EEs was presented in Chapter 1; for example, males develop malformed genitalia, females 
enter puberty earlier, and both males and females exhibit reduced fertility and increased 
incidence of hormone responsive cancers.  As stated in Section 2.2.3, it is thought that these 
observed outcomes depend on timing, level and route of exposure [23, 96-101].  A specific 
example of this type of variability of outcome in humans is the SERM behaviour of breast 
cancer drugs OHT and RAL. These two drugs have different effects on different target tissues 
(bone and uterus) which is a direct result of the different populations of coregulatory proteins 
present in the different target cells, i.e. the cell context.  The in vitro assays for estrogenicity 
(Section 2.6) also demonstrate this variability in effect.  The quantitative measure of 
estrogenicity obtained from these assays depends on the host cell, the reporter construct and 
the receptor type, all of which contribute to the variability in measured estrogenicity shown in 
Figure 2.16. 
Strong evidence exists for the molecular basis for this variability.  In the case of GEN, the 
cell context can influence the conformation of the RL-complex [78, 257] [258].  When GEN 
is co-crystallised with hERβ in the absence of coregulatory peptide, the RL-complex takes 
the antagonist conformation.  When co-crystallised in the presence of a particular 
coregulatory peptide, the RL-complex is forced to take the agonist conformation because the 
coregulatory peptide binds to the RL-complex preventing H-12 from occupying the groove.   
Combining these two observations, I suggest that that the variability in biological outcomes 
observed with exposure to EEs is a result of ligand flexibility.   The endogenous estrogens are 
rigid molecules and they are able to engage the receptor protein to produce a stable RL-
complex with a well-defined topology.  The rigidity of the endogenous estrogens will be 
discussed in Section 3.3.2.  The flexibility inherent in the molecular structures of the EEs do 
not result in a well-defined RL-complex.  Instead, this flexibility allows a multiplicity of 
energy-equivalent receptor-ligand conformations that are able to differentially recruit 
coregulatory proteins, thus affecting gene transcription.  Ligand flexibility may also 
contribute to the partial agonist/antagonist nature of many EEs.  Ligand flexibility coupled 
with generally lower binding affinity will result in RL-complexes being more transient and 
thus less able to interact with DNA and the cellular transcription machinery long enough to 
complete gene transcription.     
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In this chapter, two computational docking approaches, rigid receptor docking (RRD) and 
induced-fit docking (IFD), were used to examine this hypothesis.   
3.2 Theoretical Background 
3.2.1 Ligand Structure and Transcription 
The two hERs (α and β) have different expression levels in different cell types.  This 
differential expression combined with varying types and relative concentrations of 
coregulatory proteins present in specific cell types provides a complex control mechanism for 
estrogen target gene transcription. 
The molecular structures of the endogenous estrogens are rigid and induce a precise 3D 
conformation in the hER on binding.  This precise conformation is observed in solved protein 
crystal structures and is described as the agonist conformation.  This conformation leads to 
predictable patterns of gene transcription in target cells.  Endogenous estrogens are pure 
agonists for the hER – they always up-regulate gene transcription in target cells. 
Pharmaceuticals have been designed that completely block transcription in all target cells 
(pure antagonists) and that block transcription in some target cells but not others (selective 
modulators).  These pharmaceuticals also produce predictable effects.  The molecular 
structures of selective modulators are also rigid and have been shown by solved protein 
crystal structures to induce a radically different conformation (the antagonist conformation, 
Figure 2.6) in the hER on binding.  The selective modulators for hERα (e.g. RAL and OHT, 
Figure 2.7) have been designed as ‘wedges’ that actively engage the receptor protein to 
stabilise this conformation.  Selective modulators for hERβ (JJ3, 3AS, ETC, Table A. 7) are 
also rigid molecules, but in contrast to the hERα SERMS, they do not have and do not require 
the large ‘wedge’ feature that the hERα SERMS have to stabilise the antagonist 
conformation.   
Antagonist action is achieved by H12 occupying the coregulatory protein binding site - a 
structurally conserved cleft on the surface of the ER LBD where the LXXLL motif of the 
coregulatory molecule binds.   The suggested mechanism of antagonism is the competition 
between the coregulatory proteins and H12 for the binding site [259].  The position of H12 in 
the agonist conformation is unique but in the antagonist conformation, it is not [259].  Based 
on study of the hER and other NRs, it has been proposed that “upon ligand binding, H12 
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would dynamically adopt one of (at least) two stable positions as dictated by the binding 
characteristics of the ligand” [260].     
Experimental evidence suggests that the selective modulator nature of these pharmaceuticals 
is a result of small variations in the exact topology of the antagonist conformation that are 
induced by the differences in the 3D shape of the drug molecule.  This evidence was 
produced by in vitro binding studies where the ability of the receptor-ligand complex to bind 
with different peptides that mimic different classes of coregulatory proteins is measured [88, 
258].  These in vitro assays are complemented by solved crystal structures with the peptide 
co-crystallised with the receptor-ligand complex. 
Crystal structures of endogenous estrogens and pharmaceuticals bound to the two hERs have 
been solved.   Crystal structures can only be obtained when the molecule interacts with the 
receptor in a well-defined manner.  Each of the many millions of receptor-ligand complexes 
within the crystal must have exactly the same 3-dimensional array of atoms in order to solve 
the crystal structure.  Not all attempts to produce protein crystals with drug candidates as 
ligands are successful.  In many cases, the crystal does not grow large enough or the crystal is 
not of sufficient quality to allow the structure to be solved [85].  The crystal structure is 
described as having ‘static disorder’ in these ill-defined regions.  In these cases, the ligand is 
not able to stabilise the receptor conformation, leading to static disorder in large enough 
regions of the complex that prevent the structure from being solved.  
These small variations in the ligand’s molecular structure lead to differences in the ability of 
the receptor-ligand complex to recruit the cofactors needed to initiate gene transcription.  The 
selective nature of the ligand’s action also depends on the selection of cofactors available in 
the target cell and their relative concentrations.  The importance of the ligand’s molecular 
structure in achieving the desired therapeutic effect is well known in medicinal chemistry 
[259].    
One environmental estrogen, GEN, has similar selective modulator properties [261].  GEN is 
a rigid molecule but has dimensions and overall shape that are different from the estrogens or 
the pharmaceuticals.  hERα has been co-crystallised with GEN and the complex has the 
agonist conformation [257].  When co-crystallised with GEN, hERβ adopts the antagonist 
conformation [78], but when GEN and hERβ are co-crystallised in the presence of a peptide 
designed to mimic a specific coregulatory protein, hERβ adopts the agonist conformation 
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[257].  The rationale given is that the relative free energies of the two H12 conformations of 
hERβ-GEN complex are similar, with the antagonist conformation being slightly more stable.  
This concept is illustrated in Figure 3.1. The presence of the peptide mimic provides 
additional stabilisation necessary to produce the agonist conformation [257].  Thus, it appears 
that with GEN, both the receptor type and cell context determine whether it behaves as an 
agonist or antagonist. While hERβ may have a lower energy barrier between the agonist and 
antagonist conformations, it has been suggested that the opposite is true for hERα [259, 262].  
GEN is not able to induce the antagonist conformation in hERα because it does not have the 
‘wedge’ shape required to stabilise the hERα antagonist conformation.  
 
Figure 3.1.  Illustration of proposed relative stability of the agonist and antagonist conformations of the 
two hERs.   
 
Molecular dynamics simulations of the binding of DES with hERα  [263] have shown that the 
hydrogen bond between His524 and the DES ligand hydroxyl is present for 97% of the 
simulation time.  At the other end of the ligand, the hydrogen bond network fluctuates 
between Glu353, Arg394, a water molecule and the DES ligand hydroxyl and results in the 
equivalent of 1.5 hydrogen bonds over the simulation time.   Since His524 is free to rotate to 
break and re-form H bonds with the ligand, the authors suggest that hydrogen bonding with 
His524 is not absolutely required for ligand binding but serves to stabilize the binding mode.   
3.2.2 Receptor Protein Structure and Conformation 
The agonist and antagonist conformations of the LBD of hERα are shown in Figure 3.2.  The 
helix notation is shown on both conformations.    Note the difference in position of H12.  In 
the agonist conformation it is closed over the binding cavity while in the antagonist 
conformation it is folded back onto the LBD to occupy the cofactor binding site.  In Figure 
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3.3, the agonist and antagonist conformations are shown, highlighting the important regions 
of the protein structure that are influenced by ligand binding.  Note the uncoiling of H11 that 
results in a lengthening of the loop between H11 and H12 to allow H12 to occupy the 
cofactor binding site [81].  The three key ligand-residue interactions are shown in Figure 3.4. 
 
(a) hERα LBD agonist conformation (PDB 1ERE) 
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hERα LBD antagonist conformation (PDB 1ERR) 
Figure 3.2.  hERα ligand binding domain in the (a) agonist and (b) antagonist conformations.  Helices 1-
12 are indicated along with the co-crystallised ligand (E2 or RAL) and the binding cavity water molecule. 
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Figure 3.3.  Comparison of hERα agonist and antagonist models showing regions of H8 where His524 
interacts and regions of H11-H12 that are changed as a result of ligand binding.  The agonist protein 
structure is shown in grey and the antagonist structure is shown in green and blue. The ligands (E2 and 
RAL) are both shown in green.  Note the difference in position of His 524 shown in yellow and the 
resulting uncoiling of H11.  The uncoiling of H11 results in a lengthening of the loop between H11 and 
H12 to allow H12 to reach the cofactor binding site. 
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Figure 3.4.  Key ligand-reside interactions for E2 with hER.  hERα (1ERE) is shown in green and hERβ 
(3OLS) is shown in pink.  The two residue substitutions between the receptors are also shown (Leu384-
Met336 and Met421-Ile373).    
 
3.2.3 Computational Docking 
Computational docking is the computer simulation of binding of a ligand to a receptor and is 
a tool that is routinely used in pharmaceutical research.  Docking can be used for the 
selection of potential drug candidates from a collection or library of possible lead chemicals 
in a process known as virtual screening or in the design of drug molecules [264-267].  
Docking in the form of virtual screening is less frequently used in the study of endocrine 
disrupting chemicals because the tolerance for false negatives (rejecting a compound that is 
in fact endocrine active) is much lower than in drug discovery [268].  One study has been 
reported where computational docking was used in conjunction with additional chemical 
knowledge to successfully select endocrine disrupting chemicals from a collection of weakly 
active and inactive compounds [269]. Computational docking has been used in the study of 
endocrine disrupting chemicals to explore the binding interactions of specific compounds 
with the ER, for example polybrominated diphenyl ethers [270], polychlorinated biphenyls 
and dichlorodiphenyltrichloroethane (DDT) and its metabolites [271], phytoestrogens and 
polyphenols [75] and pesticides [272].  Molecular dynamics simulations have also been used 
Chapter 3 – Computational Docking 
78 
 
to study the interaction of both drug targets and endocrine disrupting chemicals with the ER 
[263, 273-275]. 
Computational docking is used to predict the preferred orientation of a ligand within the 
receptor binding cavity and to estimate the binding energy (affinity) for the ligand-receptor 
complex.  Much of the computational docking done with the ER has been for drug 
development [265, 267] for treatment of breast cancer, osteoporosis and prostate diseases.  
Currently, a very active area in estrogen receptor drug research is the development of 
compounds which are SERMs that selectively up- or down-regulate gene transcription 
controlled by one of the two ERs. 
Computational docking requires a collection of computer programs to perform the necessary 
calculations.  There are many tools to choose from depending on the objectives of the study 
and the degree to which the programs need to be adapted to a particular purpose.  Since the 
objective of this study was to use the tool to study a biological system (rather than to develop 
computer code to simulate a biological process or to improve the performance of a tool) a 
commercially available and extensively validated software package with an easy to use 
graphical interface was chosen.  Schrödinger Suite 2010 was used as the primary tool for this 
work.   
The basis of computational docking is the lock-and-key model first described by Fischer in 
1894 [276]. As the name suggests, the three dimensional structures of the ligand and the 
receptor are both considered rigid and complement each other like a key fits a lock.   It is now 
recognised that the ligand and receptor structures change during the binding process. The 
introduction of a ligand to the receptor binding cavity modifies the chemical and structural 
environment of the binding cavity, for example by formation of salt bridges or expulsion of 
water molecules, causing the energy landscape of the protein to change.  The mutual 
interaction between receptor and ligand can result in an energy state of the complex that is 
lower and more stable than the separate receptor and ligand, thus leads to ligand binding.  
The receptor and ligand undergo a mutual accommodation process that results in small scale 
adjustments in atom positioning of both the ligand and receptor.  The movement in the 
receptor is usually confined to a region very near the binding cavity and is often not 
translated or amplified to distant parts of the protein structure.  This model, described as 
induced fit, was first presented by Koshland in 1958 [277]. However, long range changes in a 
protein receptor structure are now known.  Recent advances in computational capacity have 
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led to current efforts to model these larger movements, but it remains difficult to accurately 
model these larger movements because of the size and complexity of the molecules involved. 
Computational docking is based on static models of the receptor and ligand, exploring how 
the ligand can adopt a shape that best complements and interacts with the binding cavity of 
the receptor.  Small-scale changes in the protein structure in the vicinity of the binding cavity, 
termed flexibility, are now being considered in docking applications with varying degrees of 
accuracy and efficiency [264].  Docking is based on static models of the receptor and the 
minimisation of the potential energy of the receptor-ligand complex.  Docking calculations 
do not consider the kinetic energy of the system, so large-scale movements of the receptor 
that may occur as a result of ligand binding (e.g. large conformational changes in the protein 
structure some distance from the binding cavity) cannot be modelled using docking methods.  
Molecular dynamics models do consider the kinetic energy of the system (e.g. that caused by 
perturbations to the structure that displace it from a potential energy minimum) and are used 
to study receptor motion such as these conformational changes.  Having said this, docking 
studies may be able to shed light on the small local changes (triggers) that occur and are then 
amplified through the protein structure resulting in the large conformational change. 
The docking process begins with choosing or developing geometric and chemical 
descriptions of the separate receptor and small molecule structures.  The receptor model is 
normally derived from an x-ray crystal structure of the receptor, either with a co-crystallised 
ligand or without (i.e. apo).  The ligand model is usually developed using a 3D chemical 
structure drawing tool. Both the receptor and ligand models are energy minimised before 
docking begins.  Energy minimisation involves finding the position of atoms in a structure 
such that the total energy of the structure is at a local minimum of potential energy.  Then, 
using search algorithms and force field interactions, the docking process seeks to find optimal 
placements of the small molecule in the receptor binding cavity.  These potential complexes 
are ranked using a scoring function and the binding affinity for each complex is calculated.  
From the candidate poses the best pose is chosen.  The general steps in the docking process 
are illustrated in Figure 3.5. 
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Figure 3.5.  Generalised ligand-receptor docking process. 
 
Protein-ligand docking methods generally consist of two components:  a ligand placement 
algorithm to enumerate and test possible poses for the ligand in the receptor protein’s binding 
cavity and a scoring function to evaluate the energy of each ligand pose and to compare the 
optimum pose of one candidate ligand to those of other candidate ligands.   
The ligand placement algorithm is a method to place the ligand in various candidate poses 
(positions or orientations) in the binding cavity of the receptor.  The topography of the 
binding cavity is represented on a 3-dimensional grid and the ligand is placed in different 
positions within this grid.  Though this could be done randomly or exhaustively, most 
algorithms use heuristics (rules of thumb based on the chemistry and geometry of the atoms 
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involved) or standard computer search optimization techniques (strategies to identify and 
disregard pathways that are not likely to lead to favourable results) to reduce the 
computational effort needed to identify good candidate poses.   
The scoring function calculates the energy of the receptor-ligand complex and ranks poses of 
a given ligand relative to one another to allow the comparison of poses of different ligands.  
Ideally, the numerical value of the scoring function should correspond directly to the binding 
affinity of the ligand for the protein, so that the ligands with the best score are the best 
binders.  Current scoring functions have been well validated and generally provide a good 
approximation for binding affinity, although the degree of accuracy varies with the particular 
scoring function and receptor under study.  If the numerical accuracy of a particular scoring 
function is not sufficient for the purpose at hand, docked receptor-ligand complexes can be 
re-scored using one of many different scoring functions available [278-280]. 
3.2.3.1 Rigid Receptor Docking 
The simplest approach to ligand docking is to assume that both the receptor protein structure 
and ligand are fixed as illustrated in Figure 3.6.  The ligand must be an exact lock-and-key fit 
to the receptor for docking to be successful and the calculated binding affinity to be high.   
Receptor Receptor Receptor
Ligand fits receptor 
perfectly like a key in a 
lock.  Ligand will be 
successfully docked 
and the calculated 
binding affinity will be 
high.
Ligand is too wide 
to fit receptor 
binding site and 
cannot be docked.
Ligand is too narrow 
to fit binding site 
well.  It may dock 
but the calculated 
binding affinity will 
be low.
 
Figure 3.6.  Illustration of the limitations of rigid receptor – rigid ligand docking. 
 
This strategy is very restrictive and often results in either unrealistic complexes (e.g. very 
close positioning of atoms or the ligand interacting unexpectedly or incorrectly with parts of 
Chapter 3 – Computational Docking 
82 
 
the receptor) or failure to identify possible valid complexes.  This approach is used mostly as 
screening tool or as part of a filtering step in a complex workflow such as simulating protein 
structure flexibility.  Most often, rigid receptor docking is used with flexible ligands.  
Because the receptor cannot move, the degrees of freedom of the problem are those of the 
ligand: three translational, three global-rotational, and one internal dihedral rotation for each 
rotatable bond.  It is generally assumed that bond lengths and the angles formed by adjacent 
bonds do not change.  In this case, the ligand is able to adapt to the binding site to achieve a 
complex with favourable binding affinity, as illustrated in Figure 3.7. 
Receptor
Ligand
Ligand
Receptor Receptor
Ligand
Rotational degrees of freedom allow the ligand to adapt 
to the geometry of the binding site during docking.
 
Figure 3.7.  Illustration of the rigid receptor-flexible ligand docking concept. 
 
3.2.3.2 Flexible Receptor Docking 
Although it is well known that a protein will usually experience some degree of 
conformational change during the binding process, most docking tools still treat the protein as 
a rigid structure [281, 282]. The reason for this approximation is the huge increase in 
computational complexity that is required to fully model protein flexibility. In order to obtain 
results of docking computations in a realistic time frame, different representations and 
simplifications of protein flexibility have been implemented that avoid direct generation and 
search of thousands of potential protein structure conformations.  
The simplest approach to representing protein flexibility is the concept of a ‘soft’ receptor. 
Soft receptors can be implemented by relaxing the high energy penalty that the system incurs 
when an atom in the ligand overlaps an atom in the receptor structure. By using a scaling 
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factor to reduce the van der Waals contributions to the total energy score, the receptor is 
effectively made softer, allowing, for example, a larger ligand to fit in a binding cavity 
determined experimentally for a smaller molecule.  The rationale behind this approach is that 
the receptor structure has some inherent plasticity which allows it to adapt to slightly 
differently shaped ligands through small variations in the orientation of binding cavity 
residue side chain and backbone positions. If the change in the receptor conformation is small 
enough, it is assumed that the receptor is capable of adapting to this small change by 
absorbing and distributing the disruption through the local structure, even though the 
conformational change itself is not modelled explicitly. It is also assumed that the change in 
protein conformation does not result in a sufficiently high energy penalty to offset the 
improved interaction energy between the ligand and the receptor. The main advantages of 
using soft receptors are that docking algorithms are unchanged and the computational cost of 
evaluating the scoring function is the same as for the rigid case. 
Another approach to representing protein flexibility is an iterative approach of docking with a 
soft receptor followed by energy minimisation of the entire protein-ligand complex.  An 
ensemble of candidate poses for a ligand within the receptor binding cavity is obtained using 
soft docking methods.  These candidate poses are then ranked and a selection of the top-
ranked poses is subjected to energy minimisation which allows the protein structure to ‘relax’ 
around the ligand.  These minimised receptor-ligand complexes are then re-scored to produce 
an ensemble of most favourable complexes.  This approach requires a significant increase in 
computational effort, but is still achievable on a desktop computer.  For situations where the 
receptor structure is known to be well defined and retains its integrity on ligand binding, this 
induced-fit approach is reasonable [283].  However, this approach is not able to model large-
scale conformational changes that may be triggered by ligand binding.  As suggested earlier, 
this type of approach could be useful in identifying the small trigger changes in protein 
structure that are amplified to result in large-scale conformational changes. 
3.2.3.3 Scoring Functions 
Scoring functions are used to estimate the free energy of binding (binding affinity) of a ligand 
to a receptor.  Scoring functions can be empirical or based directly on force field calculations.  
Force fields quantify the interaction energy between the receptor and ligand and the internal 
energy of the ligand by summing energy contributions of non-bonded interactions such as 
stretching, bending, torsion, van der Waals and electrostatic.  Force field scoring functions do 
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not model individual or specific entropy contributions of solvent effects on binding such as 
the desolvation energies of the ligand and protein.  These effects are taken into account using 
implicit solvation methods rather than explicit solvation methods.  Implicit solvation treats 
the solvent as a continuum with a dielectric constant that may or may not be uniform through 
the continuum and the ligand or protein as a particle with some appropriate charge.  Explicit 
solvation models individual water molecules in the vicinity of the ligand and protein.  
Implicit solvation models are less computationally demanding and have been sufficiently 
well developed that they are effective for most systems [284].  Empirical scoring functions 
are weighted sums of independent contributions to binding energy (e.g. hydrogen bonding, 
van der Waals, hydrophobic, electrostatic, solvent effects).  The weighting factors for 
empirical scoring functions are obtained using statistical methods such as regression analysis 
using a large and diverse ‘training’ set of receptor-ligand pairs that represent many different 
classes of receptor proteins and ligand structures and known experimental binding affinity 
data.  General purpose empirical scoring functions such as those provided by software 
packages have been ‘calibrated’ against a diverseset of ligand-receptor pairs and perform well 
in most circumstances [282, 285, 286].  They are able to indicate which of two ligands has 
greater affinity but less able to accurately determine which of two poses of a given ligand is 
preferred, especially with highly flexible ligands [264, 267].  Scoring functions can be 
developed that are specific to the receptor under study [273].  Such custom scoring functions 
may be more accurate for prediction of binding energy of new ligands for that particular 
receptor or for selecting the best pose for a given ligand, but are limited in application to that 
particular system.  The custom scoring function approach is most often used in drug design 
while the general scoring functions are used for virtual screening applications.  For this study, 
the general scoring function is most appropriate because the objective is to evaluate both 
multiple poses or clusters of similarity and the differences among ligands, rather than being 
able to accurately determine which of the resulting poses is the best and using that 
information to refine the structure of the ligand to improve binding affinity. 
3.2.3.4 Molecular Dynamics 
To simulate the binding process with as much detail as possible and avoid some of the 
limitations of soft receptor models, force field based simulation methods such as Monte Carlo 
or molecular dynamics are used. Molecular dynamics (MD) computations apply the laws of 
classical mechanics to compute the motion of the atoms in a molecular system.  Monte Carlo 
(MC) methods are based on a random sampling of the conformational space. The main 
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advantage of these methods is that they are very accurate and can model explicitly all degrees 
of freedom of the system including the individual solvent molecules if necessary. 
Unfortunately, the high level of accuracy in the modelling process comes with a prohibitive 
computational cost. State of the art molecular dynamics protein simulations can only simulate 
periods ranging from 10 to 100 ns, even when using large parallel computers or clusters. 
Given that diffusion and binding of ligands takes place over a longer time span, full 
simulations are often not possible to obtain.  MD and MC simulations can be applied to a 
portion of a protein structure, such as within a specified radius of the ligand binding cavity, or 
to a pre-minimised structure for a limited sampling period producing informative and useful 
results [274, 279]. 
With this computational docking study, the ability of the environmental estrogens to stabilise 
the estrogen receptor in a particular conformation will be investigated.  The molecular 
structures of the environmental estrogens are more flexible and there are no solved crystal 
structures of these more flexible molecules bound to the hER in the literature.  This could be 
because no attempts have been made or because crystals of sufficient quality could not be 
produced to warrant publication. 
The key features of the RL-complex to be investigated are  
 The existence of multiple distinct energy-equivalent poses for a given ligand and 
whether they have the potential to result in different effects on gene expression 
 The details of the interactions of the ligand with the receptor, particularly with 
His524/475 and the implications for the ligand’s ability to stabilise the RL-complex. 
3.3 Materials  
3.3.1 Receptor Models 
Computational docking relies on models of the receptor protein structure.  These models are 
developed from published x-ray crystal structures.  Because the estrogen receptor exists in 
two forms (α and β) and has two biologically active conformations (agonist and antagonist), a 
number of different x-ray crystal structures were required to capture this diversity.  For this 
work, the x-ray crystal structures of the human estrogen receptor ligand binding domain listed 
in Table 3.1 were obtained from the Protein Data Bank (PDB) [287].  The model developed 
from the crystal structure is identified by the PDB code.  Four additional PDB entries were 
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used as references for orientations of ligands within the binding site but were not used as 
models for docking as summarised in Table 3.2.   
The differences in the models for the key ligand-residue interactions are illustrated in Figure 
3.8. 
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Table 3.1.  X-ray crystal structures of the human estrogen receptor ligand binding domain obtained from 
the Protein Data Bank (PDB) [287].   
PDB  
Code 
Receptor  
(mutations) 
Receptor  
Conformation 
Ligand Resolution  
(Å) 
Chain Coregulatory  
Protein 
Fragment 
Reference 
1ERE hERα  Agonist E2 3.10 A no [77] 
1A52 hERα  Agonist E2 2.80 A no [288] 
1X7R hERα  Agonist  GEN 2.00 A yes [257] 
3ERD hERα  Agonist DES 2.03 A yes [81] 
2P15 hERα 
(S537Y) 
Agonist EZT 1.94 A no [289] 
2B23 hERα 
(S537Y) 
Agonist Apo  2.10 B yes [85] 
1ERR hERα  Antagonist RAL 2.60 A no [77] 
3ERT hERα  Antagonist OHT 1.90 A no [81] 
1XPC hERα  Antagonist AIT  1.60 A no [290] 
3OLS hERβ Agonist E2 2.20 A yes [291] 
1X7J hERβ  Agonist GEN 2.30 A yes [257] 
1L2J hERβ  Antagonist ETC 2.95 A no [262] 
1QKM hERβ  Antagonist GEN 1.80 A no [78] 
2JJ3 hERβ  Antagonist JJ3 2.28 A no [292] 
2QTU hERβ Antagonist 3AS 2.53 A no [293] 
 
Table 3.2.  Additional x-ray crystal structures of the estrogen receptor ligand binding domain obtained 
from the Protein Data Bank (PDB) [287]. 
PDB 
Code 
Receptor 
(mutations) 
Receptor  
Conformation 
Co-
crystallised 
Ligand 
Notes 
2QE4 hERα Agonist JJ3 Complements model 2JJ3.  Does not have a co-
crystallised coregulatory protein fragment. 
The solved structure does not include H12.  
Whether H12 was not resolved sufficiently to be 
included in the published co-ordinate file or whether 
it was not present as part of the protein to begin with 
was not apparent from the literature reference [292]. 
1L2I hERα Agonist ETC Complements model 1L2J [262]. Co-crystallised 
with coregulatory protein fragment. 
1QKN rat ERβ Antagonist RAL Complements 1ERR. Does not have a co-
crystallised coregulatory protein fragment. 
RAL is in a similar orientation to 1ERR [78] 
2FSZ hERβ Antagonist OHT Complements 3ERT.  OHT is in a similar 
orientation to 3ERT, but H12 is displaced by a 
second OHT molecule occupying the coregulatory 
protein binding cleft [294]. 
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(a) Glu353 and Arg394.  A-ring anchor. 
 
(b) His524.  D-ring end of binding cavity. 
 
Figure 3.8.  Variation in positions of key ligand binding residues in different hERα models.  The grey 
residues are from the agonist models. The orange residues are from 2B23, purple residues from 3ERT, 
light green from 1ERR and pink from 1XPC.  Note conservation of residue positions in (a) at the A-ring 
anchor and flexibility in (b) the D-ring end of the binding cavity. 
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3.3.2 Ligand Structures 
Computational docking requires a model for each ligand.  This model is developed from the 
3D structure of the ligand.  The 3D structures for the co-crystallised ligands were extracted 
from the PDB files.  The 3D structures for all other ligands were constructed using the 
software tools of the Schrödinger Suite.  Models for 51 individual molecules representing 47 
unique compounds are needed for this study.  The 2D structures for these ligands are given in 
Table A. 7.   
All of the ligands were minimised to find the conformation of the ligand that had the lowest 
internal energy.  This calculation searched the entire conformation space of the ligand, 
including ring conformations (e.g. 6-member ring boat/chair conformations) and rotational 
degrees of freedom.  For the ring conformation search, only those with minimised energy 
within 50 kJ/mol of the lowest energy conformation were retained.  For the steroids (E1, E2, 
E3 and EE2) and phytoestrogens (COUM, GEN, DAID, EQ) only one conformation was 
found and it is on this basis that the steroids and phytoestrogens are described as rigid.   
3.3.3 Experimental Binding Affinity Data 
One of the goals of computational docking is to accurately predict the binding energy of a 
ligand-receptor complex.  To evaluate the accuracy, experimental binding energy data are 
needed and for this study are obtained from the literature. 
Competitive binding assays are the most common method for determining binding affinity for 
a ligand.  The displacement of [
3
H]-E2 bound to the receptor (ligand binding domain or entire 
receptor) by the compound under study is measured.  A series of samples are prepared, each 
containing a known but different amount of the compound of interest and a known but a large 
excess (relative to the receptor concentration) of [
3
H]-E2.  The mixtures are incubated and 
after a period of time, the protein with bound ligand is separated from solution.   The 
radioactivity due to the protein-bound [
3
H]-E2 is measured.  The concentration of compound 
required to displace 50% of the [
3
H]-E2 (IC50) is determined.  The relative binding affinity 
for the compound is calculated as a ratio to the IC50 of E2 determined under the same 
conditions.   
In some cases, IC50 is reported rather than a relative binding affinity.  When this occurs, Ki, 
the binding affinity for the inhibitor, must be calculated from the experimental data using the 
equation [295] 
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where [S] is the concentration [
3
H]-E2 and Ks is the binding affinity of [
3
H]-E2 to ER.  If [S] 
and Ks are not reported, the data cannot be used. 
Experimental ΔGbind values are calculated from experimentally determined values from the 
equation: 
               
where R is the gas constant and T is the temperature at which the Ki was determined. 
The experimental values for Gibbs free energy of binding from the literature were tabulated 
for each of the ligands of interest.  Table 3.3 summarises for each of the ligands of interest 
the average ΔGbind and the standard deviation where more than one literature value was 
found.  Also presented in Table 3.3 is the preference ratio which is simply the ratio of binding 
energies for hERα/hERβ.  A preference ratio greater than one indicates the ligand will bind 
hERα with a greater affinity than hERβ.  The literature references are summarised in Table A. 
8. 
Table 3.3.  Experimentally determined ΔGbind (kJ/mol).  Values are averages of multiple literature values 
where a standard deviation is reported. NB = does not bind; NM = not measured.  See Appendix for 
literature references.  
 hERα hERβ Preference Ratio 
hERα/hERβ 
Crystal Structure  
Available Ligand Avg Stdev Avg Stdev 
E1 -46.5 3.1 -39.4  1.18  
E2 -52.8 3.1 -51.8 3.3 1.02 x 
E3 -46.4 3.4 -46.0  1.01  
T -18.5  NM   
EE2 -50.3 0.2 -47.1  1.07  
DES -54.8 4.4 -53.4 4.5 1.03 x 
BPA -36.3 2.4 -38.0 5.2 0.96  
4tOP -35.4  -36.6  0.97  
4NP -36.4 6.7 -39.3  0.93  
GEN -42.3 5.3 -49.3 5.3 0.86 x 
DAID -35.7 4.4 -38.9 4.8 0.92  
COUM -50.4 3.4 -53.4 4.4 0.94  
R-EQ -39.2 1.4 -38.4 4.3 1.02  
S-EQ -39.1 4.2 -43.6 4.2 0.90  
ENT -40.7  -31.5  1.30  
mParaben NB NB   
eParaben -29.5 1.5 -30.6 1.6 0.96  
pParaben -32.2 1.1 -34.0 1.5 0.95  
bParaben -34.0 0.8 -35.9 2.3 0.95  
BP-1 -34.5 11.2 -28.5  1.21  
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BP-2 -35.9 8.5 -34.9 0.4 1.03  
BP-3 NB NB   
OMC NB NB   
4MBC -21.2  -24.6  0.86  
RAL -51.9 4.1 -45.5 3.9 1.14 x 
OHT -51.1 5.5 -53.8 5.5 0.95 x 
EZT -54.7  NM  x 
JJ3 -42.2  -50.7  0.83 x 
AIT -47.3  -42.9  1.10 x 
3AS -39.0  -49.2  0.79 x 
ETC -42.7  -44.8  0.95 x 
 
3.4 Methods 
3.4.1 Software Tools 
The Schrödinger Suite 2010 is a proprietary software package for studying biomolecular 
interactions.  The various modules and workflows of the suite are accessed through a 
graphical user interface called Maestro.  For this work, the applications and workflows listed 
in Table 3.4 were used. The Schrodinger Suite has been extensively tested and compared to 
other software tools and its performance is consistently in the top half of the group of tested 
software tools [286, 296-300] and often one of the top-ranked tools for docking calculations.    
Glide is able to correctly redock the cocrystallised ligand with RMS deviations smaller than 1 
Å for 132 of the 279 test cases, smaller than 1.5 Å for 168 test cases, and are less than 2.0 Å 
nearly 70% of the time [301].  The GlideScore values track the experimental binding 
affinities reasonably well with the overall RMS deviation for 128 testbcases of 3.1 kcal/mol 
[301]. 
Table 3.4.  Schrödinger Suite 2010 applications used in this work. 
Application Task 
Maestro  
(Version 9.1) 
Graphical user interface for all Schrödinger applications and workflows. 
MacroModel  
(Version 9.8) 
Molecular mechanics toolkit.  Combines force fields, accurate effective solvation models, 
and advanced conformational searching methods to identify the low energy conformation 
of a single molecule (protein or small molecule) or receptor-ligand complex. 
Minimisation calculations used by other applications and workflows. 
LigPrep  
(Version 2.4) 
Generation of accurate 3D molecular models for ligand molecules, including tautomeric, 
stereochemical, and ionization variations optimized for further computational analyses.  
These tools are based on well known bond length, bond angle and atom size parameters 
and molecular geometry and bonding rules. 
Glide  
(Version 5.6) 
An extensively validated ligand placement algorithm and scoring function package to 
accurately predict binding mode for ligand-receptor complexes.   
Prime  
(Version 2.2) 
Protein structure predictions, protein structure refinement and MM-GBSA calculations. 
Workflow Task 
Protein Correcting common structural problems (e.g. missing residues or residue side chains) and 
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Preparation 
Wizard (2010) 
creating reliable, all-atom protein models.   
Induced Fit 
Docking (2009) 
A novel method for fast and accurate prediction of ligand induced conformational changes 
in receptor active cavities.  Combines Glide and Prime to exhaustively consider possible 
binding modes and the associated conformational changes within the receptor binding 
cavity. 
 
The process for docking as implemented in the Schrödinger Suite is illustrated in Figure 3.9.  
The ensemble of poses obtained as output from this process can be further evaluated to obtain 
information from force field scoring functions. 
Download PDB file of protein
Delete duplicate protein chains
Delete water molecules not involved in ligand binding
Fix bond orders of co-crystallised ligand
Add missing residues (fill gaps) using primary amino acid sequence
Add hydrogen atoms
Minimise filled gaps  
Crude Protein 
(Receptor) Structure
Protein Preparation Wizard
Align structure in workspace
Assign bond orders and formal charges
Fill missing side chains of residues using primary amino acid sequence
Add hydrogen atoms
Cap termini
Refine structure to relieve strain and re-orient side chains
Prepared Protein 
(Receptor) 
Structure
Extract ligand from 
Prepared Protein 
(Receptor) Structure
Build ligand in Maestro
LigPrep 
Set ionisation state
Generate stereoisomers
Generate tautomers
Generate ring conformations
Minimise structures
Prepared Ligand 
Structure
Docking 
Grid
Glide Dock
or
Induced-Fit Dock
Ranking and 
Selection
of Best Pose
 
Figure 3.9.  Schrödinger Suite ligand docking process. 
3.4.2 Receptor Model Development 
The x-ray crystal structures of the hER LBD listed in Table 3.1 were used to develop models 
for docking.  Where multiple chains were present in the PDB file, chain A was used except as 
noted in Table 3.1.  The atom co-ordinate files as downloaded from the PDB are not 
immediately ready for use in computational docking.  In some of the crystal structures, small 
sections of the protein may not be completely resolved due to static disorder of atoms in the 
crystal.  These unresolved segments result in gaps in the atom co-ordinate files.  These gaps 
in the protein structure (missing residues) were filled using the primary amino acid sequence 
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of the receptor.  The gaps were energy minimised in two stages using MacroModel.  First, 
only the added residues were allowed to move, with the remainder of the crystal structure 
frozen.  Then, the entire structure was minimised.  All minimisations were required to 
converge to 0.05Å.  All water molecules except for the one involved in the hydrogen bond 
bridge with Glu353 and Arg394 in hERα models and Glu305 and Arg346 in hERβ models 
were removed.  To facilitate visual comparisons, all models were aligned in the Maestro 
workspace to 1ERE.  The PDB atom co-ordinate files do not include hydrogen atoms and 
include information only on which atoms are to be connected, not bond order.  In some cases, 
as with unresolved segments discussed above, the side chains of individual amino acids are 
not fully resolved, leading to missing atoms in the residue side chains which requires 
correction.  The N- and C- termini of the protein chain must also be capped or blocked with 
neutral groups to prevent computational artifacts from the charges at the bare ends of the 
protein chain.  An N-methyl group is normally added to the C-terminus and an acetyl group is 
added to the N-terminus to provide neutral methyl groups at the ends of the chain.  The 
Protein Preparation Wizard was used to assign bond orders, add hydrogen atoms, fill in 
missing side chains, cap chain termini, assign hydrogen bonds within the corrected protein 
structure and to perform a final minimisation of the model.   
3.4.3 Ligand Structure Development 
The molecular structures of the co-crystallised ligands were extracted from the PDB files.  
The molecular structures for all other ligands shown in Table A. 7 were constructed in 
Maestro.  For each ligand, LigPrep was used to determine the ionisation state for carboxylic 
acids and amines at pH 7 ± 2; generate tautomers (e.g. keto-enol); generate alternate 
chiralities for all stereocentres; sample ring conformations to find low energy conformations.  
Finally, the geometry of each structure was optimised which involved allowing the structure 
to relax in all dimensions to achieve a low energy conformation.  Not all possible isomers 
were produced because of internal filtering to eliminate structures which violate geometric 
restrictions such as for fused ring systems or conflict with natural product chiralities such as 
for the steroid framework.   
For some ligands LigPrep produced more than one stereoisomer (e.g. both 17α- and 17β-
estradiol were produced).  For those ligands where it was known which stereoisomer was the 
desired or correct one, only that stereoisomer was used for docking (e.g. only 17β-estradiol 
was used).  For ENT, 4 possible isomers were produced, but only the 3R,4R isomer is found 
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in vivo [302] and only that isomer was retained for docking. For EQ, 2 possible isomers were 
produced.  Only the S isomer is found in vivo [303] and the S isomer is much more estrogenic 
than the R isomer [303, 304].  For mEHP (see Figure 3.10), the two stereoisomers produced 
by LigPrep were retained because no information could be found indicating which of the two 
stereoisomers was preferred.  Since mEHP is a metabolite of diethylhexyl phthalate (DEHP, 
CAS 117-81-7), a high volume industrial chemical with unspecified stereochemistry, it is 
likely that the metabolite is a mixture of the two isomers.  A similar situation was found for 
OMC.  The compound must be trans at the carbon-carbon double bond (CAS 546-7-3), but 
the stereochemistry of the 2-ethylhexyl moiety is unspecified, as in mEHP.  For 4MBC, there 
are two chiral centres on the camphor moiety which result in two possible stereoisomers 
(1R,4S and 1S,4R).  4MBC must also be trans at the double bond (CAS 36861-47-9). 
 
 
Figure 3.10.  Stereoisomers of mEHP derived from the parent compound DEHP. 
 
3.4.4 Rigid Receptor Docking - RRD 
RRD was done using Glide and was run from within Maestro using the applications menu.  
The first step in Glide docking was generating a receptor grid.  The binding cavity was 
defined automatically based on the size, shape and location of the co-crystallised ligand of 
the particular receptor model.  For the hERα apo structure (2B23), the centroid of the residues 
Glu353, Arg394 and His524 was used to define the location of the binding cavity and the size 
was determined by specifying ligands to be docked were less than 20 Å in length.  The 
receptor grid was kept rigid – with no van der Waals radius or charge scaling of receptor 
atoms. The ligand was docked flexibly, allowing nitrogen inversions and ring conformations.  
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No constraints (e.g. required hydrogen bonds or covalent bonds to metal atoms) were 
specified and all receptor hydroxyl groups were allowed to rotate. 
Glide XP was used for docking using default parameters.  The core, constraints and similarity 
options were not used.  The core option allows for constraint of ligand poses within the 
binding cavity based on a reference ligand.  The similarity options incorporate a similarity 
measure between a docked ligand and a reference ligand – a measure of how alike or unlike 
two molecules are.  Both the core and similarity options are useful in virtual screening 
applications for drug target development to aid in the identification of strong binding ligands 
from a pool of potential candidates, but not applicable to the task at hand.  All of the ligands 
listed in Table 3.1 were docked with all the receptor models listed in Table 3.1. 
For RRD, poses were ranked by XPPoseRank.  The calculated binding energy is given by the 
scoring function XPGlideScore.  XPGlideScore was reported in units of kcal/mol and 
converted to kJ/mol. 
3.4.5 Induced-Fit Docking - IFD 
IFD was run from within Maestro using the workflow menu.  The Glide grid was defined 
automatically based on the size and orientation of the co-crystallised ligand.  Initial Glide 
docking allows residue side chains to be trimmed (temporarily removed from the protein 
structure) automatically, based on the B-factor.  The B-factor is also called the temperature 
factor and the higher the value, the more mobile the residue side chain.  The more mobile 
side chains were trimmed as their positions were less certain.  The parameters used are 
summarised in Table 3.5. During the induced fit refinement step, the residues that were 
allowed to adapt to the placement of the ligand were those within 5 Å of the ligand, plus 
those residues on H11 where the agonist and antagonist conformations begin to diverge and 
those residues on H8 in the region where His524/475 H-bonds with the protein structure to 
either stabilise its interaction with the ligand or to stabilise itself in the absence of a ligand 
interaction.  The refinement regions are shown in Figure 3.11. 
For IFD, poses were ranked by IFDScore.  IFDScore is defined as the sum of XPGlideScore 
and 5% of the Prime energy (the total energy of the receptor-ligand complex), so this ranking 
takes into account the overall energy of the complex, not just a favourable binding energy.  
The calculated binding energy is given by the scoring function XPGlideScore. 
Table 3.5.  IFD parameters 
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Glide Grid Setup 
Box Centre Centroid of Ligand 
Box Size automatic based on co-crystallised ligand 
centroid of Glu353,Arg394 and His524 for apo model 2B23.  Box is 26 Å 
long in each direction 
Step 1:  Initial Glide Docking 
Protein Preparation Constrained 
Refinement 
Yes 
Trim Side Chains Yes, automatic based on B-factor 
receptor van der Waals scaling  0.7 
ligand van der Waals scaling 0.5 
# poses retained per ligand 5 
Step 2: Prime induced fit refinement 
Refine residues  within 5Å of ligand 
additional residues:  hERα 418-425, 514-547; hERβ 370-377, 465-501 
optimise side chains 
Step 3: Glide re-docking 
Glide Docking XP mode; 
Redock into structures within 30 kcal/mol of best structure and within the 
top 5 structures overall 
 
 
(a) agonist model refinement region 
 
(b) antagonist model refinement region 
 
Figure 3.11.  Refinement regions for agonist and antagonist models, illustrated with hERα models 1ERE 
and 1ERR.  Residues within 5Å of the ligand are shown in grey, key ligand binding residues 
(Glu353,Arg394 and His524) are shown in yellow and the additional residues included for refinement are 
indicated by the ribbon representation.  The analogous refinement regions were used for hERβ. 
3.4.6 XPGLideScore 
XPGlideScore was used in both RRD and IFD to estimate binding energy of the ligand with 
the receptor.  XPGlideScore is optimised to identify and eliminate ligand poses that would 
have unfavourable energies based on well known principles of physical chemistry (e.g. 
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inappropriate hydrophobic interactions, poor hydrogen bonding interactions) to weed out 
false positives.  As a result, more precise poses are produced [305] than with standard 
GlideScore.  The cost for this increased precision is computational time.  Standard 
GlideScore is used for ligand database enrichment to quickly identify good candidates for 
more thorough study using XPGlideScore. 
3.4.7 Validation 
Validation of the performance of both RRD and IFD examines the accuracy of both ligand 
placement and binding energy calculation. 
The accuracy of ligand placement is quantified by the root mean square distance (RMSD) of 
the heavy atoms (C, O, N, S) of the ligand in the model and the docked pose. The difference 
between calculated and experimental binding energy was determined to quantify the accuracy 
of the binding energy calculation.  The number of unique poses within the set of multiple, 
energy-equivalent poses produced was also determined. 
It is commonly accepted that the accuracy of a computation required to make chemical 
predictions is 1 kcal/mol (= 4.2 kJ/mol) [306, 307].  With this in mind, when multiple poses 
for a given ligand/model combination are produced by the docking calculation, poses with 
calculated binding energies within 4.2 kJ/mol of the top-ranked pose are described as energy 
equivalent.  Poses with calculated binding energies more than 4.2 kJ/mol from the top ranked 
pose are therefore disregarded. 
The correlation of experimental and calculated binding energies was examined for those 
ligands that have experimental binding energies as summarised in Table 3.3.  The calculated 
binding energy was considered correct if it was within ±3 kcal/mol (±12.5 kJ/mol) of the 
experimental value [301]. 
3.5 Results 
Several crystal structures were used for each of the agonist and antagonist α and β receptor 
conformations in order to capture subtle variations.  A total of 15 models were developed, 
one from each of the 15 crystal structures.  Two docking processes were used.  Rigid docking 
holds these models static and IFD allows the models to mutually adapt.  With rigid docking, 
the subtleties among the different models are retained and the docking calculation determines 
how favourably the particular ligand interacts with a given model.  Thus, for less flexible 
ligands, the ligand will only be docked into models that it fits.  Poor fitting will be evident in 
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less favourable calculated binding energies, or the failure to return a docked pose.  The more 
flexible ligands are better able to adapt to the fixed binding site topology.  Flexible ligands 
may have more poses within the binding site.  The calculated binding energies will indicate 
how ‘uncomfortable’ a particular binding site is for a particular ligand pose. Among the 
models that a flexible ligand can fit, the relative difference in calculated binding energies will 
indicate which of the different receptor-ligand complex conformations are more favourable. 
In contrast, IFD allows the receptor model to adapt to a ligand pose and one might expect 
similar individual models to converge to a common conformation for a given ligand, if the 
ligand is effective in influencing the receptor conformation.   
3.5.1 RRD and IFD validation 
3.5.1.1 Native Ligand Re-docking 
The first step in validation for both RRD and IFD was native ligand re-docking.  The ability 
of the docking procedure to correctly place the ligand and to correctly predict the binding 
energy was evaluated for 14 models.  Poses are considered energy-equivalent to the top-
ranked pose if the difference in calculated binding energies is ≤4.2 kJ/mol. The results for 
ligand position RMSD, the difference between calculate and experimental binding energy 
(ΔGbind), the number of energy-equivalent poses and the number of the energy-equivalent 
poses that are unique are summarised in Table 3.6. 
RRD correctly placed the native ligand in all but one model (shaded in red in Table 3.6).  The 
top-ranked pose for E2 in 1A52 was upside-down.  The second pose was correct and was 
energy-equivalent to the top-ranked pose with a 0.02 kJ/mol difference in calculated binding 
energy.  Of the 8 models that had multiple energy-equivalent poses, only 4 had more than one 
unique energy equivalent pose (1A52, 1ERR, 1XPC and 1QKM).  The ligands of both 1ERR 
and 1XPC have large pendant groups, and the differences in poses were in the location of this 
pendant group.  For model 1QKM, the difference in poses was due to rotation of 30° around 
the single bond connecting the A and B rings of GEN that inclined the fused flavone ring 
structure relative to the benzene A-ring. 
IFD correctly placed the ligand in all but three models (shaded in red in Table 3.6).  
However, for these three models, the correct pose was one of the multiple energy-equivalent 
poses and the details for the correct pose are given in Table 3.6.  For GEN in 1X7R, the top-
ranked pose was in backwards compared to the correct orientation, but the energy difference 
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was less than 1kJ/mol.  For GEN in 1QKM, the difference in poses is the rotation round the 
bond connecting the A and B rings, described above for the rigid docking result.  The energy 
difference in this case is 2.3 kJ/mol.  For 1L2J, the top-ranked pose is rotated by 180° along 
the length-wise axis of the ligand as compared to the correct pose.  The pose that is closest to 
the correct orientation of the ligand is still displaced slightly due to the positioning of the 
ethylene substituents. 
For both RRD and IFD, the binding energy was correctly predicted for all but the same two 
models (shaded in red in Table 3.6).  In both cases the predicted binding energies were more 
favourable than experimental.  For model 2P15, the interactions with EZT are different from 
those of the other receptor-ligand pairs, with the pendant group extending down into the 
binding cavity rather than out of the cavity.  These interactions may not be captured well with 
the scoring function as this model is likely too new to have been included in the scoring 
function calibration.  Model 1XPC is also a recent addition to the literature and also has 
different interactions than the other antagonist models (1ERR and 3ERT).  The correlation 
between experimental and calculated binding energies is shown in Figure 3.12. 
 
 
  
Table 3.6.  Validation of RRD and IFD docking procedures by native ligand re-docking.  Red shading indicates results that are outside the validation criteria.  See 
text for details. 
    RRD IFD 
   
ΔGbind 
(kJ/mol) 
ΔGbind 
(kJ/mol) 
RMSD 
(Å) 
Distinct 
/Energy 
Equivalent 
Poses 
Correct 
Pose 
ΔGbind 
(kJ/mol) 
RMSD 
(Å) 
Distinct 
/Energy 
Equivalent 
Poses 
Correct 
Pose 
 Model Ligand Expt. Calc. Diff    Calc. Diff    
ERα 
1ERE E2 -52.8 -49.0 3.7 0.15 1/1  -51.3 1.4 0.26 2/5  
1A52 E2 -52.8 -49.8 3.0 
upside-
down 
2/2 
2 
ΔG = -49.6 kJ/mol 
RMSD = 0.14 Å 
-47.5 5.3 0.25 1/4  
1X7R GEN -42.3 -48.7 -6.3 0.17 1/1  -51.7 -9.4 backwards 3/4 
3 
ΔG = -50.9 kJ/mol 
RMSD = 0.39 Å 
3ERD DES -54.8 -48.9 5.9 0.39 1/2  -52.0 2.8 0.43 2/5  
2P15 EZT -54.7 -68.9 -14.2 0.30 1/3  -87.6 -32.9 0.38 1/2  
1ERR RAL -51.9 -56.3 -4.4 0.77 2/8  -59.1 -7.2 0.52 2/4  
1XPC AIT -47.3 -64.2 -16.9 1.08 2/2  -65.5 -18.2 0.43 2/3  
3ERT OHT -51.1 -59.6 -8.6 0.38 1/3  -59.6 -8.5 0.79 3/4  
ERβ 
3OLS E2 -51.8 -42.3 9.5 1.23 1/1  -52.4 -0.6 0.33 1/1  
1X7J GEN -49.3 -45.6 3.7 0.59 1/1  -48.0 1.3 0.32 2/5  
1QKM GEN -49.3 -45.2 4.1 0.28 2/3  -48.6 0.7 0.83 2/4 
4 
ΔG = -46.3 kJ/mol 
RMSD = 0.24 Å 
2JJ3 JJ3 -50.7 -45.9 4.8 0.21 1/2  -48.7 2.0 0.85 4/5  
2QTU 3AS -49.2 -54.4 -5.2 0.12 1/1  -55.0 -5.8 0.43 1/5  
1L2J ETC -44.8 -51.1 -6.3 0.80 1/1  -53.8 -4.6 
rotated 
180° 
2/4 
4 
ΔG = -52.3 kJ/mol 
RMSD = 1.75 Å 
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(a) RRD 
 
(b) IFD 
 
Figure 3.12.  Correlation of calculated and experimental ΔGbind for RRD and IFD native ligand re-
docking.  Solid line is 1:1 correlation and broken lines indicate ±12.5 kJ/mol uncertainty region of 
calculated binding energy.   
 
3.5.1.2 Co-crystallised Ligand Cross-docking 
The second step in the validation was cross-docking of co-crystallised ligands in the other 
models.  The results for RRD and IFD are summarised in Table 3.7 and Table 3.8 
respectively.  The native docking results are also included for completeness.  In both tables, 
the calculated binding energy for the top-ranked pose is given.  Green shading indicates that 
the top-ranked pose had the ligand in the correct orientation in the receptor model.  Yellow 
shading indicates that the correct pose was energy-equivalent to the top-ranked pose.  No 
shading indicates that none of the energy-equivalent poses were correct.  ND indicates the 
ligand was not docked into the model.   
IFD was able to reproduce the correct ligand docking pattern achieved by RRD.  RRD was 
able to correctly dock both E2 and GEN into most α-agonist, β-agonist and β-antagonist 
models.  IFD had similar success for docking GEN, but less success with E2.  IFD appears to 
favour the rotation of Leu524/476 into the binding cavity and this causes a clash with the 13-
CH3 of E2.  In these situations, E2 was docked upside-down or backwards.  The β-antagonist 
ligands JJ3 and 3AS were correctly docked into 1X7R in their α-agonist positions.  IFD was 
slightly less successful in docking 3AS than JJ3, likely because the two F atoms of 3AS 
required more adjustment than the 2 H atoms of JJ3.  The third β-antagonist ligand, ETC, was 
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not correctly docked into any of the other models.  The interactions of ETC with the ERs 
appear to be very subtle.  The correct conformation of the C-ring and its ethylene substituent 
could not be achieved with most models.  IFD was able to produce the pocket needed to 
correctly position EZT into models 1ERE, 1QKM and 1L2J.  Neither RRD nor IFD was able 
to correctly dock any of the ligands into 2B23.  In 2B23, the key residues Glu353, Arg394 
and His524 are displaced significantly from the positions required for interaction with the 
ligands.  IFD is able to achieve some movement of Glu353 and Arg394 to allow the ligands 
to be placed within the binding cavity, but IFD is not able to move His524 sufficiently to 
complete the binding interaction.  IFD was also unable to successfully dock the α antagonists 
(RAL, OHT and AIT) into either the α or β agonist models.  In all cases, the large wedge of 
the ligand was compacted into the binding cavity.  The correct docking achieved with 1A52 
was a result of the deflected position of H12, allowing the wedge to be positioned in the 
entrance channel.   
The correlation of calculated with experimental ΔGbind is shown in Figure 3.13 for both RRD 
and IFD cross-docking.  Only the results where the ligand is correctly docked are included. 
Overall, the scoring function performs very well, but IFD tends to result in calculated binding 
energies that are more favourable than the experimental values for hERα. 
 
 
 Figure 3.13.  Correlation of calculated and experimental ΔGbind for RRD and IFD cross-docking.  Solid 
line is 1:1 correlation and broken lines indicate ±12.5 kJ/mol uncertainty region of calculated binding 
energy.   
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Table 3.7.  Calculated binding energies (kJ/mol) of the top-ranked pose obtained by RRD cross-docking 
co-crystallised ligands in the other models.  ND indicates the ligand was not docked in the model.  Green 
shading indicates the correct orientation of ligand was achieved.  Yellow shading indicates the binding the 
correct orientation achieved in a pose that was an energy-equivalent to the top-ranked pose. 
 
 
E2 GEN DES EZT RAL AIT OHT JJ3 3AS ETC 
ERα Agonist 1ERE -49.0 -45.1 -45.6 ND ND ND ND -50.4 -49.4 -48.5 
1A52 -49.6 -44.8 -45.5 ND -39.0 -49.2 -63.5 -52.0 -52.5 -53.6 
1X7R -45.7 -48.7 -49.1 ND ND ND ND -54.2 -54.4 -58.7 
3ERD -46.7 -48.5 -48.5 ND ND ND ND -53.2 -45.5 -58.6 
2P15 -47.8 -46.2 -46.2 -68.9 -47.6 -39.8 -52.4 -48.9 -51.4 -42.4 
ERα Antagonist 1ERR -42.6 -47.0 -45.5 -27.2 -56.3 -39.6 -53.3 -31.8 -33.0 -29.6 
1XPC -46.7 -47.2 -49.4 ND -58.1 -64.2 -61.4 -47.6 -31.3 -24.7 
3ERT -19.9 -43.7 -47.0 -23.5 -51.6 -30.5 -59.6 -28.5 -24.5 -49.8 
EBβ Agonist 3OLS -42.3 -44.4 -44.0 ND ND ND ND -47.8 -49.9 -47.7 
1X7J -42.6 -45.6 -47.0 ND ND ND -30.2 -50.5 -53.2 -50.1 
ERβ Antagonist 1QKM -45.0 -45.2 -43.1 ND ND ND ND -47.5 -42.5 -48.8 
2JJ3 -37.3 -38.9 -40.1 ND -38.8 ND -43.1 -45.9 -48.8 -48.3 
2QTU -40.9 -41.4 -40.8 ND ND -17.8 -27.6 -48.9 -54.4 -50.6 
1L2J -37.9 -41.9 -42.2 ND ND ND -28.3 -48.3 -51.1 -50.1 
 
Table 3.8.  Calculated binding energies (kJ/mol) of the top-ranked pose obtained by IFD cross-docking 
co-crystallised ligands in the other models.  ND indicates the ligand was not docked in the model.  Green 
shading indicates the correct orientation of ligand was achieved.  Yellow shading indicates the correct 
orientation achieved in a pose that was an energy-equivalent to the top-ranked pose.   
 
 
E2 GEN DES EZT RAL AIT OHT JJ3 3AS ETC 
ERα  
Agonist 
1ERE -51.3 -52.1 -52.7 -64.7 -52.0 -64.7 -58.7 -53.6 -54.1 -58.0 
1A52 -47.5 -47.4 -44.9 -57.3 -55.0 -55.9 -63.5 -53.1 -49.8 -57.2 
1X7R -52.9 -51.7 -51.3 -58.8 -63.8 -48.1 -65.1 -57.1 -56.5 -65.9 
3ERD -57.8 -48.1 -52.0 ND ND -69.2 -62.5 -67.8 -55.6 -63.1 
2P15 -54.4 -51.6 -46.0 -87.6 -56.8 -54.0 -61.9 -67.4 -59.3 -61.5 
ERα  
Antagonist 
1ERR -49.3 -49.2 -47.7 -49.2 -59.1 -60.2 -67.3 -46.8 -49.3 -52.5 
1XPC -55.1 -52.6 -53.2 -55.1 -71.3 -65.5 -68.6 -51.1 -54.4 -49.3 
3ERT -48.7 -47.0 -50.9 -43.0 -53.0 -58.4 -59.6 -51.0 -53.2 -53.8 
EBβ  
Agonist 
3OLS -52.4 -47.4 -47.4 -46.7 -39.2 -44.9 -53.6 -47.9 -53.2 -54.5 
1X7J -50.5 -48.0 -49.6 -58.8 ND -50.8 -52.8 -53.0 -52.6 -56.7 
ERβ  
Antagonist 
1QKM -44.3 -48.6 -46.9 -66.2 -50.0 -51.0 -44.7 -49.6 -51.1 -50.8 
2JJ3 -43.6 -45.4 -48.2 -53.1 -51.1 -52.5 -54.5 -48.7 -51.0 -51.7 
2QTU -46.5 -43.6 -50.6 -55.7 -58.4 -55.2 -52.8 -48.3 -55.0 -57.9 
1L2J -42.5 -44.9 -46.6 -58.7 -58.5 -47.0 -42.5 -44.7 -55.4 -52.0 
 
With the results summarised in Table 3.7 and Table 3.8, the models that were best able to 
capture the known range of interactions of ligands with the receptor were 1ERE, 1X7R, 
1ERR, 3OLS, 1X7J, 1QKM and 2JJ3.  The remainder of the study will be limited to these 
models of the hER. 
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3.5.1.3 Ligands without Crystal Structures 
The only validation that is possible for the docking of ligands without crystal structures is the 
comparison of calculated and experimental binding energies shown in Figure 3.14.  Both 
RRD and IFD predict the experimental binding energies for these ligands within the stated 
uncertainty of ±12.5 kJ/mol.  The results shown in Figure 3.14 are for the ligands identified in 
Table 3.3 as not having published crystal structures.  Their experimental binding energies are 
also given in Table 3.3. 
 
(a) RRD hERα models 
 
(b) RRD hERβ models 
 
(c) IFD hERα models 
 
(d) IFD hERβ models 
 
Figure 3.14.  Correlation of experimental and calculated binding energies for (a,b) RRD and (c,d) IFD.  
Solid line indicates 1:1 correlation; broken lines indicate stated uncertainty of ±12.5 kJ/mol. 
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3.5.2 Calculated Binding Energies 
The calculated binding energies for those ligands that do not have literature values for 
comparison are summarized in Table 3.9.  The shaded value is the most favourable binding 
energy for that ligand.  TRIC could not be docked in any of the models.  Most of the 
remaining ligands have the most favourable binding energy when docked in hERα agonist 
models.  Only 4 ligands preferred antagonist models.    mTRIC is notable in that it could only 
be docked in antagonist models and showed a considerable preference for the hERβ 
antagonist models. 
Table 3.9.  Calculated binding energies (kJ/mol) for ligands without literature values. 
 ERα ERα ERβ ERβ 
 Agonist Antagonist Agonist Antagonist 
NP-M1 -43.0 -40.9 -36.2 -36.6 
NP-M2 -42.3 -36.9 -37.3 -34.8 
NP-M3 -31.9 -35.4 -32.9 -32.1 
OMC-S -44.6 -34.3 ND -39.7 
OMC-R -44.4 -40.4 -40.9 -39.4 
BP-3 -43.5 -39.7 -41.7 -41.7 
PHBA -31.0 -28.5 -28.8 -28.4 
M-Paraben -30.9 -30.9 -30.5 -29.5 
mTRIC ND -26.3 ND -38.9 
TRIC ND ND ND ND 
3PBA -45.9 -42.3 -46.3 -40.9 
3PBOH -40.7 -39.3 -40.4 -38.7 
4OH-3PBA -40.7 -36.0 -37.1 -36.6 
4OH-3PBOH -41.3 -40.5 -38.6 -39.3 
mOP -44.0 -42.9 -44.5 -39.5 
mEHP-S -43.9 -41.2 -44.9 -46.0 
mEHP-R -44.4 -42.3 -46.4 -44.3 
mBzP -46.7 -37.3 -45.0 -41.6 
mBP -46.5 -44.1 -46.1 -32.5 
mEP -37.0 -36.1 -35.9 -36.1 
mMP -38.6 -39.6 -33.5 -34.6 
 
3.6 Discussion 
3.6.1 Challenges and Limitations in Computational Docking 
Although there is a theoretical and physical basis for the calculations in computational 
docking, the complexity of the systems necessitates assumptions and simplifications in order 
to make the problem tractable and computationally possible with current computer systems.  
These assumptions and simplifications result in the introduction of errors which can lead to 
numerical disagreement between computational results (e.g. binding energy) and 
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experimental data.  Minimising the effects of these assumptions and simplifications and 
improving their quality is an active area of research in computational chemistry. 
Defining or calibrating scoring functions to predict binding energies from computational 
results is one way to minimise the effects of these assumptions.  However, in some cases, 
these calibrated scoring functions may not be the best choice if the system under study 
behaves very differently from those used in calibrating the scoring function.  In such cases, 
the energy values produced directly by the computations may be a better choice.  
Alternatively, if the numerical accuracy of a particular scoring function is not sufficient for 
the purpose at hand, docked receptor-ligand complexes can be re-scored using one of many 
different scoring functions available [278-280]. 
For the present study, the scoring function implemented in the Schrödinger Suite is a good 
choice because hERα is one of the systems used in the calibration of the GlideScore scoring 
function and validation of the Glide docking methodology [300, 308, 309].  Glide has been 
shown to perform better than many other docking software packages in both accuracy of 
predicted binding energies and in accuracy of ligand placement [300, 308, 309].  It is 
therefore not unreasonable to expect that the calculated binding energies and ligand poses 
obtained from the Schrödinger Suite for this study of hERα and hERβ to be representative of 
what may occur in vivo.  However, for the purposes of the present work, it is still important to 
recognise that computational results may not always agree numerically with experimental 
results but should reflect the trends demonstrated by experimental results.  For these reasons, 
validation of the model results using known test scenarios is essential to gain confidence in 
the computations for predicting behaviour in unknown systems. 
One of the characteristics of rigid receptor docking is that the docked ligands tend to be 
confined to the volume described by the co-crystallised ligand in the receptor model.  Since 
the volume occupied by an agonist is generally smaller than that occupied by an antagonist, 
all ligands will be docked into both agonist and antagonist models.   
With the rigid receptor model, the binding cavity residues are held fixed and the ligand is 
required to adapt to the binding cavity to find a low energy conformation for the system.  As 
a result, the positions of the key binding cavity residues are important in determining ligand 
position within the binding cavity.  For a given ligand, the differences in key residue 
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positions may be expected to influence the most favourable conformation of the ligand in the 
binding site.   
It is therefore expected that the known orientation of a given ligand may not be produced by 
rigid receptor docking in all models, but it is expected that docking the ligand into the model 
from which it came will produce the correct pose.  It is also expected that the alternate poses 
for a given ligand in some models will have calculated binding energies that are less 
favourable than that obtained by re-docking the ligand into the model from which it came.  It 
is also possible that rigid receptor docking fails to place the ligand in the binding cavity of a 
particular model.   
When performing IFD, it is reasonable to expect that any given ligand would be docked into 
any of the models, provided that the adjustment of the models by the induced-fit procedure 
allows the model to adapt to the ligand.  Thus, using multiple models as starting points, it is 
reasonable to expect most of the models to converge to a common point which is consistent 
with the crystal structure orientation of the ligand.  This convergence should occur if the 
search space is large enough to include this point and it is a true minimum in energy for the 
system.  Depending on the flexibility of the ligand, multiple distinct and similarly favourable 
poses may be obtained and convergence to a common point may not be as clean.  The 
interpretation of this scenario is that the ligand is similar to that already observed for GEN; 
that the ligand may act as a partial agonist or partial antagonist. 
3.6.2 Validation Study 
The validation study has demonstrated that  
 both RRD and IFD can correctly place a native ligand into its model and can correctly 
place ligands with known orientations in the binding cavity of models that are similar 
to the native model.   
 the scoring function is able to predict the experimental binding energy within the 
stated uncertainty of ±12.5 kJ/mol.   
RRD worked as expected for the validation set of ligands.  Both native re-docking and cross-
docking gave the correct pose and correct binding energy (Table 3.6, Figure 3.12, Figure 
3.13).  RRD did not return a pose for ligands that were not supposed to fit into the binding 
cavity.  Specifically, the ligands with large pendant groups RAL, AIT, OHT and EZT were 
docked only in their native models.   For 8 of the 14 models, native re-docking produced 
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multiple energy equivalent poses. On examination, more than one distinct pose was found for 
only 4 of the models.       
IFD worked as expected for native re-docking.  Both the ligand poses and calculated binding 
energies were correct and were consistent with the RRD results.   IFD cross-docking results 
were not as definitive as those obtained with RRD.  Multiple distinct energy equivalent poses 
were produced for most ligands including the rigid ligands.  In contrast to RRD, IFD cross-
docking returned poses for the 3 α-antagonist ligands in the agonist models.  In these models, 
the ligand was coiled and folded to fit into the binding cavity.  These poses were considered 
invalid and were disregarded.  IFD was not expected to correctly dock these ligands in these 
models because of the position of H12.  This does illustrate the point that just because a pose 
is returned with a favourable binding energy, doesn’t mean it is a valid pose.  IFD results 
have to be carefully evaluated using knowledge of the system under study.   
IFD was not able to correctly dock the α-antagonist ligands into the hERβ antagonist models.  
All three of these ligands are known to bind to hERβ because there are experimental binding 
energies for all three ligands and because crystal structures for OHT in hERβ (PDB 2FSZ) 
and RAL in the rat ERβ (PDB 1QKN) are published.  In these crystal structures, both ligands 
take positions in ERβ analogous to their positions in ERα.  The failure of IFD to successfully 
place these ligands in the antagonist hERβ models is a result of the position of H12 and the 
loop connecting H11 and H12 in these models (Figure).  H12 is not displaced as far in the 
hERβ models as it is in the hERα antagonist models or in 2FSZ.  In the case of OHT, the loop 
at V487 clashes with what would be the position of the terminal amide of OHT, preventing 
full extension of the side chain.  The binding orientation of OHT in 2FSZ may also be aided 
by binding of a second OHT molecule to the co-activator binding site, radically displacing 
H12 and its connecting loop. 
GEN provides a particular challenge to both RRD and IFD.  GEN behaves as an agonist in 
hERα and as both an agonist and antagonist in hERβ.  Gen takes essentially the same position 
within the binding site in all three situations and the binding affinity is greater for hERβ than 
for hERα.  RRD cross-docking predicted the correct orientation of GEN 4 of 5 hERα agonist 
models and in all the hERβ models, although the flavone ring was tilted slightly compared to 
the expected orientation.  In the other hERα agonist models GEN was docked backwards.  
The backwards docking of GEN has been previously reported [273], so was not unexpected.     
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This validation has also highlighted the limitations of IFD in convergence of different models 
to a common end point.  IFD was unable to reposition the key residues of model 2B23 to 
correctly position the ligands as found in the other α-agonist models.  IFD was also not able 
to move His524 of model 3ERT to correctly dock RAL or for 1ERR to accommodate AIT.  
To accurately consider the positioning of EEs in the binding cavity, the models 1ERE, 1X7R, 
1ERR, 3OLS, 1X7J, 1QKM and 2JJ3 were deemed most representative of the behaviour of 
hERα and hERβ as these models had the best success rate in ligand cross-docking.  The 
receptor-ligand interactions represented by the other models were considered too far removed 
from the convergence point defined by E2 and GEN and possibly only achievable by the 
specially designed ligands. 
3.6.3 Important Receptor-Ligand Interactions 
The cross-docking exercise revealed two ligand interactions with the receptor models that are 
important in understanding the binding behaviour of environmental estrogens.  They are the 
rotation of the binding cavity and how this leads to the uncoiling H11 and the A-ring clamp.  
3.6.3.1 Rotation of the binding cavity 
The positions of His524/475, Leu525/476 and Ile424/376 are strongly influenced by the 
bound ligand and differ significantly between the agonist and antagonist models as illustrated 
in Figure 3.15 with 1ERE and 1ERR and in Figure 3.16 with 1ERE and 3ERT.  These 
differences create a rotation of the binding site as illustrated in Figure 3.17.  The residue side 
chains are able to take up some of the distortion of the binding site caused by the various 
ligands, but eventually, the distortion is transmitted to the backbone of the protein structure.  
The relative positions of the carbonyl and amide functionalities of the protein backbone 
determine whether the hydrogen bonding network that stabilises the α-helix structure remains 
intact with ligand binding.  The antagonist conformation is achieved by uncoiling H11 by one 
turn, lengthening the loop between H11 and H12 and thus allowing H12 to take up the 
position characteristic of the antagonist receptor model.   
In both 3ERT and 1ERR, the backbone hydrogen bond network is broken by the shift in 
position of Leu525 as shown in Figure 3.18.  The carbonyl of Leu525 forms a hydrogen bond 
with the amide and the side chain hydroxyl of Ser527, one residue earlier than in 1ERE.  This 
disrupts the subsequent backbone hydrogen bonds allowing the helix to uncoil.  In 1XPC, 
H11 uncoils one turn earlier.  In 1XPC, the ligand’s B-ring is 6-membered whereas in RAL, 
this ring is 5-membered.  The D-ring hydroxyls of the two ligands are in different positions 
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thus influencing the position of His524.  OHT does not have a D-ring hydroxyl so is unable 
to engage His524.  Instead, the side chain of His524 forms a hydrogen bond with the side 
chain carboxylate of Glu419, aiding the disruption of the backbone hydrogen bond network. 
These hydrogen bonding networks are summarised in Table 3.10 and are consistent among 
the α and β models.   
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Figure 3.15.  Comparison of 1ERR (green) and 1ERE (pink) binding cavities.  Note shift in D-ring end 
caused by RAL (green). 
 
Figure 3.16.  Comparison of 3ERT (green) and 1ERE (pink) binding cavities. Note shift in D-ring end 
caused by OHT (green) and deflection of His524 out of binding cavity because OHT does not engage with 
it. 
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Figure 3.17.  Schematic illustration of the rotation of the binding cavity between agonist (1ERE, pink) and 
antagonist (1ERR, green) models. 
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(a) Ribbon representation of H11, H12 and connecting loop for 1ERE (pink) and 1ERR (green) 
 
(b) Residues Met522-Lys529 (located in H11) of model 1ERE  
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(c) Residues Met522-Lys529 (located in H11) of model 1ERR 
 
Figure 3.18.  Mechanism of H11 uncoiling illustrated using hERα models 1ERE (pink) and 1ERR (green).   
 
Table 3.10.  Hydrogen bonding pattern (carbonyl → amide).  Residue differences between hERα and 
hERβ are highlighted in red. 
hERα  hERβ 
Agonist (1ERE) Antagonist (1ERR) Agonist (3OLS) Antagonist (1L2J) 
Met522 → Tyr526 Met522 → Tyr526 Met473 → Leu477 Met473 → Leu477 
Glu523 → Ser527 Glu523 → Glu474 → Asn478 Glu474 →  
His524 → Met528 His524 → Ser527 His475 → Met479 His475 → Asn478 
Leu525 → Lys529 Leu525 → Leu476 → Lys480 Leu476 →  
Tyr526 → Cys530 Tyr526 → Leu477 → Cys481 Leu477 →  
Ser527 → Lys531 Ser527 → Asn478 → Lys482 Asn478 →  
Met528 → Val533 Met528 → Met479 → Val484 Met479 → Cys481 
Lys529 →  Lys529 → Lys480 →  Lys480 → 
 
A measure of the disruption of the α-helix structure is the relative angle between the 
backbone carbonyls between His524/475 and Leu525/476.  The positions of His524 and 
Leu425 of hERα (His475 and Leu476 equivalent in hERβ) of all 7 of the hER receptor 
models with agonist ligands bound are shown in Figure 3.19.  The side chain of His524/475 
is able to take up the disruption caused by the variation in length of agonist ligands so as not 
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to disturb the orientations of the backbone carbonyls that participate in hydrogen bonding in 
the backbone of H11.   
 
Figure 3.19.  The effect of agonist binding on positions of both His524/Leu425 of hERα and 
His475/Leu476 in hERβ.  All hERα and hERβ models are shown. Note conservation of position of protein 
backbone carbonyls as indicated by yellow circles and position of Leu side chain.  The His side chain 
takes up the ligand-imposed distortion. 
A similar view of the hERα antagonist models are shown in Figure 3.20 with model 1ERE 
(green) included for reference.  The circles are in exactly the same position as in Figure 3.19.  
The effect of antagonist binding on the relative positions of the two backbone carbonyls is 
clear.  The side chains of His524 and Leu525 are significantly shifted and are unable to 
accommodate the disruption without disturbing the backbone hydrogen bonding of H11.  
This leads to a breakdown in the α-helix structure of H11, lengthening the loop connecting 
H11 and H12, allowing H12 to rest in the coregulatory protein binding groove.   
In hERβ, the disruption of the protein backbone at His475/Leu476 caused by antagonist 
binding is more dramatic than that for hERα, as shown in Figure 3.21.  As discussed in 
Section 3.2.1, hERβ antagonist molecules do not require the large ‘wedge’ substituent to 
maintain the antagonist conformation of hERβ.  For the hERβ antagonist ligands to maintain 
the antagonist conformation of hERβ, the disruption of the protein backbone at 
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His475/Leu476 must therefore be more dramatic and extensive.   As a result, the hERβ 
antagonist ligands do not need to be able to physically block the closed position of H12. 
The relative positioning of the carbonyls between His524/475 and Leu525/476 in each of the 
models was measured using the dihedral angle tool in Maestro.  The angle is defined in 
Figure 3.22 and the results are summarised in Table 3.11.  This angle is larger for antagonists 
than for agonists in both models and may be diagnostic of the agonist/antagonist behaviour of 
EEs. 
 
Figure 3.20.  The effect of antagonist binding on positions of His524/Leu525 of hERα.  Models 1ERR, 
1XPC and 3ERT are shown in orange.  The yellow circles indicate where the carbonyls are located in the 
agonist receptor conformation of Figure 3.19. The model 1ERE is shown in green for reference.  Note the 
dislocation of the backbone carbonyls.   
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Figure 3.21.  The effect of antagonist binding on positions of His475/Leu476 of hERβ.  Models 1L2J, 
1QKM, 2JJ3 and 2QTU are shown in purple.  The yellow circles indicate where the carbonyls are located 
in the agonist receptor conformation of Figure 3.19. The model 3OLS is shown in green for reference.  
Note the dislocation of the backbone carbonyls. 
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Figure 3.22.  Definition of the dihedral angle between the backbone carbonyls of His and Leu. 
 
Table 3.11.  Dihedral angle measured for each of the models with the co-crystallised ligand in place.  
Ligand length as measured between opposing hydroxyl groups is also given. 
 Model Ligand Dihedral Angle Ligand Length (Å) 
hERα Agonist 
 
3ERD DES 15.5 12.1 
1X7R GEN 16.5 12.2 
1L2I ETC 18.9 12.1 
1ERE E2 21.1 11.0 
1A52 E2 21.1 11.0 
hERα Antagonist 1XPC AIT 22.9 11.6 
1ERR RAL 29.3 11.7 
3ERT OHT 32.4 10.7 
hERβ Agonist 3OLS E2 16.4 11.0 
1X7J GEN 18.5 12.2 
hERβ Antagonist 2JJ3 JJ3 20.1 11.9 
2QTU 3AS 21.8 12.0 
1L2J ETC 24.1 12.1 
1QKM GEN 25.0 12.2 
 
 
The diagnostic ability of the dihedral angle was evaluated with the IFD cross-docking results.  
When cross-docked in 1ERE, GEN caused the dihedral angle to decrease from 21.1° to 16.4°, 
the same angle as seen with GEN in 1X7R.  In contrast, when cross-docked in 1X7R, E2 
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results in an opening of the dihedral angle to 18.9°, approaching the angle seen in 1ERE.  The 
longer ligand (GEN) is able to stretch the binding cavity to actively engage both ends of the 
binding cavity, resulting in a decrease in the dihedral angle, straightening the α-helix 
structure of H11, possibly producing small changes in the positioning of H12 over the 
binding cavity.  The shorter ligand (E2) is able to contract the binding cavity slightly, but the 
13-CH3 of E2 prevents the binding cavity from collapsing by holding Leu525 in place. 
E2 was correctly docked in 1ERR, causing the dihedral angle to decrease slightly from 29.3° 
to 28.2°.  A larger change was not seen because E2 engaged the key residues in a similar 
manner to RAL.  The inability of IFD to model large changes in protein structure may also 
have attenuated the response.  However, when OHT was docked in 1ERR, the dihedral angle 
decreased to 18.5°.  OHT was not able to engage His524 because it does not have a D-ring 
hydroxyl, thus allowing the His524-Leu525 pair to collapse into the binding site.  This 
collapse was seen because the exact positioning of the wedge of OHT was different in the 
cross-docking pose of OHT in 1ERR from that of OHT in its native crystal structure.   
A similar pattern was seen with hERβ models.  GEN resulted in a decrease in the angle when 
cross-docked in 3OLS and E2 caused an increase in angle when cross-docked in 1X7J.   
The most convincing evidence for the dihedral angle to indicate agonist or antagonist 
behaviour is in model 1A52 where H12 is deflected away exposing the entrance channel for 
positioning of the antagonist ligand wedge, yet the binding cavity residues are in the agonist 
conformation.  All 3 of the α-antagonists (AIT, OHT and RAL) were correctly docked in 
1A52 causing the dihedral angle to increase from 21.1° to 26.0°, 26.1° and 29.7° respectively.   
Thus, if the dihedral angle for hERα poses is less than 21.1°, the ligand is most likely to 
behave as an agonist.  For hERβ, a slightly narrower angle of 18.5° differentiates agonists 
from antagonists. 
The ligand’s ability to effectively engage both ends of the binding cavity, in addition to 
having a wedge to physically reposition H12 in hERα determine the ligand’s ability to 
influence the receptor conformation.  
3.6.3.2 A-ring Clamp 
The second feature of the binding site that plays a key role in ligand positioning is the 
alignment of Phe404/356 and Leu387/339.  These two residues, if they remain vertically 
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aligned, will capture the aromatic ring of the ligand.  If the aromatic ring is phenolic, this 
capture facilitates hydrogen bond formation with Glu353/303 and Arg394/346 and the water 
molecule.  This behaviour is described herein as the ‘A-ring clamp’ and is illustrated in 
Figure 3.23.  The deflection of Phe404 in model 3ERT is a result of the position of the ligand 
OHT. 
The A-ring clamp is the primary ligand positioning mechanism within the binding cavity.  
This clamp will retain a ligand within the binding cavity even the ligand is not able to engage 
the D-ring end of the binding cavity. 
 
 
Figure 3.23.  A-ring clamp.  Note conservation of Leu387 and Phe404 positions in all of the hERα models, 
both agonist and antagonist conformations. The green residues and the position of E2 are from 1ERE. 
 
3.6.4 Modelling of EEs 
RRD placed all of the EEs within the binding cavity of all models.  The resulting poses had 
many common features.  The A-ring clamp recognised the benzene ring of the ligand, 
regardless of whether it was phenolic (as in the parabens) or not (as in the phthalate 
monoesters).  In all models except 3ERT, the orientation of the ligand benzene ring was 
coincident with that of the A-ring of E2.  In 3ERT the clamp was displaced, allowing the 
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benzene ring to be inclined relative to that of E2.  This positioning of the ligand by the 
benzene ring allowed the rest of the ligand structure different opportunities to interact with 
the binding cavity, depending on what parts it could reach.   
In contrast, IFD did not dock all of the EEs in all of the models.  TRIC and 4MBC were not 
docked in any of the models.  Although these ligands had a benzene ring that could be 
captured by the A-ring clamp, other features of these ligands including Cl atoms (TRIC) and 
large bulky hydrophobic substituents (4MBC) resulted in poor interactions with the balance 
of the binding cavity.  The inability to dock TRIC is not surprising given the conflicting 
estrogenicity data presented in Section 2.7.1.2.  4MBC is estrogenic as indicated in Chapter 2 
and does have a published binding energy (Table 3.3).  Also, mTRIC was docked only in the 
α and β antagonist models.     
The EEs were grouped according to type of interactions with the binding cavity.  The group 1 
ligands had sufficient length (>10 Å) and a second hydroxyl functionality to potentially 
interact with the binding cavity in an E2-like way. Group 1 included the phytoestrogens 
(COUM, DAID and EQ) and the other steroid ligands (E1, E3 and EE2).  These ligands were 
similarly docked by both RRD and IFD.  The phytoestrogens COUM, DAID and EQ are 
planar molecules of similar structure to GEN and it was not surprising that they were docked 
in similar positions to GEN.  The same was true of the steroid ligands.  Their poses were the 
same as E2.  The group 1 ligands are rigid in comparison to the other EEs, with at most, one 
rotational degree of freedom (DAID, EQ) and are most ‘estrogen-like’.  The phytoestrogens 
resulted in dihedral angles in the range of 17.5-18.4, greater than that of GEN (16.5).  The 
steroid ligands had dihedral angles in the range 17.7-19.4, less than the angle of E2 (21.1).  
The poses for the group 1 compounds obtained with 1ERE are shown in Figure 3.24.  
Analogous poses for these ligands were obtained in the other models.  For the steroid ligands, 
only one distinct pose was obtained.  For the phytoestrogens, both RRD and IFD often 
returned more than one distinct energy-equivalent pose.  These additional poses were 
backwards or upside-down compared to the first pose, but lying in the same plane.  These 
multiple poses are a direct result of the ligands not having features similar to the steroids (i.e. 
the 13-CH3 and both hydroxyl groups are phenolic) to introduce asymmetry to the molecule 
and to determine a single, best fit position within the binding cavity.   
The 13-CH3 of E2 also positions Leu525/476 to stabilise the α-helix structure of H11.  The 
co-operation between His524/475 and Leu525/476 influences the position of Met528/479, 
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further stabilising H11.  If His524/475 is allowed to hinge open, Leu525/476 can collapse 
into the binding cavity, pulling Met528/479 with it and disrupting the α-helix structure of 
H11 as shown in Figure 3.25.  This feature was also illustrated earlier as the rotation of the 
binding site (Figure 3.17). Note that none of the group 1 ligands allows the collapse of 
Leu525/476.     
 
COUM 
 
DAID 
 
EQ-S 
 
E1 
 
E3 
 
EE2 
 
Figure 3.24.  RRD (pink) and IFD (green) poses for group 1 ligands obtained with model 1ERE. E2 
(orange) is shown in each image for comparison.  Residues in orange are from the model and apply to the 
RRD pose.  Residues shown grey show the position refinement obtained with IFD. Note for E1, E3 and 
EE2 the RRD and IFD ligand poses are nearly identical.  For COUM, GEN, DAID and EQ multiple poses 
are observed. 
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E2 in 1ERE 
 
RAL in 1ERR 
 
AIT in 1XPC 
 
OHT in 3ERT 
 
Figure 3.25.  Co-operation of His524 and Leu525, acting as a swinging gate to influence the position of 
Met528 in response to an agonist ligand (E2) and three different antagonist ligands (RAL, AIT and 
OHT). Note how RAL, AIT and OHT have allowed Leu to collapse into the binding cavity. 
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The ligands of the second group have a biphenyl-like structure, with 2 degrees of rotational 
freedom around the central atom (C or O).  These ligands generally had more energy 
equivalent poses, but only 1-3 distinct poses.  When free in solution, these ligands are not 
planar.  They adopt various conformations that minimise interactions between the opposing 
benzene rings, as illustrated with BPA and BP-1 in Figure 3.26.  The common feature of this 
group of ligands is that except for 4OH-3PBOH, they do not span the binding cavity in an 
E2-like pose.  The ligands are captured by the A-ring clamp but the second benzene ring is 
either oriented up the entrance channel, interacting with Thr347/299 as shown for BPA in 
Figure 3.27, or oriented downward into the binding cavity as shown for BP-3 in Figure 3.27.  
These ligands are not large enough to act as a wedge like RAL or OHT, but they are oriented 
in a similar fashion as shown in Figure 3.27.  This orientation leaves His524/475 free to find 
a stable orientation independent of the ligand.  The dihedral angles for these ligands range 
from 16.0 to 21.1, indicating agonist behaviour. 
 
(a) BPA 
 
(b) BP-1 
 
(c) BPA overlay on E2 attempting to co-locate the 
hydroxyls 
 
(d) PBA overlay on E2 with A-rings co-located. 
 
Figure 3.26.  Energy-minimised conformations of BPA and BP-1 as free ligands in aqueous solution.  BPA 
is also shown overlaid on E2 (shown in orange), contrasting the positions of BPA when attempting to co-
locate the hydroxyls with those of E2 and co-locating the A-rings of BPA and E2.  
  
 
 
 
BPA 
 
BP-3 
 
BP-2 
 
BP-1 
  
 
 
ENT 
 
3PBOH 
 
4OH-3PBA 
 
4OH-3PBOH 
 
Figure 3.27.  RRD (pink) and IFD (green) poses for group 2 ligands obtained with model 1ERE. E2 (orange) is shown in each image for comparison.  Residues in 
orange are from the model and apply to the RRD pose.  Residues shown grey show the position refinement obtained with IFD. 
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The poses obtained for 3PBOH in 1ERE and 1ERR, shown in Figure 3.28, are typical of the 
multiple energy-equivalent poses obtained for all of the EEs.  The difference in binding 
energy between the most favourable (green) and least favourable (purple) of the three poses 
in 1ERE is 2.25 kJ/mol.  The dihedral angle varies from 14.5 (green) to 20.6 (light blue) to 
20.9 (purple), all less than the angle with E2.  For the two poses obtained with 1ERR, the 
difference in binding energy is only 1.1 kJ/mol and the dihedral angle decreases from 33.1 
(green) to 26.9 (purple), becoming more agonist-like.   
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(a) 3PBOH in 1ERE.   The difference in binding energy between the most favourable (green) and  
least favourable (purple) of the three poses is 2.25 kJ/mol.  The dihedral angle varies from 14.5 (green)  
to 20.6 (light blue) to 20.9 (purple). 
 
(b) 3PBOH in 1ERR.  The difference in binding energy between the most favourable (green) and least  
favourable (purple) of the two poses is 1.1 kJ/mol.  The dihedral angle varies from 33.1 (green) to  
26.9 (purple). 
 
Figure 3.28.  Multiple distinct energy-equivalent poses obtained for 3PBOH in 1ERE and 1ERR .   
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The third group of ligands are described as mono-phenolic.  They have a single phenolic 
functionality with a mainly aliphatic tail.  All of these ligands are captured by the A-ring 
clamp and the phenolic ring occupies a position analogous to the A-ring of E2.  The smallest 
of the ligands, 4HBA, is able to rotate by 60° either left or right of the standard E2 orientation 
as shown in Figure 3.29, because its tails is not long enough to interact with the central part 
of the binding cavity to maintain the E2-like orientation.  Two of the metabolites of NP have 
terminal aliphatic hydroxyl groups.  For NP-M1 and NP-M2, RRD has the aliphatic 
hydroxyls interacting with His524/475 while IFD shows a variety of other interactions, 
including NP-M2 oriented backwards with the aliphatic hydroxyl interacting with the 
Glu/Arg pair and the phenolic ring oriented similar to BPA.  The terminal aliphatic 
carboxylate functional group of NP-M3 is centred within the binding cavity, not interacting 
with any residues because of its charge.  The parabens all occupy similar positions, with the 
tail following the general trajectory seen with NP. The dihedral angles are smallest for NP 
and NP-M1 at 8.6 and 11.5 respectively.  These two poses also have His524 in a position 
similar to 2B23.  All other ligands have dihedral angles between 16.9 and 20.7 and have 
His524 in an E2-compatible position.  It is not apparent what causes His to take up a position 
like the apo model with some ligands and not others.   
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NP 
 
t-OP 
 
NP-M1 
 
NP-M2 
 
NP-M3 
 
4HBA 
 
b-Paraben 
 
m-Paraben 
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p-Paraben 
 
e-Paraben 
 
Figure 3.29.  RRD (pink) and IFD (green) poses for group 3 ligands obtained with model 1ERE. E2 
(orange) is shown in each image for comparison.  Residues in orange are from the model and apply to the 
RRD pose.  Residues shown grey show the position refinement obtained with IFD. 
 
The fourth and last group of ligands are described as non-phenolic.  They have a benzene ring 
but no E2-like phenolic hydroxyl.  These ligands behave in one of two ways.  Either they are 
captured by the A-ring clamp with the carboxylate interacting with the ARG residue and with 
the aliphatic tail occupying the central region of the binding cavity; or the benzene ring takes 
a position similar to the second BPA ring and is oriented up the binding channel with the 
carboxylate pointing into the centre of the binding cavity.  None of the phthalate monoesters 
had published binding energies and the estrogenicity assays indicated very little if any 
activity.  The calculated binding energies for these compounds indicated moderate affinity, of 
the same order as BPA and NP (ΔGbind ≈ -40 kJ/mol).    
3.6.5 Comparison with Published Docking Studies 
Given the importance of the hER in breast cancer, one might expect a large body of 
computational docking literature.  In fact, there is little in the literature for comparison.  This 
could be a result of the proprietary nature of the search for drugs to treat breast cancer.  Most 
of what has been published on docking with hER is in relation to QSAR validation studies 
where docking has been used to explain or justify predicted binding affinity of drug targets 
and to evaluate predicted biological activity parameters [279, 310-313].  In all of these 
studies, only rigid receptor docking was used and the interactions described are in relation to 
designing a drug target with an effective ‘wedge’. 
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A few studies have considered EEs (e.g. polychlorinated biphenyls [271], COUM [314] and 
two obscure phytoestrogens [315]).  All of these studies used only rigid receptor docking and 
the focus was calculation of binding energies.   
With the docking of PCBs [271], the authors report multiple energy equivalent poses for 
these flexible ligands.  However, these ligands are highly hydrophobic and do not possess a 
phenolic hydroxyl so do not interact with the ER in an E2-like way, but are instead confined 
to the highly hydrophobic, large volume space in the centre of the binding cavity.  
The docking of COUM [314] also shows multiple positions of the ligand in the binding site, 
similar to that reported in this work. 
Two studies attempt to use docking to identify potential agonist/antagonist behaviour of EEs 
have been reported.   
In the first study [316], the authors use rigid docking to calculate the binding energies of 
4NP, 4t-OP and BPA in both agonist and antagonist models and use the difference in 
calculated binding energies to predict agonist/antagonist behaviour.  For these three ligands, 
they predict agonist behaviour which is consistent with results of biological assays and with 
the present study.  However, it is not clear how they were able to get rigid docking to 
successfully dock RAL and OHT into the model for 1ERE.  This study did not examine the 
interaction of these ligands with the receptor.   
In the second study on polybrominated diphenyl ethers [270], the authors examined the poses 
obtained by docking these ligands into 4 rigid receptor models.  They classified the ligand as 
an antagonist if more than 50% of the 20 lowest energy poses obtained from the aggregate set 
of all 4 models demonstrated antagonist features such as the ligand extending up the entrance 
of the binding cavity.  The authors used only antagonist conformation models for this study 
so it is not known whether the ligands would prefer this ‘antagonist-like’ pose in an agonist 
model and could potentially disrupt the agonist conformation. 
3.7 Conclusions  
The RRD validation study using multiple receptor models demonstrates that the models and 
software are able to correctly place the ligand in the receptor binding site and correctly 
predict the corresponding binding energy.  This was done in 3 stages:  docking the co-
crystallised ligand in its native model, cross-docking co-crystallised ligands in the other 
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models, and docking ligands for which experimental binding energies are available but not 
crystal structures.  Success in all three of these stages strongly supports the credibility of the 
binding modes and calculated binding energies produced for those ligand-receptor complexes 
without experimental data.  This success also gives confidence that the receptor models are 
valid for use in modelling receptor flexibility. 
The IFD validation study followed the same structure as the RRD validation study and 
similarly demonstrated that the models and software were able to correctly place the ligand in 
the receptor binding site and correctly predict the corresponding binding energy at all three 
stages.  This success gives confidence that the predictions of ligand position within the 
binding site and the calculated binding energies are plausible for the EEs of interest. 
The details of the interactions of co-crystallised ligands and the EEs with the binding site 
were examined and several features were identified that appear to be important and 
diagnostic in determining whether a ligand will bind with the receptor and whether it will 
induce the agonist or antagonist conformation of the receptor.  First, the positions of the 
residues ‘A-ring’ end of the binding cavity described as the ‘A-ring anchor’ (Figure 3.8) and 
‘A-ring clamp’ (Figure 3.23) are highly conserved among agonist and antagonist 
conformations of the receptor models with the co-crystallised ligands docked and remain so 
with the docking of the EEs.  This feature recognises the phenolic hydroxyl functionality of 
the ligand and affects a ‘capture’ of the ligand in the binding cavity.  Second, the ‘D-ring’ 
end of the binding cavity (Figure 3.8) is much more responsive to the ligand, provided the 
ligand is able to engage this end of the binding cavity through a hydrogen bond with the His 
residue.  Third, the interaction (or lack thereof) of the ligand with the His residue propagates 
back up the protein backbone to cause a disruption between the His and Leu residues which 
appears to be indicative of the eventual uncoiling of H11 to allow H12 attain the antagonist 
position covering the AF-2 cofactor binding site.  For all agonist models of both hERα and 
hERβ, the backbone carbonyls have highly conserved positions (Figure 3.19) and a well 
defined dihedral angle.  In contrast, the disruption caused by antagonists leads to an opening 
of this angle (Figure 3.20 and Figure 3.21) and the disruption is much larger for hERβ than 
for hERα.  This is clearly demonstrated by the measured angles for GEN in hERβ, where in 
the agonist conformation, the angle is larger than that of E2 (indicating potential antagonist 
behaviour) and this crystal structure could only be produced by co-crystallising with a 
peptide designed to mimic the binding of a coregulatory protein in the AF-2 site, preventing 
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H12 from occupying the site.  When hERβ is bound with GEN and crystallised without a 
coregulatory peptide, the conformation obtained is the antagonist.  This is in contrast to GEN 
in hERα where only the agonist conformation is obtained and the angle obtained is smaller 
than that for E2 suggesting agonist behaviour.  
The IFD results also indicate that when E2 is docked, the dihedral angle converges to a 
specific value regardless of whether the agonist or antagonist models were used in docking.  
This demonstrates that there is sufficient flexibility modelled by the IFD approach for the 
receptor to respond to ligand influences if they exist.   
For EEs that most closely resemble the endogenous steroids (Group 1 ligands, Section 3.6.4) 
even though multiple positions of the ligand within the binding cavity were obtained, they 
produced the same binding site residue positions as those obtained with E2 and angles less 
than that of E2 suggesting agonist behaviour.   
For EEs that have a biphenyl structure, and for some ligands two hydroxyl groups to 
potentially interact with both ends of the binding cavity (Group 2 ligands, Section 3.6.4), 
multiple energy equivalent poses were obtained.  These poses resulted in different binding 
site residue positions from those obtained with E2 and angles less than that of E2 suggesting 
agonist behaviour.  The poses for these ligands indicated they did not engage with the His 
residue, leaving the D-ring end of the binding site to find a low energy conformation that was 
not directly influenced by the ligand.  As a result, the receptor-ligand complex may be more 
vulnerable to the external influence of the suite of cofactors present in the particular cell type.  
This vulnerability is increased with the Group 3 and Group 4 ligands which have 
progressively more flexibility less ability to directly interact with the D-ring end of the 
binding cavity.  All of the Group 3 and 4 ligands resulted in angles narrower than that for E2, 
suggesting agonist behaviour.  None of the EEs studied demonstrated an ability to open the 
dihedral angle beyond that for E2 and to suggest antagonist behaviour. 
In summary, ligand flexibility reduces the ability of the ligand to stabilise the RL-complex 
conformation.  The RL-complex can be described as ‘floppy’ or pliable as indicated by the 
large variation in dihedral angles measured for the ligands.  Also indicative of the lack of 
constraint of the RL-complex are the multiple, distinct energy-equivalent complexes 
proposed by the docking study.  These pliable RL-complexes can be influenced by the 
population of coregulatory proteins present in the target cell.  The biological response that is 
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obtained is therefore a function of both the ligand and the cell context.  In addition, flexible 
ligands can form multiple distinct energy equivalent RL-complexes.  Each RL-complex 
potentially leads to the selection of different genes that are transcribed in a given cell type 
because a different selection of coregulatory proteins may be recruited. 
The flexibility of the ligands and their ability to produce pliable receptor-ligand complexes 
may explain why exposure to a single compound produces different effects in males and 
females and produces different effects depending on when during development or life stage 
the exposure occurs.  The adverse effects attributed to fetal exposure (e.g. abnormalities in 
male genitalia or precocious puberty in females) are very different to those attributed to adult 
exposure (e.g. reduced fertility, susceptibility to hormone responsive cancers), but it cannot 
be ruled out that the effects seen in adults do not have a root in fetal exposure.   
To further investigate the hypothesis of multiple, distinct, energy equivalent hER-EE 
complexes, the studies reported in the literature that characterised the behaviour of OHT and 
RAL in different cell contexts could be undertaken with selected EEs.  In particular, the 
results from such studies obtained for GEN, BPA and NP would be most illuminating, as 
these ligands represent various points on the spectrum of ligand flexibility.   
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4.1 Introduction 
The objective of this part of the study was to develop and validate a sample extraction and 
analysis method for the quantification of EEs in human urine and amniotic fluid.  Both gas 
chromatography-mass spectrometry (GC-MS) and liquid chromatography-mass spectrometry 
(LC-MS) have the required sensitivity and specificity for the task.  While LC-MS has the 
benefit of not requiring derivatisation, sample-to-sample differences in matrix composition 
can lead to ionisation suppression and/or enhancement, potentially hindering quantification.  
GC-MS was chosen because instrumentation was available.   
Previous studies of EEs in human fluids (urine, serum and amniotic fluid) have addressed 
subsets of the target analyte list of this study:  phytoestrogens [144, 148-150, 317], phenols 
only [141, 318, 319], parabens only [320], phenols and parabens [140, 321], benzophenones 
[322], phthalate monoesters [142, 145, 146, 323].  Even for the reports of multiple subsets of 
EEs, the analyses were done with separate methods [324].  Of these 16 studies, only 5 used 
GC-MS and determined phytoestrogens [148-150] and phenols [141, 318].  The remaining 
studies used LC-MS (for BPA only [319]) or LC-MS/MS. 
The target analytes are challenging to determine by GC-MS because they are relatively polar 
with hydroxyl and/or carboxylic acid functional groups.  Because of their ability to form 
intermolecular hydrogen bonds, these analytes have low volatility.  The active hydrogen atom 
also makes these compounds prone to adsorption onto glass and metal surfaces within the 
instrument, leading to poor chromatographic peak shape (tailing).  In addition, the biological 
matrix of urine and amniotic fluid poses a challenge with high concentrations of organic 
acids, amines and sugars.  The extraction conditions and cleanup procedures used to achieve 
very clean extracts of biological samples for a subset of compounds (e.g. steroids and other 
phenols) will remove the organic acid target analytes.  Finally, the small volume of sample 
requires sensitivity in the ppb range, despite these challenges. Based on the literature reports 
of EEs in human urine and amniotic fluid presented in Chapter 1, the method will need to 
have an instrument detection limit less than 2 ng/mL and a method detection limit less than 1 
ng/mL after accounting for the sample concentration factor. 
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4.2 Theoretical Basis 
4.2.1 Sample Preparation by Solid Phase Extraction 
Solid phase extraction (SPE) is a technique used to isolate and concentrate compounds of 
interest from a sample.  In this case, SPE is used to separate the organic analytes from an 
aqueous matrix containing inorganic salts and protein.  The analytes are retained on the solid 
adsorbent as the sample flows over the adsorbent.  The retained organic analytes are then 
eluted into an organic solvent for analysis.  The adsorbent is packed into a bed sandwiched 
between two frits in a syringe barrel and a vacuum is used to draw the sample through the 
cartridge at a constant flow rate.  The typical experimental setup is shown in Figure 4.1.   
 
 
 
 
(a) SPE cartridge 
 
(b) SPE cartridges on vacuum manifold 
 
Figure 4.1.  A typical solid phase extraction (SPE) experimental setup. 
Waters Oasis HLB SPE cartridges were used for this work.  The adsorbent is a hydrophilic-
lipophilic balanced copolymer of divinylbenzene and N-vinylpyrrolidone [325].  The 
advantages of this material over traditional coated silica phases include no undesirable silanol 
activity, broader operational pH range, lower breakthrough of polar compounds and 
improved recoveries of hydrophobic compounds.  This material is also tolerant to the bed 
going dry during the extraction process, making them much easier to use. 
4.2.2 Analytical Derivatisation 
The reactive hydrogen atom of the hydroxyl and carboxylic acid functional groups must be 
derivatised for GC-MS analysis [326-329].  There are several different reagents that can be 
used for analytical derivatisation and some reagents work better for some target analytes than 
others [330].  The derivatisation strategy of choice for phenols and aromatic acids converts 
the hydroxyl group to a trimethylsilyl (TMS) ether and the carboxylic acid to a TMS ester as 
shown in Figure 4.2.   
SPE adsorbent
Frits
Syringe barrel
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Figure 4.2.  Derivatisation of hydroxyl and carboxylic acid functional groups to TMS ether and ester. 
While TMS derivatives are more chemically and thermally stable and more volatile than 
other derivatives [330], they are moisture sensitive and can be readily hydrolysed on 
exposure to ambient air.  The esters are more easily hydrolysed than the ethers [330].  
Derivatisation reduces the polarity of the analyte and increases its volatility making GC 
separation easier, while at the same time, increasing the sensitivity of MS detection [326-329, 
331].  The increase in molecular weight that results from derivatisation also moves the MS 
fragmentation pattern to higher m/z where there is less chance of matrix interference.  
However, because of its composition, a large fraction of the matrix for these samples will 
also be derivatised.  Several of the target analytes have multiple active hydrogen atoms to 
derivatise.  A few of the target analytes do not require derivatisation as they do not have 
active hydrogen atoms. 
Analytical derivatisation requires optimisation of the reaction conditions (e.g. solvent, 
derivatisation reagent, catalyst, temperature, time) to ensure the analytes are reproducibly, if 
not fully derivatised and that undesired products (e.g. structural isomers, degradation 
products) are not formed.  With the derivatisation of steroids, several derivatisation artifacts 
have been reported such as conversion of EE2 to E1 [332-336] and subsequent derivatisation 
of the enol form of keto-enol tautomers [337-340] that can then be derivatised.  Partial 
derivatisation of multi-functional analytes can be acceptable if the level of derivatisation is 
reproducible, such as for GEN [341]. Derivatisation requires the removal of water from the 
extract and any alcohol solvent used in the extraction.  Solvent evaporation must also 
minimise loss of volatile target analytes. 
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The reagent chosen for derivatisation was N,O-bis(trimethylsilyl)trifluoroacetamide (BSTFA, 
Figure 4.3).  BSTFA has two main advantages over other reagents.  First, the reaction by-
products (Figure 4.3) are more volatile than the reaction by-products of other reagents.  
Second, the fluorine atoms result in less fouling by deposits of silica on heated surfaces such 
as the ion source.  BSTFA is also able to act as its own solvent.  BSTFA is strong silylating 
reagent and is able to derivatise even sterically hindered active hydrogen atoms, such as the 
17β-OH of E2 and EE2.   
 
Figure 4.3.  Reaction scheme for derivatisation of phenol by BSTFA. 
Addition of a second component such as trimethylchlorosilane (TMCS, Figure 4.4(a)) or 1-
(trimethylsilyl)imidazole (TMSI, Figure 4.4(b)) in concentrations ranging from 1% to 50%  
increases the strength of the derivatising reagent [330].  TMSI is advantageous in the current 
application because it does not react with aliphatic amines and is particularly useful in 
silylating hindered alcohols such as the 17β-OH of E2 and EE2 [330, 335]. 
 
 
 
 
 
(a) TMCS 
 
 
 
(b) TMSI 
 
Figure 4.4.  Reagents used to increase the derivatisation strength of BSTFA. 
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Analytical derivatisation can be accomplished using the reagent as solvent or with the 
addition of a co-solvent to either suppress undesired side reactions or enhance the desired 
reaction [338, 342, 343].  Three solvents are commonly evaluated:  dimethylformamide 
(DMF), pyridine (PYR) and acetonitrile (ACN).  PYR acts as an HCl acceptor and is 
particularly useful when TMCS is present in the reagent mixture.  For BSTFA derivatisation, 
ACN has been used to prevent derivatisation of carbonyl steroids via keto-enol 
tautomerisation[338]. Because it is polar and aprotic, ACN can also increase the derivatising 
strength of the reagent or reagent mixture.  Both DMF and PYR have been used to prevent 
breakdown of di-TMS-EE2 [334, 344] when BSTFA/TMCS mixtures are used.  A reaction 
temperature above 40 °C for at least 30 minutes is normally required to achieve maximum 
derivatisation yield [338].  Higher temperatures, up to 100 °C and longer times are needed to 
derivatise more hindered and less reactive hydrogens. 
More than 20 individual reports of analytical derivatisation with GC-MS analysis for the 
determination of phytoestrogens, phenols, steroids, and phthalates in a variety of biological, 
environmental and food matrices were reviewed.  While no common approach was found, 
several themes were repeated.  BSTFA alone did not give complete derivatisation of the 
target analytes.  TMCS (1%) alone or with TMSI (2%) with BSTFA did result in complete 
derivatisation, especially if the compound had more than one reactive hydrogen and if the 
reactive hydrogen was sterically hindered.  Reaction temperature and time on the order of 70 
°C for at least 30 minutes were required.  When TMCS was present, PYR was the solvent of 
choice to scavenge the HCl produced during the reaction.  ACN was also advantageous, 
especially when TMCS was not present.   
4.2.3 GC-MS Analysis 
The analysis of a sample by GC-MS requires rapid and complete vaporisation of the sample 
as it is injected onto the GC column.  Separation of the components occurs based on 
differential distribution of the components between the mobile phase (helium carrier gas) and 
the stationary phase coated on the inside of the column.  The components with the highest 
volatility and that are least able to interact with the stationary phase elute earlier than those of 
lower volatility and with a higher preference for interacting with the stationary phase.  The 
column is located in an oven that is heated, and the temperature is increased during the 
analysis to both sharpen the later eluting peaks and to reduce analysis time.  Detection by MS 
can be done in either SCAN or SIM mode.  In SCAN mode, a range of mass to charge ratio 
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(m/z) is scanned providing the complete mass spectrum as each peak elutes from the column.  
In SIM mode, selected ions (m/z) are monitored.  The advantage of SIM mode over SCAN 
mode is a large increase in sensitivity because only m/z of interest are monitored.  This 
increase in sensitivity is achieved at the expense of obtaining qualitative information that can 
be used to identify unknowns.  The analysis of ppb level components requires the use of SIM 
mode. 
4.2.4 Principles of Analytical Method Validation  
With complex matrices such as biological fluids, the analysis of ppb level components 
requires careful validation of the sample preparation and instrumental analysis methods 
[345].  The purpose of validation is to ensure the signal attributed to a particular target 
analyte is due to the presence of that analyte and to nothing else, that the correct result is 
reported and that the method is reproducible from one day to the next over normal 
operational conditions [346, 347].  Method validation usually begins with the instrumental 
analysis and analysis of standards.  Once a robust analysis method is available, validation 
then is then able to consider the sample preparation steps.  Method validation also provides 
an opportunity to quantify the performance criteria of the method. Performance criteria 
typically include accuracy, precision, reproducibility, selectivity, sensitivity, stability, 
extraction efficiency and quantification range [345]. 
Accuracy and precision are fundamental to validation.  Accuracy is how close to the ‘correct’ 
or true value the analysis result is.  Precision is the measure of analysis variability in 
achieving the correct result on repeated attempts.  Accuracy is quantified by the % relative 
error (%RE) which is defined as the absolute value of the difference between analysis result 
and target concentration, expressed as a percentage of target concentration.  Precision is 
quantified by the % relative standard deviation (%RSD) of repeated analyses.  %RSD is 
defined as the ratio of the standard deviation to the mean of the analysis result expressed as a 
percentage.  Accuracy and precision are usually determined at the instrumental analysis level 
by repeated analysis of standards of known composition.  Three standards spanning the 
calibrated range are normally used to assess accuracy and precision.   
Variability increases as the concentration of the analyte approaches the limit of detection 
(LOD) [347].  Guidelines for acceptable limits of analysis accuracy and variability as a 
function of analyte concentration are given in Table 4.1.   
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Table 4.1.  Guidelines for acceptable levels of analysis variability and % recovery as a function of analyte 
concentration [345, 347]. 
Analyte Concentration  
(ppb) 
Accuracy 
(%RE) 
Analysis Variability  
(%RSD) 
% Recovery 
100 20 15 80-110 
10 20 21 60-115 
1 20 30 40-120 
 
Repeatability is how well the entire sample extraction, cleanup and analysis process can be 
repeated on the same day and on subsequent days and can be assessed by statistical analysis 
using duplicate samples or blank samples spiked with known amounts of target analytes.  
Selectivity is the ability of the method to detect the target analyte in the presence of potential 
interferences from the sample matrix.  SPE is used to remove many of the potential 
interferences and to get a sample into a solvent amenable to instrumental analysis, but 
extraction can also take with it compounds that are not of interest but are chemically similar 
to the target analytes.  The instrumental analysis method must then be able to ‘see’ the target 
analytes in the presence of these other matrix components.  MS detection is highly selective 
compared to other detection methods (e.g. UV-Vis) but confirmation of selectivity is still 
required.  The selectivity of MS detection in selected ion monitoring (SIM) mode comes from 
selecting specific ions from the target analyte fragmentation pattern to detect.  One ion is 
used as the quantification ion and others are used as qualifier ions.  The ratios of the 
quantification to qualifier ion intensities must match within a pre-determined range (normally 
15%) and the chromatographic peak must be found at a specific retention time for the peak to 
be identified as the target analyte. It is possible for a co-eluting compound to contribute 
intensity to one or more of the selected ions, thus upsetting the intensity ratios.  In this 
situation, the peak is not identified automatically by the software.  If, after examination of the 
SIM data, if there is confidence that the interference doesn’t affect the quantification ion, the 
peak can be manually identified as the target analyte. 
Sensitivity is defined as the lowest concentration of target analyte that can be measured with 
an acceptable level of accuracy and precision.  Typically, accuracy within 20% [345] with 
precision depending on analyte concentration as specified in Table 4.1 are set as acceptable 
limits for determining the lower limit of quantification (LLOQ) for trace bioanalytical 
methods.  The instrumental limit of detection (LOD) differs from the LLOQ in that it is 
determined based on standards rather than samples and does not include the sample 
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extraction and cleanup steps of the method.  The LOD is often defined as the concentration 
that corresponds to some factor k above the standard deviation of the instrument signal 
obtained from multiple blank measurements.  The value of k is normally set at 3 [347].  With 
chromatographic methods this definition is problematic.  The chromatographic signal is peak 
area and this requires the target analyte to be present at a measurable concentration.  Clearly 
this is not a desirable feature of a blank.  In place of a blank measurement, the lowest 
calibration standard is often used.  The standard deviation of multiple measurements of the 
standard at this level is determined and multiplied by k to obtain an instrument LOD. 
Characterisation of stability must be done at several points in the method, for example; 
storage of stock solutions of calibration standards and other reagents, extracted/prepared 
samples (as they sit in the autosampler waiting for analysis), freeze-thaw stability, benchtop 
stability (stability of samples for the length of time it takes to complete sample preparation 
operations).  Ideally, conditions and timing of operations can be controlled to minimise their 
effects on sample stability. 
Extraction efficiency or recovery is a measure of how well the target analyte can be removed 
from the original sample and presented to the detector.  Ideally, recovery should be high to 
achieve the best sensitivity possible, but at a minimum, recovery should be precise and 
reproducible [345].  Acceptable limits on recover vary with the concentration of the target 
analyte as summarised in Table 4.1.  In this application, recovery is monitored in each sample 
by the addition of a known amount of isotopically labelled (
13
C or 
2
H) surrogate standards 
representing each group of target analytes.  The recovery of these surrogates is determined 
and used to correct measured concentrations of the target analytes. 
The quantification range is the range of concentrations that can be reliably determined using 
the method.  The lower limit of this range is the LLOQ and the upper limit of quantification 
(ULOQ) is defined as the highest concentration of the target analyte that can be determined 
by the method, usually with the same accuracy and precision criteria as the LLOQ.  Samples 
with target analyte concentrations above the ULOQ can be determined by dilution of the 
sample, provided dilution integrity is demonstrated. 
4.2.5 Calibration 
The heart of an analytical method is the calibration curve – the equation that relates the 
measured signal intensity (e.g. peak height or peak area, the dependent variable, y) to the 
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concentration of a calibration standard (the independent variable, x).  Ideally this relationship 
will be linear and will have a zero intercept, such that the equation of the line is y = mx+0.  
With MS analyses where the concentration range covers an order of magnitude or more, it is 
not unusual for the calibration curve to be nonlinear, for example quadratic: y = ax
2
+bx+0.  
Regression analysis is used to determine the coefficients for the equation so that the 
concentration, x, can be obtained for a measured analytical signal, y.  Regression analysis 
assumes the variance of the measured analytical signal is constant across the range of 
concentration, and often this is not the case [348].  The variance of measurement is often 
much larger at the higher end of the concentration range than at the lower end.  This results in 
an unintended and undesirable weighting of the regression results leading to a bias toward 
higher concentrations and a reduction in the accuracy of determining lower concentrations.  
Weighted regression analysis can be used to counteract this effect, but the choice of 
weighting factor is not straightforward and must be done by test and evaluation as described 
by Almeida et al. [348].  The best weighting factor is chosen by calculating the percent 
relative error (%RE) obtained by comparing the result obtained from the weighted regression 
with the expected (nominal) concentration for a range of standards spanning the calibration 
range.  A plot of %RE as a function of nominal concentration should appear as a randomly 
distributed and tightly clustered band around the concentration axis.  The smaller the 
variation in %RE as a function of concentration, without showing any specific trend will 
indicate the best weighting factor of those evaluated.  Typical weighting factors are 1/x
1/2
, 
1/x, 1/x
2
, 1/y
1/2
, 1/y, 1/y
2
.  If measurement of the analytical signal is the largest source of 
uncertainty, weightings in y are the best choice.  If preparation of calibration standards is the 
largest source of uncertainty, weightings in x are the best choice [349, 350]. 
4.3 Materials 
4.3.1 Instrumentation 
A Shimadzu QP2010s GC-MS system was used for the method development and sample 
analysis.  It was equipped with a split/splitless injection port, electronically controlled carrier 
gas flow, AOC-20 100 vial autosampler and a quadrupole MS detector with 70 eV electron 
impact ionisation source (EI positive ion).  The MS was tuned using perfluorotributylamine 
(PFTBA) and the autotune function of the GC-MS workstation software. 
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4.3.2 Equipment 
A Techne sample concentrator equipped with stainless steel needles was used for solvent 
evaporation under N2 flow.  The needles were solvent cleaned prior to each use.  A Techne 
Dri-Block DB-3D with three 8 position aluminium heating blocks was used for gentle heat 
during solvent evaporation and for heating the analytical derivatisation reaction.  The Dri-
Block is digitally controlled, capable of constant temperature heating up to 200 °C with a 
stability of ± 0.15 °C at 100 °C; ± 1 °C accuracy in temperature set point and position to 
position variability in temperature of ±0.2 °C at 40 °C 
The IST VacMaster 20 position SPE vacuum manifold was used for SPE sample prep.  It was 
equipped with integrated stopcock/needle taps made of Teflon and a vacuum/flow controller 
to adjust flow rate through the SPE tubes. 
4.3.3 Labware 
All glassware was silanised to reduce loss of target analytes by adsorption to glass surface.  
All plasticware (pipette tips, centrifuge tubes) was made of 100% polypropylene to minimise 
contamination due to leaching of plasticizers from the material [351].   
4.3.4 Standard Materials, Reagents and Solvents 
Pure compounds, solvents and other reagents were purchased from suppliers as summarised 
in Table A. 10 and Table A. 11, and were of highest purity available.  All solvents were 
HPLC or GC/LC-MS grade. Aqueous solutions were prepared in reagent grade water (18.3 
MΩ) obtained from in-house water purification systems (Milli-Q and Sartorius).   
β-glucuronidase (type H-1) and arylsulphatase enzymes, isolated from Helix pomatia, were 
used for deconjugation of glucuronide and sulphate metabolites.  The product was purchased 
from Sigma Aldrich (product number G0751, lot # 068K38091V).  The activity of the 
material was 1.926x10
6
 units/g solid for β-glucuronidase and 2.376x104 units/g for 
arylsulphatase.  The reaction conditions for this product are 37 °C and pH 5.0. 
The buffer used for the enzyme deconjugation reaction (Enzyme Buffer, 1 M NH4OAc) was 
prepared by dissolving 33 mL glacial acetic acid and 77 g of ammonium acetate in reagent 
water, diluting to a final volume of 1L and adjusting pH to 5.0 at 20 °C. 
0.1M formic acid solution was prepared by diluting 3.8 mL formic acid (98%) to 1 L with 
reagent water. 
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Synthetic urine was prepared as specified in Table A. 12 using available materials and 
reagent water.  Synthetic urine was used as a simulated sample matrix to develop the SPE 
method.  The synthetic urine was stored at room temperature and vacuum filtered through a 
0.2 μm membrane filter prior to each use. 
4.3.5 Preparation of Quantitative Standards 
Individual stock standards of each compound were prepared gravimetrically at a nominal 
concentration of 400 ppm in HPLC grade ACN. E3 was dissolved in EtOH, GEN and DAID 
were dissolved in 1:4 DMSO:EtOH as these compounds were not soluble in ACN at 400 
ppm.  These standards were stored in vials with Teflon-lined silicone septum seals.  These 
standards were stored at the same temperature as the pure compound (room temperature, 
refrigerated or frozen) as summarised in Table 4.2. Mixtures of native target analytes for 
qualitative purposes were prepared from these individual standards.   
Table 4.2.  Storage conditions for stock standards. 
Storage Temperature Target Analytes 
Room Temperature (20 °C) All compounds except those listed below. 
Refrigerated (4 °C) ENT 
Freezer (-20 °C) GEN, DAID, EQ 
 
Mixtures of native target analytes for quantitative purposes were prepared gravimetrically as 
stock standard mixtures according to compound class at nominal concentration of 400 ppm 
by dissolving 0.01 g of material in 25.0 mL solvent, as summarised in Table 4.3.  The 
steroids were dissolved in EtOH, and the phytoestrogens were dissolved in 1:5 DMSO:EtOH.   
Table 4.3.  Stock standard mixtures (400 ppm nominal) for quantitative analysis. 
Mixture Components Solvent Storage 
Main 
TRIC, mTRIC, 4HBA, mPBN, ePBN, pPBN,  
bPBN, 4NP, 4NC, NP, 4tOP, BPA, 3PBOH, 3PBA 
ACN 
Room  
Temperature  
(20 °C) 
Phthalates mMP, mEP, mBP, mBzP, mEHP 
Steroids E1, E2, E3, EE2 
UV filters BP1, BP2, BP3, OMC, 4MBC 
ENT ENT EtOH 
Refrigerated  
(4 °C) 
Phytoestrogens GEN, DAID, EQ 1:4 DMSO:EtOH 
Freezer  
(-20 °C) 
Internal Standard BPC ACN 
Room  
Temperature  
(20 °C) 
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The stock mixtures were combined and diluted to a single intermediate mixture at 5 ppm in 
ACN.  The 5 ppm mixture was stored at -20 °C.  Working standards at concentrations of 1 
ppm or lower were prepared in ACN immediately before use.  
The working internal standard was prepared at a concentration of 1 ppm in ACN and was 
stored at room temperature. 
Isotopically labelled recovery surrogates were supplied as solutions at 1000 or 100 ppm or as 
neat materials.  
13
C6-E2 was supplied as 100 μg quantity of neat material in a vial.  To this 
vial, 1 mL ACN was added to produce a 100 ppm standard.  The stock standards were stored 
at -20 °C.  Neat 4NP-D4 and BP-rec were used to prepare 400 ppm stock standards in ACN 
and were stored at room temperature.  The surrogate mixture was prepared at 1000 ppb in 25 
mL ACN by diluting appropriate aliquots of the various solutions.  The working surrogate 
mixture was stored at -20 °C. 
The enzyme deconjugation reaction control standard prepared at 400 ppm by dissolving 0.01 
g each of 4NP-glucuronide and 4NC-suphate in 25 mL Enzyme Buffer.  A working standard 
at 1 ppm conjugate (0.6 ppm free compound) was prepared by diluting the stock solution with 
Enzyme Buffer.  Both the stock and working standards were stored at 4 °C.   
The enzyme solution was prepared fresh immediately before use by dissolving 0.01 g 
lyophylised powder in 10 mL Enzyme Buffer.  The specific activity of this solution was 
approximately 2000 U/mL β-glucuronidase and 24 U/mL arylsulphatase. 
4.4 Methods Development 
4.4.1 GC-MS Method Development  
The first step in the method development was to establish conditions for GC separation, MS 
detection and derivatisation conditions. 
4.4.1.1 GC Separation  
For trace analysis, splitless injection is used as a large fraction of the injected sample reaches 
the column.  Splitless injection without solvent focusing was used because the analytes are 
significantly less volatile than the solvent and are adequately focused by interaction with the 
column stationary phase. The sample is in ACN so the initial temperature must be above the 
boiling point of the solvent (81.6 °C).  The GC temperature program is given in Table 4.4.  
The long final hold time was needed to ensure the least volatile components of the biological 
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samples were eluted before the next injection.  The temperature gradient was optimised to 
achieve near baseline separation of the target analytes while retaining narrow, sharp peak 
shape. 
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Table 4.4.  GC temperature program. 
Parameter Value 
Injection mode Splitless, 1 μL injection volume, 1 min sampling time, 5 min vent time 
Inlet temperature 250 °C 
Inlet pressure program 200 kPa (3 mL/min) for 1 min, then constant flow at 1 mL/min  
Transfer line temperature 250 °C 
Column oven program 100 °C hold 5 min, 10 °C/min to 300 °C, hold 20 min; 45 min total run 
time 
MS ion source 
temperature 
200 °C 
 
ACN is not a preferred solvent for GC analysis due to its large vapour volume.  At 250 °C 
and an inlet pressure of 200 kPa, a 1 μL injection volume of ACN produces 275 μL of 
vapour.  The inlet liner volume for the instrument is approximately 670 μL.  The 1 μL ACN 
injection fills the inlet liner to approximately 40% capacity.  This prohibits the use of larger 
injection volumes for improving detection limits.  The general rule of thumb [352] is to keep 
the injection vapour volume less than 75% of the inlet liner volume to prevent backflash of 
the sample out of the inlet which would lead to large injection volume uncertainties.  Under 
the same conditions, a sample dissolved only in the derivatisation reagent, BSTFA, would 
produce a vapour volume of approximately 54 μL.   
4.4.1.2 Analytical Derivatisation 
The initial procedure for analytical derivatisation was to pipette an aliquot of the target 
compound or mixture into a 5 mL reaction vial and evaporate the solvent by gentle heating at 
40 °C under a gentle stream of N2 using the sample concentrator.  The vial was removed from 
the concentrator as soon as the solvent was evaporated to minimise loss of the more volatile 
target analytes.  To the dry residue, 200 μL of derivatisation reagent and 100 μL solvent was 
added.  The reaction vial was sealed with a Teflon lined silicone septum cap and was heated 
at the desired temperature for the desired length of time in the well of the heating block.  
However, as calibration check data was acquired, higher than desired variability was found, 
especially with the more volatile target analytes.  The procedure for preparing calibration 
standards was changed to remove the need for solvent evaporation.   
The final calibration standards were prepared by spiking the reaction vial with 100 ng internal 
standard and evaporating the solvent.  To each vial, the native and/or surrogate spikes were 
added along with a volume of ACN to make the total volume up to 100 μL.  To this was 
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added the 200 μL volume of derivatisation reagent BSTFA/TMSI (98:2) and the mixture 
heated at 80 °C for 60 minutes.  The vials were allowed to cool for 10 minutes.  The vials 
inverted and rolled to ensure the contents were well mixed, then allowed to stand for an 
additional 5 minutes for the contents to settle.  A 200 μL aliquot of the standard was 
transferred to an amber autosampler vial fitted with a 250 μL glass insert and Teflon-lined 
silicone septum.   
Different reagents mixtures were evaluated by derivatisation of each compound individually 
and by derivatisation of a 500 ppb mixture of all target analytes.  The mixtures tested were:  
BSTFA, BSTFA/TMCS (99:1), BSTFA/TMCS/TMSI (97:1:2) and BSTFA/TMSI (98:2).   
Over time, the use of both BSTFA/TMCS and BSTFA/TMCS/TMSI resulted in a residue 
building up on the guard column and in the inlet liner which seriously impaired both 
chromatography and the stability of the derivatives due to active sites on the column.  PYR 
was tried as a HCl scavenger, but impurities in the solvent were substantially higher than 
observed with ACN when standards analysed in SCAN mode, so this system was not 
considered any further.  These two systems may be acceptable for use with subsets of the 
target analyte suite, as indicated by literature reports, but was judged as unacceptable for the 
entire suite of analytes of interest in this study. 
The final reagent mixture tested was BSTFA/TMSI with ACN as a co-solvent.  This mixture 
resulted in less fouling of the analytical column, particularly when an inlet liner with glass 
wool deactivated after assembly was used.  Several inlet liners were tested and the Restek 
SKY technology proved to be the most robust. 
4.4.1.3 MS Detection  
The MS was operated in two modes – SCAN for qualitative and semi-quantitative analysis 
during method development and SIM once derivatisation conditions and GC separation 
parameters were established.  The final SIM schedule is summarised in Table x in the 
Appendix.  The ion used for quantification was chosen based on a compromise between 
relative intensity and the absence of matrix interferences.  At least one qualifier ion was used 
for each compound. Where possible two or three were used.  For the compounds with only 
one qualifier ion, the second or third qualifier ions originally selected had significant matrix 
interferences rendering them useless. 
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4.4.2 Calibration and QA/QC Procedures 
Once the derivatisation conditions were established, the GC-MS was calibrated.  Samples and 
standards were run as a batch using the autosampler.  Calibration standards covering the 
range of 1 – 100 ppb were prepared along with a reagent blank.  Two injections of each 
standard were made to assess both instrument stability and degradation of the standards over 
the duration of the batch run.  Quantification was done using an internal standard that was 
added in a known and constant amount (100 ng) to every sample and standard that was 
analysed.  The calibration curve was based on peak area ratio to the internal standard as a 
function of concentration ratio to the internal standard.  Internal standard quantification 
accounts for injection-to-injection drift in instrument response and sample-to-sample volume 
differences. 
With each batch, three calibration check standards (high, mid and low range), comparatives 
and other QA/QC samples as needed were analysed.  Comparatives were prepared whenever 
samples were spiked with natives or surrogates.  The comparative is an aliquot of the 
standard of the same volume as delivered to the sample, delivered directly to the reaction vial 
for derivatisation.  It serves as a check on pipette operations and any degradation of the 
standard.  The comparative is not affected by sample extraction losses.  Ideally the 
comparative agrees within the analytical uncertainty of its target concentration.   
4.4.3 Calculations 
Calibration curves were established within the GC-MS instrument software.  The calibration 
curve for each target analyte was constructed using the ratio of peak areas of target analyte 
peak and internal standard as the dependent variable (y) and the ratio of concentration of 
calibration standard to internal standard concentration as the independent variable (x).  A 
quadratic curve with forced intercept was fit to the data using a 1/y
2
 weighting factor.   
Two correction factors are needed to correct the reported concentration for the native 
analytes:  the spike volume correction factor (FV) and the surrogate recovery correction factor 
(FRC).  FV adjusts for variation in the actual spike volume delivered to the sample and is 
calculated for the surrogate spike used for all samples and the native spikes used in QC 
samples. Because the comparatives were subject to solvent evaporation, the more volatile 
compounds may be affected, so the average FV obtained for BPA and E2 was used for all 
compounds.  FRC corrects for recovery through the sample extraction process.  Thus, 
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where Ci(comparative) = reported concentration in comparative for compound i; 
 Ci(target) = theoretical concentration in standard for compound i; 
 CSi(reported) = reported concentration for recovery surrogate i in sample 
 CSi(target) = theoretical concentration for recovery surrogate i; 
 Ci(reported) = reported concentration for compound i in sample. 
 CRCi = recovery corrected concentration for compound i in sample. 
Because the calibration standards were based on a 1 mL sample volume and the biological 
sample volumes were larger (2.0 or 2.5 mL), the recovery corrected concentration for each 
compound then had to be corrected for the sample aliquot volume to standard volume ratio 
(VS) to give the concentration in the original sample (Ci): 
   
    
  
 
The quantification and qualification ions and the recovery surrogate for each of the target 
analytes are summarised in Table 4.5. 
4.4.4 Sample Extraction Method Development 
4.4.4.1 General SPE Method 
The general method for SPE is shown in Figure 4.5.  The flow rate through the adsorbent bed 
was 1-2 mL/min.  The solvent was evaporated from the SPE eluate and the dry residue taken 
up in solvent, spiked with 100 ng internal standard, derivatised and analysed by GC-MS. 
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4.4.4.2 Spiked Water and Synthetic Urine 
Initial trials for optimisation of the SPE method, as summarised in Table 4.6, were done with 
spiked reagent water and synthetic urine.  The synthetic urine was filtered before each use as 
it was prone to going cloudy on storage.  3 mL or 4 mL aliquots (n=2 to 4) were spiked with 
100 ng or 10 ng natives and 100 ng surrogates or with 100 ng surrogates only.  The surrogate-
only spiked samples were used as reagent blanks.  For the first trial, the samples were 
incubated at 37 °C for 60 min to simulate the enzyme deconjugation reaction, acidified by the 
addition of 500 μL formic acid (98%) and then extracted using the general SPE method 
outlined above.  Trial 2 omitted the incubation and acidification steps.   
  
Chapter 4 – Analytical Method Development 
156 
  
 
Table 4.5.  Initial and final quantification (Q) and qualification (Q1, Q2, Q3) ions and recovery surrogates 
for each target analyte. 
RT 
(min) 
Target Analyte 
Initial m/z Final m/z Initial 
Recovery 
Surrogate 
Final Recovery 
Surrogate Q Q1 Q2 Q Q1 Q2 Q3 
12.75 mParaben 209 224  224 209 193  13C6-mParaben 
13C6-mParaben 
12.94 4NP 196 150  196 211   D4-4NP D4-4NP 
13.70 eParaben 193 238  238 193 210  13C6-mParaben 
13C6-mParaben 
13.87 mMP 89 237 163 237 163 238  13C6-mEP 
13C6-mEP 
14.45 4HBA 267 223 193 223 193 282  13C6-mParaben 
13C6-mParaben 
14.66 OP 207 208  208 151 191  13C12-Tric 
13C12-Tric 
14.63 mEP 223 251  223 251   13C6-mEP 
13C6-mEP 
14.92 pParaben 210 193 195 252 237   13C6-bParaben 
13C6-bParaben 
15.86 4NC 284 299  284 299   D4-4NP D4-4NP 
16.12 bParaben 210 195 193 195 266 251  13C6-bParaben 
13C6-bParaben 
16.67 mBP 223 149 221 223 149 163  13C6-mEP 
13C6-mEP 
16.99 3PBOH 183 227 272 272 227 257 211 13C12-BPA 
13C12-BPA 
17.78 NP 179 180 292 292 180 165  13C6-NP 
13C6-NP 
18.06 3PBA 271 227  271 227 286 197 13C6-3PBA 
13C6-3PBA 
19.30 4MBC 254 105  254 239   13C12-Tric 
13C12-Tric 
19.42 BP-3 285 286 242 286 242   BP-rec 13C12-BPA 
19.59 mEHP 221 223 149 223 221 239  13C6-mEHP 
13C12-BPA 
19.85 mTric 302 304  302 254 232  13C12-Tric 
13C12-Tric 
19.87 Tric 200 345 347 345 310   13C12-Tric 
13C12-Tric 
20.00 BP-1 343 344 105 344 164 271  BP-rec 13C12-BPA 
20.47 mOP 239 187  239 223 221  13C6-mEHP 
13C12-BPA 
20.50 mBzP 91 179 194 179 222 194  13C6-mEHP 
13C12-BPA 
20.60 BPA 357 358  357 358 372  13C12-BPA 
13C12-BPA 
21.53 OMC 178 161  178 161 290  13C12-Tric 
13C12-Tric 
23.46 BP-2 519 520  519 520 445  BP-rec 13C12-BPA 
23.69 Equol 192 177 193 386 267   D4-Gen 
13C12-BPA 
24.25 E1 342 257 218 342 244 327  13C6-E2 
13C6-E2 
24.51 E2 285 416 326 326 416 285  13C6-E2 
13C6-E2 
25.37 EE2 425 285 229 440 425   13C6-E2 
13C6-E2 
25.57 Ent 180 181  442 165   D4-Gen 
13C12-BPA 
26.01 E3 297 504  504 414 386  13C6-E2 
13C6-E2 
26.35 Daid 398 399  398 383 184 355 D4-Gen 
13C12-BPA 
26.45 Gen-triTMS 471 472  471 472 228  D4-Gen not determined 
26.78 Gen-diTMS    414 399 415 416  not determined 
Recovery Surrogates 
12.75 13C6-mParaben 215 230  230 215 199    
12.92 D4-4NP 200 154  200 154     
14.63 13C6-mEP 227 255  255 227     
16.12 13C6-bParaben 216 201 199 272 257     
17.78 13C6-NP 185 298 186 298 186 171    
18.06 13C6-3PBA 277 233  277 292 233 203   
18.69 BP-rec 123 288 193 273 288 193    
19.59 13C6-mEHP 225 227 153 227 153 243    
19.86 13C12-Tric 206 357 359 359 372 374    
20.59 13C12-BPA 369 370  370 369 384    
24.51 13C6-E2 288 422 332 288 422 332    
26.44 D4-Gen-triTMS 474 475 476 475 476 402    
26.76 D4-Gen-diTMS    402 417 418    
Internal Standard 
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21.20 IS-BPC 385 386  386 385 400    
 
 
Figure 4.5.  General SPE process. 
 
 
 
  
 
Table 4.6.  Solvent combinations, enzyme deconjugation reaction conditions and derivatisation conditions for SPE method validation and enzyme deconjugation 
reaction trials. 
Parameter Trial 1 
(28 Oct 2010) 
Trial 2 
(8 June 2011) 
Trial 3 
(7 July 2011) 
Trial 4 
(8 July 2011) 
Trial 5 
(9 July 2011) 
Trial 6 
(12 July 2011) 
Trial 7 
(15 July 2011) 
Matrix 3 mL synthetic urine 
3 mL Reagent water 
(n=2 each) 
3 mL synthetic 
urine 
(n=2 each) 
4 mL synthetic 
urine diluted with 2 
mL Enzyme Buffer 
(n=3 total) 
4 mL synthetic 
urine diluted with 
2 mL Enzyme 
Buffer 
(n=2 total) 
4 mL synthetic 
urine diluted 
with 2 mL 
Enzyme Buffer 
(n=3 total) 
4 mL synthetic urine 
diluted with 2 mL 
Enzyme Buffer 
(n=4 total) 
4 mL synthetic urine 
diluted with 2 mL 
Enzyme Buffer 
(n=2) 
Natives  
Spike 
100 ng 
0 ng 
100 ng 
10 ng 
0 ng 
0 ng 0 ng 0 ng 0 ng 100 ng 
0 ng 
Surrogate  
Spike 
100 ng 100 ng 100 ng 100 ng 100 ng 100 ng 100 ng 
Enzyme  
Control Spike 
no no 55 ng 55 ng 55 ng 55 ng 55 ng 
Enzyme  no no 0.04 mg 0.08 mg 0.2 mg 0.25 mg 0.25 mg 
Incubation 37 °C for 60 min no 37 °C for 30, 60 
and 120 min 
37 °C for 60 and 
120 min 
37 °C for 60, 
120, 240 min 
37 °C for 30, 60, 120, 
240 min 
37 °C for 120 min 
Acidification/ 
Buffer 
500 μL formic acid 
(98%) after incubation 
no 500 μL formic acid 
(98%) after 
incubation 
500 μL formic 
acid (98%) after 
incubation 
500 μL formic 
acid (98%) after 
incubation 
500 μL formic acid 
(98%) after 
incubation 
500 μL formic acid 
(98%) after 
incubation 
Condition 3 mL each MTBE, 
MeOH, H2O 
3 mL each 
MTBE, MeOH, 
H2O 
3 mL each MTBE, 
MeOH, H2O 
3 mL each 
MTBE, ACN, 
MeOH, H2O 
3 mL each 
MTBE, ACN, 
MeOH, H2O 
3 mL each Hex, 
MTBE, ACN, 
MeOH, H2O 
2 mL each Hex, 
MTBE, MeOH, H2O 
Load quantitative transfer 
2 x 1 mL 0.1 M formic 
acid 
quantitative 
transfer 
2 x 1 mL 0.1 M 
formic acid 
quantitative 
transfer 
1 mL 0.1 M formic 
acid 
quantitative 
transfer 
1 mL 0.1 M 
formic acid 
quantitative 
transfer 
1 mL 0.1 M 
formic acid 
quantitative transfer 
1 mL 0.1 M formic 
acid 
quantitative transfer 
1 mL 0.1 M formic 
acid 
Wash 3 mL MeOH/H2O 
(40:60) 
3 mL 0.1M formic acid 
1 mL MeOH/H2O 
(40:60) 
3 mL 0.1M 
formic acid 
3 mL 
MeOH/H2O 
(5:95) 
1 mL MeOH/H2O 
(5:95) 
1 mL MeOH/H2O 
(5:95) 
1 mL 0.1 M 
formic acid 
1 mL 
MeOH/H2O 
(5:95) 
1 mL MeOH/H2O 
(5:95) 
1 mL MeOH/H2O 
(5:95) 
  
Parameter Trial 1 
(28 Oct 2010) 
Trial 2 
(8 June 2011) 
Trial 3 
(7 July 2011) 
Trial 4 
(8 July 2011) 
Trial 5 
(9 July 2011) 
Trial 6 
(12 July 2011) 
Trial 7 
(15 July 2011) 
Elute 2 x 3 mL MTBE/MeOH 
(90:10) 
5 mL 
MTBE/MeOH 
(90:10) 
1 mL MTBE 
4 mL 
MTBE/MeOH 
(90:10) 
1 mL MTBE 
4 mL 
MTBE/ACN 
(80:20) 
1 mL ACN 
4 mL MTBE 
1 mL ACN 
Tube A: 3 mL 
Hex/MTBE (50:50) + 
2 mL ACN/MTBE 
(20:80) 
Tube B: 2 mL 
MTBE/MeOH 
(90:10) 
Tube A: 2 mL 
Hex/MTBE (50:50)  
Tube B: 4 mL 
MTBE/MeOH 
(60:40) + 1 mL 
MTBE + 2 mL 
MeOH 
Dry Na2SO4 cartridge Na2SO4 
cartridge 
Na2SO4  
in collection tube 
MgSO4  
in collection tube 
MgSO4  
in collection tube 
acidify aq. layer in 
Tube A and remove, 
dry organic layer 
over MgSO4  
acidify aq. layer in 
Tube A and remove, 
dry organic layer 
over MgSO4  
Derivatisation 
Conditions 
BSTFA/TMCS/TMSI 
(97:1:2) 
60 °C, 30 min 
BSTFA/ TMSI 
(98:2) 
60 °C, 30 min 
BSTFA/ TMSI 
(98:2) 
80 °C, 30 min 
BSTFA/ TMSI 
(98:2) 
80 °C, 30 min 
BSTFA/ TMSI 
(98:2) 
80 °C, 30 min 
BSTFA/ TMSI (98:2) 
80 °C, 30 min 
BSTFA/ TMSI (98:2) 
80 °C, 30 min 
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4.4.5 Metabolite Deconjugation Reaction  
The final step in method development was validating reaction conditions for enzyme 
deconjugation of glucuronide and sulphate metabolites.  The reaction conditions were 
evaluated using 4 mL aliquots of synthetic urine diluted with 2 mL Enzyme Buffer.  The 
enzyme control standard was spiked at 100 μL (equivalent to 55 ng deconjugated compound).  
0.5 mL of freshly prepared enzyme solution was added to each sample.  Samples were 
incubated at 37 °C for 30, 60, 90, 120 and 240 minutes.  The enzyme reaction was quenched 
by acidification of the mixture with 500 μL formic acid (98%).  After quenching, samples 
were spiked with 100 ng surrogates, extracted and analysed. 
4.4.6 Pooled Amniotic Fluid Sample 
A small amount of pooled amniotic fluid (approx. 20 mL) was available for a final test of the 
extraction methodology and the enzyme deconjugation reaction.  For the extraction 
methodology test, four 2.5 mL aliquots of the pooled fluid were diluted with 4 mL Enzyme 
Buffer and 2 mL reagent water.  Two aliquots were spiked with 100 ng natives and all 4 were 
spiked with 100 ng surrogates.  The samples were extracted following the procedure 
summarised in Table 4.7 and analysed.  For the enzyme deconjugation reaction test, five 2 
mL aliquots of the pooled fluid were diluted with 4 mL Enzyme Buffer and 4 mL reagent 
water.  Two of the aliquots were spiked with 100 ng natives, two aliquots were spiked with 
55 ng of the Enzyme Control mix and the last aliquot used as a blank.  All 5 aliquots had the 
enzyme solution added and were incubated.  All aliquots were processed following the 
procedure outlined in Table 4.7. 
Table 4.7.  SPE procedure for pooled amniotic fluid samples. 
Parameter SPE Extraction Trial Enzyme Deconjugation Trial 
Matrix 2.5 mL amniotic fluid diluted with  
4 mL Enzyme Buffer and  
2 mL reagent water 
2 mL amniotic fluid diluted with  
4 mL Enzyme Buffer and  
4 mL reagent water 
Natives Spike 125 ng 0 or 100 ng 
Surrogate Spike 100 ng 100 ng 
Enzyme Control 
Spike 
no 0 or 55 ng 
Enzyme  no 0.5 mg 
Incubation no 37 °C, 2 hours 
Acidification no 500 μL formic acid (98%) after incubation 
Condition 2 mL each Hex, MTBE, MeOH, H2O 2 mL each Hex, MTBE, MeOH, H2O 
Load quantitative transfer 
1 mL 0.1 M formic acid 
quantitative transfer 
4 mL 0.1 M formic acid 
Wash 1 mL MeOH/H2O (5:95) 4 mL MeOH/H2O (5:95) 
Elute Tube A: 2 mL Hex + 2 mL Hex/MTBE 
(50:50) 
Tube A: 1 mL MTBE + 2 mL Hex + 2 mL 
Hex/MTBE (50:50) 
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Tube B: 1mL MTBE + 2 mL 
MTBE/MeOH (60:40) + 4 mL MeOH 
Tube B: 2 mL MTBE/MeOH (60:40) + 4 
mL MeOH 
Dry acidify aq. layer in Tube A and remove 
dry organic layer over MgSO4 
acidify aq. layer in Tube A and remove 
dry organic layer over MgSO4 
Derivatisation 
Conditions 
BSTFA/ TMSI (98:2) 
80 °C, 30 min 
BSTFA/ TMSI (98:2) 
80 °C, 30 min 
 
4.5 Results 
4.5.1 Derivatisation Reagent Evaluation 
Three different derivatisation reagent mixtures were evaluated using 500 ng aliquots of the 5 
ppm Natives mix and 250 μL of each reagent: BSTFA only, BSTFA/TMCS (99:1) and 
BSTFA/TMCS/TMSI (97:1:2).  The reaction conditions were 60 °C for 30 min.  The results 
are given as ratio of peak area of the target analyte to that of the internal standard and are 
shown in Figure 4.6.  The error bars indicate 1σ on the average of 4 injections over a period 
of 13 h.  The only significant differences between reagents are for EE2 and GEN.  The peak 
monitored for EE2 is that of the di-TMS derivative and it is only present with the 3-part 
reagent.  For GEN, the tri-TMS derivative is monitored and this peak area ratio decreases 
with the addition of TMCS compared to that obtained with BSTFA only.  The addition of 
TMSI restores the peak area ratio.  For the compounds that do not have an active hydrogen 
(4MBC, mTRIC and OMC) none of the reagents affects the peak area ratio.  Based on these 
results and the difficulties encountered with TMCS, the reagent mixture chosen for further 
use was BSTFA/TMSI (98:2).  The reaction conditions of 60 °C for 30 min were also used as 
earlier tests with standards indicated longer reaction time and higher temperature did not 
improve peak area ratio response.  A comparison of the two-part and three-part reagent 
performance under reaction conditions of 60 °C for 30 min is shown in Figure 4.7.  
Figure 4.6 also gives an indication of the relative sensitivity of the analysis for the range of 
analytes.  This difference in sensitivity is a direct consequence of the fragmentation patterns 
of the analytes.  NP and 4t-OP produce a single dominant fragment.  In contrast, 4MBC 
fragments extensively.  The mass spectra for 4t-OP and 4MBC are shown in Figure 4.8.  4t-
OP was quantified using m/z 207 and 4MBC was quantified using m/z 254. 
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Figure 4.6.  Comparison of derivatisation reagents (12 Oct 2010). 
 
 
Figure 4.7.  Comparison of the performance of two reagent mixtures, BSTFA/TMCS/TMSI (97:1:2) and 
BSTFA/TMSI (98:2), under reaction conditions of 60 °C and 30 min. 
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(a) 4t-OP 
 
(b) 4MBC 
 
Figure 4.8.  Fragmentation patterns for 4t-OP and 4MBC. 
 
4.5.2 Sample Extraction 
Establishing a SPE method that achieves high recovery for the diverse set of target analytes 
involves optimisation of several factors which may work in opposition to one another.  The 
challenges faced included high recovery, reduction or management of co-extracted water and 
separation of water-soluble matrix components (e.g. sugars, amino acids, salts and protein).  
The factors optimised included choice of solvent, the order in which the solvents were 
applied and amounts used and choice of drying agent.  Seven separate trials of extraction 
conditions were completed, as summarised in Table 4.6.  The performance of each trial was 
monitored using labelled surrogate recovery.  The surrogate recoveries for each of the trials 
are compared in Figure 4.12. The recoveries of natives were also monitored as necessary. 
The starting point for the optimisation was Trial 1.  Surrogate recoveries range from less than 
20% for 
13
C6NP to 90% for 
13
C6E2.  BP-rec was not included in the surrogate mix used for 
this trial.  The high variability for D4-GEN is due to the difficulties with the derivatisation 
reaction for this compound.   
100 200 300 400 500 600
0.0
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75.0
100.0
%
207
73
151 19191 27811553 343313 437 562 599514377 484410
100 200 300 400 500 600
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The native recovery results for SPE trial 1 are shown in Figure 4.9.  The recovery corrected 
results were acceptable at ±20% of target (100 ng), except for 4t-OP, 3PBOH, 4MBC, 
mTRIC and BP-3.  There were no differences in recoveries between synthetic urine and 
reagent water matrices, except for 3PBOH.  The recovery surrogate used for 4t-OP, 4MBC 
and mTRIC was 
13
C12TRIC and was selected based on similarity of partition coefficient 
(logP, Table A. 13).  Using 
13
C6NP as recovery surrogate over-corrected and using 
13
C12BPA 
under-corrected the concentrations for these compounds.  For 3PBOH, EQ, ENT and DAID, 
13
C12BPA was used as recovery surrogate.  This choice could account for the over-correction 
for EQ and ENT.  The blank (unspiked) levels for the target compounds are low as shown in 
Figure 4.10.  For mEHP, mBzP, EQ and GEN, it is possible that either contamination or an 
interference with the quantification m/z is contributing to the peak area interpreted as the 
target analyte.  No interferences were observed for ENT. 
 
 
Figure 4.9.  SPE trial 1, 100 ng spiked synthetic urine and reagent water results.  Recovery corrected 
concentration as a percentage of the comparative.  Error bars indicate ±σ on the average (n=2).  Yellow 
lines indicate ± 20% range on 100% recovery. 
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Figure 4.10.  Comparison of recovery corrected reagent blank levels to 100 ng spike target concentration.  
The average of two synthetic urine samples and the single reagent water sample are shown.  The error 
bars indicate ±σ on the average. 
 
These extracts were dried inline with extraction using a second cartridge filled with 
approximately 1 g Na2SO4.   The final extract volume of 6 mL took several hours to be 
reduced to dryness and a white crystalline residue was observed in the reaction vial on 
dryness.  This residue was likely Na2SO4 that had been dissolved by residual water and/or 
methanol in the extract.  The water management strategy required improvement to reduce the 
accumulation of the residue and to reduce evaporation time. 
Temporal stability was determined based on the surrogate compounds in the 4 synthetic urine 
samples and the 3 reagent water samples.  Each sample was injected 5 times over a period of 
33 hours.  Temporal stability was assessed using the variability of repeated injections of the 
samples in time. Analysis of variance (ANOVA) indicated that the within-sample variability 
as measured by the mean square error (MSE) was less than between sample variability 
(differences between the individual synthetic urine or reagent water samples).  Temporal 
stability ranged from 3% to 17% RSD and no clear trend in time was observed.  Typical 
results for 
13
C6-mParaben (most variable) and 
13
C12-BPA (least variable) are shown in Figure 
4.11.   
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(a) 13C6-mParaben  
within sample MSE = 20; between sample MSE = 731 
 
(b) 13C12-BPA 
within sample MSE = 3.6; between sample MSE = 50 
 
Figure 4.11.  Comparison of temporal stability and between sample variance for 
13
C6-mParaben and 
13
C12-BPA.  SU = synthetic urine, RW = reagent water.  Time elapsed between Inj 1 and Inj 5 was 33 
hours. 
 
Subsequent trials were designed to improve the recovery of the less polar compounds (e.g. 
NP) without loss of other compounds.  Different strategies were also evaluated to better 
manage the residual water left in the SPE cartridges after loading of the samples.  The details 
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of the trials are summarised in Table 4.6 and the surrogate recovery results are shown in 
Figure 4.12. 
The SPE conditions in Trial 2 improved recoveries slightly for some of the surrogates but the 
recoveries for others were severely compromised.  The major difference was not acidifying 
the sample prior to extraction which could have resulted in partial ionisation of mEHP and 
3PBA.  Approximately 8 months had elapsed between Trials 1 and 2 and the synthetic urine 
had become very cloudy.  Although it was filtered prior to use, dissolved proteins may have 
adsorbed E2 [321, 353], preventing it from being retained by the adsorbent.  Acidification 
would have denatured the protein, freeing E2.  Clearly the pH of the samples is a critical 
factor to control as demonstrated in the results of Trial 3 where the recoveries of mEHP, 
3PBA and E2 have been restored.  The increase in the amount of MTBE used during 
extraction may also have contributed to the improved recovery of E2.   
The decrease in recovery for mParaben and 4NP in Trial 3 was likely due to volatility.  The 
extracts in Trial 3 again took several hours to dry and a significant amount of Na2SO4 was 
dissolved by the residual water in the samples and transported to the reaction vials.     
The increase in GEN in Trial 3 could be due to two factors.  First, the installation of a new 
column and inlet liners with glass wool on the GC-MS.  The previous column had been 
fouled by non-volatile materials resulting in decomposition of GEN in the inlet or on-column.  
The glass wool in the inlet liner was deactivated in situ and is intended to reduce the 
accumulation of non-volatile material on the column.  Second, an increase in the 
derivatisation reaction temperature from 60 °C to 80 °C may have increased the yield of the 
reaction.  Both the di-TMS and tri-TMS derivatives of GEN were monitored, with the di-
TMS derivative present at about 20% of the level of the tri-TMS derivative.  The recoveries 
for the remaining surrogates were unchanged. 
Trials 4 and 5 investigated the use of an aprotic polar solvent (ACN) to replace MeOH and 
the use of MgSO4 as a drying agent in an effort to better manage the residual water content in 
the extracts.  Replacing MeOH with ACN did not change surrogate recoveries compared to 
Trial 3 as shown in Figure 4.12.  The lower variability and slightly improved recoveries for 
mParaben and 4NP are due to a reduction in solvent evaporation time. 
With Trial 5, the samples were left for 24 h at room temperature between quenching the 
enzyme reaction with formic acid after the specified time and extraction.  This is the most 
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likely reason for the loss of BPA TRIC and GEN and the larger variability observed with the 
other surrogates in Figure 4.12.  From this trial, it was clear that the samples must be 
extracted immediately after the enzyme reaction is complete. 
In Trial 6, hexane was added to the SPE extraction method to increase recovery of the 
nonpolar compounds and the eluate was collected into 2 tubes.  Tube A contained the 
nonpolar/aprotic fraction and tube B contained the polar/protic fraction.  MTBE extracts the 
residual water content into Tube A but the presence of hexane causes phase separation of the 
aqueous layer.  The aqueous layer was acidified to ensure any organic acids were partitioned 
into the organic phase.  The aqueous layer was then removed and the remaining organic layer 
was dried over MgSO4.  This strategy improved the recovery of mParaben, 4NP, NP, TRIC 
and GEN and restored BPA recovery, but the recovery of E2 degraded to Trial 2 level. The 
two extract fractions were analysed separately and the addition of MeOH was responsible for 
the restoration of BPA and GEN recovery. 
With Trial 7, a shift in retention time during the analysis moved the E2 peak so that it was not 
fully within the SIM window and could not be properly integrated.  In comparing the peak 
height to samples from Trial 5, it appeared that the recovery of E2 had been restored.  
Removing ACN from the Tube A solvent mix improved the phase separation of the aqueous 
and organic fractions, shifting the partitioning of E2 back to the organic layer.  An 
interference with the quantification ion for BP-rec resulted in a manually identified peak in 
the samples approximately 50% larger than in the comparatives, so BP-rec was not reported.  
As shown in Figure 4.12, recoveries for the other surrogates were similar to those of Trial 6.   
4.5.3 Enzyme Deconjugation Reaction 
The third SPE trial was also the first test of the enzyme deconjugation reaction.  The 
synthetic urine samples were diluted by 50% with Enzyme Buffer prior to the addition of a 55 
ng spike of the enzyme reaction control standard.  Incubation times of 30, 60 and 120 minutes 
at 37 °C were tested with 0.04 mg enzyme.  Reaction completion was determined by the ratio 
of the recovery corrected concentrations of 4NP (β-glucuronidase) and 4NC (arylsulphatase) 
to the target concentrations of 4NP and 4NC.  As shown in Figure 4.13, the arylsulphatase 
reaction approached completion but the β-glucuronidase reaction was only 55% complete 
after 120 min.   
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In Trial 4, the amount of enzyme added was increased, however the solution was 24 h old and 
had reduced activity.  The enzyme solution used in Trial 5 was 48 h old and had significantly 
lower activity than the fresh solution as seen in Figure 4.13.  From this trial, it was clear that 
the enzyme solution must be freshly prepared before use for full activity. In Trial 6, the 
quantity of fresh enzyme used resulted in essentially complete hydrolysis of both 4NP-
glucuronide and 4NC-sulphate in 120 minutes.  With Trial 7, the conditions for the enzyme 
reaction gave repeatable and stable results as shown in Figure 4.13. 
4.5.4 Pooled AF samples 
Sufficient pooled amniotic fluid was available to conduct a limited trial of the SPE procedure 
and the enzyme deconjugation reaction, as summarised in Table 4.7.  Surrogate recovery 
results are illustrated in Figure 4.15 for both tests.  For most surrogates, recovery is 
acceptable and repeatable.  The recovery for BP-rec continues to be greater than 100% 
suggesting a matrix interference with the quantification ion chosen.  GEN continues to 
behave erratically and may not be amenable to quantification by this method.  The 
distribution between di-TMS and tri-TMS derivatives is not stable and appears to be matrix 
dependent.  The recoveries for NP and TRIC remain low, approximately 40-50%. 
 
 
  
   
   
   
   
 
Figure 4.12.  Summary of surrogate recoveries for SPE trials 1-7.  Error bars indicate ±σ on the average. 
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(a) β-glucuronidase 
 
(b) arylsulphatase 
 
Figure 4.13.  Enzyme deconjugation reaction completion as a function of time for SPE Trials 3-7.  
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Figure 4.14.  %Recovery of native spike in pooled amniotic fluid samples without deconjugation reaction 
(free) and with deconjugation reaction (total). 
 
 
Figure 4.15.  %Recovery for surrogates in pooled amniotic fluid samples. 
 
With these results, the changes in quantification and qualification ions indicated in Table 4.5 
were made.  The method was then applied to the analysis of urine and amniotic fluid samples.  
Although not ideal, due to time constraints final stages of method validation was done 
concurrently with sample analysis. 
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4.5.5 GC-MS Method Validation 
4.5.5.1 Analysis Accuracy and Precision 
Ideally, accuracy is determined by analysis of a certified reference material or by analysis of 
standards prepared from materials obtained from a second, independent source.  Certified 
reference materials are not available for the analytes of interest. Cost prohibited the 
acquisition of materials from a second, independent source.  Instead, multiple sets of 
standards were prepared from the available materials at different times and by different 
analysts. 
Analysis accuracy and precision were assessed using daily calibration check standards at 
three levels (100, 10 and 1 ppb) representing the lower and mid-range concentration level 
expected for analytes and one at the upper end of the calibration range.  Accuracy was 
assessed at each level by calculating the %RE for each compound.  Precision was assessed at 
each level by calculating the %RSD for each compound.  Each calibration check standard 
was analysed a minimum of twice on each day, once at the beginning and once at the end of 
the sample batch and therefore includes contributions from instrument drift and sample 
instability.  The three different calibration standards included in this assessment were 
prepared from the same materials but by two different analysts on three different days.  The 
results summarised in Table 4.8. 
For most analytes, the method performance summarised in Table 4.8 is consistent with the 
guidelines outlined in Table 4.1.  Both GEN and DAID continued to behave erratically, so 
results for these two compounds are not reported.  The %RE for DAID is high, approximately 
45% at all levels suggesting an error in calculation, but no evidence was found.  At 1 ppb, the 
%RE for 4HBA is high at 230%, suggesting contamination.  EE2 and GEN are not detected 
at the 1 ppb level.  The average instrument accuracy and precision statistics do not vary 
greatly over the calibration range, indicating that when a compound is detected at 1 ppb, it is 
reliably detected and quantified.  The %RE is often larger at the highest concentration, likely 
a result of the weighted calibration curve fit to the data. This estimate of analytical precision 
includes contributions from day-to-day variation in preparing the standards including loss due 
to volatility of the lighter components, differences among the different calibration standards 
used and variation in the yield of the analytical derivatisation reaction and therefore 
represents a realistic estimate of uncertainty. 
Chapter 4 – Analytical Method Development 
174 
 
4.5.5.2 Instrument Limit of Detection 
The instrument limit of detection (LOD) is the LOD in the sample as presented to the 
instrument.  It does not include any concentration factors achieved during sample extraction 
and cleanup.  To determine the instrument LOD, the results from the repeated analysis of the 
1 ppb calibration standard were used.  All of the target analytes except EE2 were reliably 
detected in the 1 ppb standard.  The LOD for EE2 was determined from the 10 ppb standard.  
As summarised in Table 4.8, the instrument LODs for all target analytes except 4HBA, BPA, 
BP-2 and EE2 are less than 1 ppb. 
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Table 4.8.  Instrument accuracy (%RE) and precision (%RSD) statistics and instrument LOD (n=11) 
determined from daily calibration check standards.   
 Accuracy  
(%RE) 
Precision  
(%RSD) 
Instrument LOD  
(ppb) 
 100 ppb 10 ppb 1 ppb 100 ppb 10 ppb 1 ppb 
mParaben-13C6 19 21 10 21 20 20 0.5 
mParaben 13 17 13 21 20 20 0.6 
eParaben 7 0 5 21 25 21 0.5 
mMP 8 9 9 19 20 21 0.8 
4HBA 14 26 230 17 17 42 2.4 
mEP-13C6 32 19 22 20 18 17 0.5 
mEP 40 0 24 27 19 32 0.8 
OP 8 1 8 21 22 26 0.7 
pParaben 9 15 6 16 19 28 0.8 
bParaben-13C6 29 21 5 16 16 25 0.6 
bParaben 11 25 12 19 17 23 0.9 
mBP 12 5 17 15 18 19 0.5 
3PBOH 8 14 4 14 18 29 0.8 
NP-13C6 3 7 8 11 11 16 0.4 
NP 10 14 1 12 12 20 0.5 
3PBA-13C6 13 17 0 15 15 21 0.5 
3PBA 21 17 1 17 16 25 0.8 
BP-rec 7 9 8 17 20 22 0.6 
4MBC 25 6 2 20 25 31 0.9 
BP-3 18 15 10 13 21 23 0.8 
mEHP-13C6 26 12 4 12 22 22 0.5 
mEHP 37 3 7 14 22 29 0.9 
mTric 19 16 3 15 21 30 0.8 
Tric-13C12 10 15 6 14 18 24 0.5 
Tric 21 21 9 15 19 25 0.6 
BP-1 7 0 11 10 22 25 0.5 
mBzP 27 17 25 13 21 23 0.7 
BPA-13C12 1 16 4 9 13 32 0.8 
BPA 6 5 10 11 13 33 1.7 
OMC 15 12 0 16 24 28 0.7 
BP-2 4 1 3 13 21 55 1.4 
Equol 17 17 23 9 15 29 0.6 
E1 11 10 12 15 19 31 0.7 
E2-13C6 11 24 11 15 17 17 0.4 
E2 15 2 22 14 18 20 0.3 
EE2 17 21 ND 22 21 ND 3.4 
Ent 16 20 14 20 27 28 0.7 
E3 19 12 12 16 23 38 0.7 
Daid 46 49 47 28 33 30 ND 
Gen-D4-triTMS 1 5 35 66 65 18 ND 
Gen-triTMS 3 9 61 69 76 75 ND 
Gen-D4-diTMS 143 427 ND 43 25 ND ND 
Gen-diTMS 116 341 ND 42 27 ND ND 
Min 
(excluding Daid, Gen) 
1 0 0 9 11 16 0.3 
Max 
(excluding Daid, Gen) 
40 26 230 28 33 55 3.4 
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4.5.5.3 Method Accuracy and Precision 
Ideally, method accuracy and precision are determined using matrix blanks.  Matrix blanks 
are by definition identical to samples in every way except that they do not contain the target 
analytes.  For these samples, true matrix blanks were not available.  Two approaches were 
used to estimate method accuracy and precision: spiked reagent blanks and spiked composite 
urine and amniotic fluid samples.   
4.5.5.3.1 Spiked Reagent Blanks 
Reagent blanks (0.1 M formic acid and Enzyme Buffer, 5 mL) were spiked with 100 ng and 
10 ng natives when the urine and amniotic fluid samples were aliquotted and diluted and 
returned to the freezer.  These spiked reagent blanks were analysed after 4-11 days of storage.  
The results are summarised in Table 4.9 and illustrated in Figure 4.16.   
The 10 ng spike results for 4MBC and OMC are influenced by an interference on the 
quantification ion that gives high blank levels. For both matrices, the 100 ng spike results are 
generally within the 40-120% recovery range.  There are differences between the two 
matrices for mMP, NP, 3PBA, BP-3 and mTric, with the recovery from 0.1M formic acid 
greater than from the Enzyme Buffer.  The pH of the matrix during storage is likely the main 
factor (pH < 3 for 0.1 M formic acid; pH = 5 for the Enzyme Buffer).   
The recoveries for the 10 ng spike are higher than for the 100 ng spike.  This is due to the 
high background levels in the extracts as compared to the standards.  This issue will be 
discussed further in section 4.6.1.   
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Table 4.9.  % Recovery of 100 ng and 10 ng native spikes from reagent blanks. 
 0.1 M Formic Acid 
(n=1) 
Enzyme Buffer 
(n=2) 
 100 ng 10 ng 100 ng 10 ng 
   avg stdev avg stdev 
mParaben 103 123 90 4 147 24 
eParaben 92 77 89 2 107 3 
mMP 100 102 55 11 81 2 
4HBA 102 64 93 5 69 21 
mEP 87 76 86 7 97 12 
OP 49 69 51 21 83 21 
pParaben 103 129 83 4 128 21 
bParaben 91 125 80 7 137 20 
mBP 119 145 104 5 208 3 
3PBOH 90 118 77 8 142 2 
NP 92 103 51 28 75 18 
3PBA 119 164 90 2 181 9 
4MBC 17 0 34 13 14 25 
BP-3 115 188 60 16 101 21 
mEHP 83 136 83 5 44 54 
mTric 100 114 32 24 54 17 
Tric 111 142 78 25 127 16 
BP-1 111 246 108 9 187 8 
mBzP 76 139 103 12 190 27 
BPA 81 147 88 1 119 1 
OMC 89 20 32 24 6 14 
BP-2 102 196 118 24 262 25 
Equol 77 126 92 1 223 8 
E1 126 228 94 8 251 6 
E2 101 173 81 2 174 2 
EE2 136 176 109 10 232 43 
Ent 103 168 132 31 273 37 
E3 127 214 94 3 183 17 
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(a) 100 ng spike 
 
(b) 10 ng spike 
 
Figure 4.16.  Comparison of %recovery of 100 ng and 10 ng native spikes in reagent blanks.    Error bars 
indicate ±σ on the average for Enzyme Buffer (n=2). Green lines indicate 40-120% recovery limits Yellow 
lines indicate recovery limits for spike concentration (80-110% for 100 ng, 60-115% for 10 ng). 
4.5.5.3.2 Spiked Composite Samples 
Composite urine and amniotic fluid samples were prepared by combining aliquots of 
individual samples.  The composite samples were then aliquotted and spiked at 100 ng, 10 ng 
and 0 ng of natives, then processed and analysed with the individual samples.  The percent 
recovery of the spiked amount was calculated after recovery correction and blank (unspiked 
sample) correction.  The results are shown in Figure 4.17 and summarised in Table 4.10  for 
the 100 ng spike and Table 4.11 for the 10 ng spike.  For clarity, the 10 ng spiked urine 
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results are not included in Figure 4.17.  GEN and DAID continued to be erratic and the 
results are not reported.   
The overall performance for both matrices is better with the 100 ng spike than the 10 ng spike 
and is considerably better with amniotic fluid than urine.  This is a clear indication of the 
difficulties with the matrix.  With the urine matrix, the results are also better with the total 
samples than the free samples because the larger, better defined peaks were easier to identify 
and integrate above the matrix background.  Matrix issues will be addressed in the discussion 
on selectivity and sensitivity in section 4.6.1. 
Table 4.10.  Average %Recovery and standard deviation for the 100 ng spike of urine and amniotic fluid 
samples (n=3).  NQ indicates analyte not quantified.   
 Urine (free) Urine (Total) AF (Free) AF (Total) 
 Average Stdev Average Stdev Average Stdev Average Stdev 
mParaben 92 13 123 93 114 12 108 15 
eParaben 98 9 115 46 101 8 100 10 
mMP 83 8 88 1 95 8 93 10 
4HBA 130 69 45 NA 97 12 85 14 
mEP 101 44 177 145 101 17 98 21 
OP 54 5 79 14 71 9 67 2 
pParaben 84 9 125 81 100 11 96 7 
bParaben 54 12 69 15 89 2 88 3 
mBP 145 34 101 106 105 23 94 28 
3PBOH 30 13 22 5 93 6 95 7 
NP 109 16 66 17 105 6 91 9 
3PBA 95 17 121 17 110 12 105 9 
4MBC 71 54 46 17 108 29 38 10 
BP-3 65 24 83 104 114 46 80 7 
mEHP 125 28 79 3 90 3 91 4 
mTric 109 2 28 1 108 25 62 4 
Tric 103 14 105 79 99 10 90 7 
BP-1 85 9 73 62 122 5 124 13 
mBzP NQ NA 59 28 90 8 124 13 
BPA 68 6 89 13 87 6 92 3 
OMC 97 28 18 2 116 14 74 10 
BP-2 16 2 5 2 126 23 117 34 
Equol 83 11 289 361 102 18 104 14 
E1 91 9 65  121 9 107 20 
E2 127 11 56 9 96 5 89 9 
EE2 232 45 210 50 134 7 128 22 
Ent 125 2 NQ NA 131 19 134 34 
E3 80 38 1248 NA 106 12 71 14 
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Table 4.11.  Average %Recovery and standard deviation for the 10 ng spike of urine and amniotic fluid 
samples (n=3).  NQ indicates analyte not quantified.   
 Urine (free) Urine (Total) AF (Free) AF (Total) 
 Average Stdev Average Stdev Average Stdev Average Stdev 
mParaben 141 59 660 793 138 14 190 35 
eParaben 166 41 351 389 98 23 121 3 
mMP 108 8 112 NA 120 11 148 21 
4HBA 904 1261 571 NA 72 53 119 11 
mEP 371 314 1731 NA 86 25 146 66 
OP 21 NA 189 92 80 22 110 24 
pParaben 109 67 626 747 138 11 159 11 
bParaben NQ NA 204 NA 135 14 156 13 
mBP 464 NA 195 89 175 36 218 66 
3PBOH 130 37 NQ NA 148 7 195 15 
NP NQ NA 921 NA 162 17 158 23 
3PBA 231 28 NQ NA 201 17 240 33 
4MBC 343 NA NQ NA 266 183 135 63 
BP-3 113 114 612 682 227 75 138 16 
mEHP 440 112 76 16 161 8 164 29 
mTric 206 23 NQ NA 184 51 93 4 
Tric 517 46 719 911 177 3 153 36 
BP-1 305 7 405 455 263 27 265 42 
mBzP 110 NA 175 188 201 12 399 131 
BPA 115 6 122 6 144 11 141 14 
OMC 220 92 45 NA 139 58 86 8 
BP-2 111 42 18 21 266 74 332 81 
Equol 149 23 5733 NA 185 59 229 28 
E1 242 272 171 NA 277 14 175 48 
E2 1101 167 128 NA 181 15 188 32 
EE2 492 123 584 75 228 34 297 61 
Ent 491 305 9 NA 226 87 248 70 
E3 219 72 6915 9390 159 9 90 68 
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(a) 100 ng spike of Urine 
 
(b) 100 ng spike of Amniotic Fluid 
 
(c) 10 ng spike of Amniotic Fluid 
 
Figure 4.17.  Recovery of 100 ng and 10 ng spiked amounts in composite urine and amniotic fluid 
samples.  Yellow lines indicate 40-120% recovery limits. 
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4.5.5.4 Selectivity and Sensitivity 
Selectivity was assessed with both daily calibration check standards and spike recovery 
samples.  The level of interferences present in the daily calibration check standards ought to 
be low, but if present would be most evident at the lowest concentration level, with %RE 
increasing dramatically as the concentration of the target analyte decreased.  Only 4HBA 
showed any indication of interferences present in the daily calibration check standards.   
The spike recovery results for the reagent blanks and amniotic fluid at 100 ng are generally 
within the 40-120% recovery limits but at 10 ng, the results indicate the potential for over-
estimating analyte concentrations.  This is a direct result of forced manual identification as 
discussed in section 4.6.1.  The spike recoveries at both 100 and 10 ng are not particularly 
instructive for the urine samples due to the high natural concentrations of target analytes.  
These results are subject to large uncertainties due to the ‘small difference between two large 
numbers’ phenomenon.   
4.5.5.5 Extension of the Calibration Range 
At the completion of sample analysis, additional standards were analysed to extend the 
calibration range from 100 ppb to 1000 ppb.  This was necessary to report the target analytes 
in the urine samples that were present above 100 ppb.  To ensure consistency with the initial 
calibration, the set of standards used to extend the range overlapped with the existing 
calibration at 50, 75 and 100 ppb levels.  The highest level included in the extended 
calibration range was 750 ppb because several of the quantification ions were saturated at 
1000 ppb.  No calibration check data is available above 100 ppb. 
4.5.5.6 Method LLOQ 
With these challenges, the best estimates of measurement uncertainty and LOQs are obtained 
from an ad-hoc evaluation of the data. The lowest concentration for each analyte in the 
sample as presented to the instrument was identified and it represents the smallest peak that 
could be reliably identified by manual inspection of the chromatogram and examination of 
the ion ratios of the candidate peak.  From this concentration, the reported sample 
concentration (corrected for surrogate recovery and aliquot volume) was identified.  This 
reported concentration is the best estimate of LLOQ and is given in Table 4.12 for each of the 
sample matrices.  A corrected concentration lower than this level was set to “NQ” for “not 
quantifiable”.  With reagent blank subtraction, it is possible to obtain a concentration lower 
than the LLOQ.  If the reagent corrected concentration was less than 1σ of the reagent blank 
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mean, the blank corrected concentration was set to NQ. The best estimate of ULOQ is the 
concentration of the highest calibration standard, nominally 100 ppb.  Because of the 
nonlinear calibration curve, uncertainty increases with extrapolation outside the range defined 
by the calibration standards.  
Table 4.12.  Best estimate of LLOQ (ng/mL) for target analytes in different matrices. 
 Urine  
n=88 
Amniotic Fluid 
n=70 
 Min Detects Min Detects 
mParaben 2 33 0.4 29 
eParaben 22 44 1.1 3 
mMP 3 37 0.6 24 
4HBA 126 38 18 32 
mEP 6 32 2.6 65 
OP ND 0 ND 0 
pParaben 3 27 1.5 6 
bParaben 17 1 2.0 3 
mBP 36 7 4.8 22 
3PBOH ND 0 ND 0 
NP ND 0 ND 0 
3PBA ND 0 ND 0 
4MBC 53 2 2.8 68 
BP-3 5 4 1.2 58 
mEHP 46 43 5.8 67 
mTric ND 0 ND 0 
Tric 2 26 0.6 44 
BP-1 8 5 0.4 53 
mOP ND 0 ND 0 
mBzP 5 7 ND 0 
BPA 2 44 0.7 68 
OMC ND 0 13 68 
BP-2 4 42 0.1 8 
Equol 6 23 0.2 13 
E1 15 36 6.3 36 
E2 7 18 1.5 35 
EE2 ND 0 ND 0 
Ent 10 23 3.7 49 
E3 8 38 4.4 68 
Daid not reliably quantified in any samples 
Gen not reliably quantified in any samples 
 
4.5.5.7 Extraction Efficiency 
Extraction efficiency was monitored for each sample using labelled surrogates.  The average 
recovery and %RSD for each surrogate by sample type are summarised in Table 4.13.  BP-
rec was intended to be the recovery surrogate for the benzophenones, but an interference 
made it useless.  An interference also affected the recovery of 
13
C6-mEHP.  In both cases, 
13
C12BPA was used instead.  The recoveries for the remaining surrogates were acceptable, 
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within the range of 45-99%.  The %RSD is a measure of reproducibility of extraction over all 
samples of a given type and is less than 20%. 
4.5.5.8 Method Reproducibility 
Method reproducibility is a measure of how well the entire sample extraction and analysis 
method performs on the same sample on the same day and different days.  Reproducibility 
was assessed using the composite amniotic fluid samples prepared for the matrix spike study.  
Three unspiked composite samples were processed through the free analysis and three were 
processed through the total analysis.  The results are shown in Figure 4.18.  The %RSD on 
the average of the three samples for each analyte was calculated and plotted as a function of 
reported concentration, as shown in Figure 4.19.  The %RSD on the three repeats ranges from 
1% to 86%, with the highest variability generally observed with the lowest reported 
concentration. 
Table 4.13.  Extraction efficiency for urine and amniotic fluid samples as measured by %Recovery of 
surrogates. 
Surrogate Urine Amniotic Fluid 
 Free Total Free Total 
 Average %RSD Average %RSD Average %RSD Average %RSD 
13
C6mParaben 54 17 64 18 66 13 66 10 
D4-4NP 69 12 66 21 81 16 80 11 
13
C6mEP 60 24 59 29 74 15 80 15 
13
C6bParaben 68 20 76 26 89 12 86 7 
13
C6NP 45 20 59 15 76 14 69 10 
13
C63PBA 74 10 74 17 88 12 80 8 
BP-rec 159 34 194 43 115 6 100 6 
13
C6mEHP 87 13 104 18 122 12 104 8 
13
C12Tric 52 11 60 20 94 8 85 5 
13
C12BPA 99 9 96 11 99 9 92 5 
13
C6E2 72 10 76 19 99 8 92 8 
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Figure 4.18.  Reproducibility of analysis for composite amniotic fluid samples (n=3).  Error bars indicate 
±σ on the average. 
 
Figure 4.19.  Correlation of analysis variability (%RSD, n=3) with reported concentration as determined 
by the analysis of unspiked composite samples of amniotic fluid for both the free and total analyses.   
4.6 Discussion 
4.6.1 Selectivity and Sensitivity  
Ideally, spike recovery studies are done using matrix blanks.  Matrix blanks are by definition 
identical to samples in every way except that they do not contain the target analytes.  Since 
matrix blanks were not available, spiked reagent blanks and pooled samples were used. 
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With the spike recovery samples, results were generally within the 40-120% range for both 
reagent blanks and composite amniotic fluid samples at 100 ng.  With the spiked urine 
samples, some compounds showed good results, others did not.  For example, the 4HBA 
spiked amount was substantially under-reported in urine for two reasons.  First, the high 
natural concentration of this compound in urine was on the order of 1000 ppb.  Determining 
the contribution of a 100 ng spike on top of this large natural concentration is subject to 
considerable uncertainty due to the small difference between two large values.  The 
extrapolation beyond the calibration range further increases uncertainty.  This situation is also 
present for other compounds, particularly with the total samples.  With the urine samples, the 
signal attributable to the 10 ng spike is well within the measurement uncertainty (nominally 
±20% at 100 ppb, Table 4.8) at the natural levels of most of the compounds and therefore not 
useful.   
With the reagent blanks and amniotic fluid samples, the natural levels are much lower and the 
spike recovery results are much better.  There are still a few difficulties with the results.  
Interferences due to the matrix are a problem as illustrated with the following example for 
3PBOH. 
To be correctly identified as a target analyte, the peak in the chromatogram must be within a 
narrow window (±0.1%) of the expected retention time and the ratio of quantification to 
qualifier ions must be within a specified range (±15%).  However, the peaks have width at the 
base on the order of 0.09 min which is independent of peak height.  Thus, peaks at lower 
concentration are shorter than those at higher concentration and more difficult to detect over 
the baseline and less certain for assignment of retention time.  Figure 4.20 shows 3PBOH in 
different contexts, a standard, spiked at 10 ng in a reagent blank and amniotic fluid and not 
present in amniotic fluid.  In the 10 ppb standard, the peak is well defined and free of 
interferences – all ions follow the same Gaussian peak shape.  In both the reagent blank 
(Enzyme Buffer), and the amniotic fluid sample (diluted with Enzyme Buffer), the 
quantification ion (m/z 272, black trace) is well defined but the three qualifier ions have 
contributions from nearby peaks.  The contribution to m/z 211 (brown trace) makes this ion 
useless as a qualifier ion.  In both the reagent blank and the spiked amniotic fluid sample, the 
peak had to be manually identified to be included in the report because the ion ratios were not 
within the specified range.  The peak shown in panel (d) is of the unspiked amniotic fluid 
sample.  The peak at RT = 16.964 min is outside the window for identification as 3PBOH and 
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also does not meet the ion ratio criteria, but this peak will contribute to the area of the 10 ng 
spike peak as it is within the base width of the 10 ng 3PBOH peak.  Although the reported 
concentration of this peak is only 2.4 ppb, the nonlinear calibration curve results in a much 
larger apparent contribution to concentration because the area increase occurs on a larger 
peak at a point in the calibration curve where the slope is greater.  This is the main reason for 
the over-recovery of the 10 ng spike samples.  The same situation is present with the 100 ng 
spike samples, but the relative contribution of the interference peak is much smaller.   
 
(a) 3PBOH in 10 ppb standard 
 
(b) 3PBOH at 10 ng in reagent blank 
 
(c) 3PBOH at 10 ng in amniotic fluid 
 
(d) 3PBOH not present in amniotic fluid 
 
Figure 4.20.  SIM chromatograms showing the interference effect on 3PBOH.  X-axis is retention time 
(min), Y-axis is detector signal.  See text for explanation. 
A similar phenomenon affects 4MBC, but with a different outcome.  In this case, the peak 
size of the spike is relatively small compared to the size of the interference peak.  The result 
of blank subtraction is again a small difference between two large numbers and the large 
variability in spike recovery.  The blank subtraction works well for the 100 ng spike in the 
free analysis of amniotic fluid where the interference peak is smallest, but rapidly deteriorates 
as the interference peak grows relative to the spiked amount in the total analysis of amniotic 
fluid and in both the free and total analyses of urine. 
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The matrix effect on actual samples is two-fold.  First, the target analyte must be present in 
sufficient quantity to provide both a detectable peak with the correct ion ratios to be 
identified automatically by the software.  A compound by compound review of each sample 
can lead to confident identification of additional peaks provided the evidence for 
identification remains strong, as with the case of 3PBOH in the spiked sample given above.  
If the situation as illustrated with 4MBC is present, only very large concentrations of the 
target analyte may be detected, and likely only by manual verification.  Thus, the complexity 
of the matrix has negative effects on both selectivity and sensitivity which will be different 
for each target analyte and each sample type.  The effect may also be dependent on the 
composition of the individual sample, making a general statement about selectivity and 
sensitivity very difficult to formulate.  However, with careful inspection and sound 
judgement, target analyte identification can be confidently achieved. 
 
(a) 4MBC in 10 ppb std 
 
(b) 4MBC at 10 ng in amniotic fluid 
 
(c) 4MBC in unspiked amniotic fluid 
 
 
Figure 4.21.  SIM chromatograms showing the interference effect on 4MBC.  -axis is retention time (min), 
Y-axis is detector signal.  See text for explanation. 
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4.6.2 Problems with GEN and DAID 
The challenges encountered in determining GEN and DAID were due to the complexity of 
the sample matrix and they were greater for the urine samples than for the amniotic fluid 
samples.  These challenges were a direct result of the scope of the target analyte list which 
included carboxylic acids as well as phenols.   
Initially, the derivatisation reaction performed well for GEN and DAID in the calibration 
standards, and for extraction of spiked reagent water (Figure 4.9).  Matrix related problems 
began to appear with the spiked synthetic urine samples (Figure 4.9).  Subsequent changes to 
the SPE extraction method intended to improve recovery of the less polar analytes led to the 
deterioration of the performance of the derivatisation reaction for GEN and DAID as is 
evident in Figure 4.12.  The situation further deteriorates with extraction of real AF samples 
as seen in Figure 4.14 and Figure 4.15.  By the time the urine samples were attempted, the 
results for GEN and DAID were not useful as the calibration standards were now being 
affected.  Several possible explanations can be offered: 
 Incomplete derivatisation, leading to formation of both di- and tri-TMS derivatives.  It 
is also possible that mono-TMS derivative was formed, but it was not determined.  
The partitioning among the possible derivatives was also not reproducible for either 
the samples or standards. 
 Competition for derivatisation reagent by matrix components leading to interferences 
with either the kinetics or equilibrium of the reaction for GEN and DAID. 
 Decomposition of the derivatives in the GC inlet due to fouling by non-volatile 
residues.  This is quite likely as the previously well-behaved calibration standards 
began to be affected. 
 Non-volatile, insoluble residue left in the reaction vials, even after cleaning, that 
interfered with the derivatisation reaction for GEN and DAID. 
As discussed in Section 4.1, previous studies of EEs in human fluids (urine, serum and 
amniotic fluid) have addressed subsets of the target analyte list of this study.  None of these 
studies considered both acidic and phenolic analytes in the same extraction and derivatisation 
method.  The published methods for determining phytoestrogens including GEN and DAID 
by GC-MS with TMS derivatisation [354-359] have two common features in the sample 
cleanup procedures.  First, liquid-liquid extraction of the aqueous samples (pH 3-5) is 
performed using a nonpolar solvent such as ethyl acetate or diethyl ether.  These solvents will 
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preferentially extract the phenols, and because most aliphatic and aromatic carboxylic acids 
have pKa values less than 4, they are partially, if not fully ionised in the aqueous phase.  This 
extraction, therefore, leaves the carboxylic acids behind in the aqueous phase.  Second, the 
extract is further cleaned up using gel filtration chromatography to further remove potential 
interferences to the derivatisation reaction.   
4.7 Conclusion 
4.7.1 Final Method 
With the results from the pooled AF samples, several changes to the quantification and 
qualification m/z were made (see Table 4.5) in an effort to reduce interferences. This was 
successful in most cases, but interferences were still present with 4MBC, OMC, BP-rec and 
13
C6-mEHP.  Unfortunately, GEN and DAID are not amenable to this method because of the 
matrix interferences with the derivatisation reaction. 
The final SPE method parameters are summarised below. 
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Table 4.14.  SPE procedure for pooled urine and amniotic fluid samples. 
Parameter SPE Extraction Free SPE Extraction Total 
Matrix 2 mL urine or 2.5 mL amniotic fluid 
diluted with  
 4 mL 0.1 M formic acid   
2 mL urine or 2.5 mL amniotic fluid  
diluted with  
4 mL Enzyme Buffer and  
4 mL reagent water 
Surrogate Spike 100 ng 100 ng 
Enzyme Control 
Spike 
no 55 ng 
Enzyme  no 0.5 mg 
Incubation no 37 °C, 2 hours 
Acidification pH <3 on dilution 500 μL formic acid (98%) after incubation 
pH <4 
Condition 2 mL each Hex, MTBE, MeOH, H2O 2 mL each Hex, MTBE, MeOH, H2O 
Load quantitative transfer 
1 mL 0.1 M formic acid 
quantitative transfer 
1 mL 0.1 M formic acid 
Wash 1 mL 0.1 M formic acid 
1 mL MeOH/H2O (5:95) 
1 mL 0.1 M formic acid 
4 mL MeOH/H2O (5:95) 
Elute Tube A: 1 mL Hex/MTBE (50:50) + 2 mL 
Hex + 2 mL Hex/MTBE (50:50) 
Tube B: 4 mL MTBE/MeOH (60:40) + 2 
mL MeOH 
Tube A: 1 mL Hex/MTBE (50:50) + 2 mL 
Hex + 2 mL Hex/MTBE (50:50) 
Tube B: 4 mL MTBE/MeOH (60:40) + 2 
mL MeOH 
Dry acidify aq. layer in Tube A and remove 
dry organic layer over MgSO4 
acidify aq. layer in Tube A and remove 
dry organic layer over MgSO4 
Derivatisation 
Conditions 
BSTFA/ TMSI (98:2) 
80 °C, 60 min 
BSTFA/ TMSI (98:2) 
80 °C, 60 min 
 
4.7.2 Method Validation 
The traditional method performance and validation metrics were at some points difficult to 
apply to this method because of the matrix challenges.  These difficulties affected GEN and 
DAID to the point that these two analytes could not be reliably determined by the method. 
The analysis method performed very well for daily calibration check standards as 
summarised in Table 4.8.  The method was stable over the 4 weeks of sample analysis as 
illustrated in the control charts in Figure A. 1 and derivatised samples were stable over the 
typical duration of a batch as illustrated in Figure 4.11.  The SPE method performed well for 
analyte recovery as summarised in Table 4.13.   
The instrument LOD was acceptable at less than 1 ppb for all but 4 compounds.  The 
instrument LODs for EE2, 4HBA, BPA and BP-2 were 3.4, 2.4, 1.7 and 1.4 ppb respectively.  
Attempting to determine LLOQ and ULOQ from spiked samples was difficult due to the 
matrix interferences and their effects on quantification of the spiked samples as discussed in 
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section 4.6.1.  The ad-hoc evaluation of LLOQ resulted in acceptable overall performance 
and the method is deemed fit for purpose. 
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5.1 Introduction 
Human gestational exposure to EEs can be measured by chemical analysis of amniotic fluid 
collected early in the second trimester of pregnancy, during diagnostic amniocentesis.  This 
study was granted human ethics approval from both the New Zealand Health and Disability 
Upper South Regional A Ethics Committee and the University of Canterbury Human Ethics 
Committee. 
A cohort of 32 New Zealand women was recruited for the study after diagnostic 
amniocentesis at the Christchurch Women’s Hospital.  The recruitment materials are included 
in the Appendix.  A total of 38 women were invited to participate and the first 32 to give 
informed consent were included in the study.  No specific selection criteria were used.  The 
women were aged 19.6-43.3 years (mean = 31.8, median = 32.7).  There were 16 male and 16 
female fetuses of gestational age 14.9-20.6 weeks (mean = 17.6, median = 17.0).  No other 
demographic data was collected on the mothers.   
Amniotic fluid and matched maternal urine samples were collected from each mother.  The 
maternal urine samples were used to obtain an indication of recent maternal exposure to the 
EEs of interest in the study.   
In this study, it is assumed that maternal exposure is well represented by a single urine 
sample.  Three studies provide evidence to support the assumption that a single urine sample 
represents an individual’s exposure to EEs.  In the first study [360], temporal variability and 
daily reproducibility of urinary measures of seven phthalate monoesters was evaluated in 46 
U.S. women on two consecutive days.  The daily levels were strongly correlated (Pearson 
correlation coefficient between the 0.5 and 0.8).  The authors suggested that even with the 
short half-lives of phthalates, women’s patterns of exposure may be sufficiently stable to 
assign an exposure level based on a single first morning void urine measurement.  In another 
study [361], the temporal variability in urinary phthalate metabolite levels over 3 months 
among 11 U.S. men was evaluated.  Up to nine spot urine samples were collected for each 
man during this time period. Although substantial day-to-day and month-to-month variability 
in each individual’s urinary phthalate metabolite levels were seen, a single urine sample was 
moderately predictive of each subject’s exposure over 3 months.  In a third study [324], urine 
samples from 35 U.S. children aged 6-10 years were analysed for 13 EEs including phthalate 
metabolites, phytoestrogens and phenols.  Six samples were collected from each child over a 
6 month period.  The authors found that the 6-month average concentration was predicted by 
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a sample collected at the start of the interval as well as by a sample collected at the end of the 
interval. They also suggested that an annual urine sample used for exposure assessment in 
longitudinal studies might be reflective of a participant’s year-long exposure for these 
chemicals.  
5.2 Materials 
5.2.1 Plastic Labware 
Labware as described in Chapter 5 was used.  Additional items included 
 Sterile polystyrene centrifuge tubes – 15 mL 
 Sterile polypropylene centrifuge tubes – 50 mL and 15 mL 
 Sterile polypropylene urine specimen containers 60 mL 
 Polypropylene pipette tips 
 Syringe tip filters, 7.5 mm diameter, 0.22 μm pore, PTFE membrane in polypropylene 
housing. 
5.2.2 Reagents 
Reagents as described in Chapter 5 were used.   
5.3 Methods  
The analytical method described in this chapter has slight modifications from that 
summarised in Table xxx.  These modifications were made to improve the SPE cleanup to 
reduce matrix effects during analysis, to improve recovery of the nonpolar analytes and to 
improve water removal from the final extracts.  The modifications include increased dilution 
of the sample, larger quantitative transfer and SPE tube wash volumes and adjustment of the 
elution solvent volumes.  These changes are detailed in Table 5.1. 
5.3.1 Sample Collection 
Amniotic fluid and maternal urine samples were collected following the hospital’s standard 
procedure using the standard collection vessels.  The urine and amniotic fluid samples were 
delivered to the hospital laboratory within 1 hour of collection and were processed 
immediately.  The urine samples (approximately 20 mL each) were split, with a 5 mL sample 
sent for creatinine analysis and the remaining sample stored at -20 °C.  The amniotic fluid 
samples (approximately 10 mL) were processed following the hospital laboratory standard 
procedures for the diagnostic tests.  The samples were centrifuged to separate cellular 
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material from the supernatant fluid.  The supernatant fluid was collected into a sterile 
centrifuge tube and stored at -20 °C.  At the completion of sample collection (approximately 
3 months), the samples were transported to the analytical chemistry laboratory and stored at -
80 °C for approximately 1 year until analysis. 
The urine samples were collected in 60 mL polypropylene cups and the amniotic fluid 
samples were collected in 20 mL polystyrene tubes. 
5.3.2 Sample Preparation 
Samples were processed in batches of 10-12 with additional QA/QC samples and standards.   
Urine samples were thawed at room temperature, transferred to 50 mL sterile polypropylene 
centrifuge tubes and centrifuged at 5,000 g and 4 °C for 10 minutes to separate insoluble 
material.  Two 15 mL sterile polypropylene centrifuge tubes were prepared for each urine 
sample, one containing 5 mL 0.1 M formic acid and the other containing 5 mL Enzyme 
Buffer.  A 2 mL aliquot of urine was added to each tube and those not analysed on that day 
were returned to the -80 C freezer.  A composite urine sample were prepared for QA/QC 
purposes for each batch of urine samples by combining 1mL aliquots of each of the 
individual urine samples in that batch in a sterile 50 mL centrifuge tube.  This composite 
sample was then aliquotted into formic acid and enzyme buffer in the same way as the 
individual samples.  For each batch, three identical composite urine samples were prepared.  
For 5 of the 32 urine samples, duplicate aliquots in both formic acid and enzyme buffer were 
made.  Reagent blanks, 3 each of formic acid and enzyme buffer were also made. 
Amniotic fluid samples were thawed at room temperature and 3 mL aliquots were added to 5 
mL formic acid and 5 mL enzyme buffer, as done with the urine samples.  Two composite 
amniotic fluid samples were made by combining 2 mL aliquots of each sample into two 50 
mL centrifuge tubes. These two composite samples were identical and were prepared from 24 
of the 32 samples that had sufficient volume.  This composite sample was aliquotted into 
formic acid and enzyme buffer in the same way as the individual amniotic fluid samples.  For 
each batch, three composite samples and one reagent blank were made.  The aliqotted and 
diluted samples were stored in the freezer at -80 °C until analysis. 
5.3.3 Sample Extraction 
The diluted samples were thawed at room temperature.  Samples diluted into 0.1 M formic 
acid were used for the analysis of free (unconjugated) analytes.  The individual urine or 
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amniotic fluid samples were spiked with 100 ng Recovery Surrogates.  Three composite QC 
samples were used for each batch.  One was spiked with 100 ng Natives, the second was 
spiked with 10 ng Natives and the third was not spiked with Natives.  All three were spiked 
with 100 ng Recovery Surrogates.  A reagent blank was spiked with 100 ng Recovery 
Surrogates.  Because of their protein content, the amniotic fluid samples had an additional 3 
mL of reagent water added to reduce the viscosity of the samples.  All samples were vortex 
mixed and extracted following the SPE procedure outlined in Table 5.1. 
Samples diluted into Enzyme Buffer were used for the analysis of total (free + conjugated) 
analytes.  Three composite QC samples were used for each batch.  One was spiked with 100 
ng Natives, the second was spiked with 10 ng Natives and the third was not spiked with 
Natives.  A reagent blank was spiked with 100 ng Recovery Surrogates.  All samples were 
spiked with 55 ng Enzyme Control Standard and 500 μL Enzyme and incubated at 37 °C for 
90 min.   At the end of the incubation time, the reaction was stopped by addition of 500 μL 
formic acid (98%).  All samples were then spiked with 100 ng Recovery surrogates.  An 
additional 3 mL of reagent water was added to the amniotic fluid samples.  All samples were 
vortex mixed and extracted following the SPE procedure outlined in Table 5.1.    
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Table 5.1.  SPE procedure for urine and amniotic fluid samples. 
Parameter Free (unconjugated) Analysis Total (Free + Conjugated) Analysis 
Matrix 2 mL urine or  
3 mL amniotic fluid diluted with  
5 mL 0.1M formic acid  
Amniotic fluid diluted with an 
additional 3 mL reagent water 
2 mL urine or  
3 mL amniotic fluid diluted with  
5 mL 0.1M formic acid  
Amniotic fluid diluted with an 
additional 3 mL reagent water 
QA/QC Sample 
Natives Spike 
100, 10, 0 ng 100, 10, 0 ng 
Surrogate Spike 100 ng 100 ng 
Enzyme Control 
Spike 
no 55 ng 
Enzyme  no 0.5 mg 
Incubation no 37 °C, 90 min 
Acidification on dilution 500 μL formic acid (98%) after incubation 
Condition 2 mL each Hex, MTBE, MeOH, H2O 2 mL each Hex, MTBE, MeOH, H2O 
Load quantitative transfer 
2 mL 0.1 M formic acid 
quantitative transfer 
2 mL 0.1 M formic acid 
Wash 2 mL 0.1 M formic acid 
4 mL MeOH/H2O (5:95) 
2 mL 0.1 M formic acid 
4 mL MeOH/H2O (5:95) 
Elute Tube A: 1 mL Hex/MTBE (50:50) + 4 mL 
Hex + 2 mL Hex/MTBE (50:50) 
Tube B: 2 mL MTBE/MeOH (60:40) + 2 
mL MeOH 
Tube A: 1 mL Hex/MTBE (50:50) + 4 mL 
Hex + 2 mL Hex/MTBE (50:50) 
Tube B: 2 mL MTBE/MeOH (60:40) + 2 
mL MeOH 
Dry acidify aq. Layer in Tube A and remove 
dry organic layer over MgSO4 
acidify aq. Layer in Tube A and remove 
dry organic layer over MgSO4 
Derivatisation 
Conditions 
BSTFA/ TMSI (98:2) 
80 °C, 60 min 
BSTFA/ TMSI (98:2) 
80 °C, 60 min 
 
5.3.4 Sample Derivatisation 
The Tube A fraction was filtered to remove MgSO4 particles using a PTFE syringe tip 
membrane filter on transfer to the derivatisation reaction vial.  The solvent was then 
evaporated to near dryness.  The Tube B fraction was added to the reaction vial and the 
solvent evaporated to dryness.  All solvent evaporations were done with the vials sitting on a 
surface maintained at 40 °C with a gentle nitrogen stream.  The samples were split to retain a 
portion for future requirements.  To the dry residue, a 100 μL aliquot of internal standard 
solution containing 100 ng of internal standard in ACN and 100 μL of MeOH were added.  
The samples were allowed to stand for 5 minutes and were vortex mixed to ensure full 
dissolution.  A 100 μL aliquot of the sample was archived in an autosampler vial fitted with a 
250 μL insert and stored at -20 C.  The remaining sample was evaporated to dryness to 
remove MeOH, then taken up in 200 μL derivatisation reagent BSTFA/ TMSI (98:2) and 100 
μL ACN.  The mixture was vortex mixed and then heated at 80 °C for 60 min.  The samples 
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were allowed to cool for 15 minutes, the vials rolled to ensure complete mixing of contents 
and a 200 μL aliquot was transferred to an autosampler vial fitted with a 250 μL insert ready 
for GC-MS analysis. 
5.3.5 QA/QC  
A reagent blank and 3 matrix spike samples (100, 10 and 0 ng Natives) were processed 
simultaneously with each batch of 10-12 samples.  Comparative standards of the 100 and 10 
ng Natives spikes and the 100 ng Surrogate spike were prepared and analysed along with 
daily calibration check standards at 100, 10 and 1 ppb.  The comparatives and calibration 
check standards were prepared directly in reaction vials for solvent evaporation, archive 
splitting and derivatisation.  With the urine samples, individual sample duplicates were 
prepared for 5 samples because the composite material used to prepare the matrix spike 
samples was different for each batch.  With the amniotic fluid samples, the composite 
material used for matrix spike samples was the same for all batches and these samples served 
as replicates.  The calibration check standards and comparatives were injected twice, once at 
the beginning and once at the end of each batch.  Two samples were also injected twice 
during each batch.  One randomly selected sample was injected twice sequentially and the 
first sample of the batch was injected again after the last sample of the batch.  These repeat 
injections were used to monitor sample stability through the duration of the batch analysis. 
5.4 Results 
5.4.1 Calculations 
For each sample, the reported concentration for each target analyte was corrected for 
surrogate recovery and for aliquot volume as described in Chapter 5.  The average 
concentration of each target analyte was calculated for the reagent blanks (n=6) for the free 
and total analyses.  This concentration was then used to produce separate blank profiles for 
the urine and amniotic fluid samples that were correctly scaled for the sample aliquot volume.  
The appropriate average blank profile was then subtracted from the recovery and volume 
corrected sample profile to give the final concentration result.  The complete dataset is given 
in the Appendix. 
Chapter 5 – Gestational Exposure to Environmental Estrogens 
202 
 
5.4.2 QA/QC 
Control charts were prepared for the representative compounds from the calibration check 
standards and duplicate samples and repeat injections of samples were assessed for stability 
as summarised in Chapter 4. 
For the analysis of total (free + conjugates) concentration, the % Completion of reaction was 
monitored by the enzyme control standards and summarised in Table 5.2.  % Completion was 
calculated with reference to the reagent blank result.  For the urine samples, the urine matrix 
interferences contributed to the peak areas of both 4NP and 4NC in the same manner as 
described for 3PBOH in Chapter 4.  Based on a single composite urine sample that had the 
enzyme added but not the enzyme control standard, the matrix contribution to these two 
peaks was on the order of 25 ppb, or about 40% of the total.  The larger standard deviation 
observed with the urine samples is a result of the variable contribution of the matrix 
composition to the peak area.  Through the analysis, two samples were discovered to have 
had twice the volume of enzyme solution added.  The % Completion for these two samples 
did not differ from the other samples, indicating the enzyme reaction had gone to completion 
for all samples. 
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Table 5.2.  % Completion of enzyme deconjugation reactions (average ± σ) 
Control Standard Urine (n =  32) Amniotic Fluid (n = 
32) 
4NP (β-glucuronidase) 164 ± 60 115 ± 11 
4NC (arylsulphatase) 183 ± 63 114 ± 13 
 
Recovery corrected and aliquot volume scaled reagent blanks, an average of 6 samples each 
for the free and total analyses, are shown in Figure 5.1.  The peaks in the blanks identified as 
4MBC and OMC are interferences on the quantification ion for those two compounds.  Mass 
spectra for those peaks in the reagent blanks obtained in SCAN mode indicate the peaks are 
aliphatic hydrocarbons but identification by library search was inconclusive.  There was an 
increase in the blank level of mEHP due to the presence of the deconjugation enzyme, but the 
other phthalate monoester levels remained constant and low among all blanks.  mMP 
contamination averaged 0.6 ng/mL, approximately 65% of the level found in the free samples 
and 20% or less of the levels found in the total samples.  mEP contamination averaged 2.6 
ng/mL and was comparable to the levels found in both the free and total samples.  BPA 
contamination averaged 0.6 ng/mL and was comparable to the levels found in the free 
samples and about 67% of the levels found in the total samples. 
 
Figure 5.1.  Comparison of reagent blanks for the free and total analyses of urine and amniotic fluid.  
Error bars indicate ±σ on the average (n=6). 
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5.4.3 Urine Samples 
The maximum, minimum and median concentrations for the free analysis are shown in Figure 
5.2(a) and for the total (free + conjugated) analysis in Figure 5.2(b).  For those compounds 
quantified in both the free and total analyses, the free concentration accounted for between 
15% and 90% of the total concentration.  The correlation between free and total 
concentrations for the urine samples is shown in Figure 5.3 for those compounds detected in 
both samples.  For each analyte, the linear model determined by least squares regression and 
the coefficient of determination (R
2
) are also shown.  To measure of the strength of the linear 
correlation of amniotic fluid concentration with maternal urine concentration, the Pearson 
correlation coefficient (r) is used.  For values of r between 0.5 and 1, the correlation between 
the two variables is said to be strong and positive.  For values of r between 0 and 0.1, there is 
no correlation.  If r is negative, the correlation is negative.  The Pearson correlation 
coefficient for the dependence of the free and total concentrations for each of the analytes of 
Figure 5.3 is given in Table 5.3.   
The linear model that is shown in Figure 5.3 is not intended to be used as a predictive tool for 
estimating amniotic fluid concentration based on maternal urine concentration, but rather to 
indicate the linear correlation between the two observed concentrations.  For this reason, 
determining the confidence interval on the regression line is not an appropriate way of 
assessing the significance of the relationship.  Instead, the probability that the observed data 
are uncorrelated (i.e. r = 0) can be estimated by the following statistic which has a Student’s t 
distribution [362]. 
      
     
      
 
Where N = number of paired observations 
 r = Pearson correlation coefficient 
This t-statistic can then be compared to the critical t-value from the Student’s t distribution 
with N-2 degrees of freedom and the probability (p) that the t-statistic is greater than the 
critical t-value due entirely to chance can be calculated.  If the probability, p, is less than 
0.05, then the correlation is not statistically significant at the α = 0.05 significance level.  In 
other words, there is at most a 1 in 20 chance that the correlation is not statistically 
Chapter 5 – Gestational Exposure to Environmental Estrogens 
205 
 
significant.  The t-statistics, p-values and classification of the correlation as statistically 
significant or not are summarised in Table 5.3. 
The free and total concentrations 4HBA are very similar and not unexpected given the 
hydrophilic nature of the compound.  In contrast, eParaben does not follow the pattern 
established by mParaben and pParaben.  As indicated by the Pearson correlation coefficient, 
the dependence is weak.  bParaben was not detected in the free analysis of any samples.  For 
TRIC, the correlation shown in Figure 5.3 is not strong and may be negative as suggested in 
Table 5.3.  The correlation of free and total concentrations for BPA is also weak.   
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(a) Free concentration (ng/mL) 
 
 
(b) Total (free + conjugates) concentration (ng/mL) 
 
Figure 5.2.  Free concentrations (a) and total concentrations (b) of EEs in maternal urine.  Lines indicate 
maximum and minimum, green boxes indicate the range between the mean and median values. 
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Figure 5.3.  Correlation of free and total urine concentrations.   
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Table 5.3.  Pearson correlation coefficient (r) and statistical significance for the correlation of free and 
total concentration of EEs in maternal urine. (NS = not statistically significant, S = statistically 
significant) 
Compound 
Pearson 
(r) 
Description of 
Correlation 
N t 
p 
(1-tail) 
Significance 
(a=0.05) 
Tric -0.34 medium negative 15 1.29 0.11 NS 
eParaben -0.24 weak negative 30 1.31 0.10 NS 
BPA 0.14 weak positive 20 0.58 0.28 NS 
4HBA 0.38 medium positive 30 2.19 0.02 S 
mMP 0.54 strong positive 28 3.27 1.43E-03 S 
mParaben 0.64 strong positive 28 4.27 1.02E-04 S 
pParaben 0.66 strong positive 22 3.88 3.99E-04 S 
Ent 0.72 strong positive 20 4.39 1.43E-04 S 
BP-1 0.76 strong positive 8 2.84 0.01 S 
mEP 0.84 strong positive 26 7.49 2.97E-08 S 
BP-3 0.94 strong positive 9 7.52 1.80E-05 S 
Equol 0.97 strong positive 3 3.70 0.02 S 
    
5.4.4 Amniotic Fluid Samples 
The maximum, minimum and median concentrations for the free analysis are shown in Figure 
5.4(a) and for the total (free + conjugated) analysis in Figure 5.4(b).  In comparison to the 
urine samples, the free compound accounted for a slightly larger fraction (18% to100%) of 
the total concentration in amniotic fluid.  With few exceptions, there was also no difference 
between the median concentrations for male and female fetuses as shown in Figure 5.5.  In 
the free analysis, bParaben and EQ were each detected once in male samples and BP-2 was 
only detected in two female samples.  In the total analysis, eParaben was detected only in two 
male samples while BP-2 was detected only in 5 female samples.  The median concentrations 
of mEP, BPA and OMC were higher in female samples and the median concentration of 
mMP was higher in the male samples, but by ANOVA, the differences were not statistically 
significant at the 95% confidence level.   
The correlation of free and total concentrations in amniotic fluid are shown in Figure 5.6 for 
those compounds with sufficient (N>2) data.  The Pearson correlation coefficient for these 
correlations is given in Table 5.4.  With the exception of BP-1, the correlation between free 
and total concentrations is medium to strongly positive. 
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(a) Free concentration (ng/mL) 
 
 
(b) Total (free + conjugates) concentration (ng/mL) 
 
Figure 5.4.  Free concentrations (a) and total concentrations (b) of EEs in amniotic fluid.  Lines indicate 
maximum and minimum, green boxes indicate the range between the mean and median values. 
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(a) Free concentration (ng/mL) 
 
 
(b) Total (free + conjugates) concentration (ng/mL) 
 
Figure 5.5.  Comparison of free and total median concentrations of EEs in amniotic fluid for male and 
female fetuses. 
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Figure 5.6.  Correlation of free and total amniotic fluid concentrations 
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Table 5.4.  Pearson correlation coefficient (r) and statistical significance for the correlation of free and 
total concentration of EEs in amniotic fluid. (NS = not statistically significant, S = statistically significant) 
Compound 
Pearson 
(r) 
Description of  
Correlation 
N t 
p 
(1-tail) 
Significance 
(a=0.05) 
BP-1 0.19 weak positive 21 0.85 0.20 NS 
BP-3 0.39 medium positive 25 2.01 0.03 S 
Ent 0.50 strong positive 19 2.39 0.01 S 
Tric 0.71 strong positive 20 4.30 1.7E-04 S 
4HBA 0.79 strong positive 29 6.71 1.2E-07 S 
mEP 0.92 strong positive 8 5.67 2.3E-04 S 
5.5 Discussion 
5.5.1 Matrix Challenges 
The analysis of urine samples was more difficult than amniotic fluid because of the 
differences in matrix.  Urine has much higher concentrations of organic acids and other 
species that the SPE method could not remove because the suite of target analytes included 
organic acids, specifically the phthalate monoesters.  All literature reports of phthalate 
monoesters in urine and amniotic fluid used SPE with LC-MS/MS as the analytical method.  
LC-MS/MS is much more selective than GC-MS because of the use of tandem mass 
spectrometers in detection.  In MS/MS detection, the ionisation process is gentle, producing 
only a molecular ion or adduct ion, called the parent ion, of the target analyte.  The first MS 
selects this parent ion for transport to a reaction cell where it is further fragmented.  
Fragments specific to the target analyte are then selected by the second MS for detection.  
The two-stage selection process is highly specific for the compound of interest.  The first 
stage greatly reduces the amount of co-eluting material from reaching the detector and the 
second stage allows specific identification of the parent ion based on its unique fragmentation 
pattern in comparison to any other possible species that are able to pass the first selection 
stage.  Unfortunately, LC-MS/MS instrumentation was not available for this study. 
5.5.2 Correlation of Maternal Urine and Amniotic Fluid Concentrations 
The exposure assessment of Chapter 7 is based on the assumption that fetal exposure is 
directly related to maternal exposure.  Maternal exposure was assessed by analysis of urine 
samples collected at the same time as amniotic fluid samples.  The maternal urine samples 
represent exposure over the previous 6-12 hours while amniotic fluid samples may represent 
cumulative fetal exposure.  Since maternal exposure to the compounds of interest is mainly a 
function of daily lifestyle and environment, it is not unreasonable to assume that the exposure 
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chronic rather than acute and results in a reasonably steady level of the target analytes in the 
body.     The rationale is that their normal daily routine whereby exposure to the chemicals of 
interest occurs is not altered significantly because the participants had no a priori knowledge 
of the study. As discussed in Section 5.1, this assumption is reasonable and the total amniotic 
fluid concentrations are expected to correlate with total maternal urine concentrations.   
 
The amniocentesis procedure required the mother to have a full bladder, so to account for 
variable dilution of the urine samples by an increase in water ingestion in the hours before the 
procedure, the maternal urine concentrations of the target analytes were normalised to the 
urine creatinine concentration.  The biological mechanisms that control amniotic fluid 
volume are insensitive to short term fluctuations in maternal hydration, so no correction was 
required.  The correlations are shown in Figure 5.7 and the Pearson correlation coefficients 
are given in Table 5.5.  BP-2 was found in only 3 paired samples and at very low 
concentrations, so there is insufficient data to evaluate a possible correlation. The trendline 
shown for EQ suggests a negative correlation whereas the Pearson correlation coefficient 
suggests no correlation.  The measured concentrations are low in comparison to other 
compounds.  The very low concentration found in the matching urine sample for the amniotic 
fluid sample showing  ~ 6 ng/mL could be due to the short timeframe of exposure that the 
maternal urine samples represent.  EQ is produced by bacteria in the gut from DAID and it is 
possible that that mother had not ingested soy products in the previous day but had in the 
past.  A similar explanation could apply to the two amniotic fluid samples showing high 
concentrations of ENT compared to their matching urine samples.  Poor chromatography 
distorted the peak shape in the amniotic fluid sample matched to the urine sample with mMP 
at ~300 ng/mg creatinine.  The short lifetime of the derivatised samples (less than 24 hours) 
precluded dilution and re-analysis for samples showing high concentrations. 
The lack of correlation observed for mBP is most likely a result of the low concentrations 
found in comparison to the other phthalate monoesters.  Contamination from the enzyme 
solution is not likely an issue given the absence of mBP in the reagent blanks (Figure 5.1). In 
contrast, the poor correlation observed for mEHP is likely a result of enzyme contamination.   
The lack of correlation observed for E1 and E2 were not unexpected because the placenta 
controls the levels of E1 and E2 that the fetus is exposed to.  The correlation observed for E3 
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was expected because the placenta excretes E3 into both maternal and fetal circulations.  The 
maternal serum E3 level is actually diagnostically important for Down’s Syndrome and 
intrauterine growth restriction [363].   
 
 
  
 
   
   
  
   
   
  
   
  
 
 
Figure 5.7.  Correlation of total amniotic fluid and maternal creatinine-corrected concentrations of the target analytes. 
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Table 5.5.  Pearson correlation coefficient (r) and statistical significance for the correlation of total 
concentrations of EEs in amniotic fluid and maternal urine. (NS = not statistically significant, S = 
statistically significant) 
Compound 
Pearson 
(r) 
Description of 
Correlation 
N t 
p 
(1-tail) 
Significance 
(a=0.05) 
BP-2 -0.58 strong negative 4 1.00 0.19 NS 
mBP -0.38 medium negative 18 1.66 0.06 NS 
E1 -0.18 weak negative 29 0.95 0.18 NS 
E2 -0.08 not correlated 29 0.41 0.34 NS 
EQ 0.06 not correlated 9 0.17 0.43 NS 
ENT 0.34 medium positive 19 1.48 0.08 NS 
BPA 0.36 medium positive 25 1.85 0.04 S 
4HBA 0.45 medium positive 29 2.59 0.01 S 
E3 0.49 medium positive 29 2.89 3.6E-03 S 
mEHP 0.49 medium positive 14 1.93 0.04 S 
mMP 0.56 strong positive 5 1.17 0.15 NS 
mEP 0.73 strong positive 28 5.49 3.6E-06 S 
BP-3 0.86 strong positive 16 6.17 6.7E-06 S 
mParaben 0.87 strong positive 11 5.38 1.1E-04 S 
BP-1 0.88 strong positive 16 6.87 1.9E-06 S 
Tric 0.90 strong positive 22 9.34 2.1E-09 S 
pParaben 0.95 strong positive 5 5.07 1.9E-03 S 
 
5.6 Conclusions and Recommendations 
From Figure 5.7 it is clear that a small but measurable quantity of EEs reach the fetus.  The 
correlation between maternal urine and amniotic fluid concentrations is positive and medium 
to strong (Table 5.5) for those compounds with sufficient data and levels above the 
quantification limit of the analysis.  The correlations are also statistically significant for BPA, 
4HBA, E3, mEHP, mEP, BP-3, mParaben, BP-1, Tric and pParaben.   The correlations for 
BP-2, mBP, E1, E2, EQ and ENT are not statistically significant, possibly for the following 
different reasons: 
 Exposure to BP-2 is very low for this cohort.  A survey of product composition would 
confirm whether this ingredient is present in topical sunblock or other products 
available in Christchurch; 
 mBP concentrations are low compared to the other phthalate monoesters; 
 E1 and E2 are strictly controlled by the placenta and levels in amniotic fluid are 
expected to be independent of those in the mother; 
 EQ and ENT are present due to naturally occurring components of soy and grains and 
their presence is highly dependent on maternal diet.  As a result, these compounds 
may show much greater temporal variation in maternal urine than in amniotic fluid. 
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These correlations are observed despite the difficulties encountered in the analysis of these 
samples by GC-MS.  The results are considered valid and can be used in the exposure 
assessment of Chapter 6. 
GEN and DAID could not be determined by the GC-MS method.  This is unfortunate 
considering the potentially significant contribution these two compounds may make to the 
estrogenicity of the mixture.  Literature data suggest that GEN and DAID concentrations 
could be in the range of 40 ng/mL (Figure 2.15), much greater than any of the other 
compounds determined in this study. 
It is highly desirable to have the archived sample fractions analysed by LC-MS/MS to 
confirm the GC-MS results and improve the quality of the dataset for those compounds not 
amenable to the GC-MS method. 
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6.1 Introduction 
Fetal exposure to EEs might lead to a number of adverse outcomes as reviewed in Chapter 1.  
As this exposure is to a mixture of chemicals that can act in unison with or in opposition to 
one another, predicting the outcome of the exposure is difficult.  Further complicating matters 
is that the same exposure will have different outcomes on the male and female fetus because 
of differences in sensitivity to estrogen signalling.  The objective of this chapter is to bring 
together the results of the measurements made in this study with those available in the 
literature to determine whether the potential magnitude of exposure is likely to be of concern.  
This analysis will address only the estrogenic action of the exposure.  However, it must be 
kept in mind that this estrogenic action does not occur in isolation and that the opposing 
androgenic action is also present, but at this stage, not quantifiable.  The methodology used 
here is equally applicable to androgenic action once sufficient data are available. 
6.1.1 Characterisation of Fetal Exposure 
Fetal exposure begins with maternal exposure.  Because the exposure of interest is 
environmental, the most likely pathways are ingestion, dermal and inhalation.  Pathways 
typically associated with therapeutics (e.g. injection) have been disregarded in this study.  It 
is reasonable to assume that maternal exposure to many of these chemicals is chronic and low 
level, as suggested specifically for BPA [364] rather than acute and of high level because 
these compounds are present in many of the products used daily, if not multiple times a day 
and in food and water.  Chronic, low level exposure may lead to a pseudo-constant low level 
of the compounds in the body, rather than the rapid increase and clearance profiles observed 
in acute dosing studies, and may affect clearance rates (e.g. by induction of metabolic 
enzymes).  For other compounds like GEN and DAID that are found in foods like soy, 
exposure levels may show more temporal variation, depending on the frequency of exposure.  
Each of the maternal exposure pathways has different metabolic and elimination pathways 
associated with it that can either transform or reduce the amount of the compound reaching 
maternal circulation.  The model of fetal exposure is illustrated in Figure 6.1.   
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Figure 6.1.  Illustration of fetal exposure model. 
6.1.2 Role of the Placenta 
As discussed in Chapter 1, transport across the placenta occurs by simple diffusion for 
hydrophobic compounds and by facilitated and active transport for hydrophilic compounds. 
The EES are hydrophobic and therefore diffuse across the placental membranes from 
maternal circulation to fetal circulation.  As diffusion is driven by a concentration gradient, 
diffusion back to the mother will only occur if the concentration in the fetal compartment is 
higher than in the maternal compartment.  With a chronic low level exposure scenario for the 
mother, it is possible that maternal levels will reach a pseudo-steady state and that fetal levels 
will a reach steady state that is dependent on maternal levels. 
The only way out of the fetal compartment for conjugated species is by active transport.  The 
active transporters present in the placenta are both highly substrate specific and nonspecific.  
Both the placenta and fetal tissues have deconjugation enzymes and this may facilitate 
recirculation of EEs within the fetal compartment. 
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Some EEs are known inhibitors of placental conjugation enzymes (Table 2.4).  This action 
will contribute indirectly to the upset of hormone balance within the fetal compartment and 
possible aggravation or suppression of the genomic response to EEs. 
6.1.3 Accumulation in Amniotic Fluid 
Once in the fetal circulation, a compound is subject to the metabolic and elimination 
pathways that are active in the fetus.  Fetal xenobiotic metabolism is significantly less active 
than adult metabolism and exhibits some different pathways than present in the adult.  For 
example, the fetus will preferentially sulphate rather than glucuronidate molecules for 
excretion in fetal urine.  Fetal elimination pathways can deposit metabolites and elimination 
products in the amniotic fluid, sequester them in meconium, or return them to the mother via 
circulation. The fetus actively swallows amniotic fluid and expels fluid from the lungs into 
the amniotic fluid [174, 178, 365-367].  The fluid expelled from the lungs is a transudate of 
fetal plasma and extracellular fluid which is produced in part from the amniotic fluid.  
Therefore amniotic fluid makes intimate contact with the respiratory and gastrointestinal 
tracts of the fetus and diffusion across fetal skin readily occurs until skin keratinisation occurs 
at approximately 20 weeks.  With this intimate contact, the compositions of fetal plasma, 
interstitial fluid and amniotic fluid are similar, and therefore it is possible for any and all 
tissue types within the fetus to be exposed to EEs prior to skin keratinisation.  After skin 
keratinisation, compounds eliminated in fetal urine mix with the amniotic fluid.  Amniotic 
fluid is still swallowed and lung fluid is still produced and expelled, but the free diffusion 
across fetal skin decreases significantly. 
The amnion membrane encloses and retains amniotic fluid during pregnancy.  The placenta 
and umbilical cord structures are outside the amniotic membrane and do not come in direct 
contact with amniotic fluid [363].  In general, fluid flux through the amniotic membrane is 
regulated by epithelial tissues, which have tight junctions (TJs).  TJs prevent the passage of 
molecules and ions through the space between cells, as in the blood-brain barrier.  To be 
transported across the membrane, materials must actually enter the cells by diffusion or active 
transport [368].  The active transporters that are present in the placental membrane are also 
present in the amnion membrane [369], but their localisation and function suggest that their 
role is to prevent accumulation of xenobiotics and endogenous metabolites within the cells of 
the amniotic membrane rather than as a fetal protection mechanism.   
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With samples of amniotic fluid collected prior to 20 weeks, the total concentration of EEs 
(free + conjugated) increases with time and represents the total exposure of the fetus to these 
chemicals up until that point in time.  The rationale for this is as follows.   
1. Transport of free neutral, hydrophobic compounds such as EEs across the placenta is 
by simple diffusion which is driven by the concentration gradient between maternal 
and fetal blood.   
2. Given that the only exposure route for the fetus is via the placenta, the only way for a 
hydrophobic compound to enter the fetal circulation is by diffusion across the 
placenta. 
3. Transport of protein bound compounds across the placenta may be possible if 
progesterone is present in the placenta or maternal circulation at a level high enough 
to inhibit MDR1 active transport.  Some EEs are known to bind to plasma proteins 
(see section 2.9.5) and thus may end up in the fetal circulation by this mechanism. 
4. Sulphate or glucuronide conjugates produced by maternal metabolism and present in 
maternal blood do not cross the placenta given the localisation and unidirectional 
function of active transporters such as MRPs, BCRPs and OATs. 
5. For chronic maternal exposure to EEs, blood levels of the EEs may remain elevated 
and may attain a steady state.  With diffusion driven transport across the placenta, 
maternal circulation may serve as a constant supply of EEs to the fetus. 
6. The final barrier in the placenta en route from maternal to fetal circulation is the fetal 
capillary endothelium.  Aside from the two steroid-sulphate-specific OATs listed 
above, it is not known which, if any, of the other active transporters are present at this 
location.  Simple diffusion is the primary mechanism by which molecules can cross, 
therefore limiting the rate of transport of polar, hydrophilic molecules across the 
barrier.  It is therefore highly likely that once an EE enters the fetal compartment and 
is conjugated, it remains there until birth. 
7. Sulphatase and glucuronidase enzymes are present in fetal tissues and the placenta.  
They may serve to recirculate EEs within the fetal compartment by cleaving the 
respective conjugates.   
Wittassek et al. have suggested that the ‘turnover’ of amniotic fluid may facilitate elimination 
of EEs (phthalate metabolites in their study) via the placenta [151].  This statement is 
incorrect.  In fetal physiology, the turnover of amniotic fluid that is described is the 
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recirculation of fluids within the fetal compartment through the swallowing of amniotic fluid 
and expelling fluid from the lungs, not a wholesale volume exchange with the mother.  The 
movement of amniotic fluid (primarily water) into the maternal circulation across the 
membranes of the uterus has not been directly measured but appears to have little effect on 
fluid volume [172].  What does cross these membranes is likely to be only water, not solutes, 
as there are 5 layers of membranes separating the amniotic fluid and the uterine wall.  The 
only exchange between mother and fetus is via the placenta, its active transport mechanisms 
and passive diffusion. 
6.2 Comparison with Literature 
6.2.1 Maternal Urine 
The results from this study for total concentration of EEs in maternal urine are compared with 
literature values in Figure 6.2.  The results from this study are consistent with other studies 
representing a range of lifestyles and countries (Table 2.3).  This study is the first to report 
urine levels of BP-1 and BP-2.  Six other target analytes (4t-OP, NP, mOP, mTric, 3PBA and 
3PBOH) were included in the analysis but were not detected in any of the samples.  The 
levels found in this study are consistent with those reported in the literature.  For some 
compounds, e.g. the parabens, the levels from this study are in the higher range of the 
literature data.  The literature data set was assembled from adult urine results and includes 
both males and non-pregnant females in addition to pregnant females.  It is possible that the 
levels in male urine for some of the ingredients in personal care products are lower than in 
female urine, because of the differences in the use of these products. 
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Figure 6.2.  Comparison of total (free + conjugated) maternal urine concentrations of EEs obtained in this 
study with aggregate literature data.  White bars indicate the range between lowest and highest literature 
median values, grey bars indicate range between maximum and minimum literature reported values.  
Green lines indicate the range between maximum and minimum values reported in this study and the 
blue diamond indicates the median value for this study. 
 
6.2.2 Amniotic Fluid 
The results from this study for total concentration of EEs in amniotic fluid are compared with 
literature values in Figure 6.3.  Literature data are available only for the phthalate 
monoesters, BPA and the phytoestrogens (Table 2.5).  This study is the first to report levels 
of parabens, UV filters and triclosan in human amniotic fluid.  Six other target analytes (OP, 
NP, mOP, mTric, 3PBA and 3PBOH) were included in the analysis but were not detected in 
any of the samples.  The literature concentrations of the endogenous steroids (E1 and E2) 
shown in Figure 6.3 are the free concentrations.     
The comparison with literature values must be made cautiously because some of the literature 
studies may underestimate amniotic fluid concentrations, especially with samples collected in 
the early 2
nd
 trimester.  Several studies have used only β-glucuronidase deconjugation.  As 
indicated in Chapter 1, the fetal glucuronidation pathway is much less active than the 
Chapter 6 – Exposure Assessment 
230 
 
sulphation pathway.  The glucuronidation pathway does not develop until later in gestation 
and at term it is only about 30% of the activity of the adult.  In contrast, the activity of the 
fetal sulphation pathway is high during early gestation and decreases in activity as gestation 
advances.  As a result, the majority of the conjugates present in AF collected in the early 2
nd
 
trimester are most likely sulphates, not glucuronides.  The studies affected are all those that 
have reported phthalate monoesters and one study reporting BPA and the phytoestrogens as 
identified in Table 2.5.  The reason for the choice of enzyme in the studies identified in Table 
2.5 was to avoid potential contamination of their samples by phthalates present in the Helix 
pomatia derived β-glucuronidase / arylsulphatase mixed enzyme.  The blank and other 
control samples of the present study indicated only the mEHP results were affected by 
contamination of the Helix pomatia derived β-glucuronidase / arylsulphatase mixed enzyme.  
The reagent blank levels for the other phthalate monoesters were low and repeatable or not 
detected and adequately accounted for any contamination. 
The levels reported in this study for a cohort of 32 New Zealand mothers are consistent with, 
and in some cases, lower than the levels reported in the literature.  Median levels of mEP, 
mBP, BPA and ENT in the New Zealand cohort were lower than the median literature values 
and mBzP was not detected.  The median levels for mEHP and EQ in the New Zealand 
cohort were similar to those reported in the literature.  Unfortunately, the results for GEN and 
DAID from this study were not reliable enough to be used because of instability of the TMS 
derivatives during analysis.   
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Figure 6.3.  Comparison of total (free + conjugated) amniotic fluid concentrations of EEs obtained in this 
study with aggregate literature data.  White bars indicate the range between lowest and highest literature 
median values, grey bars indicate range between maximum and minimum literature reported values.  
Green lines indicate the range between maximum and minimum values reported in this study and the 
blue diamond indicates the median value for this study.   
 
6.3 Relative Estrogenic Load 
To estimate the increase in estrogenic load that the fetus is exposed to as a result of these 
levels of EEs in amniotic fluid, the relative estrogenic potency (Figure 2.16 and Table A. 6) 
of the compound was used.  As there are few data on the relative potency of the compounds 
of interest for hERβ, this discussion will be limited to hERα.   
There is some uncertainty as to how to handle the contribution of E3 to the total estrogen 
activity.  As discussed in section 2.8, E3 is known to behave as an antagonist to E2 when 
present in equal or up to 10-fold excess concentrations of E2, resulting in an 85% suppression 
in E2-mediated transcription.  But, when E3 is present alone or in concentrations 50 fold 
greater than E2, it behaves as a weak agonist. In this study, free E2 was not detected, but the 
literature indicates free E2 concentrations in amniotic fluid are approximately 0.24 ng/mL for 
male fetuses and 0.28 ng/mL for female fetuses [52].  These levels are below the limit of 
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quantification of the analytical method used in the current study (1.5 ng/mL, Table 4.12).  
Free E3 was determined in this study and was approximately 3.2 ng/mL.  Therefore, it is 
possible that E3 behaves as an antiestrogen in amniotic fluid, thus reducing the potency of 
E2.  
A similar behaviour has been reported for both GEN and DAID as discussed in section 2.7.4.  
Both compounds were able to reduce E2-mediated transcription by 20% when present in 
equal concentrations to E2, but how this behaviour changed as a function of concentration 
ratio was not investigated.  The concentrations of GEN and DAID in amniotic fluid are 
expected to be much greater than E2 (see Figure 2.15); however the suppressive effects of 
GEN and DAID cannot be included in the estimate of relative estrogenicity because the 
concentration dependence of the suppressive effects has not been characterised. 
As discussed in Section 2.8, synergistic effects have also been reported for mixtures of BP-1, 
BP-2 and BP-3 with or without E2 and for BPA and NP each with E2.  These compounds, 
when present together in mixtures can result in an estrogenic signal that is larger than 
predicted by the sum of the concentrations, however, no information is available as to how 
the synergistic effect changes with mixture composition or concentration of E2.  Therefore, 
the effects of such synergism cannot be considered in this study. 
There are two possible scenarios, representing conservative and worst-case situations, for the 
relative estrogenic load experienced by the fetus in response to the levels of endogenous and 
environmental estrogens in amniotic fluid.  In the conservative scenario, the free 
concentrations of the EEs and endogenous estrogens and their lowest reported estrogenic 
potencies are used.  The potencies of E2 and E3 are set to their independently determined 
values.  In the worst-case scenario, the total (free + conjugated) concentrations of the EEs and 
the free concentrations of the endogenous estrogens are used.  The highest reported 
estrogenic potencies are used, however to reflect the antiestrogenic behaviour for E3, the 
potency for E3 is set to zero and the relative potency of E2 is reduced by 85%.  The two 
scenarios are summarised in Table 6.1. 
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Table 6.1.  Comparison of conservative and worst-case scenarios for relative estrogenic load experienced 
by the fetus up to 20 weeks gestation. 
 Conservative Scenario Worst-case Scenario 
Concentrations of  
endogenous estrogens 
Use free concentration 
(Table A. 14 and Table A. 15) 
Use free concentration 
(Table A. 14 and Table A. 15) 
Relative estrogenic potency  
of endogenous estrogens 
Use lowest literature potency values 
(Table A. 6) 
Use highest literature potency values  
(Table A. 6) 
Concentrations of  
environmental estrogens 
Use measured free concentrations  
(Table A. 14 and Table A. 15)  
but set GEN and DAID  
concentrations to zero 
Use total concentrations 
(Table A. 16 and Table A. 17) 
Relative estrogenic potency  
of environmental estrogens 
Use lowest literature potency values 
(Table A. 6) 
Use highest literature potency values  
(Table A. 6) 
Mixture effects 
None considered.   
Assume simple additivity 
Use greatest antiestrogenic  
effect of E3. 
 
These two scenarios represent the extremes of potential influence of the EEs.  The 
conservative scenario favours the effects of endogenous estrogens while the worst-case 
scenario favours the effects of the EEs. The total concentration of an EE represents a worst-
case scenario of exposure as it assumes the compound enters the fetal circulation via simple 
diffusion across the placental membrane as the free compound and is subsequently 
conjugated by the fetus.  Because the fetal plasma, extracellular fluid and amniotic fluid 
compositions are considered similar at this stage of fetal development, the compound is free 
to diffuse through the fetal tissues and may not necessarily be immediately transported to the 
kidneys/liver for conjugation.  In contrast, endogenous hormone levels are tightly controlled 
and only the free hormones are active.  The concentration of the EE or endogenous estrogen 
is multiplied by the relative potency and the sum for all compounds calculated.  In both 
scenarios, the literature reported concentrations of free E2 in amniotic fluid for male and 
female fetuses are used.  Because GEN and DAID were not reliably determined in this srudy, 
the median total (free + conjugate) concentrations from the literature are used in the worst-
case scenario (GEN = 1.54 ng/mL and DAID = 5.48 ng/mL).  The free concentrations of 
GEN and DAID are set to zero in the conservative scenario. 
The results for each scenario for each individual are shown in Figure 6.4.  In the conservative 
scenario, the EEs account for 0-9% of the relative estrogenic load of the amniotic fluid for 
female fetuses and 0-10% for male fetuses.  In contrast, the EEs account for 14-64% of the 
relative estrogenic load of the amniotic fluid for female fetuses and 16-78% for male fetuses 
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in the worst-case scenario.  The highest male and female estrogenic loads shown in Figure 
6.4(b) arise from higher than average levels of TRIC and BPA in those samples. 
The results summarised in Table 6.2 and illustrated in Figure 6.5 are obtained by repeating 
the calculation using the median free and total concentrations for the male and female fetuses.  
In this case, there is little difference in the total load of the amniotic fluid of male and female 
fetuses with either scenario.  However, in the worst-case scenario the potential contribution 
of EEs to the estrogenic load of the amniotic fluid could approach 40% for both male and 
female fetuses.  The major contributor to the differences shown in Figure 6.5 is the anti-
estrogenic behaviour of E3 in reducing the transcriptional activity of E2. 
Table 6.2.  Relative estrogenic load of the amniotic fluid for the conservative and worst-case scenarios 
using the median amniotic fluid composition. 
 Conservative Worst-Case 
 Female Male Female Male 
Endogenous 0.346 0.316 0.042 0.039 
Environmental 0.007 0.009 0.023 0.026 
Total 0.353 0.325 0.065 0.065 
%Environmental 2% 3% 36% 40% 
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(a) Individual results for the conservative scenario 
 
 
 
(b) Individual results for the worst-case scenario 
 
Figure 6.4.  Relative estrogenic load of amniotic fluid for each individual estimated by the conservative 
and worst-case scenarios 
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Figure 6.5.  Median relative estrogenic load of amniotic fluid for male and female fetuses estimated by the 
conservative and worst-case scenarios. 
6.4 Discussion 
This assessment has addressed only the estrogenic potency of amniotic fluid in terms of its 
potential to up-regulate hER-mediated gene transcription, which is only one small facet of a 
highly complex and variable situation.  There are many co-operating and competing factors at 
play, especially in attempting to predict the end effects of this type of exposure.  Even with 
the simplifications and assumptions that have been applied to this analysis, it is plausible that 
fetal exposure to EEs could account for a substantial (40%) increase in the estrogenic potency 
of the amniotic fluid for both male and female fetuses.  With the list of EEs continually 
growing, this contribution could increase.  Androgenic potency is the opposing factor and a 
similar analysis could be performed if similar data on androgenic potency and amitotic fluid 
concentrations of environmental androgens were available.  At this time, sufficient data are 
not available in the literature to conduct such a study.   
Other competing and co-operating factors have been identified in which the target analytes of 
this study play a role.  Anti-androgenic activity is a co-operating factor exhibited by the 
parabens, the phthalate monoesters, BP-3 and 4MBC.  The parabens also have anti-aromatase 
activity which inhibits estrogen biosynthesis and competes with their estrogenicity. The 
phthalate monoesters are not estrogenic or androgenic in any of the in vitro assays, but animal 
studies have repeatedly shown phthalate exposure results in adverse effects on the male 
reproductive system due to their anti-androgenic activity.  Recent monitoring of human 
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pregnancy and newborns has found indications of similar effects.  Triclosan is another 
compound with conflicting activities.  Depending on the assay, it is estrogenic, anti-
estrogenic and not estrogenic; not androgenic and androgenic.   
GEN, DAID and E3 are antagonists in the presence of E2.  Both GEN and DAID are able to 
reduce E2-mediated transcription by 20% when present at a 1:1 concentration ratio with E2.  
E3 is able to reduce E2-mediated transcription by 25% at a 1:1 concentration ratio with E2 
and by 85% when present at a 10:1 concentration ratio. 
The effects of exposure to a mixture of chemicals that are at the same time estrogenic and 
anti-androgenic have not yet been studied.  It is not known whether this type of mixture 
would amplify one mode of action over the other, resulting in observed effects of both modes 
of action or result in entirely new observed effects.   
6.5 Conclusions 
It is abundantly clear that the human fetus is exposed to measurable quantities of EDCs at a 
critical time in gestation when they have the opportunity to cause the greatest adverse effects.  
The levels of EEs found in amniotic fluid are strongly correlated with maternal exposure and 
are reached through normal, daily lifestyle choices that expectant mothers make.  The women 
who participated in this study did not make any changes to their daily routines based on a 
priori knowledge of participation in this study because they were not recruited for the study 
until after the samples had been obtained for medical diagnostic reasons.  The strength of the 
correlations between maternal urine and amniotic fluid levels obtained in this study for a 
large number of the target analytes show that maternal urine levels could provide reliable 
estimates of amniotic fluid levels with a much less invasive method of sample collection.    
Even with the simplifications and assumptions that have been applied to this analysis, it is 
plausible that fetal exposure to EEs could account for a substantial (40%) increase in the 
estrogenic potency of the amniotic fluid for both male and female fetuses.  While there is 
insufficient information to be able to definitively assess or predict the biological effects of the 
exposure to EEs on the fetus, should actual conditions be similar to the worst-case scenario 
presented in this study, there is real potential for EEs to interfere with E2-mediated 
transcription.  The developmental consequences of this interference are difficult to predict 
because the role of EDCs play in upsetting androgen-mediated transcription and endogenous 
steroid synthesis and metabolic pathways are even less well understood.  The possible 
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mechanisms and consequences of EE interference with E2-mediated transcription will be 
discussed in Chapter 9. 
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7.1 Introduction 
The purpose of this work was to obtain experimentally measured binding energies for EEs 
with the hER.  As was found in Chapter 3, the binding energy for many EEs of interest is not 
known.  Endogenous estrogens bind to the receptor with high affinity, but EEs have much 
lower affinity.  Knowledge of the kinetics of binding (i.e. how fast or slowly a ligand 
associates with and dissociates from the ER) would also be useful in interpreting 
computational docking results and extending the computational modelling to include 
molecular dynamics. It is also desirable to have a rapid screening method for determining 
whether the components in a mixture can bind to the ER before putting the effort into detailed 
chemical analysis.  This chapter presents the development of a method for studying the 
kinetics of binding of EEs to the ER and for quantifying equivalent estrogenic load of a 
mixture of EEs.  Equivalent estrogenic load is defined as the concentration of E2 that 
produces the same instrument response as a sample of unknown concentration.  This concept 
will be discussed in more detail later in the chapter.  
The method uses the technique of surface plasmon resonance (SPR).  Method development 
begins with establishing a procedure to covalently attach the ER-LBD protein to the SPR 
sensor chip.  Once a functional ER surface is achieved it can be used to study the kinetics of 
binding of individual EEs to the ER, giving both reaction rate constants and equilibrium 
binding constants.  Then, using the same surface, a method for quantifying the estrogenic 
load of a mixture of EEs can be developed. 
The kinetic studies will provide insight to the ER-ligand binding mechanism, quantifying 
how quickly or slowly the EEs associate with and dissociate from the ER.  Equilibrium 
studies will provide a consistent set of binding affinity measurements for the suite of EEs. 
Binding affinity data are needed for model validation in the computational docking study 
presented in Chapter 4.   
This chapter begins with a brief overview of reaction kinetics and equilibrium studies as they 
pertain to ER-ligand interactions.  Next, the fundamentals of the SPR technique are 
presented. The results of the experimental work follow.  The first experiment was a validation 
of instrument sensitivity.  Subsequent experiments were different attempts at immobilising 
the ER-LBD to the sensor chip.  As will be shown, the SPR experiments were only partially 
successful.  The discussion will explain what the difficulties were and how they may be 
overcome in future work. 
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7.2 Theoretical Basis 
7.2.1 Reaction Kinetics 
The first step in the classic genomic mechanism of estrogenic action is the binding of the 
ligand (L) to the ER (R) to form the receptor-ligand complex (RL).   
 
This type of reaction is described as a 1:1 bimolecular interaction and the reaction rapidly 
reaches equilibrium.  The association reaction rate constant, ka, is a second-order rate 
constant and the dissociation reaction rate constant, kd, is a first-order rate constant.  At 
equilibrium, the strength of ligand binding to the receptor is described by the equilibrium 
dissociation constant KD (also called binding affinity) which is defined as 
 D   
      
    
 
 d
 a
 
KD has units of M and decreases with increasing affinity between the ligand and receptor.  KD 
can also be interpreted as the concentration of ligand L at which 50% of the binding sites of R 
are occupied. 
To determine the association and dissociation rate constants, experimental conditions are 
established where [L] is in a large excess and thus remains constant.  Under these conditions, 
the binding interaction follows pseudo-first order kinetics [370-372] with an integrated rate 
equation: 
                
        
where  
[RL]t = concentration of receptor-ligand complex at time t 
[RL]eq = concentration of receptor-ligand complex at equilibrium 
kobs = experimentally determined pseudo-first order reaction rate constant 
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[RL]t is measured as a function of t and nonlinear regression is used to fit the integrated rate 
equation to the experimental data to obtain the value for kobs.  For a reversible reaction, kobs is 
directly proportional to the free ligand concentration [L]: 
              
The value of kobs is then determined at several ligand concentrations [L] and a plot of kobs as a 
function of [L] is linear with slope equal to ka and y-intercept equal to kd.  A simulated 
example of the data from this type of experiment is shown in Figure 7.1.   
The pseudo-first order integrated rate equation is often called the Langmuir model because at 
equilibrium the Langmuir isotherm can be derived [370].  At equilibrium [RL] is constant, 
the association and dissociation reaction rates are equal and experimental conditions can be 
set such that [R] << [L] and that [L]is high enough that it can be considered constant.  In this 
case,  
     
      
  
 
which can be rewritten, giving the Langmuir isotherm equation 
     
   
  
  
   
 
In an experiment where some signal S is measured that is directly proportional to [RL], then 
[R] is directly proportional to Smax, the maximum signal theoretically possible when all 
receptor sites are occupied by the ligand.  A plot of S vs. [L] gives a curve of the form of a 
square hyperbola and nonlinear least squares regression can be used to obtain values for KD 
and Smax. 
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(a) Increase in [RL] as a function of time for constant [R] and different [L]. 
 
(b) Increase in pseudo-first order rate constant (kobs) as a function of [L] obtained from 
data shown in panel (a). 
 
Figure 7.1.  Simulated data from for a pseudo-first order kinetics experiment. Values 
for ka=1.3x10
6
 M
-1
s
-1
, kd=1.2x10
-3
 s
-1
 and KD=0.9 nM are for E2-hERα [373]. 
7.2.2 Kinetics of ER Ligand Binding 
The only study of ER-ligand binding kinetics found in the literature [373], reports association 
and dissociation reaction rate constants and equilibrium dissociation constants for 6 ligands 
as illustrated in Figure 7.2.     
From Figure 7.2, the association reaction rate constants for the endogenous hormones (E1, E2 
and E3) are very similar, but the dissociation reaction rate constants are different resulting in 
the differences in equilibrium dissociation constants.  Of the three endogenous hormones, E2 
dissociates the slowest and forms the most stable complex with ER.  All of the agonist 
ligands (E1, E2, E3, BPA, DES) associate quickly, but their dissociation rates vary 
dramatically.  BPA associates and dissociates quickly, resulting in a weak complex.  DES 
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associates very quickly but dissociates slowly thus forms a very stable complex.  In contrast, 
the antagonist, OHT, associates slowly and dissociates slowly, forming a complex with 
stability similar to E1 and E3.  This behaviour is not surprising given the large size of the 
molecule compared to the endogenous hormones and the precise fit of the pendant group 
needed to stabilise the antagonist conformation of the receptor. 
 
(a) Association reaction rate constant (ka) 
 
(b) Dissociation reaction rate constant (kd) 
 
(c) Equilibrium dissociation constant (KD) 
 
Figure 7.2.  Association (ka) and dissociation (kd) reaction rate constants and 
equilibrium dissociation constant (KD) measured by SPR [373]. 
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7.2.3 Equilibrium Studies 
KD can also be determined directly via equilibrium experiments such as competitive binding 
assays.  For example, the US EPA has adopted a conventional competitive binding assay as 
their standard method for identifying potentially estrogenic compounds.  This assay uses rat 
uteri as the source of ER [374].  The uteri are taken from Sprague-Dawley rats and the tissue 
is processed to produce a rat uterine cytosolic (RUC) fraction containing the ER protein. The 
uterus contains mainly ERα and a small but not insignificant proportion is ERβ [375].  
Mixtures of the RUC with [
3
H]-E2 at a constant concentration plus increasing amounts of the 
test chemical are incubated with the cytosol preparation at 4 °C for 18 h.  The unbound 
chemicals are removed by adsorption on dextran-charcoal and the residual radioactive 
concentration of the cytosol preparation is counted by scintillation.  The drawbacks to this 
method include the use of radioactive materials, the tissue extract contains a mixture of both 
α and β ERs, and of course the sacrifice of animals.  Similar assays are available that use 
expressed proteins instead of those obtained from tissue sources.  The purpose of this type of 
assay is to identify chemicals that have the potential to compete with endogenous estrogens 
for binding to the ER.  This type of assay does not provide any information on whether the 
chemical tested acts as an agonist or antagonist of gene expression, or how efficiently gene 
expression is up or down-regulated by the chemical.   
The ability to obtain only ERα or ERβ ligand binding domains using cellular expression 
systems has shown that the two receptors have different binding affinities for all ligands 
tested (See Table x in Chapter 3).  In most cases, the difference is small.  But, in some cases 
the difference is significant, and those ligands are described as selective ER modulators 
(SERMs).  As drug targets, SERMs are important as they are able to treat a disease that 
involves only one of the two receptors without activating the receptor not involved in the 
disease (e.g. treating breast cancer without triggering or worsening osteoporosis).   
Most of the studies using expressed ERs for binding studies report IC50 rather than KD for the 
compound of study.  In the context of enzyme inhibition, IC50 is the concentration at which 
an inhibitor is able to prevent 50% of the substrate present from binding.  For competitive 
binding studies, IC50 is related to the competitive inhibitor KD by the Cheng-Prusoff equation 
[295]: 
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where [S] is the concentration of substrate and KM is the concentration of substrate at which 
enzyme activity is at half maximal.  In the context of enzyme inhibition, KM is not the KD of 
the substrate. However, in the context of hormone-receptor binding inhibition, the activity of 
the receptor is at half-maximum when it is 50% occupied by the target hormone.   For the ER, 
competitive inhibition studies are done using the target hormone E2.  So, in this case KM = KD 
for E2.   
Some binding affinity data for EEs are available in the literature however they must be 
carefully reconciled because they have been produced by varying methodologies, using 
different sources of ER and under different conditions.  There is very little information on the 
kinetics of the binding of EEs – how quickly the chemicals associate with and dissociate from 
the ER [373].  Knowledge of the kinetics underlying the binding of EEs to the ER will be 
useful in explaining the range of biological outcomes of animal exposure studies. 
7.2.4 Principles of Surface Plasmon Resonance 
SPR is a technique that has been applied to studies of biomolecular interactions with great 
success [376, 377].  Initially, SPR was used to study protein-protein interactions but recent 
advances in instrumentation have enabled the study of protein-small molecule interactions 
such as enzyme-substrate and receptor-ligand.  SPR offers the possibility of rapid screening 
for biological activity that compliments traditional analytical chemistry in the identification 
of endocrine disrupting chemicals.  SPR can be used to quantify total biological activity of a 
sample of unknown composition and analytical chemistry provides the means to identify and 
quantify individual components that contribute to the biological activity.   
Instruments from two manufacturers, Biacore and Bio-Rad, dominate the SPR literature 
[378].  The two instruments are based on the same principle but differ in their operation.  
Much of the published literature is based on the Biacore instrument as it was the first 
commercially available system.  The discussion below relates to the Bio-Rad ProteOn XPR36 
instrument that was used for this work.   
The principle of SPR is illustrated in Figure 7.3.  In this example, the receptor protein is 
immobilised on the very thin gold surface adhered to the base of an inverted prism. The base 
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of the prism (the top side) is exposed to a flowing liquid that transports the analyte to the 
surface to interact with the immobilised receptor protein.  Light of a fixed angle of incidence, 
θ, is directed up through the prism and onto the back of the thin gold film.  Light incident on 
the back of the gold surface is reflected back through the prism to a detector.  As a result of 
the surface plasmon phenomenon (explained below) that occurs at the gold surface, the 
intensity profile of the reflected light is altered.  A minimum in the intensity of the reflected 
light now occurs at a particular wavelength and angle of reflectance that both depend on the 
refractive index of what is in contact with top side of the gold surface (ns) [379-381].   
 
 
Figure 7.3.  The principles of SPR.  The magnitude of the shift in angle of reflected light 
is dependent on the refractive index (mass density) at the surface. 
In the Bio-Rad instrument, the incident light is produced by a LED (light emitting diode) and 
is incident at a fixed angle.  The reflected light is directed to a CCD (charge capture device) 
which captures a 2D image of the reflected light beam.  Using this type of detector, the 
minimum in intensity can be located within the image and the difference in position measured 
with respect to a reference signal image.  This shift in position of the minimum is the 
‘resonance shift’ and is related to the change in refractive index of the sample in contact with 
the gold surface.  The refractive index change is proportional to the change in mass at the 
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surface caused by the binding and release of the analyte molecule (ligand) by the immobilised 
receptor protein.  
Surface plasmons consist of the collective oscillations of nearly free electrons in the metal 
film and their associated evanescent electromagnetic waves.  A p-polarized lightwave can 
resonantly couple with a surface plasmon wave propagating at the interface of the metal film 
and the sample layer.  When this resonant coupling occurs (i.e. at the resonance angle), the 
energy in the incident lightwave is converted into surface plasmon waves and dissipated 
through ohmic heating; relatively little of the incident light is reflected from the interface to 
the detector when the metal film thickness is optimized. At other angles or wavelengths, most 
of the light is reflected off of the sensor surface.  The SPR phenomenon creates a minimum in 
the reflectivity at an angle or wavelength that depends on ns.  The resonance angle for a given 
wavelength varies as a function of ns [382]. The signal that is measured is the shift in the 
minimum of the optical reflectivity curve and is reported in response units (RU).  The shift is 
dependent on both the change in mass and the change in refractive index at the surface of the 
sensor chip.  Careful control and matching of bulk properties of the analyte solutions to the 
running buffer is necessary to minimize effects of changes in refractive index due to changes 
in bulk properties of the solutions.  1 RU = 10
-6
 change in refractive index [383].   
7.2.5 Coupling to the SPR sensor chip 
The active surface of the SPR sensor chip is composed a modified alginate polymer that has 
exposed carboxylic acid groups.  The usual method of binding the selected species to the chip 
surface is by amine coupling to these carboxylic acid groups.  The species to be bound must 
have a terminal amine group.  The carboxylic acid surface is activated by injecting a solution 
of EDAC (N-ethyl-N’-(3-diethylaminopropyl)carbodiimide) and sulfo-NHS (N-
hydroxysulfosuccinimide sodium salt).  The species to be bound to the sensor chip surface 
will displace sulfo-NHS.  Any unreacted sites are deactivated with ethanolamine.  The 
reaction scheme is illustrated in Figure 7.4.   
For kinetics experiments there is a trade-off between the density of the immobilised species 
on the surface (i.e. how many immobilised molecules per unit area) and mass transfer.  High 
density increases the signal measured, but if the density is too high, mass transfer of the 
analyte to a binding site is compromised, thus affecting the results of the kinetics experiment.  
An important part of method development is finding the optimum ligand density where signal 
intensity is high but mass transfer issues are minimized. 
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Figure 7.4.  The sensor chip surface is activated by EDAC/sulfo-NHS to provide a good 
leaving group for the subsequent coupling of a molecule with a terminal amine group to 
the surface.  Unused activated binding sites are deactivated using ethanolamine. 
7.2.6 Review of SPR-based ER Binding Assays 
SPR has been used to study ER-ligand interactions using a traditional competitive binding 
assay [384-387].  The small molecule ligand (e.g. E2) was immobilised on the SPR sensor 
chip surface.  The ER was incubated with the test chemical and injected, resulting in a 
competition between the immobilised and free ligands for binding with the receptor. Because 
the SPR signal is proportional to the mass change that occurs on binding at the chip surface, 
monitoring the interaction of the high molecular weight receptor protein in solution with the 
immobilised ligand gives a large signal.   
SPR has also been used to study ER-DNA interactions [388-390].  The consensus DNA 
sequence estrogen response element (ERE) was immobilized onto the sensor chip.  The full-
length ER was incubated with the ligand of choice.  Two receptor-ligand complexes will 
come together in solution to form a dimer which will bind to the immobilised ERE.  
However, the unliganded ER monomer can also bind to the ERE, interfering with the desired 
signal.  Careful control of experimental conditions such as incubation time and temperature is 
necessary to ensure optimal performance. 
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SPR can also be used to study the interaction of the ligand bound ER with different co-
activator proteins [230], providing information on the transcriptional activation of ER by the 
ligand under study.  In this study, the co-activator protein was immobilized onto the sensor 
chip.  The ER was incubated with various estrogenic compounds and injected over the 
immobilised co-activator protein.  The agonist/antagonist behaviour of the ligands was 
determined since the ligand-bound ER LBD will not bind to the immobilised cofactor if it is 
in the antagonist conformation. 
All three of these strategies work well for studying individual ligands but none of them are 
applicable to the study of mixtures. 
The study by Rich et al. [373] is the only SPR study of ER-ligand interactions to immobilise 
the receptor on the sensor chip.  The ER-LBD was expressed with an N-terminus poly-
histidine tag.  A His4 monoclonal antibody was produced and immobilized onto the sensor 
chip.  This antibody recognizes and binds to a 4-histidine sequence.  The His-tagged ER-LBD 
was then captured by the immobilized antibody.  Because the ER-LBD has only one His tag, 
this ensures it is bound to the sensor chip surface in an orientation that allows the 
conformational change to occur on ligand binding.  One advantage of this strategy is that the 
LBD-ligand complex can be easily removed from the antibody after the interaction 
experiment by washing the surface with a mild acid solution.  However, the antibody – His-
tag binding affinity is not strong, so careful control of experimental conditions (buffer, pH, 
etc.) is needed so that the ER-LBD is not removed from the surface during the measurement. 
7.2.7 Quantifying Estrogenic Load 
One of the objectives of this study was to develop a SPR-based method to screen individual 
chemicals, known mixtures of chemicals and environmental or biological samples of 
unknown composition for their ability to bind with the ER.  With SPR, the measurements 
occur under constant flow conditions and a period of time is required for the signal to 
stabilise at an equilibrium condition.  The signal at equilibrium is proportional to the mass 
change at the surface due to analyte binding.  Because the analytes of interest in this study 
have similar molecular weights (150-300 Da is similar within the resolution of 1 RU in SPR), 
the method is in effect a counter for molecules that have bound to the immobilised receptor.   
For a sample containing a single analyte, the SPR signal obtained under equilibrium 
conditions is proportional to the analyte concentration as shown in Figure 7.5 for E2 and 
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BPA.  Figure 7.5 was produced using actual experimental data for the interaction of hERα 
with E2 and BPA extracted from figures in Rich et al. [373].   
 
 
Figure 7.5.  SPR signal as a function of ligand concentration for E2 and BPA. (Produced 
from data taken from Figures in [373]). 
The method can be calibrated to quantify an unknown concentration of a single analyte in a 
sample if and only if it is the only analyte in the sample that will bind to the receptor.  
Because the measurements are made under equilibrium conditions, the magnitude of the 
signal obtained is also dependent on the binding affinity of the analyte for the receptor.  A 
lower affinity analyte (BPA, KD= 210 nM) will produce a smaller signal than a higher affinity 
analyte (E2, KD= 0.9 nM) at the same concentration as shown in Figure 7.5.  Thus, the signal 
obtained for a mixture will depend not only on the amount each of the analytes in solution but 
also on their binding affinities.  In this way, the method measures what can be defined as 
equivalent estrogenic load of a mixture.  In the context of this SPR method, equivalent 
estrogenic load is defined as the concentration of E2 that produces the same signal as the 
sample of unknown composition.  This measurement of equivalent estrogenic load can also 
be used to compare the relative binding affinities of single chemicals or mixtures to that of a 
reference compound (e.g. E2).   From the example in Figure 7.5, the equivalent estrogenic 
load of a sample containing 3 μM BPA is approximately 0.08 μM.  Stated another way, it 
takes 3 μM BPA to produce the same receptor occupancy as 0.08 μM E2. 
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Because the SPR signal is related to the mass gain on binding, other instruments require 
immobilisation of the small molecule on the sensor chip surface and the receptor protein in 
the flowing solution if the mass of the small molecule is lower than about 500 Da. However, 
to be able to handle mixtures of chemicals, the ER protein must be immobilised on the sensor 
chip. The Bio-Rad instrument used in this study has superior sensitivity compared to its 
competitors allowing the novel approach to estrogenic load screening. 
7.3 Design of a SPR-based Estrogenic Load Biosensor 
The ligand binding pocket of the ER is deep in the centre of the receptor and ligand binding is 
accompanied by a large conformational change in the ER structure that results in the ligand 
being fully enclosed in the pocket.  In contrast, most enzymes (including CAII enzyme used 
in the instrument validation experiments described later in the chapter) have a readily 
accessible active site close to the outer surface of the protein.  This highly accessible binding 
site facilitates rapid turnover of substrate to product.  These differences are illustrated with 
the structures of human CAII and hERα shown in Figure 7.6.  
Most SPR applications use amine coupling (section xx) to covalently bind one of the two 
reactants to the sensor chip surface.  The protein may be attached via one or more of the 
surface lysine residues or the N-terminal amine.  This arbitrary orientation of the protein on 
the surface could result in total or partial obstruction of the binding site.  For the current 
application it is critical to ensure that the hER is attached to the sensor chip surface without 
interfering with ligand access to the binding cavity and the resulting conformational change.   
The hER LBD is commercially available as an N-terminus GST-fusion protein.  In this 
construct, the glutathione S-transferase (GST) enzyme is attached to the N-terminus of the 
hER.  The GST enzyme has a very high affinity for reduced glutathione (GSH) which 
facilitates isolating the fusion protein from the cell lysate of an expression system using 
affinity chromatography.  This high affinity binding can be exploited to immobilise the GST-
hER LBD via interaction with GSH that has been covalently bound to the sensor chip.       
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(a) human CAII (PDB 3M04) in complex with an inhibitor 
 
(b) hERα with E2 (PDB 1ERE) 
 
Figure 7.6.  Structure of human CAII (PDB 3M04) in complex with an inhibitor 
showing the readily accessible surface active site, in comparison to the fully enclosed 
deep ligand binding pocket of hERα with E2 (PDB 1ERE).  
7.3.1 GST and Affinity Separations 
Glutathione S-transferases (GSTs) are a family of enzymes present in both eukaryotic and 
prokaryotic cells that play a role in phase II metabolism of xenobiotics [122]. In humans, 
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GSTs conjugate electrophilic and lipophilic xenobiotics with reduced glutathione (GSH, 
Figure 7.7) to increase their solubility in the aqueous cellular and extracellular media, 
facilitating their removal from the body by the kidneys and liver.   
The GSTs are large enzymes (23-29 kDa).  The GST tag increases the size of the fusion 
protein quite significantly.  For the hER LBDs, the GST tag increases the molecular weight 
of the protein by 50%.  GSTs have a high affinity for GSH (KD = 80-220 nM [391]) which 
makes it attractive for affinity purification of expressed proteins.   
GST affinity chromatography is used to purify GST-tagged proteins.  GSH is covalently 
bound to agarose or cross-linked agarose beads. The beads can be mixed directly with the 
crude protein solution or packed in a column through which the crude protein solution is 
passed.  The GST tag binds the immobilised GSH with high affinity.  The desired fusion 
protein is retained on the support while undesired material is washed away.  The desired 
protein is then eluted by flushing with a high concentration solution of GSH.    This system is 
attractive for SPR because it facilitates refreshing the surface of the sensor chip.  If the 
immobilised protein becomes inactive, it can be readily removed by flushing the sensor chip 
with a high concentration solution of GSH, as done to elute the retained protein in affinity 
chromatography.  If the immobilised GSH becomes oxidised, form glutathione disulphide 
(GSSH, Figure 7.7), it may be readily reduced by common disulphide bond reducing agents 
such as dithiothreitol (DTT, Figure 7.7).  
 
 
 
(a) reduced glutathione (GSH) 
 
(b) oxidised glutathione (GSSH) 
 
 
 
(c) dithiothreitol (DTT) 
 
Figure 7.7.  Structures for reduced glutathione (GSH), oxidised glutathione (glutathione 
disulphide, GSSH) and the reducing agent dithiothreitol (DTT). 
A number of different affinity media are available.  GSH is attached to the support at either 
the sulfhydryl group or the amine group via a spacer of between 10 and 12 atoms in length.  
The chemical structure of one medium [392] is shown in Figure 7.8. The spacer arm in this 
case is described as a hydrophilic spacer. 
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Figure 7.8.  Structure of S-linked glutathione (Thermo Scientific [392]). 
Spacers are required to relieve steric hindrance between the GSH molecule and the surface of 
the support and to allow the protein access to the GSH molecule to effectively bind.  Even 
short (4-6 atoms) spacers are effective in relieving the steric hindrance [393, 394].  Initially, 
hydrophobic spacer arms were used [395] as shown in Figure 7.9.  This spacer arm is derived 
from the amine coupling of 6-aminohexanoic acid to the support surface. The ligand is 
covalently bound to the terminal carboxylic acid by some appropriate method (e.g. amine 
coupling as done with the surface).   
 
 
Figure 7.9.  An example of a hydrophobic spacer arm. 
Previous attempts reported in the literature to make this linkage more hydrophilic resulted in 
poorer affinity of the protein to the ligand.  The hydrophobic interactions between the spacer 
arm and the protein were discovered to be important and to contribute to the overall affinity 
of the protein for the tethered ligand [395].  It is also important to have the ligand attached to 
the support in such a way that it does not interfere with the protein binding process.  The 
efficiency of protein purification was greatly increased by attaching the GSH molecule via 
the sulfhydryl group with a long tether because the tether allows for hydrophobic interactions 
with the GST tag which increases the binding affinity between GSH and the GST tag [396]. 
The success of GST-GSH affinity chromatography relies on not only the correct orientation 
of GSH on the spacer arm but also interactions of the GST with the spacer arm.  These 
interactions can be understood by examining the 3D structure of GST bound to GSH.  The x-
ray crystal structure for GST bound to GSH has been solved (PDB 1PKW, [397]) and is 
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shown in Figure 7.10.  The binding site is broad and open on the surface of the protein.  GSH 
is oriented with the sulfhydryl group pointed into the binding site and the amino group 
accessible from the top surface.  The opening to the binding site is approximately 30 Å in 
diameter.  Another structure of GST with S-hexyl-GSH bound has also been published [398] 
(PDB 1K3L) and shows GSH in a similar orientation.  The C6 chain attached to the sulfhydryl 
group of GSH lies in a groove along the bottom of the binding site.  This groove opens to the 
back surface of the protein.  Presumably this is where the substrate to which the enzyme will 
attach GSH is positioned.  It is clear from these structures why a longer tether is required for 
immobilising GSH via the sulfhydryl group and how the additional protein-tether interactions 
have the capacity to increase binding affinity.     
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GST bound to GSH (PDB 1PKW) 
 
GST bound to S-hexyl-GSH (PDB 1K3L) 
  
 
Figure 7.10.  Protein structure for GSH bound to GST ([397]) and S-hexyl-GSH bound 
to GST ([398]) viewed from different angles.  Note the surface location of the GSH 
binding site, how the amino group of GSH is protruding from the top surface of the 
binding site and how the C6 chain extends back through the protein structure towards 
an opening on the back surface.   
7.3.2 Tethering Options  
For the SPR application, a tether needs to be designed that is approximately 12 atoms long 
that can be amine coupled to the SPR sensor chip and that GSH can be attached to via the 
sulfhydryl group.  A process has been reported for thiol coupling to SPR sensor chips [399, 
400]. The scheme is shown in Figure 7.11.  The process begins with the standard 
EDAC/sulfo-NHS activation of the sensor chip.  A reactive disulfide group from 2-(2-
pryidinyldithio)ethanamine (PDEA) is then introduced.  Deactivation of the residual 
EDAC/sulfo-NHS activated carboxylic acid surface is accomplished with ethanolamine.  The 
sulfhydryl group of the species to be bound to the sensor chip reacts at the disulfide, 
displacing 2-thiopyridine.  Deactivation of the unused disulfide is accomplished using L-
cysteine.  PDEA is commercially available or can be synthesized following the scheme 
shown in Figure 7.12 [399, 401, 402].  By replacing 2-cysteamine by 8-amino-1-octanethiol 
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(Figure 7.13), an analogue of PDEA can be prepared that incorporates a longer tether.  The 
final sensor chip surface with GSH attached is shown in Figure 7.14. 
 
 
Figure 7.11.  Disulphide activation of surface for thiol coupling. 
 
 
 
Figure 7.12.  Synthesis of PDEA. 
 
 
 
Figure 7.13.  8-amino-1-octanethiol. 
 
 
 
Figure 7.14.  Thiol coupling of GSH to sensor chip surface with an alkane tether. 
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If the alkane tether of Figure 7.14 is too hydrophobic, a polyethylene glycol (PEG) tether 
could also be used.  The carboxy-PEG4-amine (Figure 7.15) is commercially available, but a 
slightly different coupling strategy is needed.  The PEG4 is first bound to the sensor chip 
surface by standard amine coupling.  After coupling, the ethanolamine deactivation is 
performed to deactivate the unused surface groups.  Then, the carboxylic acid group on the 
PEG4 tether is then activated to bind PDEA and GSH is coupled to the PEG4 tether.  Finally, 
unused PEG4 tethers are deactivated by L-cysteine. This scheme is shown in Figure 7.16. 
 
 
Figure 7.15.  Carboxy-PEG4-amine. 
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Figure 7.16.  Stepwise construction of a PEG4-tethered GSH surface.   
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7.4 Methods and Materials 
7.4.1 Bio-Rad ProteON XPR36 Instrument 
In the Bio-Rad instrument, the sensor chip has a 6x6 matrix of interaction spots, as shown in 
Figure 7.17.  Different protein receptors or protein receptor densities can be immobilized 
across the 6 ‘ligand’ channels and different analytes or analyte concentrations can be injected 
across the 6 ‘analyte’ channels allowing for multiple conditions or repeats of the same 
conditions to be run in a single experiment.  The space between the interaction spots are used 
as reference channels to correct for small differences in bulk refractive index of the solutions 
injected in each of the channels [383].  The flow direction is described as ‘vertical’ for the 
ligand channels and ‘horizontal’ for the analyte channels.  
 
 
Figure 7.17.  Bio-Rad ProteOn XPR36 sensor chip 6x6 matrix. 
As the analyte solution flows over the receptor immobilised on the sensor chip surface, the 
analyte diffuses from the bulk to the surface where it interacts with the immobilised receptor. 
The signal that is measured in SPR is proportional to the reflective index change which 
results from the mass increase due to the binding of the analyte species with the receptor.  
Thus, the signal is proportional to the increase in concentration of the receptor-ligand 
complex [RL].  The ligand concentration [L] remains constant due to the flow conditions, so 
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for most receptor-ligand interactions, pseudo-first order kinetics can be assumed and the data 
analysis presented in Section XX applies [379]. 
7.4.2 A Typical SPR Experiment 
A typical SPR experiment is outlined in Figure 7.18.  The basic methodology is the same for 
both kinetics and equilibrium studies, only the data processing differs.  For a kinetics 
experiment, the shapes of the association and dissociation curves are analysed to give forward 
and reverse rate constants.  For an equilibrium experiment, only the association curve is 
needed and only the net change in signal is determined. 
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Figure 7.18.  Flow chart of typical kinetics and equilibrium SPR experiments. 
7.4.3 Validation of Instrument Sensitivity 
The first experiment was a validation of instrument sensitivity and used a reagent kit supplied 
by the instrument manufacturer.  The kit is based on the reaction between the enzyme 
Chapter 7 – Binding Studies - SPR 
266 
 
carbonic anhydrase II (CAII) and its inhibitor carboxybenzene sulfonamide (CBS) and 
demonstrates the sensitivity of the instrument in detecting the interaction of a small molecule 
analyte (CBS, MW 201) with a large immobilized enzyme (CAII, MW 31 kDa).  Working 
through this experiment was important for several reasons: 
 to become familiar with SPR data processing with a system known to work 
 to understand the effects of different instrument parameters (e.g. flow rate, interaction 
times) on the results 
 to demonstrate that the instrument is able to achieve the performance criteria 
necessary for the ER kinetics studies and for the estrogenic load biosensor 
application. 
7.4.3.1 Materials 
The ProteOn Protein-Small Molecule Kit (Bio-Rad product # 176-1030) was purchased from 
Bio-Rad.  The kit includes  
 CAII/CBS pair 
 ProteOn GLM Sensor Chip (product # 176-5012)   
 amine coupling reagents (EDAC, sulfo-NHS and ethanolamine, product # 176-2410) 
 sodium acetate buffer pH 5.0 
 sodium hydroxide regeneration solution 
 instructions   
The PBS (phosphate buffer saline) running buffer was prepared from stock reagents.  The 
details of reagent composition are summarised in Table 7.1. 
Table 7.1.  Buffer and reagent names and compositions. 
Buffer/Reagent Composition 
PBS Running Buffer  
(phosphate buffered saline, pH 7.4) 
137 mM NaCl 
10 mM phosphate (Na2HPO4 + KH2PO4) 
2.7 mM KCl 
0.005% Tween-20 
3 mM EDTA 
Sodium acetate buffer 
pH 5 
10 mM  
Sodium hydroxide regeneration solution 50 mM 
N-ethyl-N’-(3-diethylaminopropyl)carbodiimide  
EDAC 
400 mM  
N-hydroxysulfosuccinimide sodium salt  
sulfo-NHS  
100 mM  
Ethanolamine HCl 1M  
carbonic anhydrase II  
CAII 
4 μM (0.125 mg/mL) 
in sodium acetate buffer (pH 5) 
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carboxybenzene sulfonamide  
CBS 
20 μM 
 
The standard sensor chip activation mixture was prepared by mixing equal volumes of EDAC 
and sulfo-NHS solutions.  The mixture must be prepared immediately before use as it has a 
half-life of only 60 minutes.  The mixture can be diluted with running buffer to achieve 
different levels of surface activation and thus different densities of protein bound to the 
surface. 
The CBS solution supplied was diluted with running buffer to produce solutions with 
concentrations of 6.67, 2.22, 0.74, 0.25 and 0.084 μM. 
7.4.3.2 Method 
The experiment followed the process outlined in Figure 7.18.  To achieve different densities 
of protein bound to the surface, channels L1-L4 were activated with the standard solution and 
channels L5 and L6 were activated with a 10x dilution of the standard solution.  Each analyte 
channel was exposed to a different analyte concentration as given in Table 7.2.  After the 
dissociation step, any remaining CBS bound to the enzyme was removed by injecting 50 mM 
NaOH.  
Table 7.2.  CBS concentrations for the six analyte channels. 
Channel CBS Concentration  
(μM) 
A1 20 
A2 6.7 
A3 2.2 
A4 0.74 
A5 0.25 
A6 0.084 
 
The instrument was left in standby mode overnight, with running buffer flowing over the 
sensor chip surface at the minimum flow rate.  The following day, additional interactions 
were performed as summarised in Table 7.3.  Interaction 7 was incomplete because there was 
insufficient volume of analyte in the vials.   
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Table 7.3.  Summary of CAII/CBS interaction parameters. 
Interaction Flow rate 
(μL/min) 
Association Time 
(s) 
Dissociation Time 
(s) 
1† 100 60 600 
2 100 60 900 
3 50 120 600 
4 50 180 600 
5 25 240 600 
6 150 60 600 
7* 200 30 600 
8 200 30 600 
9 200 45 600 
†interactions 2-9 conducted next day with instrument in standby mode overnight. 
*invalid result, incomplete injection. 
 
7.4.4 Method Development – Immobilising hER 
The first step in developing the estrogenic load biosensor is immobilising the GST-tagged 
hER LBD on the sensor chip.  A number of approaches were tried to attach GSH to the 
sensor chip: 
 Direct amine coupling of GSH to the surface via the amino group  
 Thiol coupling at the sulfhydryl group 
 Tethering GSH to the chip surface by first amine coupling a polyethylene glycol 
spacer to the chip surface then amine or thiol coupling GSH to the tether 
Method development was limited by the cost of commercially available receptor protein.  
Facilities were not available in-house to produce protein for this work. 
7.4.4.1 Method Development 1 – Direct Amine Coupling of GSH to the Sensor Chip 
The simplest way to produce a GSH surface for immobilising the GST-tagged hER-LBD was 
to directly couple GSH to the sensor chip via standard amine coupling.   
7.4.4.1.1 Materials 
The reagents and buffer solutions used in the SPR experimental work are summarised in 
Table 7.4.   
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Table 7.4.  Buffer and reagent names and compositions. 
Buffer/Reagent Composition 
PBS Running Buffer  
(phosphate buffered saline, pH 7.4) 
137 nM NaCl 
10 mM phosphate (Na2HPO4 + KH2PO4) 
2.7 mM KCl 
0.005% Tween-20 
3 mM EDTA 
N-ethyl-N’-(3-
diethylaminopropyl)carbodiimide  
EDAC 
400 mM  
N-hydroxysulfosuccinimide sodium salt  
sulfo-NHS  
100 mM  
Ethanolamine HCl 1 M  
L-Glutathione reduced  
GSH stock solution 
10 mM in running buffer 
17β-estradiol 
E2 stock solution 
10 mM in ethanol 
GST-tagged hERα functional receptor concentration was 3407 
nM as supplied 
GST-tagged hERβ functional receptor concentration was 11848 
nM as supplied 
 
L-Glutathione reduced (GSH) was purchased from Sigma-Aldrich (product # G4251, 
≥98.0%).  A stock solution of 10 mM was prepared in running buffer. Working solutions at 5 
and 0.5 μM were prepared by dilution with running buffer.  17β-estradiol (E2) was purchased 
from Sigma-Aldrich (product # E8875, ≥98%).  A stock solution of 10 mM was prepared in 
HPLC grade ethanol.  Working solutions at 10, 2, 0.1, 0.02 and 0.001 μM were prepared by 
dilution with running buffer.  GST-tagged hERα was purchased from Invitrogen (product # 
PV4543, 250 pmol).  The functional receptor concentration for this product was 3407 nM.  
Working solutions at 50 nM and 5 nM were prepared by dilution of the supplied solution with 
running buffer.  GST-tagged hERα was purchased from Invitrogen (product # PV4539, 250 
pmol).  The functional receptor concentration for this product was 11848 nM.  Working 
solution at 37.5 nM was prepared by dilution of the supplied solution with running buffer.  
The high density sensor chip (Bio-Rad product # 176-5103) was used. 
7.4.4.1.2 Methods 
The experiment followed the process outlined in Figure 7.18.  All 6 sensor chip channels 
were activated with standard the EDAC/sulfo-NHS solutions.  Two different GSH 
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concentrations were injected to see if a difference in surface density of GSH could be 
observed.  5 μM GSH was injected in channels L1-L3 and 0.5 μM for channels L4-L6.  Next, 
two different concentrations of GST-tagged hERα-LBD were injected, again to seed if a 
difference in surface density could be observed.   50 nM GST-tagged hERα-LBD was 
injected in channels L1 and L2 and 5 nM in channels L5 and L6.  Channels L3 and L4 were 
used as reference channels.   
The interaction of the immobilised hER was evaluated twice by injection of E2 in the 
concentrations listed in Table 7.5.  The first injection was performed for 300 s and the second 
injection was performed for 500 s. 
 Table 7.5.  Concentrations of E2 used for interactions with immobilised hER. 
Channel Concentration (μM) 
A1 10 
A2 2 
A3 0.1 
A4 0.02 
A5 0.01 
A6 0 (running buffer) 
 
The flow direction was then changed back to vertical to attempt to load more hER onto the 
surface.  Two injections of GST-tagged hERα-LBD were performed, using the same 
parameters as the initial injection.  
The flow direction was changed back to horizontal to perform a third interaction E2, using 
the same parameters as the first two interactions. 
The flow was changed to vertical for an attempt to regenerate all 6 channels by injecting 200 
μM GSH.  This high concentration of GSH was intended to dissociate the GST-tagged hER 
from surface by competition binding with GSH in solution.  Two injections of the 
regeneration solution were made. 
Having exhausted the supply of hERα, a final trial was made using the reference channels 
and the available hERβ.    A total of 3 injections of a 37.5 nM solution of the GST-tagged 
hERβ were made on channels L3 and L4.   
A final interaction with E2 was tried using channels L3 and L4 and the same interaction 
parameters.   
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7.4.4.2 Method Development 2 – PEG4 Tether Coupling of GSH to the Sensor Chip 
An attempt was made to couple GSH to the sensor chip using a PEG4 tether.  To simplify the 
system and to significantly reduce cost, the free GST enzyme was used to test the chip 
surface instead of the GST-tagged hER. 
7.4.4.2.1 Materials 
The reagents and buffer solutions used in the SPR experimental work are summarised in 
Table 7.6.   
Table 7.6.  Buffer and reagent names and compositions. 
Buffer/Reagent Composition 
PBS Running Buffer  
(phosphate buffered saline, pH 7.4) 
137 nM NaCl 
10 mM phosphate (Na2HPO4 + KH2PO4) 
2.7 mM KCl 
0.005% Tween-20 
3 mM EDTA 
N-ethyl-N’-(3-diethylaminopropyl)carbodiimide  
EDAC 
400 mM  
N-hydroxysulfosuccinimide sodium salt  
sulfo-NHS  
100 mM  
Ethanolamine HCl 1 M  
Carboxy-PEG4-amine 
CA(PEG)4 
3.8 mM 
2-(2-pryidinyldithio)ethanamine  
PDEA 
10 mM in running buffer 
L-cysteine 50 mM in running buffer 
L-Glutathione reduced  
GSH stock solution 
10 mM in running buffer 
Glutathione S-transferase 
GST 
50 μM as supplied 
 
Carboxy-PEG4-amine (CA(PEG)4) was purchased from ThermoScientific (product # 26120).  
The stock solution of 1 mg/mL (3.8 mM) was prepared in Milli-Q water.  Working solutions 
were prepared by dilution with running buffer.  2-(2-pryidinyldithio)ethanamine  (PDEA) 
was purchased from GE HealthCare (product # BR-1000-58).  The stock solution of 10 mM 
was prepared in running buffer. L-cysteine was purchased from Sigma-Aldrich (product # 
168149, 97%).  The stock solution of 50 mM was prepared in running buffer. Glutathione S-
transferase was purchased from Sigma-Aldrich (product # G5663, ≥85%).  The medium 
density sensor chip (Bio-Rad product # 176-5012) was used. 
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7.4.4.2.2 Methods 
The method development was undertaken in two stages.  First, a single channel on the sensor 
chip was used to assess the instrument responses to the construction of the surface.  Then, the 
remaining sensor chip channels were used to study the effect of PEG density on the 
construction of the surface.   
The surface was constructed in stages.  First, CA(PEG)4  was coupled to the EDAC/sulfo-
NHS activated surface and unused activation sites on the surface deactivated with 
ethanolamine.  Then, the terminal acid of the coupled CA(PEG)4  was activated for coupling 
PDEA using EDAC/sulfo-NHS.  Unused activated CA(PEG)4  sites were deactivated using 
ethanolamine.  Next, GSH was coupled to the PDEA activated CA(PEG)4 and unused sites 
were deactivated using L-cysteine.  Finally, GST is bound to the tethered GSH.   
For the first test, only channel L1 was activated.  Running buffer was injected on the other 
channels. Two injections of CA(PEG)4  were made using a 0.5 μM solution.  A third injection 
was made using 38 μM.  PDEA was injected at a concentration of 50 μM.  GSH was injected 
at a concentration of 5 μM.  Multiple additional injections of GSH on channel L1 were done 
with concentrations increasing from 100 μM to 5 mM to see if GSH binding could be 
observed.  Any unused PDEA activation was then deactivated before injection of GST.  
Multiple injections of GST were then made at concentrations increasing from 5 μM to 50 μM 
to see if binding could be observed.  Finally, a regeneration solution of 5 mM GSH was 
injected to see if any bound GST could be displaced. 
For the second test, an attempt was made to vary the density of GSH tethered to sensor chip 
by varying the initial activation level.  Channels L2-L5 were activated with different dilutions 
of the standard EDAC/sulfo-NHS as summarized in Table 7.7. Running buffer was injected 
on channel L6 for a reference and on previously used channel L1.  The concentrations of the 
different reagents injected to construct and test the surface are summarised in Table 7.8.   
Table 7.7.  Dilutions of standard EDAC/sulfo-NHS solution used to vary density of GSH 
on sensor chip. 
Channel Dilution 
L2 1:10 
L3 1:100 
L4 1:200 
L5 1:1000 
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Table 7.8.  Reagent concentrations used to construct and test sensor chip surface. 
Reagent Concentration 
CA(PEG)4 56 μM 
PDEA 100 μM 
GSH 5 mM 
GST 50 μM 
7.5 Results 
7.5.1 Validation of Instrument Sensitivity 
Instrument sensitivity was validated using the kit supplied by the Bio-Rad.  This kit was also 
used to study the effects of instrument parameters on kinetics and equilibrium experiments.  
Selected results are presented below to illustrate the type of data produced by the SPR 
instrument and its interpretation.  Understanding and interpreting these features will be 
important in evaluating the results obtained in the method development experiments.  
Figure 7.19 shows the baseline adjusted sensorgrams for channel A1 for the immobilisation 
of CAII on the sensor chip and an interaction experiment.  A sensorgram is a plot of SPR 
sensor signal (RU) as a function of time (s).  The other channels are identical except for 
regions 8a and 8b.  Region 8 is the interaction experiment and for the other channels, the 
level reached is progressively lower because each channel is exposed to a lower 
concentration of CBS in the dilution series.  The regions numbered 1-9 are described in Table 
7.9.   
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Figure 7.19.  Baseline adjusted sensorgram showing surface activation, CAII 
immobilisation, surface deactivation, followed by analyte association and dissociation 
reactions.  Numbered regions are described in Table 7.9. 
Table 7.9.  Description of numbered regions of Figure 7.19. 
Region Description 
1 Baseline of unmodified sensor chip surface, flow in vertical direction. 
2 Activation of sensor chip surface for amine coupling of CAII.  Channels L1-L4 
follow the higher curve (2a).  Channels L5 and L6 follow the lower curve (2b) as 
they were exposed to a 10x dilution of the standard activation solution.   
3 Baseline after activation.  Note increase in signal from region 1.  
4 CAII enzyme immobilization.  The CAII enzyme solution was injected on channels 
L1-L3, L5-L6 (4a).  Channel L4 (4b) is not exposed to the CAII solution.  
5 Deactivation of unreacted activation sites. 
6 Flush with running buffer followed by rotation of flow to horizontal direction for 
analyte injection.   
7 Baseline of sensor chip with running buffer flowing in horizontal direction prior to 
analyte injection. 
8 Interaction of CBS with CAII.  The association reaction occurs for 60 s (8a) while 
CBS is injected.  The dissociation reaction occurs for 600 s while the channels are 
flushed with running buffer (8b).  Each analyte channel was exposed to a different 
analyte concentration as given in Table 7.2.  Channel A1 is shown in Figure 7.19.  
Channels L1-L6 are exposed to the same concentration. Note difference in response 
between L4 (green trace, reference channel) and the other channels. 
9 Regeneration of surface.  Injection of 50 mM NaOH to regenerate CAII, removing 
any residual bound CBS. 
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The amount of CAII immobilised on each spot can be quantified using the data of Figure 7.19 
and the corresponding data for the other channels.  The difference between region 7 and 
region 3 gives the amount of immobilized ligand in each channel.  Using the software region 
averaging tool, the net changes in RU for each ligand/analyte interaction spot summarized in 
Table 7.10 were obtained.  As can be seen, the 10x dilution of the activation solution resulted 
in approximately half the amount of ligand bound to ligand channels 5 and 6.  The spot to 
spot variability is very low, on the order of 1%. 
 
Table 7.10.  Amount of ligand bound to each ligand/analyte interaction spot as 
quantified by the net increase in signal (RU). 
Ligand 
Channel 
Analyte Channel 
1 2 3 4 5 6 Avg %RSD 
1 604 594 598 595 585 606 597 1.3% 
2 606 604 604 606 607 613 607 0.6% 
3 596 600 602 598 598 598 599 0.3% 
5 308 309 312 308 307 310 309 0.6% 
6 309 309 310 311 308 310 310 0.4% 
 
7.5.1.1 Kinetics Analysis 
The reaction between CBS and CAII is a simple 1:1 bimolecular interaction.  As the inhibitor 
interacts with the enzyme bound to the surface of the sensor chip, a complex is formed 
following first order kinetics. When the analyte solution is washed away from the chip, CBS 
dissociates from the enzyme.  The classic Langmuir adsorption isotherm model without mass 
transfer was chosen to fit the kinetics data.  This assumes that the binding is equivalent and 
independent for all binding sites and that the reaction is not limited by mass transfer (i.e. 
analyte diffusion to the surface is faster than the reaction).  The validity of this assumption 
was evaluated in the course of data processing.   
For the kinetics experiment, the analyte CBS was injected at a constant flow rate for a 
specified period of time.  The association time is the contact time during which the desired 
volume of analyte solution is injected and the analyte binds with the immobilised enzyme 
CAII.    Immediately after the injection, running buffer is flowed over the sensor chip for the 
dissociation time.  During this time the analyte dissociates from the ligand.  At the conclusion 
of the dissociation time, the regeneration event injects a solution to remove any undissociated 
analyte from the enzyme in preparation for the next injection.  Nine different interaction 
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experiments were done at different analyte flow rates and contact times to evaluate the effect 
of these two parameters determining the reaction rate constants and the equilibrium constant. 
The interaction parameters are summarised in Table 7.3. 
The data processing steps implemented by the software include automated baseline 
adjustment, automated injection time alignment and automated removal of artifacts from the 
data (e.g. spikes produced by bubbles in the flow path).  The ligand channel L4 was used as a 
reference to subtract from the other channels to correct for nonspecific binding, drift and bulk 
refractive index changes. A typical set of association-dissociation curves is shown in Figure 
7.20.  Each of the 6 curves corresponds to one of the 6 analyte concentrations (A1-A6) listed 
in Table 7.9.  There is a data set similar to this one for each of the 5 ligand channels, and for 
every interaction experiment. 
 
 
Figure 7.20.  Association-dissociation curves after automated processing and reference 
channel subtraction.  (Ligand 1 from Interaction 1) 
To analyse the kinetics experiment, the association and dissociation phases of the experiment 
must be identified.  For Figure 7.20, the association phase begins at t=0 and ends at t=60.  
Within this window the signal increases from zero and gradually reaches a limit value 
approaching 30 RU for the analyte of the highest concentration.  This level indicates the 
system has reached equilibrium under the conditions present for the concentration of analyte 
present.  The dissociation phase begins at the next data point past t=60 and continues for 600 
s. 
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Nonlinear curve fitting is used to derive estimates of the association rate constant (ka) and the 
dissociation rate constant (kd) from the association and dissociation curves shown in Figure 
7.20.  The reaction rate constants and the equilibrium constant are determined for each 
interaction and ligand channel using the series of analyte concentrations.  The average values 
for the three constants for the high ligand density (ligand channels L1-L3) and low ligand 
density (ligand channels L5 and L6) were calculated for each interaction (set of experimental 
conditions).  The results are shown in Figure 7.21.  The equilibrium constant (KD) shown in 
Figure 7.21 is determined by the ratio of kd to ka.  According to the kit instruction booklet, ka 
should be in the range 1.6x10
4
 to 4.8x10
4
 M
-1
s
-1
 and kd should be in the range 1.9x10
-2
 to 
5.7x10
-2
 s
-1
.  These ranges are indicated by the red lines in Figure 7.21.  There is a factor of at 
least 3 difference between the lowest and highest ka value predicted by the various 
interactions.  The range of possible results for KD, as calculated from the range of ka and kd 
values given, is also indicted by red lines in Figure 7.21.  The yellow line indicates the most 
likely value, based on these given values.   
For nonlinear regression, the χ2 test for goodness of fit was used to compare the experimental 
data to the model chosen to fit the data.  If the parameters for the model obtained by the 
nonlinear procedure produce a good approximation to the true model, χ2 will be close to 1.  
Poorer fits will have larger χ2 values. As can be seen in Table 7.11, the χ2 values indicate very 
good fits with the exception of Interaction 1.  The curves fit to the data from interaction 4 are 
shown in Figure 7.22.  Clearly, the instrument has no difficulty detecting the refractive index 
change resulting from the lowest concentration analyte standard, A6. 
Table 7.11.  Summary of χ2 values for nonlinear regression.  
 Interaction 
Ligand 1 2 3 4 5 6 8 9 
1 17.75 1.76 1.54 1.03 1.41 1.17 0.96 1.15 
2 7.84 1.75 1.76 0.98 1.41 1.13 0.96 0.99 
3 6.8 1.78 1.8 1.08 1.51 1.17 1.19 0.97 
5 10.17 1.46 1.61 1.03 1.23 1.18 1.35 0.99 
6 10.1 1.52 1.77 1.02 1.16 1.13 1.05 1.06 
 
The shape of the association curve is determined by the flow rate and contact time and has a 
strong influence on the value of the ka obtained from the nonlinear regression. The 
dissociation reactions were all done at a flow rate of 100 μL/min, so the dissociation rate 
constant obtained should not show much variation.  Figure 7.23 shows the interaction curves 
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for selected flow rates and contact times.  Interaction 8 (highest flow rate and shortest contact 
time) has the lowest values for ka and highest values for KD.  Interactions 4 and 6 have the 
highest values for ka and the lowest values for KD.  The length of time that the association 
reaction curve has at equilibrium, i.e. approaching a constant value before the dissociation 
reaction begins, is a critical feature in determining the shape of the curve.  Interaction 8 did 
not reach equilibrium, thus resulting in a higher predicted ka value.  Another factor is the 
slope of the curve between t=0 and approaching the constant value.  The combination of a 
steep slope and poorly defined equilibrium level will further influence the parameters 
estimated by the nonlinear regression.  Flow rate influences the slope of the curve and both 
flow rate and contact time influence the length of time at equilibrium. 
One concern with choosing the Langmuir model is that it does not account for mass transfer 
limits on the rate of reaction.  If mass transfer was an issue, there would be a significant 
difference between rate constants and dissociation constants obtained from the low and high 
ligand density channels.  This difference is not observed, suggesting mass transfer is not a 
limiting factor for this experiment.   
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Figure 7.21.  Effect of experimental conditions on rate constants and the dissociation 
constant.  Error bars indicate 1σ on the average for experimental data.  Red lines 
indicate range of expected values as provided in kit information. The yellow line 
indicates the most likely value for KD based on the given ka and kd values. 
 
  
 
 
Figure 7.22.  Curves fit by nonlinear regression to association and dissociation phases of the experimental data from Interaction 4.  All 6 
ligand channels are shown. 
 
  
 
Interaction 1 (100 μL/min, 60 s) 
 
Interaction 4 (50 μL/min, 180 s) 
 
Interaction 6 (150 μL/min, 60 s) 
 
Interaction 8 (200 μL/min, 30) 
 
Figure 7.23.  The shape of the association reaction curve strongly influences the parameters that are derived by the nonlinear regression.  
Experimental conditions (flow rate and contact time) influence the shape of the association curve. 
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7.5.1.1.1 Equilibrium Analysis 
If only the equilibrium constant is required, the best way to obtain it is directly by nonlinear 
least squares regression fitting the Langmuir isotherm model rather than from the kinetics 
analysis and calculating the ratio         .  The results obtained by the equilibrium 
analysis tool in the instrument software are shown in Figure 7.24.   
Interactions 1 and 2 were done under the same flow conditions but interaction 2 was done 
after the sensor chip was exposed to a low, continuous flow of running buffer overnight while 
the instrument was in standby mode. This has obviously affected the surface in some way, 
but since the sensor chip was not used on the third day, it cannot be determined whether the 
affect was stabilisation (temperature, saturation of surface matrix) or deterioration (e.g. loss 
of enzyme activity). The effect of flow rate on KD is apparent from the results for interactions 
8 and 9. 
 
 
Figure 7.24.  Equilibrium constant obtained from equilibrium analysis of the 
experimental data.  Red lines indicate range of expected values as provided in kit 
information. The yellow line indicates the value for KD calculated from the given ka and 
kd values.  Error bars indicate ±1σ on the average. 
Figure 7.25 shows the dependence of KD on flow rate.  As the shape of the association curve 
becomes distorted at higher flow rates, the calculated KD increases.  As shown in Figure 7.23, 
the shape of the association curve for interaction 8 has not reached a constant level before the 
dissociation phase of the interaction was started, indicating equilibrium had not been reached.  
The nonlinear regression is required to extrapolate where the equilibrium level is located 
based on the initial portion of the association curve.  This is in contrast to interaction 4 where 
the equilibrium level is well defined. 
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Figure 7.25.  Effect of flow rate and contact time during association phase on KD.  The 
shorter contact time of 30 s at the flow rate of 200 μL/min resulted in a higher value of 
KD than the longer contact time of 45 s. 
7.5.2 Method Development – Immobilising hER 
7.5.2.1 Method Development 1 – Direct Amine Coupling of GSH to the Sensor Chip  
In this experiment, an attempt was made to couple GSH directly to the sensor chip and to use 
the affinity between GSH and the GST-tag to immobilise the GST-hERα fusion protein to the 
sensor chip in a known orientation. 
The sensorgrams obtained for directly coupling GSH to the sensor chip are shown in Figure 
7.26.  The increase in signal due to GSH injection is relatively small and constant among the 
6 channels and is superimposed on a sloping baseline.  The sloping baseline is caused by the 
gradual change in bulk refractive index resulting from gradual removal of residual unreacted 
activation reagent as the GSH solution flows over the surface.  No difference among the 
channels is observed.  This suggested all 6 channels have similar loadings of GSH despite the 
difference in concentration between channels L1-L3 and L4-L6 and that all 6 channels may 
be saturated with GSH.   
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Figure 7.26.  Coupling of GSH to sensor chip. The increase in signal due to GSH 
injection is relatively small and constant among the 6 channels and is superimposed on 
a sloping baseline.  The sloping baseline is caused by the gradual change in bulk 
refractive index resulting from gradual removal of residual unreacted activation 
reagent as the GSH solution flows over the surface.   
Since the GSH loading appeared to be similar across all 6 ligand channels, the concentration 
of GST-tagged hERα-LBD was changed to achieve different protein densities.  Sensorgrams 
of channels L1 and L2 with reference channel L3 subtracted are shown in Figure 7.27.  The 
initial increase in signal from t=0 is due to the change in bulk refractive index from running 
buffer to that of the protein solution.  As the solution flows, the slower increase in signal is 
expected to be due to the association of the GST-tagged hERα-LBD with the immobilised 
GSH.  At the end of 300 s, the running buffer again flows.  The difference in signal level with 
the running buffer flowing after 300 s suggests the GST-tagged hERα-LBD has bound to the 
chip surface.  
The 50 nM hERα solutions for channels L1 and L2 were prepared separately and a dilution 
error occurred during the preparation of the solution used for channel L2.  This is reflected in 
the differences in responses of channels L1 and L2 observed in Figure 7.27.  The 5 nM 
L1 L2 
L3 L4 
L5 L6 
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solutions used for channels L5 and L6 were prepared by dilution of the 50 nM solutions 
prepared for channels L1 and L2 and the difference in response is also observed in the 
sensorgrams for channels L5 and L6 shown Figure 7.28.  The amount of ER bound to the 
sensor chip is determined by difference between pre-injection zero and post injection zero as 
summarised in Table 7.12.    Different amounts of GST-tagged ERα were bound to each 
channel (L1 > L2 > L5 > L6). The ranking is consistent with the dilution error noted for 
channel L2 and the propagation of that dilution error into the solution used on channel L6.   
In all 4 channels, the signal is still increasing at the end of the 300 s injection interval 
suggesting additional immobilisation of protein may be possible.  The stability of the baseline 
after injection suggests that there is an affinity capture, not just a non-specific adsorption of 
the protein to the surface.  Non-specific adsorption would appear as a rapidly declining signal 
after the running buffer flow was started, as seen in Figure 7.26. 
 
 
Figure 7.27.  Sensorgrams of channels L1 and L2 with reference channel L3 subtracted.  
The initial increase in signal from t=0 is due to the change in bulk refractive index from 
L3 
L2 L1 
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running buffer to that of the protein solution.  As the solution flows, the slower increase 
in signal is the association of the GST-tagged hERα-LBD with the immobilised GSH.  At 
the end of 300 s, the running buffer again flows.  The difference in signal level with the 
running buffer flowing after 300 s suggests the GST-tagged hERα-LBD has bound to 
the chip surface.  
 
 
 
Figure 7.28.  Sensorgrams of channels L5 and L6 with reference channel L3 subtracted.  
Injection of GST-tagged hERα-LBD begins at t=0. 
Table 7.12.  Pre-injection and post-injection SPR signal values (RU) 
 
Binding of GST-tagged ERα 
Average SPR signal (RU) 
Ligand Channel / 
Analyte Channel Pre Injection Zero Post Injection Zero RU Increase 
L1 (A1-A6) 0.01 186 186 
L2 (A1-A6) -0.19 116 116 
L5 (A1-A6) 0.06 93 93 
L6 (A1-A6) 0.04 33 33 
 
L6 
L5 L4 
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With the apparent success at capturing the GST-tagged hERα-LBD, the flow direction was 
changed for injection of E2 standards to see if binding of E2 to the immobilised ER could be 
detected.  Five standard solutions of E2 in running buffer were prepared covering a wide 
range of concentrations as summarized in Table 7.13.  The stock E2 solution was prepared at 
10 mM in ethanol (EtOH) and then diluted to the desired concentrations with running buffer.  
These standards were injected at a flow rate of 30 μL/min for 300 s.  The dissociation phase 
was 600 s long with running buffer flowing at 30 μL/min.  
Table 7.13.  Concentrations of analyte solutions for ERα-E2 interaction. 
Solution ID E2 Concentration 
(μM) 
A1 10 
A2 2 
A3 0.1 
A4 0.02 
A5 0.001 
A6 0 (buffer blank) 
 
The sensorgrams obtained for the interaction of E2 are shown in Figure 7.29 for channels L1 
and L2 and no indication of E2 interacting with the immobilised ER is seen.  A second 
injection of the series of standards was made with no difference in result.   
To further investigate, the data from the second injection was viewed by analyte channel (A1-
A6) as shown in Figure 7.30.  From Figure 7.30, there is a difference in the bulk refractive 
index of the 5 solutions (A1-A5) as compared to the buffer blank (A6) as summarised in 
Table 7.14.  The bulk refractive index measured at the end of injection is increases with 
increasing E2 concentration, suggesting the solutions do in fact have E2 present.  In neither 
injection did the association phase reach equilibrium, as indicated by the continuously 
increasing signal.  What might be observed in these interactions is merely non-specific 
adsorption of E2 to the protein or sensor chip, and is further supported by the declining signal 
during the dissociation phase.  None of the sensorgrams resemble those obtained with the 
small molecule kit shown in Figure 7.20 and Figure 7.22.    
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Figure 7.29.  Reference channel 3 subtracted from Interaction channels 1 and 2.  Curves 
A1-A6 are E2 concentrations as given in Table 7.13. 
 
L3 
L1 L2 
Chapter 7 – Binding Studies - SPR 
289 
 
 
 
Figure 7.30.  View of E2 interaction data by analyte channel.  Each panel corresponds to 
different E2 concentration.  Traces are from L1-L6.  L3 and L4 are reference channels.  
No difference between reference channels and channels with GST-tagged ERα is 
observed. 
 
Table 7.14.  RU difference at end of E2 standard injection shown in Figure 7.30. 
Analyte Standard Signal Increase (RU) 
A1 (10 μM) 234 
A2 (2 μM) 80 
A3 (0.1 μM) 50 
A4 (0.02 μM) 43 
A5 (0.001 μM) 40 
A6 (blank) 43 
 
At this stage, a number of different tests were considered to try to understand what was 
happening.  Additional injections of GST-tagged hERα were made, resulting in the 
incremental increase in SPR signal illustrated in Figure 7.31.   
A
6 
A
5 
A
4 
A
3 
A
2 
A
1 
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Another attempt to measure the interaction of hERα with E2 was made.  No interaction seen 
and the sensorgrams were no different from those shown in Figure 7.27 and Figure 7.28.  The 
sensor chip was left in the instrument with a low flow of running buffer over the weekend. 
 
 
 
Figure 7.31.  Incremental ERα binding measured by the net increase in SPR signal after 
each injection. 
To remove the affinity bound receptor from the sensor chip surface, a regeneration solution 
of 200 μM GSH in running buffer was used.  The first regeneration did not give the expected 
result.  The signal was expected to be lower after the regeneration than before and a 
difference among the 6 channels was expected as the channels had different amounts of ER 
were bound.  Also expected was a difference between channels 3 and 4 and the other 
channels as those two channels did not have ER bound.  An increase of about 16 RU was 
observed.  A second injection of 300 μL (30 μL/min for 600 s) was made and obtained a 
similar increase (average 19 RU) in all 6 channels.  This suggested an adsorption of GSH to 
the surface of the sensor chip and that any previously bound ER (if any) may have been 
removed by the low flow of running buffer over the weekend. 
Assuming the results obtained thus far indicate that the sensor chip did not have any ER 
bound, another attempt was made to bind ER.  In their study, Rich et al. [373] used a 2 μM 
solution of ER injected at 10 μL/min for 5 min.  If all ER was captured, the chip would have 
been loaded with 100 pmol of ER.  With the 50 nM GST-tagged hERα solution, the 150 μL 
injection volume used would give a loading of only 7.5 pmol.  The three injections performed 
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would give a loading of 22.5 pmol.  It is possible that insufficient protein was bound to the 
surface to give a measurable signal with the E2 interaction test. 
The vial of GST-tagged ERβ-LBD available contained 250 pmol and was diluted with 1 mL 
of running buffer to produce a solution is 37.5 nM.  Two injections of 150 μL this solution 
would give a loading of 75 pmol, but there was sufficient quantity of protein to do this for 
only two of 6 channels.  The ERβ solution was injected onto channels L3 and L4 of the 
sensor chip to ensure no interference from other channels.  An average net increase of 57 RU 
for channels L3 and L4 was observed.  An average change for the running buffer injections 
on the other 4 channels is 2.9 RU.  A second injection was done resulting in an average net 
increase of 58 RU for channels L3 and L4 and an average change for the running buffer 
injection on the other channels is 1.9 RU.  To achieve a third injection of ERβ, 150 μL of 
running buffer was added to the ERβ vials and mixed.  A third injection of 150 μL was done.  
For this injection a lower net increase in RU was expected since solution was diluted by 
approximately one third.  The average net increase of 14 RU for channels L3 and L4 was 
observed.  The average RU change for the buffer on the other 4 channels was again 1.9 RU.   
Assuming that these RU increases on channels L3 and L4 are a result of ERβ capture, the 
flow direction was changed to the analyte channels and an injection of E2 the standards 
described in Table 7.13 was done.  Sensorgrams similar to those shown in Figure 7.29 were 
obtained.  These results suggest no binding of E2. 
7.5.2.2 Method Development 2 – Tether Coupling of GSH to the Sensor Chip 
With the failure to capture GST-tagged hER via direct coupling of GSH to the sensor chip, 
two different tethers were tested.  Instead of using the GST-tagged hER, only the GST 
enzyme was used to test the functionality of the surface. 
The carboxy-PEG4-amine was the first tether evaluated.  The PEG was successfully coupled 
to the sensor chip surface and GSH was successfully coupled to the PEG.  But, attempts to 
capture the GST protein were unsuccessful.  The density of the PEG tether was successfully 
varied but without success in GST capture.  The changes in SPR signal observed suggested 
that the PEG tether may be facilitating a tightly bound water molecule network at the surface 
of the chip, excluding buffer salts, and causing steric interference with the binding of the 
protein to the GSH.  The evidence of this was an unusual decrease in SPR signal with 
attachment of the tether. 
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The second tether evaluated was the aminohexanoic acid.  Although shorter, the hydrophobic 
nature of this tether was reported in the literature to be advantageous in GST-GSH affinity 
binding as the hydrophobic interactions between the GST protein and the tether tended to 
stabilize the binding.  The SPR signal confirmed a stepwise construction of first the tether to 
the surface, then GSH to the activated tether.  However, binding of the GST protein again 
was not observed.  Variation in density of tether did not result in any capture.   
At this point, further investigation was needed before planning additional experiments. 
7.6 Discussion 
7.6.1 Validation of Instrument Sensitivity 
The kit worked as expected.  Values for ka, kd and KD were within the ranges expected using 
both kinetic and equilibrium analysis wizards.   
The effects of experimental conditions on the rate constants and equilibrium constant derived 
from the measurements were examined.  The results showed that a well-defined equilibrium 
level is required for both kinetic and equilibrium analyses.  The flow rate and contact time 
determine the duration of the equilibrium level.  A flow rate should be chosen to give an 
initial slope in the association reaction that is not too steep or too shallow. 
Considering all results, the experimental parameters implemented in interactions 2-6 appear 
optimal for the CAII/CBS system.  Increasing the contact time for interactions 8 and 9 may 
improve the results.   
These results also demonstrate that the instrument has the required sensitivity to be able to 
detect the interaction of a small molecule (MW = 201 Da) with an immobilised enzyme down 
to a concentration of 0.084 μM (17 ng/mL, 17 ppb).  This sensitivity is well within the range 
of expected concentrations of EEs in biological samples such as urine and amniotic fluid (see 
Chapter 1).  The binding affinity of CBS to CAII is on the order of 1 μM, which is also the 
same order of magnitude of many EEs (see Chapter 1).   
These results demonstrate that the instrument has sufficient sensitivity to proceed with 
method development for the estrogenic load biosensor. 
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7.6.2 Kinetics Scuttle an Elegant Idea 
With the lack of success of capturing GST via two different approaches to tethering GSH to 
the sensor chip, the GST affinity chromatography literature was revisited.  An unexpected 
limitation was discovered and it relates to the effect binding kinetics has on the capture 
efficiency of a GST-tagged protein by immobilized GSH on the sensor chip. 
The GST affinity chromatography media technical documentation described that the kinetics 
of binding for GST was much slower than for other affinity strategies such as polyhistidine 
tags.  The following analysis of the experimental conditions and recommended procedures 
for GST affinity chromatography and batch purification revealed a potential reason for the 
lack of success in capture.  
The GE Healthcare Affinity Chromatography handbook [403] suggest a maximum linear 
velocity of 75 cm/h (0.2 mm/s) for small packed columns.  Harper and Speicher [404] 
recommend that for a 2.5-cm-diameter column, a sample-loading flow rate of ≤ 0.1 ml/min is 
necessary to achieve complete binding of the GST fusion protein to the column at 4 °C.  
These conditions are equivalent to a linear velocity of 3.4 x10
-3
 mm/s.  The geometry of the 
Bio-Rad SPR flow channel is 450 µm x 100 µm.  The minimum flow rate of 25 µL/min in 
this channel results in a linear velocity of 9.3 mm/s.  This flow rate is approximately 46 times 
higher than the flow rate suggested by GE Healthcare and 2700 times higher than the 
recommended flow rate suggested by Harper and Speicher.   
Tessema et al. [391] determined the dissociation constant, KD, of a GST fusion of green 
fluorescent protein (GST-GFP) with immobilized GSH to be 108 nM for high density GSH 
beads and 190 nM for low GSH density beads in equilibrium binding experiments.  They also 
conducted kinetic experiments to determine binding and dissociation rate constants for the 
binding of their GST-GFP with immobilized GSH.  The association rate constant (ka) was 
2.6x10
3
 M
-1
s
-1
 for both high and low GSH density beads while the dissociation rate constant 
(kd) differed for the high and low GSH density beads (1.3x10
-4
 s
-1 
and 6.4x10
-4
 s
-1
 
respectively).  The dissociation constants determined by the kinetic experiments (50 nM and 
250 nM) differed from those determined in the equilibrium experiments.   
In comparison to the association and dissociation rate constants shown in Figure 7.2 for hERα 
ligands, the association reaction for GSH-GST is slow and comparable to that of OHT with 
hERα.  The dissociation reaction is also slow, marginally faster than OHT from hERα but not 
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as fast as that of E2 from hERα.  The experimental conditions used to obtain the results for 
E2 and OHT [373] are a flow rate of 50 μL/min and a concentration of 1 μM and an 
interaction time of 30 s and 3 minutes respectively.  The simulated association reaction 
curves for E2 and OHT are shown in Figure 7.32. Indeed, from the shape of the curve, the 
OHT-hERα association would not have been expected to reach equilibrium until 30 minutes.  
So, it is not surprising that under the conditions attempted with GST-tagged hER (50 nM at 
30 μL/min for 300 s) that very little hERα capture was observed.   
 
(a) E2-hERα 
 
(b) OHT-hERα 
 
Figure 7.32.  Simulated association reaction curves using published rate constant and 
dissociation constant data for E2-hERα and OHT- hERα.  Both curves assume a 
fractional receptor occupancy of 0.0001 and a concentration of 1 μM of ligand 
concentration in the injected solution. 
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7.7 Conclusions 
This study demonstrated that although the binding affinity of GST for GSH is high enough to 
make this system a logical candidate for immobilising GST-tagged proteins to the SPR sensor 
chip surface, the kinetics of the binding reaction are too slow for this approach to be 
successful.  In order for the GST-GSH strategy to work, a stopped-flow condition is needed 
to allow the GST-tagged protein to interact with the surface.  Incubation times of 30 minutes 
or more are recommended in affinity chromatography methods to ensure the desired protein 
is bound before flushing away undesired material.  The stopped-flow feature is not available 
on the Bio-Rad instrument, so the development of the biosensor using the GST-tagged ER 
was abandoned.   
As mentioned earlier, the kinetics of nickel affinity chromatography for purification of His-
tagged proteins are much faster, and His-tagged proteins have been used successfully in SPR 
experiments in the literature [405].  Unfortunately, a commercial source of His-tagged ER 
was not available and neither was the capacity to produce the protein in-house, so the 
investigation of this approach must be left for another time.     
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8.1 Introduction  
This chapter reports on an attempt to use isothermal titration calorimetry (ITC) to study the 
thermodynamics of the interaction of endogenous estrogens and environmental estrogens 
with the hER.  An understanding of the relative contributions of enthalpy and entropy to the 
Gibbs free energy of binding complements the kinetic information on the reaction, leading to 
a clear picture of the mechanism of interaction of EEs with the hER. This understanding will 
lead to better predictions of the biological outcomes of exposure to environmental estrogens 
and to the identification of additional compounds as having estrogenic potential. 
This chapter begins with a brief review of the thermodynamics of the receptor-ligand 
interaction.  The principles of ITC and the key factors in designing and ITC experiment are 
then presented.  The results of the experimental work follow.  These studies were conducted 
concurrently with the SPR experiments discussed in Chapter 7.  As with the SPR 
experiments, the ITC experiments were limited by both the cost and format of commercially 
available hER.  The discussion will explain the difficulties encountered and how they may be 
overcome in future work. 
8.2 Theoretical Basis 
8.2.1 Reaction Thermodynamics  
For the reaction,   
 
where R is the receptor, L is the ligand and RL is the complex formed by non-covalent 
interaction of R and L, the rate constant for the association (forward) reaction is ka and the 
rate constant for the dissociation (reverse) reaction is kd.  At equilibrium, the equilibrium 
association constant KA is given by 
    
  
  
 
    
      
 
The dissociation constant, KD, is simply the inverse of the association constant, 1/KA.  The 
standard Gibbs free energy change of the reaction, ΔG°, is given by  
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or 
            
where R is the universal gas constant and T is the temperature in Kelvin.  A negative value 
for ΔG° indicates that the receptor-ligand complex is more stable than the individual isolated 
receptor and ligand species.  ΔG° is related to the enthalpy and entropy of the system by   
              
where ΔH° is the standard enthalpy change and ΔS° is the standard entropy change for 
complex formation. Thus, by measuring ΔH° (observed ΔH corrected for non-specific 
effects, expressed per mole of substance) and KA over a range of temperatures, a full 
thermodynamic characterization of the interaction is obtained: 
             
     
         
 
 
ΔG° provides a concentration independent parameter that allows comparison of the affinities 
of interactions for different ligands with the receptor.  ΔG° has a number of different 
contributions:  intermolecular contacts (non-covalent bonds), conformational changes, 
hydrophobic interactions, ionisation effects and changes in rotational/translational motion 
[406].   
The change in enthalpy, ΔH°, is a measure of the heat energy associated with going from the 
free to the bound state and can be thought of as the net heat associated with the making and 
breaking of non-covalent bonds in forming the biomolecular complex.  This value includes 
not only the bonds associated with ligand binding but also any conformational changes of the 
components of the interaction.  As a result, ΔH° can be complicated to interpret.  When 
coupled with high-resolution structural detail of the interacting molecules (such as computer 
docking studies), comparison of ΔH° terms for interactions with a given biomolecule and 
subtly modified ligands can give some insight into the importance of specific, non-covalent 
bond formation [406, 407].  The ΔH° of interaction is temperature dependent – it varies 
according to the change in heat capacity (∆Cp).  It may increase or decrease with temperature.  
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The measured ΔH° may also be dependent on the choice of buffer solution or pH if the 
interaction is accompanied by a protonation event [408].  The use of a buffer with a high ΔH° 
of ionization will enhance binding enthalpy.  The choice of buffer may have a dramatic effect 
such that in one buffer, the reaction may be exothermic and in another buffer, the reaction is 
endothermic.  The number of protonation events that occur on binding can be determined 
from data from experiments in different buffers [406, 407]. 
The change in entropy term, ΔS, is more difficult to interpret.  Entropy is a measure of the 
tendency of the system to disorder.  While the coming together of two molecules imposes 
some order on the system due to reduction in translational/rotational entropy and reduction in 
atomic degrees of freedom (configurational entropy), the release of water molecules from the 
binding site to the bulk solvent results in disorder [406]. 
Thus, for the receptor-ligand complex to form, ΔG° must be negative and enough heat must 
be produced (negative ΔH°) to counter any increase in order (negative ΔS°) that is achieved 
when the two isolated, solvated molecules bind to form a single complex. 
8.2.2 Thermodynamics of E2-hER Ligand Binding 
At 20 °C, the binding of hER and E2 has a KD of 0.9 nM [373] and this corresponds to a ΔG° 
of -50.8 kJ/mol.  The binding of E2 to hER is entropy driven at temperatures between 0 °C 
and 17 °C (ΔH° = 0 at 17 °C) and enthalpy driven at temperatures above 37 °C (TΔS° = 0 at 
37 °C) [407].  Between 17 °C and 37 °C the binding is driven by both enthalpy and entropy.  
At 25 °C, ΔH° accounts for only 37% of ΔG°.  The switch to enthalpy driven binding at 
physiological temperature (37 °C) is interpreted as a minimum in the activation energy 
needed to disrupt the water molecule cages that shield the hydrophobic portions of the protein 
from the bulk aqueous solvent.  Within the temperature range of 0 °C and 37 °C, the variation 
in ΔG is small ( 6 kJ/mol) [407], but the relative contributions of ΔH° and ΔS° change 
dramatically.   
The binding of E2 to ER also has a large negative molar heat capacity ΔCP° of -2.4 kJ mol
-1
 
K
-1
 and is typical of protein-ligand interactions.  This has been attributed to the large negative 
vibrational contributions that result from the tightening of the binding cavity around the 
bound ligand and the repositioning of H12 to close the binding cavity [407]. 
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The ability to describe the binding of environmental estrogens to the hER in this way will be 
useful in developing a clear picture of the molecular mechanism of action of environmental 
estrogens and will help to rationalise the varied biological outcomes of exposure. 
8.2.3 Isothermal Titration Calorimetry 
Isothermal titration calorimetry measures the change in enthalpy (heat) involved in a 
chemical reaction or physical process.  Heat can be taken in from the surroundings 
(endothermic) or given up to the surroundings (exothermic).  The amount of heat is 
proportional to the amount of reaction that has occurred, the number of moles of material 
involved and the enthalpy change for the reaction [409].  Enthalpy (ΔH) is measured in 
kcal/mol or kJ/mol.  The rate at which heat is exchanged can also be measured and is equal to 
the rate of reaction.  ITC can be used to simultaneously determine the equilibrium association 
constant of a reaction (KA) and ΔH [409].  By measuring the enthalpy, it is possible to 
quantify the exact enthalpic and entropic contributions to the overall free energy.  Thus, for 
two interactions that have similar affinities and free energies, there can be very different 
enthalpic and entropic components to the free energies, driven by such factors as changes in 
protein secondary or tertiary structure and degree of hydration [410]. 
Observed enthalpies arise largely as a result of changes in interatomic interactions.  The most 
important of these interatomic interactions for biological systems is the hydrogen bond.  The 
magnitude of the interaction enthalpy is dependent on bond lengths and bond angles.  The 
sign of the reaction indicates whether there is a net favourable (negative) or unfavourable 
(positive) redistribution of the hydrogen bond network between reacting species [410].  
Hydrophobic interactions are related to the relative degrees of disorder in the free and bound 
systems and therefore these interactions are reflected in the entropy change.  The release of 
water molecules from a ‘wet’ surface to the bulk solvent is a common source of favourable 
entropy.  Coupled with the inability of non-polar groups to hydrogen bond with the 
surrounding water molecules, this is the main reason for the strong energetic influence of 
hydrophobicity in biology [410].  These types of interactions are typically characterized by a 
small enthalpy change, either positive or negative, and a favourable (positive) entropy 
change.  A large negative change in heat capacity is thought to arise from the accommodation 
of non-polar groups by water and is therefore another useful indicator of hydrophobic 
interactions [410]. 
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Conformational changes are entropically unfavourable.  Large unfavourable entropies are 
often indicative of an ‘induced fit’ during the interaction and are often seen in receptor 
binding [410]. 
Modern ITC instruments can measure heat change rates as small as 0.1 µcal/s (0.4 µJ/s).  
This sensitivity allows the determination of KA as large as 10
8
 to 10
9
 M
-1
 for reactions with 
rates in the range of 10
-12
 mol/s [409]. 
Calorimetric measurements can be made in different ways.  ITC is based on the power 
compensation method.  The calorimeter cell is controlled at a constant temperature 
(isothermal).  Constant cooling is applied to the cell.  The cell is kept at a constant 
temperature using a temperature controller and heater.  As the chemical reaction takes place, 
heat produced or required by the reaction is compensated for by controlling the power applied 
through the heater.  The raw signal is the power (µcal/s or µJ/s) that is applied through the 
heater to maintain the cell at a constant temperature. 
The experiment is designed so that one component of the reaction is placed in the cell and the 
second component is titrated into the cell using a syringe injection.  Multiple small volumes 
of titrant are added, with enough time allowed between injections for the calorimeter to return 
to the constant temperature set point. 
Typical ITC data is shown in Figure 8.1.  Panel (a) shows the differential power signal 
recorded in the experiment. Each peak corresponds to the heat released on addition of an 
aliquot of the titrant.  If KA is large and the molar ratio of ligand to receptor protein at the 
beginning of the titration is low, then virtually all of the ligand is bound to the receptor and 
all the peaks are of similar area.  As the fractional saturation increases, the amount of heat 
produced gradually decreases.  Eventually all the binding sites are saturated.  Small heat 
changes measured after saturation are caused by the heat of ligand dilution and other 
nonspecific effects.   
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Figure 8.1.  Typical ITC data (courtesy Dr. R. Hutton, University of Canterbury). 
Integration of each peak individually gives the apparent heat change per addition, Δqi,app. The 
apparent heat change has contributions from the binding reaction, dilution and other 
nonspecific effects: 
                            
The apparent heat change is proportional to the cell volume, the change in bound ligand 
concentration and the apparent molar enthalpy of association: 
                                  
After integration with respect to time and normalization per mol of added ligand, ΔHapp, KA 
and n can be calculated by nonlinear least squares analysis implemented in the software of 
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the instrument. The integrated data is presented as a sigmoidal plot (panel (b) of Figure 8.1). 
The ΔHapp obtained from this analysis is a global property of the system corrected for 
nonspecific effects; it reflects the total heat released or absorbed in the calorimetric cell.  
Other processes such as solvent reorganization, protonation effects or direct, non-covalent 
bonds also contribute and experiments must be designed to attempt to identify and quantify 
those contributions. 
To obtain reliable binding constants, the concentrations of the interacting species must be in 
the correct range.  If the concentration of binding sites is very much higher than 1/KA, all the 
ligand added will be bound until saturation and the binding isotherm of Figure 8.1(b) will 
have a rectangular shape with the slope approaching infinity.  In the opposite case, the 
isotherm will be very shallow and full saturation will be difficult to approach.  For accurate 
values of KA, the concentration of receptor binding sites should not be much higher than 
1/KA.  A dimensionless value, c, is defined as the product of KA and the total binding site 
concentration, in this case equal to the active receptor concentration [R]: 
         
As a rule of thumb, c-values between 10 and 100 give accurate KA values, but sometimes the 
concentration of R is not useful.  Under some conditions, the c-value range may be extended 
to 1-1000 [411].  For tight binding, the concentration of the receptor may be too low to give 
measurable heat changes.  This places an upper limit on the KA that can be accurately 
measured of approximately 10
9
 M
-1 (ΔG  -50 kJ mol-1).  At the other end, if binding is very 
weak, the concentration of M may be so high that aggregation of receptor protein molecules 
can obscure the binding reaction.  Often ΔG is dependent on temperature, pH, ionic strength, 
so experimental conditions can be found to measure it.  The E2-hER system, with a ΔG° of 
approximately -51 kJ/mol, is at the limit of the operating range of the instrument.  
Environmental estrogens have much lower affinities for the hER, falling within the operating 
range of the instrument. 
ITC titrations can also be done by titrating a strongly binding ligand into a solution 
containing the receptor already saturated with a weaker ligand [412].  Free binding energies 
are obtained from such a displacement experiment if the strong and weak ligands exhibit 
suitable differences in binding enthalpy.  
 
Chapter 8 – Binding Studies - ITC 
305 
 
8.3 Methods and Materials 
8.3.1 Methods 
8.3.1.1 Isothermal Titration Calorimeter 
The instrument available for use is the VP-ITC MicroCalorimeter by MicroCal of 
Northampton, MA, USA [413].  The instrument has two cells, the reference cell and the 
sample cell as shown in Figure 8.2.   
 
Figure 8.2.  Schematic of VP-ITC instrument, adapted from [413].   
The sample cell is fitted with a syringe driven by a stepper motor to deliver the titrant to the 
cell.  The temperature difference between the two cells is measured.  This temperature 
difference is used to determine how much power must be applied to the heater to maintain 
constant temperature.  The reference and sample cells are coin-shaped and each have a 
working volume of 1.4 mL and must be completely filled during operation.  The instrument 
has a sensitivity of 0.1 µcal.  Each injection of titrant should produce or require 3-5 µcal of 
heat to produce good results. Titrant injection volumes are typically 3-15 µL and 10-15 
injections are made.  Three or four injections should be beyond the saturation of binding 
sites, giving ‘control heat’ data within the experiment.  The ‘control heat’ collectively refers 
to heat produced by dilution, mixing of the titrant with the cell contents and other non-
specific heats.  Experiments should be done at several different temperatures as the binding 
constant and heat of binding are usually temperature dependent, while the stoichiometry of 
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the reaction is not.  By conducting experiments at different temperatures, the heat capacity of 
the reaction can also be determined. 
8.3.1.2 Study Design 
Documented measurements of the equilibrium dissociation constant (KD) for the E2-hER 
interaction are on the order of 0.5 nM, giving KA in the range of 2x10
9
 M
-1
.  This is near the 
limit of sensitivity of the instrumentation.  The KA value for BPA is on the order of 2x10
5
 M
-
1
.  The large difference in KA values for E2 and BPA creates two scenarios for designing 
experiments:  tight binding for E2 with hER and weak binding of BPA with hER. 
8.3.1.2.1 Tight Binding Scenario – E2 
The study of tight binding reactions is limited by the low concentration of receptor required 
to achieve c-values in the range of 1-1000.  The receptor concentrations for the desired c-
values are given in Table 8.1.  To maximise the heat produced by the reaction, the highest 
practical hER concentration of 50 nM is chosen for the initial experiments. This 
concentration is a compromise between sensitivity and having sufficient material to conduct 
several experiments. 
Table 8.1.  hER concentrations for a range of c-values for the reaction of E2 with hER. 
c-value 
hER concentration (nM) 
Ligand = E2; KA = 2x10
9
 
1 0.5 
10 5 
100 50 
1000 500 
 
With the concentration of receptor selected, the concentration of the E2 solution injected 
needs to be determined.  It is desirable to achieve a titration ratio of at least 2 when the c-
value is in the range of 10-500 [411].  The titration ratio is defined as the ratio [L]/[R] 
achieved at the end of the experiment.  Assuming a cell volume of 1.4 mL, and 10 injections 
of 10 µL each (100 µL total volume injected), the final concentration of E2 in 1.5 mL will be 
100 nM with 150x10
-12
 moles of E2 injected in 100 µL.  This gives a titrant solution in the 
syringe with an E2 concentration of 1.5 µM. 
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8.3.1.2.2 Weak Binding Scenario - BPA 
The study of weak binding interactions is limited by the high concentration of receptor 
required to meet the usual c-value criteria of 1-1000 as shown in Table 8.2.  If a c-value of 1 
is chosen, approximately 13 vials of ER are required to achieve 2 mL of a 5 µM solution 
(sufficient for one experiment).  This is clearly not feasible or cost effective. 
Table 8.2.  hER concentrations for a range of c-values for the reaction of BPA with hER. 
c-value 
hER concentration (μM) 
Ligand = BPA; KA = 2x10
5
 
1 5 
10 50 
100 500 
1000 5000 
 
Successful experiments can be done at c-values down to 10
-4
 if designed correctly [411].  For 
BPA, a receptor concentration of 50 nM will give a c-value of approximately 0.01, which 
may be sufficient for a successful experiment.  At low c-values, the titrant must be added to 
great excess to achieve significant binding site population.  The range of titration, Rm, is then 
defined by  
    
   
    
 
  
 
 
Where Rm = [L]/[R] in the cell after the last injection [411].   
With c = 0.01, Rm = 1316.  As above, with [R] = 50 nM, 10 injections of 10 µL, the total 
number of moles of BPA injected into the cell will be 1x10
-7
, giving a titrant solution in the 
syringe with BPA concentration of 1 mM. The solubility of BPA is in the range of 120-300 
ppm in water at 20 °C, which corresponds to a concentration of 0.5 to 1.3 mM.  The desired 
concentration of BPA may just be achieved in aqueous solution. 
8.3.1.2.3 Data Reduction 
The question of what experiments to use as controls to correct for other contributions to the 
measured heat change in the E2 into hERα experiment is now considered.  The total heat 
change observed in the experiment of titrating E2 into hERα (          ) includes 
components from the heat of interaction of E2 with hERα (         ), the heat of dilution 
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of the E2 solution (    ), the heat of dilution of the hERα solution (      ) and an 
instrument blank (      ).   
                                            
                                            
The heat of dilution of the E2 solution is obtained by titrating the E2 solution into the buffer 
used to dissolve hERα.   
                    
                    
The heat of dilution of the hERα solution is obtained by titrating the reagent blank into the 
hERα solution.   
                       
                        
An instrument blank is obtained by titrating buffer into buffer.  The total heat change for each 
experiment contains a contribution from the instrument blank.  To minimize errors due to 
subtraction, the following approach is used, where each term in the equation is directly 
measured: 
                                              
8.3.2 Materials 
The full-length receptor proteins hERα and hERβ were purchased from Invitrogen (product # 
P2187 and P2466 respectively).  The ligand binding domains for hER available had the GST 
tag (as used in the SPR experiments).  The effect of the GST tag on ligand binding to the hER 
in solution was not known, so the full length receptor was chosen for the ITC experiments.   
A quantity of 750 pmol active receptor is provided in each vial and the molar concentration 
of active receptor is on the order of 2.5 – 5 µM.  The quantity of protein available is a 
limiting factor for these experiments.   
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The supplied hER was buffer exchanged to remove the glycerol and other preservatives from 
solution.  Buffer exchange was done by ultrafiltration using a Vivaspin 500 tube (Sartorius).  
This device has a capacity of 500 µL and polyethersulfone (PES) membrane of different 
molecular weight cut-offs.  The tube available has a 10 kDa MW cut-off.  The hER was 
buffer exchanged into the ITC buffer described below.   
The 750 pmol of hERα was buffer exchanged and diluted into 4 mL ITC buffer to give a 
concentration of 188 nM.  This solution was further diluted to 3 aliquots of 50 nM for the 
first experiment.  The 750 pmol of hERβ was buffer exchanged into 2 mL ITC buffer to give 
a concentration of 375 nM.   
The buffer used for dissolving the receptor protein and preparing titrant solutions (ITC 
buffer) was 50 mM Tris-HCl, 500 mM KCl, 2 mM DTT, 1 mM EDTA and was prepared 
from stock reagents. 
A stock solution of E2 (Sigma Aldrich product # E8875, ≥98%) was prepared in methanol 
(MeOH, HPLC grade) at a concentration of 7.3 mM.  An aliquot of 3.4 µL of the stock E2 
solution was diluted to 25 mL in the ITC buffer to produce a 1.5 µM solution for the hERα 
experiment.  This solution contained 3.36 mM MeOH.  The buffer blank solution used for the 
ITC titration was prepared by adding 3.4 µL MeOH to 25 mL of ITC buffer. 
The 375 nM hERβ gives a c-value of 750 for E2 as the titrant.  This increase in receptor 
protein concentration requires a titrant concentration of 10 μM.  This E2 solution was 
prepared by diluting a 32 μL aliquot of the stock E2 solution to 25 mL with ITC buffer.  The 
reagent blank was prepared by diluting a 32 μL aliquot of the MeOH to 25 mL with ITC 
buffer.   
8.3.3 Experiment 1 
Prior to starting the series of experiments, the reference cell was filled with degassed Milli-Q 
water.   
The series of experiments described in Table 8.3 was conducted at 20 °C.  The initial titrant 
injection volume of 5 µL was discarded as it often is affected by tiny bubbles and other 
disruptions caused by inserting the syringe into the measurement cell and starting the stirring.    
A total of 15 injections of titrant were done.  Each experiment takes approximately 1 hour to 
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complete, after the initial stabilisation time has passed.  The instrument operating parameters 
are summarised in Table 8.4.   
The series of experiments described in Table 8.3 was repeated using the 375 nM solution of 
hERβ instead of the 50 nM hERα solution.  Since there was sufficient receptor protein for 
only one titration, the receptor blank titration was not done and only one interaction titration 
with E2-hERβ was done. 
Table 8.3.  Series of ITC experiments with E2 and hERα. 
Experiment Cell Contents Syringe Contents 
Double Blank ITC Buffer ITC Buffer 
Reagent Blank ITC Buffer 3.4 mM MeOH in ITC Buffer 
Titrant Blank ITC Buffer 1.5 µM E2 ITC Buffer 
Receptor Blank 50 nM hERα 3.4 mM MeOH in ITC Buffer 
Interaction 50 nM hERα 1.5 µM E2 
Interaction 50 nM hERα 1.5 µM E2 
 
Table 8.4.  Experimental conditions for ITC experiments listed in Table 8.3.  Series of 
ITC experiments with E2 and hERα.. 
Parameter Value 
Cell Temperature 20 °C 
Titrant injection volume  10 µL 
Initial titrant injection volume  5 µL 
Total number of titrant injections 15 
Reference power  10 µcal/sec 
Initial delay 300 s 
Injection duration 20 s 
10 s for initial 5 µL injection 
Injection spacing 210 s 
Filter period 2 s 
8.4 Results  
8.4.1 First ITC Experiment with hERα 
The series of titrations described in Table 8.3 were completed.  The double blank titration 
was repeated twice, the reagent blank titration was repeated three times, the titrant blank was 
repeated twice and a single titration of E2 into 50 nM hERα was obtained.  Examples of the 
raw data obtained for each titration are shown in Figure 8.3.  The software tools were used to 
integrate the area of each peak and calculate the amount of heat produced on each injection.  
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The net heat change is normalized to the concentration of the injected titrant (E2) in the cell 
after each injection.  The results are illustrated in Figure 8.4. 
The peaks corresponding to heat production with each titrant volume addition shown in 
Figure 8.3 are very small and show no difference between the various blank and reaction 
titrations.  Overall, the expected trend of decreasing peak area (Figure 8.1) is absent for the 
reaction titration.  There is no difference in the heat of reaction obtained from these data 
(Figure 8.4), suggesting the concentration of hERα is too low and the quantity of heat 
produced is below the sensitivity limit of the instrument.   
   
 
 
Figure 8.3.  The raw ITC data for double blank, reagent blank, titrant blank and the 
interaction of E2 with hERα. 
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Figure 8.4.  Apparent heat change per mol of titrant for double blank, reagent blank, 
titrant blank and the interaction of E2 with hERα. 
 
8.4.2 Second ITC Experiment with hERβ 
Since the initial experiment with the 50 nM hERα solution did not produce a measurable 
signal, a single experiment at the maximum concentration of receptor protein achievable was 
attempted using the available supply of hERβ.  The double blank and two each of reagent 
blank and titrant blank titrations described in Table 8.3 were done before the single E2-hERβ 
interaction was done.  Examples of the raw data obtained for each titration are shown in 
Figure 8.5.  The net heat change is normalized to the concentration of the injected titrant (E2) 
in the cell after each injection.  The results are illustrated in Figure 8.4. 
There are indications in Figure 8.6 that a signal may be observed.  The increase in observed 
heat production follows the expected trend, with the lowest amount of heat produced with the 
buffer into buffer titration and the largest amount of heat produced with E2 into hERβ 
titration.  The increase in heat production between the double blank and reagent blank is due 
to the presence of 31 mM MeOH; the difference between reagent and titrant blank is due to 
the presence of 10 μM E2, but the expected pattern (Figure 8.1) is still not observed. 
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Figure 8.5.  The raw ITC data for double blank, reagent blank, titrant blank and the 
interaction of E2 with hERβ. 
 
 
Figure 8.6.  Apparent heat change per mol of titrant for double blank, reagent blank, 
titrant blank and the interaction of E2 with hERα. 
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8.5 Discussion  
ITC is a technique that can be used to measure the heat of reaction such as that evolved or 
consumed in the binding of a protein and ligand.  It was proposed to use this technique to 
study the heat evolved when E2 or selected environmental estrogens bind with the ER.  Initial 
attempts at measurements with E2 suggested that the heat involved could be quite small.  The 
general methodology suggested in the literature for designing ITC experiments were followed 
for the initial experiments, but unfortunately these experiments were unsuccessful.   
The results suggest that ITC experiments are possible if sufficiently high protein 
concentration in the reaction cell can be achieved.  In contrast to the results shown in Figure 
8.4 obtained with a protein concentration of 50 nM, there are measurable differences in the 
various blank titrations and the interaction titration obtained with a protein concentration of 
375 nM and shown in Figure 8.6.  The double blank titration gives a very small apparent heat 
change as would be expected.  This difference is mainly due to the temperature difference 
between the solution in the syringe and the solution in the reaction cell.  The increase in 
apparent heat change for the reagent blank compared to the double blank is due to the MeOH 
content of the titrant and the heat released on dilution of the MeOH.  The small increment 
between the reagent blank and the titrant blank is due to the presence of E2 and the additional 
heat released on dilution of E2.  The marginal increment in apparent heat change for the 
titration of E2 into the hERβ solution could be due to any number of factors such as the 
interaction of MeOH with the protein or binding of E2.  Ideally, reagent blank titration into 
the protein solution would be done to quantify and correct for interactions not due to the 
binding of E2 and the protein.  It is not clear from the results shown in Figure 8.6 whether a 
curve of the shape shown in Figure 8.1 would emerge with increased protein concentration or 
whether the molar ratio is not high enough to have reached the point in the curve where the 
slope increases. 
In an effort to identify potential alternate reaction conditions, a simple assessment of the heat 
expected from the system was undertaken. 
For E2 binding with hER, the value for KA of 2x10
9
 M
-1
 gives a free energy of binding 
(ΔGbind) of -52 kJ/mol from the equation 
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Recall from Section 8.2.2 that for E2 binding hER at 25 °C, ΔH accounts for only 37% of ΔG 
or approximately -20 kJ/mol.   
For the first ITC experiment, an active receptor concentration of 50 nM in the measurement 
cell was achieved.  Thus, the amount of protein present in the measurement cell (1.4 mL) 
is7x10
-11
 mol.  This amount of protein would be expected to produce a maximum heat change 
of 1.4 µJ (-20 kJ/mol x 7x10
-11
 mol).  This heat change is 10% of the minimum heat change 
of 15 µJ suggested as a target by the manufacturer.  For the second ITC experiment, the 
protein concentration was 7.5 times greater, producing a maximum heat change of 11 µJ, still 
below the recommended minimum heat change.   
It is possible to do ITC experiments using only the LBD of the ER rather than the full-length 
protein as demonstrated by Kallen et al.[414].   
8.6 Conclusion 
These experiments have demonstrated that, for the instrument available, significant quantities 
of receptor protein are required to study both tight-binding and weak-binding receptor-ligand 
interactions.  The protein concentration is the single most important determinant of the 
magnitude of the heat signal produced by the reaction and the general methodology presented 
in the literature can be improved by using what is known about the system (i.e. an estimate of 
the KA and either available data or assumptions about the relative contributions of ΔH and ΔS 
to ΔG) to estimate the magnitude of the heat change produced by the reaction of interest.  
This estimate of expected heat change could then be compared to the sensitivity of the 
instrument to determine whether the experiment is likely to be successful under the specific 
conditions.   
The results of the experiments at the highest receptor concentration that was achieved 
strongly suggest that if sufficient quantities of receptor protein were available, the 
measurements would be successful.   
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9.1 Overall Conclusions  
This study had two main objectives: 
 Assess human fetal exposure to EEs and estimate the increase in estrogenic load due to 
this exposure in relation to that from endogenous estrogens 
 Consider the biomolecular interaction of the EEs with the hER in an attempt to 
rationalise the varied and sometimes contradictory observed adverse outcomes that have 
been hypothesised to result from such exposure. 
To achieve the first objective, paired samples of human amniotic fluid and maternal urine were 
collected from a cohort of 32 New Zealand women following a diagnostic amniocentesis 
procedure.  The required analytical methods were developed and validated for analysis of these 
samples.  The suite of 30 target analytes included 15 compounds determined for the first time in 
human amniotic fluid and 6 compounds determined for the first time in human urine.   
The analytical method developed to determine the EEs in amniotic fluid and urine samples 
differs from previously published methods (Table 2.3 and Table 2.5) in that it attempts to 
determine both acidic and phenolic compounds at the same time.  This requirement posed 
several significant challenges that were only partially overcome.  The method performed well for 
determining the acidic phthalate monoesters and phenolic compounds with the exception of the 
phytoestrogens GEN and DAID.    Although the phytoestrogens in urine, amniotic fluid and 
other matrices have been successfully determined by GC-MS by TMS derivatisation, the 
published methods [149, 354-359] all employ extensive sample cleanup procedures which would 
remove both the less polar phenolic analytes as well as the acidic analytes from the sample 
extract.  The method developed in this study worked well for the calibration standards and for 
the SPE trials with spiked reagent water.  The difficulties arose with the analysis of real samples.  
There are several possible explanations for the poor performance with these analytes.  First, 
incomplete and irreproducible derivatisation of GEN and DAID was observed in the real 
samples, and to some extent in calibration standards analysed at the same time as the real 
samples.  The sample matrix or even residues remaining adhered to the internal surfaces of the 
reaction vials after cleaning could be interfering with the derivatisation reaction for these 
analytes.  It is also possible that the derivatives of GEN and DAID were decomposing in the GC 
inlet due to non-volatile residues deposited in the inlet and at the top of the analytical column.   
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The results from this study for total concentration of EEs in maternal urine are consistent with 
other studies representing a range of lifestyles and countries (Figure 6.2).  This study is the first 
to report urine levels of BP-1 and BP-2.  Six other target analytes (4t-OP, NP, mOP, mTric, 
3PBA and 3PBOH) were included in the analysis but were not detected in any of the samples.  
For some compounds, e.g. the parabens, the levels from this study are in the higher range of the 
literature data.  The literature data set was assembled from adult urine results and includes both 
males and non-pregnant females in addition to pregnant females.  It is possible that the levels in 
male urine for some of the ingredients in personal care products are lower than in female urine, 
because of the differences in the use of these products. 
The results from this study for total concentration of EEs in amniotic fluid are consistent with 
literature values (Figure 6.3).  Literature data are available only for the phthalate monoesters, 
BPA and the phytoestrogens.  This study is the first to report levels of parabens, UV filters and 
triclosan in human amniotic fluid.  Six other target analytes (OP, NP, mOP, mTric, 3PBA and 
3PBOH) were included in the analysis but were not detected in any of the samples.       
The comparison of amniotic fluid levels reported in this study with literature values must be 
made cautiously.  Some of the literature studies may underestimate amniotic fluid 
concentrations, especially with samples collected in the early 2nd trimester because these results 
were obtained using only β-glucuronidase deconjugation.  As indicated in Chapter 1, the fetal 
glucuronidation pathway is much less active than the sulphation pathway.   
With these results, an assessment methodology was developed to determine whether the levels of 
EEs found in amniotic fluid were cause for concern.  This was done by developing a simple 
additivity model to estimate relative estrogenic load that included an important interaction 
mechanism between two endogenous estrogens.  This model was used to estimate the proportion 
of the total estrogenic signal attributable to the EEs and to endogenous estrogens.  This model 
suggested that the estrogenic signal due to EEs could be 36-40% of the total, or in other words, 
almost as large as the endogenous estrogenic signal.  This is definitely a cause for concern, 
particularly for male fetuses.  This assessment was also based on a thorough review of the 
physiology and metabolism of the maternal-fetal-placental unit, which suggests that once EEs 
enter the fetal compartment, they become trapped and can be recirculated in the same way as 
endogenous estrogens.  This finding is in contrast to what has previously been assumed [151], 
that the ‘turnover’ of amniotic fluid facilitates elimination of EEs via the placenta. 
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The relative estrogenic load model that was developed made use of published information on 
estrogenic potency of EEs, but was limited in several ways.  Ideally, the model would have 
included the antiestrogenic, androgenic and antiandrogenic potency of the compounds of interest 
along with their estrogenic potency.  This information is not currently available for the enough 
of the compounds of interest to be included in the model.  Additional work is needed to fully 
characterise the endocrine disrupting potential of these compounds using assays such as those 
described in Section 2.6. 
To achieve the second objective, computational docking was used to investigate the hypothesis 
put forward in this study that ligand flexibility results in multiple, distinct energy-equivalent 
receptor-ligand complexes.  Should these multiple complexes exist in vivo, this would lead to the 
second hypothesis that these complexes are not be able to interact with the transcription 
machinery of the target cell in a well-defined and reproducible way to produce a consistent and 
predictable physiological response in the tissues.   
The docking studies of this study show that the rigid endogenous steroid ligands produce a 
single, well-defined complex with the receptor (hER-E2 complex).  This result is well known 
and demonstrated by published crystal structures of the hER-E2 complex (Table 3.1). The 
docking studies also show that a single, well-defined hER-ligand complex is formed with ligands 
that have similar dimensions to E2 but that have limited flexibility such as GEN and DES.  
Published crystal structures are available for these two ligands (Table 3.1).  However, crystal 
structures have not been published for more flexible ligands such as the EEs.   The docking 
studies show that the flexible EE molecules produce multiple, distinct energy-equivalent 
complexes (hER-EE complexes).  To obtain a solved crystal structure, the individual protein-
ligand complexes must be able to come together in a reproducible way to form a crystal.  This, in 
turn, requires each protein-ligand complex in the crystal to have the same 3D orientation of 
atoms.  The inability of the flexible EEs to produce a single, well-defined hER-EE complex was 
demonstrated with this docking study.  These multiple, distinct energy-equivalent complexes, if 
present in reality, could be the reason published crystal structures do not exist for EEs. 
The structural features of the endogenous steroids that are critical in stabilising the hER-E2 
complex are the two hydroxyl functionalities (the phenolic A-ring hydroxyl and the aliphatic D-
ring hydroxyl) and the 13-CH3.  The role of the two hydroxyl groups has been previously 
recognised [77], but the importance of the 13-CH3 in stabilising the topology of the cofactor 
binding site has not.  The two hydroxyls must be separated by a hydrophobic scaffold and 
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oriented in a specific way to interact effectively with the binding site – to lock it into a well-
defined shape.  The phenolic A-ring hydroxyl positions the ligand in the binding cavity and 
serves as the main anchor.  The D-ring hydroxyl serves to capture and to orient H11 so that the 
H12 helix folds over the opening of the ligand binding site, exposing the cofactor binding site.  
These docking studies have shown that the 13-CH3 near the D-ring hydroxyl that is oriented in 
the same direction above the plane of the hydrophobic scaffold as the D-ring hydroxyl serves 
two subtle but important purposes. This methyl group prevents the binding cavity from 
collapsing inward onto the ligand as H12 closes over the binding site which in turn stabilises the 
topology of cofactor binding site located on the external surface of the complex.  To quantify the 
degree of stabilisation, the docking studies demonstrated that the dihedral angle between the 
backbone carbonyls of the His524/475 and Leu525/476 residues could be used.  Because of its 
well-defined topology, the ‘rigid’ hER-E2 complex interacts in a predictable way with the cell’s 
transcription machinery.  The IFD results indicate that when E2 is docked, this dihedral angle 
converges to a specific value regardless of the starting conformation of the receptor protein and 
that this angle is different for hERα and hERβ (21.1° and 16.4° respectively).  The degree of 
convergence decreases with the increase in flexibility of the ligand, suggesting that the hER-EE 
complexes are more pliable than the hER-E2 complexes; that the flexible ligand is unable to 
produce a well-defined, rigid complex.   
A similar situation was seen with the SERMs, OHT and RAL.  These ligands result in rigid, 
well-defined, but different antagonist conformations of hERα.  Slight differences in the topology 
of the cofactor binding site produced by the specific ligand structures result in the two 
complexes being able to recruit different cofactors in a given cell type and thus result in different 
physiological outcomes in the same target tissue.  In the uterus, OHT is able to recruit the 
specific coactivator proteins present in this cell type to achieve gene transcription but RAL is 
not.  In breast cancer cells, both compounds completely block all target gene transcription.  This 
difference in behaviour is attributed to the differences in populations of and the relative 
concentrations of the cofactors present in the two cell types and the relative ability of the 
different complexes to recruit these cofactors. This difference in topology is quantified by the 
different dihedral angles of the complexes:  29.3° for RAL and 32.4° for OHT. 
Ligands such as the phytoestrogens (GEN, DAID and COUM) have the two hydroxyl groups but 
not the 13-CH3.  The absence of the 13-CH3 along with the fact that both hydroxyls are phenolic 
allows the ligand to occupy the binding cavity with either phenolic hydroxyl playing the role of 
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the A-ring.  However, the dihedral angles measured for these different ligand poses are quite 
similar and the calculated binding energies are the same.  Thus, some variation in the topology 
of the cofactor binding site is possible when these ligands are bound.  Crystal structures have 
shown that with hERα, GEN is exclusively an agonist and that with hERβ, GEN can produce 
complexes with both agonist and antagonist conformations. But, the agonist conformation of 
hERβ is found only when specific cofactor proteins are present.  In other words, the antagonist 
conformation of the hERβ complex is more energetically favourable than the agonist complex, 
but the agonist complex can be stabilised in the cell that has the necessary cofactors present in 
the correct relative abundance.  This concept was illustrated in Figure 3.1.  These experimental 
results are reflected in the computational docking results with GEN.  The dihedral angle of the 
hERα-GEN complex is 16.5°, narrower than that of the hERα-E2 complex.  The agonist hERβ-
GEN complex has a dihedral angle of 18.5°, wider than that of hERβ-E2 and the antagonist 
conformation hERβ-GEN complex has a dihedral angle of 25.0°, the largest of all hERβ 
antagonist complexes. 
With other, more flexible ligands, computational docking suggests that a larger number of 
energy-equivalent yet distinct receptor-ligand complexes are possible.  These more flexible 
ligands may or may not have a hydroxyl group capable of playing the role of a D-ring hydroxyl 
and may or may not have a structure that is capable of supporting the binding cavity in the way 
the 13-CH3 does.  These ligands are not able to simultaneously interact in all three ways with the 
binding cavity to stabilise the rigid hER-E2-like topology of the complex.  With the hER-EE 
complexes obtained by IFD, the measured dihedral angles vary significantly while the calculated 
binding energies are the same.  As a result, the hER-EE complexes can be thought of as more 
pliable or ‘floppy’ and thus able to respond to the cell context in multiple ways, depending on 
which of the cofactors are recruited and in what order.  The relative abundance of the cofactors 
may now play a role in how the specific cell responds to the EE.  It is therefore possible that the 
EEs can behave in the same way as pharmaceutical selective modulators, initiating gene 
transcription in some target cells but not others.  It is also possible that the altered topology 
could influence the selection of which gene is transcribed in a particular target cell by 
preferentially recruiting one type of cofactor over another.   
In addition, for a ligand to be an antagonist in hERα, it requires a large pendant group to act as a 
wedge to block H12 from closing over the binding site entrance.  It also must be able to 
destabilise the α-helix structure of H11 in the region of His524 and Leu525 to allow the loop and 
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to extend to permit H12 to occupy the cofactor binding site.  In contrast, antagonists of hERβ do 
not have this wedge feature.  Because the antagonist conformation of hERβ may be slightly 
more energetically favourable than the agonist conformation as illustrated in Figure 3.1, these 
ligands are able to destabilise H11 sufficiently to spontaneously cause hERβ to adopt the 
antagonist conformation, without having to also physically block H12 from taking position over 
the binding cavity.  Thus, the docking studies suggest it may be possible for an EE to be either 
an agonist or antagonist in hERβ but because these ligands do not have a ‘wedge’ feature, they 
are only able to act as agonists, albeit weakly, in hERα.   
The flexibility of the ligands and their ability to produce pliable receptor-ligand complexes may 
also explain why exposure to a single compound produces different effects in males and females 
and produces different effects depending on when during development or life stage the exposure 
occurs.  The adverse effects attributed to fetal exposure (e.g. abnormalities in male genitalia or 
precocious puberty in females) are very different to those attributed to adult exposure (e.g. 
reduced fertility, susceptibility to hormone responsive cancers), but it cannot be ruled out that 
the effects seen in adults do not have a root in fetal exposure.   
Finally, combining the range of possible physiological effects of a single EE that are mediated 
by pliable receptor-ligand complexes, the differential distribution of hERα and hERβ in target 
tissues and the exposure to changing mixtures of EEs, each of which has a different potential 
effect profile, it is not surprising that the ability to quantify effects of measured exposures is so 
elusive.   
9.2 Future Directions 
Several points that arose during this study remain to be addressed.  The first is the importance of 
completing a confirmation analysis on the urine and amniotic fluid samples.  The analytical 
method developed for this study was not amenable to a few of the compounds, in particular the 
phytoestrogens genistein and daidzein.  These two compounds are expected to contribute a large 
fraction of the total estrogenicity of the samples.  Literature data were used in place of analysis 
results to complete the exposure assessment and to estimate the relative estrogenic load 
attributable to EEs.  A portion of each sample was archived so that in the event a future 
opportunity did arise, the dataset could be completed. 
Second, the computational docking study required experimental binding energies for 
comparison.  While the data available in the literature was used, the study considered several 
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ligands that did not have published binding energy data.  Two attempts were made to both 
measure the binding energies for the ligands of interest and to study the kinetics and 
thermodynamics of ligand binding.  The information from these experiments was intended to 
inform the computational docking study.  Although both attempts, one using SPR and the other 
using ITC, were unsuccessful in producing useful binding data, the SPR and ITC techniques 
were successfully established and insight was obtained into the approaches needed to make the 
desired measurements for protein receptors such as hER.   
The SPR study was also intended to provide a method to screen biological samples for the total 
concentration of compounds able to bind to the ER.  The results from this study would have been 
useful in validating the exposure assessment.  Both the SPR and ITC experiments would be 
successful if the capability to produce the required quantities of receptor protein could be 
established or at least readily accessed.   
Third, to further investigate the hypothesis of multiple, distinct, energy equivalent hER-EE 
complexes, the studies reported in the literature that characterised the behaviour of OHT and 
RAL in different cell contexts could be undertaken with selected EEs.  In particular, the results 
from such studies obtained for GEN, BPA and NP would be most illuminating, as these ligands 
represent various points on the spectrum of ligand flexibility.   
Finally, the model for estimating relative estrogenic load developed in this study should be 
extended to complete the assessment of the effects of exposure to environmental estrogenic and 
androgenic compounds.  This will require information on exposure of the fetus to environmental 
androgens; antiestrogenic, androgenic and antiandrogenic potency data for these compounds; 
and information on the synergistic or antagonistic effects of simultaneous exposures to 
environmental estrogens and androgens. 
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Table A. 1.  Summary of total EE concentrations measured in human adult urine (ng/mL). 
Reference [139] [139] [135] [140] [141] [142] [143] [144] [116] [116] [145] [146] [147] [148] [148] [149] [149] [150] 
Cohort mothers, 
female fetus 
mothers, 
male 
fetus 
male 
and 
female 
adult 
male 
and 
female 
adult 
human mother adults human male 
(23-
29 
yr) 
female 
(54-86 
yr) 
adult adult mother adults 
(Korean) 
adults 
(Korean) 
adult 
males 
(German) 
normal 
diet 
adult 
males 
(German) 
normal 
diet 
adult 
women 
(UK) 
GEN       2.6 35      5.7 49.8 104 64 102.5 
DAID       22.5 74      9.1 442 196 98 200.1 
EQ              3.3 16.4 14 31 6.1 
ENT       131 209      1.4 17   1104.5 
BPA    0.9 1.28  0.47      1.3   10 9  
MBP 78 79.6    13.5     1.57 41 36      
MEHP 24.6 26.3    3.3     0.9 2.7 6      
MEP 22.2 19.1    128.4     42.9 305 380      
MBzP 3 2.5    8.3     2.06 21.2 22      
MMP 7.1 6.8    0.7     0.45  1.6      
MOP            0.9       
mParaben   43.9 110               
eParaben   1 12.5               
pParaben   9.1 15.1               
bParaben   0.5 22.9               
TRIC    19         11      
2,4-DCP             2.1      
NP     0.1              
BP-3    12.3     140 60   7.5      
OMC         8 5         
4MBC         7 5         
E2              4.2 38.5    
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Table A. 2.  Summary of total EE concentrations measured in human amniotic fluid (ng/mL). 
Reference [139] [139] [190] [130] [191] [180] [179] [99] 
Cohort female 
fetus 
male 
fetus 
      
GEN   1.38    1.69 0.94 
DAID   9.52    1.44 1.08 
ENT   95.9      
BPA   0.5  8.3 0.26   
MBP 85.5 81.3  5.8     
MEHP 24 22.1  0.86     
MEP 1 1  1.2     
MBzP 1.4 1.4       
MMP 1.4 1.4       
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Table A. 3.  Summary of estrogenic potencies of selected EDCs obtained from the E-SCREEN, YES and 
ER-CALUX assays.  Unless otherwise indicated (%efficacy), the potency is for full agonist activity.  
Literature references are given in square brackets. 
Test Name E-SCREEN YES ER-CALUX 
Reporter Cell Proliferation β-galactosidase Luciferase 
Host cell MCF-7 Yeast T47D 
Receptor hERα dominant hERα hERα dominant 
m-Paraben 7.1 x 10-7 (45%) [210] 
1.5 x 10-7 (82%) [211] 
3.3 x 10-7 [203]  
e-Paraben 3.7 x 10-6 [210] 
1.5 x 10-6 (87%) [211] 
5 x 10-6 [203]  
p-Paraben 7.5 x 10-6 [210] 
1.5 x 10-6 [211] 
3.6 x 10-7 [415] 
3.3 x 10-5 [203]  
b-Paraben 1.5 x 10-5 [210] 
1.5 x 10-6 (79%) [211] 
6.7 x 10-7 [415] 
1.3 x 10-4 [203]  
bz-Paraben 1.5 x 10-5 [210] 2.5 x 10-4 [203] 
2.2 x 10-4 [416] 
 
ip-Paraben 1.2 x 10-5 [210] 
6 x 10-5 [211] 
  
ib-Paraben 1.5 x 10-5 [210] 
6 x 10-5 (95%) [211] 
  
4HBA not active [210]   
Triclosan not active [210, 217] 
agonist [213] 
1.5 x 10-2 [215] antagonist [216] 
BP-1 5.9 x 10-7 [221] 2.2 x 10-4 (96%) [222] 
3.3 x 10-4 [203] 
2.5 x 10-4 [416] 
 
BP-2 1.8 x 10-6 [221] 2.4 x 10-5 (91%) [222] 
1.4 x 10-4 [203] 
 
BP-3 3.3 x 10-7 [221] 1.4 x 10-5 (18%) [222] 
6.8 x 10-5 [223] 
1 x 10-5 (50%) [203] 
 
OMC 5.1 x 10-7 [221] 
8.3 x 10-7 [415] 
  
4MBC 4.0 x 10-7 [221] 
2.1 x 10-7 [415] 
  
BPA 1.6 x 10-5 [228] 
3.8 x 10-6 [415] 
1 x 10-4 [203] 
6.2 x 10-5 [416] 
7.8 x 10-6 [197] 
NP  8.1 x 10-4 [215] 
7.2 x 10-7 [231] 
1.4 x 10-4 [232] 
2.3 x 10-5 [197] 
4t-OP  2 x 10-4 [203]  
3PBA  not active [233]  
4OH-3PBA  not active [233]  
3PBOH  5.2 x 10-5 [233]  
4OH-3PBOH  5.2 x 10-5 [233]  
GEN ~10-3 (50%) [238] 
1.2 x 10-5 [415] 
2.9 x 10-4 [416] 6 x 10-5 [197] 
DAID ~10-3 (50%) [238]   
Equol ~10-3 [238]   
EE2  0.3 [215]  
E1 6.3 x 10-3 [415]   
E3 2.2 x 10-2 [415]   
 
  
 
 
Table A. 4.  Summary of estrogenic potencies of selected EDCs obtained from firefly luciferase reporter gene assays hosted in a variety of different cell types.  
Unless otherwise indicated (%efficacy), the potency is for full agonist activity.  Literature references are given in square brackets. 
Host cell Yeast HepG2 CHO-K1 HEK293 U2-OS 
Receptor hERα hERβ hERα hERβ hERα hERβ hERα hERβ hERα hERβ 
m-Paraben 6 x 10-7 
[196] 
1.3 x 10-5 
[196] 
        
p-Paraben 5 x 10-5 
[196] 
1.8 x 10-4 
[196] 
        
Triclosan not active 
[215] 
         
BP-1       3 x 10-4 
[134] 
   
BP-3       1 x 10-5 
[134] 
1 x 10-6 
(80%) [134] 
  
OMC       <10-6 
(42%) [134] 
not active 
[134] 
  
4MBC       <10-6 
(60%) [134] 
<10-6 
(80%) [134] 
  
BPA 4 x 10-5 
[196] 
6 x 10-3 
[196] 
4.7 x 10-3 
[225] 
7.9 x 10-3 
[225] 
    5.3 x 10-5 
[227] 
8.3 x 10-4 
[227] 
NP 2 x 10-5 
[196] 
5.8 x 10-3 
[215] 
< 10-5 
[196] 
        
mBP     not active 
[235] 
not active 
[235] 
    
mBzP     not active 
[235] 
not active 
[235] 
    
mEHP     not active 
[235] 
not active 
[235] 
    
GEN 5 x 10-5 
[196] 
7 x 10-5 
[196] 
      ~10-5 
(30%) [238] 
~10-5 
(50%) [238] 
DAID         ~10-5 
(20%) [238] 
~10-5 
(50%) [238] 
  
Host cell Yeast HepG2 CHO-K1 HEK293 U2-OS 
Receptor hERα hERβ hERα hERβ hERα hERβ hERα hERβ hERα hERβ 
Equol         ~10-4 
(80%) [238] 
~10-4 
(50%) [238] 
EE2 1.15 
[215] 
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Table A. 5.  Summary of estrogenic potencies of selected EDCs obtained from in vitro assays using unique 
reporter constructs.  Unless otherwise indicated (%efficacy), the potency is for full agonist activity.  
Literature references are given in square brackets. 
Reporter pS2 mRNA Green Fluorescent Protein 
Host cell  MCF-7 MCF-7 Ishikawa 
Receptor hERα dominant hERα dominant hERβ dominant 
BP-1 3.9 x 10-5 [224]   
BP-3 9.6 x 10-6 [224]   
OMC 4.6 x 10-6 [224]   
4MBC 2.6 x 10-6 [224]   
BPA  2 x 10-5 [226] 9 x 10-6 [226] 
GEN  2 x 10-5 [226] 9 x 10-5 [226] 
 
Table A. 6.  Statistical summary of estrogenic potencies of selected EDCs (low, median and high) for 
hERα and hERβ, as illustrated in Figure 2.16.  Missing values indicate data not available. 
 hERα hERβ 
 High Low Median High Low Median 
mParaben 7.10E-07 1.50E-07 4.65E-07 1.3E-05 1.3E-05 1.3E-05 
eParaben 5.00E-06 1.50E-06 3.70E-06    
pParaben 5.00E-05 3.60E-07 7.50E-06 1.8E-04 1.8E-04 1.8E-04 
bParaben 1.30E-04 6.70E-07 8.25E-06    
tOP 4.90E-04 2.00E-04 3.45E-04    
NP 5.80E-03 7.20E-07 1.20E-04 1.0E-05 1.0E-05 1.0E-05 
3PBOH 5.20E-05 5.20E-05 5.20E-05    
4MBC 2.60E-06 2.10E-07 7.00E-07 1.0E-06 1.0E-06 1.0E-06 
OMC 4.60E-06 5.10E-07 9.15E-07    
BP-1 3.30E-04 5.90E-07 2.35E-04    
BP-2 1.40E-04 1.80E-06 2.40E-05    
BP-3 6.80E-05 3.30E-07 1.00E-05 1.0E-06 1.0E-06 1.0E-06 
Tric 1.50E-02 1.50E-02 1.50E-02    
BPA 4.70E-03 3.80E-06 4.65E-05 7.9E-03 7.9E-03 7.9E-03 
Equol 1.00E-03 1.00E-04 5.50E-04 1.0E-04 1.0E-04 1.0E-04 
Daid 1.00E-03 1.00E-05 5.05E-04 1.0E-05 1.0E-05 1.0E-05 
Gen 1.00E-03 1.00E-05 5.00E-05 9.0E-05 9.0E-05 9.0E-05 
E1 3.92E-01 6.30E-03 1.40E-01    
E2  1.00E+00 1.00E+00 1.00E+00 1.0E+00 1.0E+00 1.0E+00 
E3 3.70E-02 2.20E-02 2.95E-02    
EE2 1.15E+00 3.00E-01 9.20E-01    
mTric       
3PBA       
Ent       
mMP       
mEP       
mBP       
mEHP       
mOP       
mBzP       
 
 
  
Table A. 7.  Structures of ligands used in docking. 
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Table A. 8.  List of references for experimental binding energy measurements given in Table 3.3.   
Author Reference 
Anstead et al. (Table 1) [417] 
Kuiper et al. (Table 1 & Table 2) [418] 
Waller et al.  [419] 
Kwon et al.  [420] 
Mueller et al.  [421] 
Rich et al.  [373] 
Usami et al.  [384] 
Lambrinidis et al.  [75] 
van Lipzig et al.  [273] 
Laws et al.  [374] 
Mueller et al.  [422] 
Muthyala et al.  [304] 
Blair et al.  [423] 
Molina-Molina et al.  [424] 
Okubo et al.  [211] 
Morohoshi et al.  [425] 
Zhu et al.  [426] 
Wolohan  [427] 
Gangloff, M.  [259] 
Chen, Z.  [428] 
Branham,W.  [429] 
Sippl, W.  [311] 
Murk, A.  [430] 
Zacharewski, T.,  [431] 
Schreurs, R.,  [432] 
Lemini, C.,  [208] 
Satoh, K.,  [433] 
Kuiper et al.  [375] 
Pfitscher et al.  [434] 
Mueller,  [435] 
Satoh,  [436] 
Nettles et al.  [289] 
Norman et al.  [292] 
Blizzard et al.  [290] 
Richardson  [293] 
Sun et al.  [437] 
Setchell et al.  [303] 
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Table A. 9.  Ligand length (Å) for the energy minimized free ligand in water.  Length is measured 
between opposing hydroxyls (or carbonyl or carboxylic acid if the ligand has only one hydroxyl). 
Ligand Length (Å) 
E1 10.91 
E2 11.03 
E3 11.03 (17β-OH)  11.16 (16α-OH) 
T 10.80 
EE2 11.04 
DES 12.08 
BPA 9.40 
GEN 12.15 
DAID 12.16 
COUM 11.37 
R-EQ 11.99 
S-EQ 11.99 
ENT 11.79 
BP-2 9.62 
4NP-M1 15.52 
4NP-M2 12.09 
4NP-M3 10.50 
4OH-3PBOH 10.57 
4OH-3PBA 10.97 
RAL 11.74 
EZT 11.01 
JJ3 11.93 
AIT 11.57 
3AS 11.91 
ETC 12.12 
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Table A. 10.  Suppliers for chemicals used in the study. 
Sigma-Aldrich CAS Cat # 
p-n-nonylphenol 104-40-5 46405-100MG 
p-tert-octylphenol 140-66-9 442858 
3-phenoxybenzyl alcohol 13826-35-2 190284-25G  
3-phenoxybenzoic acid 3739-38-6 190276-5G  
2,4-dihydroxybenzophenone 131-56-6 126217-100G  
2,2',4,4'-tetrahydroxybenzophenone 131-55-5 T16403-25G  
estrone 53-16-7 E9750-1G  
estriol 50-27-1 E1253-500MG  
ethynylestradiol 57-63-6 E4876-100MG  
4-fluoro-4'-hydroxybenzophenone 25913-05-7 274224-50G  
2,2-bis-(4-hydroxy-3-methylphenyl)propane  79-97-0 423300-1G  
β-Glucuronidase from Helix pomatia 9001-45-0 G0751-500KU  
4-Nitrocatechol sulfate dipotassium salt 14528-64-4 N7251-500MG  
4-Nitrocatechol 3316-09-4 N15553-1G  
4-Nitrophenyl-β-glucuronide 10344-94-2 73677-250MG  
4-Nitrophenol 100-02-7 35836-1G  
2,4-Dichlorophenol 120-83-2 35811-1G  
formic acid 64-18-6 06440-100ML  
Phenomenex (AccuStandard)   
monomethyl phthalate 4376-18-5 ALR-139N 
monoethyl phthalate 2306-33-4 ALR-137N 
monobenzyl phthalate 2528-16-7 ALR-134N 
mono-n-butyl phthalate 131-70-4 ALR-135N 
mono-2-ethylhexyl phthalate 4376-20-9 ALR-138N 
p-hydroxybenzoic acid methyl ester 99-76-3 ALR-130N 
p-hydroxybenzoic acid ethyl ester 120-47-8 ALR-113N 
p-hydroxybenzoic acid propyl ester 94-13-3 ALR-153N 
p-hydroxybenzoic acid butyl ester 94-26-8 ALR-085N 
p-hydroxybenzoic acid 99-96-7 ALR-069N 
2-hydroxy-4-methoxybenzophenone 131-57-7 ALR-081N 
2-ethylhexyl-p-methoxycinnamate 5466-77-3 ALR-144N 
4-methyl-benzylidene camphor 36861-47-9 ALR-073N 
triclosan 3380-34-5 PCC-0015-10x 
enterolactone  ASB-00005455-010 
Novachem (Cambridge Isotope Laboratory)   
mono-n-octyl phthalate 5393-19-1 ULM-4593-1.2     
triclosan 3380-34-5 C 17803000 
methyl triclosan 4640-01-1 C 17803300 
mono-2-ethylhexyl phthalate (13C4, 99%) NA CLM-4584-1.2     
monoethyl phthalate (13C4, 99%) NA CLM-4586-1.2     
p-n-Nonylphenol (13C6, 99%) NA CLM-4306-1.2     
Genistein (D4, 94%) NA DLM-4460-1.2     
3-Phenoxybenzoic Acid (13C6, 99%)  NA CLM-4542-SA-1.2     
Triclosan (2',4,4'-trichloro-2-hydroxydiphenyl ether) (13C12, 99%) NA CLM-6779-1.2     
p-hydroxybenzoic acid methyl ester (ring 13C6, 99%) NA CLM-8249-1.2     
p-hydroxybenzoic acid butyl ester (ring 13C6, 99%) NA CLM-8285-1.2     
17β-estradiol (13C2, 99%) NA CLM-803-1.2     
Bisphenol A (13C12, 99%) NA CLM-4325-1.2     
4-Nitrophenol (D4, 98%) 93951-79-2 DLM-296-0.25 
Sapphire Bioscience  (Alexis)   
genistein 446-72-0  ALX-350-006-M100 
daidzein 486-66-8 ALX-350-009-M050 
equol (R+S isomers) 94105-90-5 ALX-385-032-M025 
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Table A. 11.  Suppliers of solvents and other reagents. 
Supplier Product 
Fisher Scientific MeOH, EtOH 
Merck ACN 
Mallinckrodt Iso-octane, Hexanes, MTBE 
Fluka formic acid 
  
 
 
Table A. 12.  Synthetic urine recipe (McCurdy, 2005) 
Component g/L H2O 
Urea  16 
Sodium Chloride 2.32 
Potassium Chloride 3.43 
Creatinine 1.1 
Anhydrous Sodium Sulfate 4.31 
Ammonium Chloride 1.06 
Citric Acid 0.54 
Anhydrous Magnesium Sulfate 0.46 
Anhydrous Sodium Dihydrogen Phosphate 2.73 
Anhydrous Calcium Chloride 0.63 
Oxalic Acid 0.02 
Glucose 0.48 
Anhydrous Sodium Silicate (7 mg Si/kg urine) 0.071 
 
 
  
Table A. 13.  Physical properties of target analytes, recovery surrogates, enzyme reaction controls and the internal standard. 
 CAS MW MP  
(
o
C) 
BP  
(
o
C) 
ACD logP ACD logD 
(@ pH 5.5) 
Target Analyte       
bisphenol A 80-05-7 228.29 158-159 220 / 4 mmHg 3.43 3.43 
monomethyl phthalate 4376-18-5 180.16 82-82 329 1.13 -1.01 
monoethyl phthalate 2306-33-4 194.18  340 1.66 -0.48 
monobenzyl phthalate 2528-16-7 256.25  441 2.9 0.81 
mono-n-butyl phthalate 131-70-4 222.24  363 2.72 0.64 
mono-2-ethylhexyl phthalate 4376-20-6 278.34  409 4.67 2.57 
mono-n-octyl phthalate 5393-19-1 278.34   4.58 2.76 
p-n-nonylphenol 104-40-5 220.35 43-46 127-130 / 27 mmHg 6.19 6.19 
p-tert-octylphenol 140-66-9 206.32 79-82 175 / 30 mmHg 4.93 4.93 
3-(4-hydroxy-3-phenoxy)benzyl alcohol 63987-19-9 216.23   2.17 2.17 
3-(4-hydroxy-3-phenoxy)benzoic acid 35065-12-4 230.22   3.05 1.51 
3-phenoxybenzyl alcohol 13826-35-2 200.32 10 135-140 / 0.1 mmHg 3.03 3.03 
3-phenoxybenzoic acid 3739-38-6 214.22 147-149 373 3.91 2.36 
triclosan 3380-34-5 289.54 56-60 345 5.17 5.17 
methyl triclosan 4640-01-1 303.57  359 4.74 4.74 
p-hydroxybenzoic acid methyl ester 99-76-3 152.15 125-128 275 1.87 1.87 
p-hydroxybenzoic acid ethyl ester 120-47-8 166.18 114-117 297-298 2.4 2.4 
p-hydroxybenzoic acid propyl ester 94-13-3 180.2 95-98 156-157 / 3.5 mmHg 2.93 2.93 
p-hydroxybenzoic acid butyl ester 94-26-8 194.23 67-70 309 3.46 3.46 
p-hydroxybenzoic acid 99-96-7 138.12 213-217 336 1.42 0.33 
2,4-dihydroxybenzophenone 131-56-6 214.22 144-147 194 / 1 mmHg 3.17 3.17 
2-hydroxy-4-methoxybenzophenone 131-57-7 228.24 62-64 150-160 / 5 mmHg 3.64 3.64 
2,2',4,4'-tetrahydroxybenzophenone 131-55-5 246.22 198-200 531 3.16 3.16 
2-ethylhexyl-p-methoxycinnamate 5466-77-3 290.4  405 5.66 5.66 
genistein 446-72-0 270.24  555 2.96 2.96 
daidzein 486-66-8 254.24  512 2.78 2.78 
equol (S isomer) 94105-90-5 242.27  442 2.98 2.98 
enterolactone 78473-71-9 298.33  479 2.29 2.29 
17b-estradiol 50-28-2 272.38 176-180 446 4.13 4.13 
estrone 53-16-7 270.37 258-260 445 3.69 3.69 
estriol 50-27-1 288.38 280-282 469 2.94 2.94 
ethynylestradiol 57-63-6 296.4 182-163 457 4.52 4.52 
  
 CAS MW MP  
(
o
C) 
BP  
(
o
C) 
ACD logP ACD logD 
(@ pH 5.5) 
Recovery Surrogates       
Bisphenol A (D16, 98%) 96210-87-6 244.29     
Mono-2-ethylhexyl phthalate (13C4, 99%) NA 282.34     
Monoethyl phthalate (13C4, 99%) NA 198.18     
p-n-Nonylphenol (13C6, 99%) NA 226.35     
17β-estradiol (D4, 95-97%) NA 276.38     
Genistein (D4, 94%) NA 274.24     
3-Phenoxybenzoic Acid (13C6, 99%)  NA 220.22     
Triclosan (2',4,4'-trichloro-2-hydroxydiphenyl ether) (13C12, 99%) NA 315.57     
p-hydroxybenzoic acid methyl ester (ring 13C6, 99%) NA 158.15     
p-hydroxybenzoic acid butyl ester (ring 13C6, 99%) NA 200.23     
4-fluoro 4'-hydroxybenzophenone 25913-05-7 216.21 164-167  3.09 3.08 
4-Nitrophenol (D4, 98%) 93951-79-2 143.13 113-115    
Enzyme Reaction Control Standards       
4-Nitrophenyl-β-glucuronide 10344-94-2 315.23  644 -0.75 -3.68 
4-Nitrophenol 100-02-7 139.11 110-115 279 1.57 1.56 
Internal Standard       
2,2-bis-(4-hydroxy-3-methylphenyl)propane  79-97-0 256.34 138-140 238-240 / 12 mmHg 4.35 4.35 
 
  
  
Table A. 14.  Free concentrations (ng/mL) of target analytes in amniotic fluid samples of female fetuses. 
Sample ID 1 2 4 5 6 8 10 11 13 14 17 21 23 25 26 30 
mParaben 0.58 1.52 ND NQ ND 1.69 0.63 ND ND ND ND 0.96 0.75 ND NQ ND 
eParaben ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
mMP ND 0.72 ND NQ ND ND 0.84 ND ND ND 0.31 1.20 ND NQ 0.72 ND 
4HBA 25.08 11.91 NQ 20.07 20.15 NQ NQ 19.86 18.29 NQ NQ 21.47 15.90 NQ NQ 16.49 
mEP 0.49 0.37 NQ NQ 0.19 NQ NQ NQ 0.21 2.15 NQ ND 0.17 ND NQ 0.39 
OP ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
pParaben ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
bParaben ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
mBP ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
3PBOH ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
NP ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
3PBA ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
4MBC NQ NQ NQ NQ NQ NQ NQ NQ NQ NQ NQ NQ NQ NQ NQ NQ 
BP-3 1.06 0.46 NQ 1.34 1.16 NQ ND 2.04 0.78 NQ NQ 0.72 ND 0.88 ND NQ 
mEHP NQ 0.35 0.25 NQ 0.27 0.18 NQ NQ 0.42 0.22 NQ NQ 0.19 0.18 0.27 NQ 
mTric ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
Tric 0.59 0.34 0.63 ND NQ ND ND 0.48 ND ND ND 2.16 ND NQ 0.36 ND 
BP-1 0.36 0.37 0.46 0.41 0.55 0.41 NQ 0.53 0.43 ND NQ 0.20 ND ND 0.14 0.29 
mBzP ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
BPA NQ 0.18 0.07 0.37 0.25 NQ NQ 0.28 NQ NQ NQ NQ NQ 0.26 0.12 NQ 
OMC NQ NQ NQ NQ NQ NQ NQ NQ NQ NQ NQ NQ NQ NQ NQ NQ 
BP-2 ND ND ND 0.04 ND ND ND ND 0.14 ND ND ND ND ND ND ND 
Equol ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
E1 ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
E2  ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
EE2 ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
Ent 2.05 2.60 ND ND 3.43 ND NQ 1.38 2.45 2.41 NQ 2.47 2.78 ND ND ND 
E3 2.08 3.09 6.13 NQ NQ 3.24 4.94 NQ NQ 4.86 1.44 NQ 2.70 3.22 3.89 NQ 
 
  
  
 
Table A. 15.  Free concentrations (ng/mL) of target analytes in amniotic fluid samples of male fetuses. 
Sample ID 3 7 9 12 15 16 18 19 20 22 24 27 28 29 31 32 
mParaben ND ND 0.61 ND NQ 0.38 0.67 ND NQ ND 0.73 1.59 ND ND ND 0.61 
eParaben ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
mMP ND 0.34 0.53 0.40 NQ 0.48 ND NQ 0.29 0.51 0.57 ND ND ND ND ND 
4HBA 14.57 NQ 21.96 13.52 NQ NQ 25.15 16.92 NQ NQ 20.08 17.08 NQ NQ 15.53 19.94 
mEP 0.38 NQ NQ NQ NQ 0.01 NQ NQ NQ NQ 0.14 0.42 NQ 0.45 0.21 1.43 
OP ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
pParaben ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
bParaben ND ND ND ND ND ND ND ND ND ND ND 0.95 ND ND ND ND 
mBP ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
3PBOH ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
NP ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
3PBA ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
4MBC NQ NQ NQ NQ NQ NQ NQ NQ NQ NQ NQ NQ NQ NQ NQ NQ 
BP-3 ND ND 1.16 ND NQ ND 0.95 0.65 NQ NQ 0.61 0.76 NQ NQ 0.35 0.79 
mEHP NQ NQ NQ 0.27 0.29 NQ 0.53 0.26 NQ 0.45 0.38 NQ NQ NQ NQ NQ 
mTric ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
Tric 0.46 0.40 0.48 ND 1.75 ND NQ 0.26 2.31 1.77 ND NQ 0.51 ND 0.69 0.86 
BP-1 0.44 0.41 0.50 0.52 ND NQ 0.22 0.27 0.29 NQ NQ 0.32 0.17 NQ 0.20 0.20 
mBzP ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
BPA 0.77 0.34 NQ 0.67 NQ NQ NQ NQ 0.14 NQ NQ NQ NQ 0.65 NQ NQ 
OMC NQ NQ NQ NQ NQ NQ NQ NQ NQ NQ NQ NQ NQ NQ NQ NQ 
BP-2 ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
Equol ND ND ND ND ND ND ND ND ND 0.09 ND ND ND ND ND ND 
E1 ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
E2  ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
EE2 ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
Ent 2.24 1.79 3.13 ND NQ 1.53 2.13 NQ NQ 2.11 2.67 ND NQ ND 2.42 2.52 
E3 4.76 4.68 5.04 NQ NQ 6.33 2.21 NQ 2.62 3.48 NQ NQ 2.46 3.25 4.94 3.45 
 
  
  
 
Table A. 16.  Total concentrations (ng/mL) of target analytes in amniotic fluid samples of female fetuses. 
Sample ID 1 2 4 5 6 8 10 11 13 14 17 21 23 25 26 30 
mParaben ND NA NA ND ND 2.98 ND ND ND ND 3.96 13.37 ND NQ ND ND 
eParaben ND NA NA ND ND ND ND ND ND ND ND ND ND ND ND ND 
mMP ND NA NA ND ND ND ND ND 60.21 ND NQ 1.66 NQ NQ ND ND 
4HBA 35.47 NA NA 26.37 27.57 NQ NQ 28.38 36.21 NQ NQ 32.47 23.63 NQ NQ 16.50 
mEP 2.26 NA NA 2.67 2.56 NQ NQ 1.44 3.44 6.44 NQ NQ 3.46 2.78 NQ NQ 
OP ND NA NA ND ND ND ND ND ND ND ND ND ND ND ND ND 
pParaben ND NA NA ND ND ND ND ND ND ND ND 1.54 ND NQ ND 0.95 
bParaben ND NA NA ND ND ND ND ND ND ND ND ND ND ND ND 1.32 
mBP ND NA NA ND ND 3.27 ND ND 3.18 3.01 3.92 3.88 4.45 NQ NQ 2.32 
3PBOH ND NA NA ND ND ND ND ND ND ND ND ND ND ND ND ND 
NP ND NA NA ND ND ND ND ND ND ND ND ND ND ND ND ND 
3PBA ND NA NA ND ND ND ND ND ND ND ND ND ND ND ND ND 
4MBC NQ NA NA NQ NQ NQ NQ NQ 4.53 NQ 6.20 9.61 6.55 NQ NQ NQ 
BP-3 1.48 NA NA 1.84 2.32 NQ NQ 3.12 1.17 ND NQ 1.38 1.73 1.79 NQ NQ 
mEHP NQ NA NA NQ NQ NQ NQ NQ 2.62 2.29 4.75 NQ NQ 1.36 1.26 NQ 
mTric ND NA NA ND ND ND ND ND ND ND ND ND ND ND ND ND 
Tric 1.40 NA NA ND 0.54 ND 1.40 0.79 NQ 0.95 0.84 2.21 2.20 NQ NQ 3.22 
BP-1 0.50 NA NA 0.43 0.48 NQ NQ ND 0.48 0.43 ND ND ND 0.45 ND 0.95 
mBzP ND NA NA ND ND ND ND ND ND ND ND ND ND ND ND ND 
BPA 0.09 NA NA 0.21 0.33 NQ NQ 1.26 0.75 NQ NQ 0.08 1.16 NQ NQ 4.36 
OMC NQ NA NA 0.42 0.46 NQ NQ NQ 0.42 1.31 2.35 2.42 NQ NQ 0.53 NQ 
BP-2 ND NA NA ND ND ND ND 0.17 0.10 ND 0.13 ND ND ND ND 0.31 
Equol 5.88 NA NA ND ND ND ND ND ND 2.33 ND ND ND ND ND 1.76 
E1 5.22 NA NA 6.36 4.87 NQ 7.04 4.72 NQ 5.13 2.24 6.29 7.01 7.91 10.86 NQ 
E2  1.08 NA NA 1.38 0.76 NQ 0.92 1.46 NQ NQ 0.85 1.42 NQ NQ 1.42 1.30 
EE2 ND NA NA ND ND ND ND ND ND ND ND ND ND ND ND ND 
Ent 7.72 NA NA ND 14.36 3.36 NQ 5.21 5.06 ND ND 4.58 5.75 NQ ND 6.90 
E3 14.59 NA NA 17.51 19.40 NQ 24.59 13.40 NQ 16.79 6.03 21.66 23.25 NQ NQ 11.44 
 
  
  
 
Table A. 17.  Total concentrations (ng/mL) of target analytes in amniotic fluid samples of male fetuses. 
Sample ID 3 7 9 12 15 16 18 19 20 22 24 27 28 29 31 32 
mParaben NA ND 7.90 ND ND ND 4.44 ND ND 6.03 3.96 ND ND 1.01 1.23 3.60 
eParaben NA ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
mMP NA 0.46 0.50 ND ND ND ND ND ND ND ND ND NQ ND ND NQ 
4HBA NA 18.66 28.66 19.84 NQ NQ 33.60 25.59 NQ NQ 28.59 16.35 NQ NQ 18.07 19.10 
mEP NA 2.52 2.83 3.02 2.87 3.43 2.88 ND 3.10 3.13 NQ NQ 1.32 2.18 2.17 2.99 
OP NA ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
pParaben NA ND 1.84 ND ND ND 0.57 ND ND ND ND ND ND ND ND ND 
bParaben NA ND ND ND ND ND ND ND ND ND ND 1.90 ND ND ND ND 
mBP NA ND 2.62 ND ND ND 3.47 2.23 ND 2.67 3.37 NQ NQ 1.87 1.86 NQ 
3PBOH NA ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
NP NA ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
3PBA NA ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
4MBC NA NQ NQ NQ 5.02 11.57 6.75 NQ NQ NQ 7.19 NQ NQ NQ NQ NQ 
BP-3 NA ND 3.99 2.24 NQ ND 1.97 5.04 NQ NQ 1.96 0.94 NQ 2.98 0.94 NQ 
mEHP NA NQ NQ NQ 2.30 2.02 NQ NQ 2.09 1.19 NQ NQ NQ NQ NQ NQ 
mTric NA ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
Tric NA NQ 1.31 0.80 ND ND 0.73 0.53 7.95 1.64 ND ND 1.26 ND NQ 2.49 
BP-1 NA NQ 2.16 0.63 NQ ND ND 1.58 0.45 ND 0.50 0.35 NQ 1.03 0.22 NQ 
mBzP NA ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
BPA NA NQ 0.18 0.08 NQ 0.23 0.20 NQ NQ 0.13 0.94 NQ NQ 1.25 0.03 NQ 
OMC NA 0.16 NQ NQ NQ 0.27 0.21 0.66 0.43 NQ 2.77 0.09 NQ NQ NQ NQ 
BP-2 NA ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
Equol NA ND ND ND ND ND ND 1.70 1.64 ND 3.74 3.28 NQ NQ ND ND 
E1 NA 11.97 9.25 NQ NQ 11.31 8.95 NQ NQ 8.15 5.24 NQ NQ 3.58 13.57 7.17 
E2  NA 2.49 1.03 NQ NQ 1.38 1.54 1.42 1.57 1.96 NQ NQ 0.71 0.46 2.21 1.10 
EE2 NA ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
Ent NA NQ ND ND ND ND 6.76 5.78 ND NQ 10.53 2.15 ND 4.59 2.32 NQ 
E3 NA 21.24 29.96 30.08 NQ NQ 17.39 18.45 NQ NQ 12.99 10.88 NQ 12.72 24.54 NQ 
 
 
  
   
   
  
   
   
 
Figure A. 1.  Representative control charts for 3 levels of calibration check samples.  Symbols indicate the average result for the day, red bars indicate the range of 
results.  A change in standard mix occurred between Sept 12 and 14 which changed the concentration of some of the target analytes. 
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